id	sid	tid	token	lemma	pos
ajlsi-2696	1	1	pa	pa	PROPN
ajlsi-2696	1	2	ge	ge	PROPN
ajlsi-2696	1	3	1	1	NUM
ajlsi-2696	1	4	pa	pa	PROPN
ajlsi-2696	1	5	ge	ge	PROPN
ajlsi-2696	1	6	61	61	NUM
ajlsi-2696	1	7	american	american	ADJ
ajlsi-2696	1	8	journal	journal	NOUN
ajlsi-2696	1	9	of	of	ADP
ajlsi-2696	1	10	life	life	NOUN
ajlsi-2696	1	11	science	science	NOUN
ajlsi-2696	1	12	and	and	CCONJ
ajlsi-2696	1	13	innovation	innovation	NOUN
ajlsi-2696	1	14	(	(	PUNCT
ajlsi-2696	1	15	ajlsi	ajlsi	ADJ
ajlsi-2696	1	16	)	)	PUNCT
ajlsi-2696	1	17	revolutionizing	revolutionize	VERB
ajlsi-2696	1	18	pediatric	pediatric	ADJ
ajlsi-2696	1	19	dermatology	dermatology	NOUN
ajlsi-2696	1	20	:	:	PUNCT
ajlsi-2696	1	21	dupilumab	dupilumab	NOUN
ajlsi-2696	1	22	’s	’s	PART
ajlsi-2696	1	23	impact	impact	NOUN
ajlsi-2696	1	24	on	on	ADP
ajlsi-2696	1	25	atopic	atopic	NOUN
ajlsi-2696	1	26	dermatitis	dermatitis	NOUN
ajlsi-2696	1	27	in	in	ADP
ajlsi-2696	1	28	kids	kids	PROPN
ajlsi-2696	1	29	eiman	eiman	PROPN
ajlsi-2696	1	30	hamza	hamza	PROPN
ajlsi-2696	1	31	ahmed	ahmed	PROPN
ajlsi-2696	1	32	elsayed1	elsayed1	PROPN
ajlsi-2696	1	33	*	*	PROPN
ajlsi-2696	1	34	,	,	PUNCT
ajlsi-2696	1	35	rabab	rabab	PROPN
ajlsi-2696	1	36	elsayed	elsaye	VERB
ajlsi-2696	1	37	ali	ali	PROPN
ajlsi-2696	1	38	hassan	hassan	PROPN
ajlsi-2696	1	39	khater2	khater2	PROPN
ajlsi-2696	2	1	volume	volume	NOUN
ajlsi-2696	2	2	3	3	NUM
ajlsi-2696	2	3	issue	issue	NOUN
ajlsi-2696	2	4	1	1	NUM
ajlsi-2696	2	5	,	,	PUNCT
ajlsi-2696	2	6	year	year	NOUN
ajlsi-2696	2	7	2024	2024	NUM
ajlsi-2696	2	8	issn	issn	X
ajlsi-2696	2	9	:	:	PUNCT
ajlsi-2696	2	10	2833	2833	NUM
ajlsi-2696	2	11	-	-	SYM
ajlsi-2696	2	12	1397	1397	NUM
ajlsi-2696	2	13	(	(	PUNCT
ajlsi-2696	2	14	online	online	ADJ
ajlsi-2696	2	15	)	)	PUNCT
ajlsi-2696	2	16	doi	doi	NOUN
ajlsi-2696	2	17	:	:	PUNCT
ajlsi-2696	2	18	https://doi.org/10.54536/ajlsi.v3i1.2696	https://doi.org/10.54536/ajlsi.v3i1.2696	PROPN
ajlsi-2696	2	19	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	2	20	article	article	NOUN
ajlsi-2696	2	21	information	information	NOUN
ajlsi-2696	2	22	abstract	abstract	ADV
ajlsi-2696	2	23	received	receive	VERB
ajlsi-2696	2	24	:	:	PUNCT
ajlsi-2696	2	25	may	may	AUX
ajlsi-2696	2	26	01	01	NUM
ajlsi-2696	2	27	,	,	PUNCT
ajlsi-2696	2	28	2024	2024	NUM
ajlsi-2696	2	29	accepted	accept	VERB
ajlsi-2696	2	30	:	:	PUNCT
ajlsi-2696	2	31	may	may	AUX
ajlsi-2696	2	32	31	31	NUM
ajlsi-2696	2	33	,	,	PUNCT
ajlsi-2696	2	34	2024	2024	NUM
ajlsi-2696	2	35	published	publish	VERB
ajlsi-2696	2	36	:	:	PUNCT
ajlsi-2696	2	37	june	june	PROPN
ajlsi-2696	2	38	04	04	NUM
ajlsi-2696	2	39	,	,	PUNCT
ajlsi-2696	2	40	2024	2024	NUM
ajlsi-2696	2	41	eczema	eczema	NOUN
ajlsi-2696	2	42	,	,	PUNCT
ajlsi-2696	2	43	or	or	CCONJ
ajlsi-2696	2	44	atopic	atopic	NOUN
ajlsi-2696	2	45	dermatitis	dermatitis	NOUN
ajlsi-2696	2	46	,	,	PUNCT
ajlsi-2696	2	47	is	be	AUX
ajlsi-2696	2	48	a	a	DET
ajlsi-2696	2	49	common	common	ADJ
ajlsi-2696	2	50	,	,	PUNCT
ajlsi-2696	2	51	non	non	ADJ
ajlsi-2696	2	52	-	-	ADJ
ajlsi-2696	2	53	communicable	communicable	ADJ
ajlsi-2696	2	54	,	,	PUNCT
ajlsi-2696	2	55	immune	immune	NOUN
ajlsi-2696	2	56	-	-	PUNCT
ajlsi-2696	2	57	mediated	mediate	VERB
ajlsi-2696	2	58	,	,	PUNCT
ajlsi-2696	2	59	inflammatory	inflammatory	ADJ
ajlsi-2696	2	60	skin	skin	NOUN
ajlsi-2696	2	61	illness	illness	NOUN
ajlsi-2696	2	62	mainly	mainly	ADV
ajlsi-2696	2	63	affecting	affect	VERB
ajlsi-2696	2	64	children	child	NOUN
ajlsi-2696	2	65	.	.	PUNCT
ajlsi-2696	3	1	it	it	PRON
ajlsi-2696	3	2	is	be	AUX
ajlsi-2696	3	3	a	a	DET
ajlsi-2696	3	4	chronic	chronic	ADJ
ajlsi-2696	3	5	condition	condition	NOUN
ajlsi-2696	3	6	.	.	PUNCT
ajlsi-2696	4	1	it	it	PRON
ajlsi-2696	4	2	causes	cause	VERB
ajlsi-2696	4	3	mental	mental	ADJ
ajlsi-2696	4	4	health	health	NOUN
ajlsi-2696	4	5	problems	problem	NOUN
ajlsi-2696	4	6	like	like	ADP
ajlsi-2696	4	7	anxiety	anxiety	NOUN
ajlsi-2696	4	8	,	,	PUNCT
ajlsi-2696	4	9	sadness	sadness	NOUN
ajlsi-2696	4	10	,	,	PUNCT
ajlsi-2696	4	11	anxiety	anxiety	NOUN
ajlsi-2696	4	12	,	,	PUNCT
ajlsi-2696	4	13	depression	depression	NOUN
ajlsi-2696	4	14	,	,	PUNCT
ajlsi-2696	4	15	hyperactivity	hyperactivity	NOUN
ajlsi-2696	4	16	,	,	PUNCT
ajlsi-2696	4	17	and	and	CCONJ
ajlsi-2696	4	18	obesity	obesity	NOUN
ajlsi-2696	4	19	.	.	PUNCT
ajlsi-2696	5	1	it	it	PRON
ajlsi-2696	5	2	is	be	AUX
ajlsi-2696	5	3	the	the	DET
ajlsi-2696	5	4	first	first	ADJ
ajlsi-2696	5	5	skin	skin	NOUN
ajlsi-2696	5	6	ailment	ailment	NOUN
ajlsi-2696	5	7	and	and	CCONJ
ajlsi-2696	5	8	the	the	DET
ajlsi-2696	5	9	fifteenth	fifteenth	ADJ
ajlsi-2696	5	10	non	non	ADJ
ajlsi-2696	5	11	-	-	ADJ
ajlsi-2696	5	12	fatal	fatal	ADJ
ajlsi-2696	5	13	disease	disease	NOUN
ajlsi-2696	5	14	.	.	PUNCT
ajlsi-2696	6	1	the	the	DET
ajlsi-2696	6	2	purpose	purpose	NOUN
ajlsi-2696	6	3	of	of	ADP
ajlsi-2696	6	4	the	the	DET
ajlsi-2696	6	5	present	present	ADJ
ajlsi-2696	6	6	research	research	NOUN
ajlsi-2696	6	7	study	study	NOUN
ajlsi-2696	6	8	was	be	AUX
ajlsi-2696	6	9	to	to	PART
ajlsi-2696	6	10	evaluate	evaluate	VERB
ajlsi-2696	6	11	the	the	DET
ajlsi-2696	6	12	safety	safety	NOUN
ajlsi-2696	6	13	and	and	CCONJ
ajlsi-2696	6	14	effectiveness	effectiveness	NOUN
ajlsi-2696	6	15	of	of	ADP
ajlsi-2696	6	16	biological	biological	ADJ
ajlsi-2696	6	17	treatment	treatment	NOUN
ajlsi-2696	6	18	for	for	ADP
ajlsi-2696	6	19	atopic	atopic	NOUN
ajlsi-2696	6	20	dermatitis	dermatitis	NOUN
ajlsi-2696	6	21	using	use	VERB
ajlsi-2696	6	22	monoclonal	monoclonal	NOUN
ajlsi-2696	6	23	antibodies	antibody	NOUN
ajlsi-2696	6	24	against	against	ADP
ajlsi-2696	6	25	non	non	ADJ
ajlsi-2696	6	26	-	-	ADJ
ajlsi-2696	6	27	biological	biological	ADJ
ajlsi-2696	6	28	treatment	treatment	NOUN
ajlsi-2696	6	29	,	,	PUNCT
ajlsi-2696	6	30	including	include	VERB
ajlsi-2696	6	31	antibiotics	antibiotic	NOUN
ajlsi-2696	6	32	,	,	PUNCT
ajlsi-2696	6	33	immunosuppressants	immunosuppressant	NOUN
ajlsi-2696	6	34	,	,	PUNCT
ajlsi-2696	6	35	demards	demards	ADV
ajlsi-2696	6	36	,	,	PUNCT
ajlsi-2696	6	37	histamine	histamine	NOUN
ajlsi-2696	6	38	antagonists	antagonist	NOUN
ajlsi-2696	6	39	and	and	CCONJ
ajlsi-2696	6	40	corticosteroids	corticosteroid	NOUN
ajlsi-2696	6	41	.	.	PUNCT
ajlsi-2696	7	1	patient	patient	ADJ
ajlsi-2696	7	2	information	information	NOUN
ajlsi-2696	7	3	was	be	AUX
ajlsi-2696	7	4	gathered	gather	VERB
ajlsi-2696	7	5	from	from	ADP
ajlsi-2696	7	6	fda	fda	PROPN
ajlsi-2696	7	7	-	-	PUNCT
ajlsi-2696	7	8	approved	approve	VERB
ajlsi-2696	7	9	clinical	clinical	ADJ
ajlsi-2696	7	10	trials	trial	NOUN
ajlsi-2696	7	11	.	.	PUNCT
ajlsi-2696	8	1	the	the	DET
ajlsi-2696	8	2	comparative	comparative	ADJ
ajlsi-2696	8	3	analysis	analysis	NOUN
ajlsi-2696	8	4	found	find	VERB
ajlsi-2696	8	5	that	that	SCONJ
ajlsi-2696	8	6	biological	biological	ADJ
ajlsi-2696	8	7	therapies	therapy	NOUN
ajlsi-2696	8	8	like	like	ADP
ajlsi-2696	8	9	dupilumab	dupilumab	NOUN
ajlsi-2696	8	10	,	,	PUNCT
ajlsi-2696	8	11	omalizumab	omalizumab	NOUN
ajlsi-2696	8	12	,	,	PUNCT
ajlsi-2696	8	13	and	and	CCONJ
ajlsi-2696	8	14	ustekinumab	ustekinumab	NOUN
ajlsi-2696	8	15	improve	improve	VERB
ajlsi-2696	8	16	symptoms	symptom	NOUN
ajlsi-2696	8	17	and	and	CCONJ
ajlsi-2696	8	18	disease	disease	NOUN
ajlsi-2696	8	19	control	control	NOUN
ajlsi-2696	8	20	in	in	ADP
ajlsi-2696	8	21	atopic	atopic	NOUN
ajlsi-2696	8	22	dermatitis	dermatitis	NOUN
ajlsi-2696	8	23	.	.	PUNCT
ajlsi-2696	9	1	non	non	ADJ
ajlsi-2696	9	2	-	-	ADJ
ajlsi-2696	9	3	biological	biological	ADJ
ajlsi-2696	9	4	treatments	treatment	NOUN
ajlsi-2696	9	5	may	may	AUX
ajlsi-2696	9	6	not	not	PART
ajlsi-2696	9	7	be	be	AUX
ajlsi-2696	9	8	as	as	ADV
ajlsi-2696	9	9	effective	effective	ADJ
ajlsi-2696	9	10	.	.	PUNCT
ajlsi-2696	10	1	early	early	ADJ
ajlsi-2696	10	2	antibiotic	antibiotic	ADJ
ajlsi-2696	10	3	exposure	exposure	NOUN
ajlsi-2696	10	4	can	can	AUX
ajlsi-2696	10	5	increase	increase	VERB
ajlsi-2696	10	6	infection	infection	NOUN
ajlsi-2696	10	7	vulnerability	vulnerability	NOUN
ajlsi-2696	10	8	.	.	PUNCT
ajlsi-2696	11	1	mild	mild	ADJ
ajlsi-2696	11	2	eczema	eczema	NOUN
ajlsi-2696	11	3	infections	infection	NOUN
ajlsi-2696	11	4	require	require	VERB
ajlsi-2696	11	5	biological	biological	ADJ
ajlsi-2696	11	6	agents	agent	NOUN
ajlsi-2696	11	7	.	.	PUNCT
ajlsi-2696	12	1	topical	topical	ADJ
ajlsi-2696	12	2	corticosteroids	corticosteroid	NOUN
ajlsi-2696	12	3	can	can	AUX
ajlsi-2696	12	4	be	be	AUX
ajlsi-2696	12	5	combined	combine	VERB
ajlsi-2696	12	6	with	with	ADP
ajlsi-2696	12	7	dupilumab	dupilumab	NOUN
ajlsi-2696	12	8	for	for	ADP
ajlsi-2696	12	9	effective	effective	ADJ
ajlsi-2696	12	10	treatment	treatment	NOUN
ajlsi-2696	12	11	of	of	ADP
ajlsi-2696	12	12	atopic	atopic	NOUN
ajlsi-2696	12	13	dermatitis	dermatitis	NOUN
ajlsi-2696	12	14	.	.	PUNCT
ajlsi-2696	13	1	studies	study	NOUN
ajlsi-2696	13	2	show	show	VERB
ajlsi-2696	13	3	that	that	SCONJ
ajlsi-2696	13	4	dupilumab	dupilumab	NOUN
ajlsi-2696	13	5	improves	improve	VERB
ajlsi-2696	13	6	symptoms	symptom	NOUN
ajlsi-2696	13	7	and	and	CCONJ
ajlsi-2696	13	8	quality	quality	NOUN
ajlsi-2696	13	9	of	of	ADP
ajlsi-2696	13	10	life	life	NOUN
ajlsi-2696	13	11	,	,	PUNCT
ajlsi-2696	13	12	making	make	VERB
ajlsi-2696	13	13	it	it	PRON
ajlsi-2696	13	14	a	a	DET
ajlsi-2696	13	15	better	well	ADJ
ajlsi-2696	13	16	option	option	NOUN
ajlsi-2696	13	17	than	than	ADP
ajlsi-2696	13	18	a	a	DET
ajlsi-2696	13	19	placebo	placebo	NOUN
ajlsi-2696	13	20	.	.	PUNCT
ajlsi-2696	14	1	fda	fda	PROPN
ajlsi-2696	14	2	recommends	recommend	VERB
ajlsi-2696	14	3	using	use	VERB
ajlsi-2696	14	4	biological	biological	ADJ
ajlsi-2696	14	5	agents	agent	NOUN
ajlsi-2696	14	6	over	over	ADP
ajlsi-2696	14	7	immunosuppressants	immunosuppressant	NOUN
ajlsi-2696	14	8	in	in	ADP
ajlsi-2696	14	9	paediatrics	paediatric	NOUN
ajlsi-2696	14	10	for	for	ADP
ajlsi-2696	14	11	improved	improved	ADJ
ajlsi-2696	14	12	immune	immune	ADJ
ajlsi-2696	14	13	results	result	NOUN
ajlsi-2696	14	14	.	.	PUNCT
ajlsi-2696	15	1	fda	fda	PROPN
ajlsi-2696	15	2	clinical	clinical	ADJ
ajlsi-2696	15	3	trials	trial	NOUN
ajlsi-2696	15	4	showed	show	VERB
ajlsi-2696	15	5	that	that	SCONJ
ajlsi-2696	15	6	dupilumab	dupilumab	NOUN
ajlsi-2696	15	7	is	be	AUX
ajlsi-2696	15	8	a	a	DET
ajlsi-2696	15	9	safe	safe	ADJ
ajlsi-2696	15	10	and	and	CCONJ
ajlsi-2696	15	11	effective	effective	ADJ
ajlsi-2696	15	12	treatment	treatment	NOUN
ajlsi-2696	15	13	for	for	ADP
ajlsi-2696	15	14	children	child	NOUN
ajlsi-2696	15	15	with	with	ADP
ajlsi-2696	15	16	moderate	moderate	ADJ
ajlsi-2696	15	17	-	-	PUNCT
ajlsi-2696	15	18	to	to	ADP
ajlsi-2696	15	19	-	-	PUNCT
ajlsi-2696	15	20	severe	severe	ADJ
ajlsi-2696	15	21	atopic	atopic	NOUN
ajlsi-2696	15	22	dermatitis	dermatitis	NOUN
ajlsi-2696	15	23	,	,	PUNCT
ajlsi-2696	15	24	reducing	reduce	VERB
ajlsi-2696	15	25	disease	disease	NOUN
ajlsi-2696	15	26	severity	severity	NOUN
ajlsi-2696	15	27	and	and	CCONJ
ajlsi-2696	15	28	improving	improve	VERB
ajlsi-2696	15	29	quality	quality	NOUN
ajlsi-2696	15	30	of	of	ADP
ajlsi-2696	15	31	life	life	NOUN
ajlsi-2696	15	32	in	in	ADP
ajlsi-2696	15	33	young	young	ADJ
ajlsi-2696	15	34	ad	ad	NOUN
ajlsi-2696	15	35	patients	patient	NOUN
ajlsi-2696	15	36	.	.	PUNCT
ajlsi-2696	16	1	keywords	keyword	VERB
ajlsi-2696	16	2	atopic	atopic	NOUN
ajlsi-2696	16	3	dermatitis	dermatitis	NOUN
ajlsi-2696	16	4	,	,	PUNCT
ajlsi-2696	16	5	pediatrics	pediatric	NOUN
ajlsi-2696	16	6	,	,	PUNCT
ajlsi-2696	16	7	dupilumab	dupilumab	NOUN
ajlsi-2696	16	8	,	,	PUNCT
ajlsi-2696	16	9	immunosuppressants	immunosuppressant	NOUN
ajlsi-2696	16	10	,	,	PUNCT
ajlsi-2696	16	11	monoclonal	monoclonal	NOUN
ajlsi-2696	16	12	antibodies	antibodie	VERB
ajlsi-2696	16	13	corticosteroids	corticosteroid	NOUN
ajlsi-2696	16	14	introduction	introduction	NOUN
ajlsi-2696	16	15	atopic	atopic	NOUN
ajlsi-2696	16	16	dermatitis	dermatitis	NOUN
ajlsi-2696	16	17	(	(	PUNCT
ajlsi-2696	16	18	ad	ad	NOUN
ajlsi-2696	16	19	)	)	PUNCT
ajlsi-2696	16	20	,	,	PUNCT
ajlsi-2696	16	21	known	know	VERB
ajlsi-2696	16	22	as	as	ADP
ajlsi-2696	16	23	eczema	eczema	NOUN
ajlsi-2696	16	24	,	,	PUNCT
ajlsi-2696	16	25	is	be	AUX
ajlsi-2696	16	26	a	a	DET
ajlsi-2696	16	27	common	common	ADJ
ajlsi-2696	16	28	,	,	PUNCT
ajlsi-2696	16	29	chronic	chronic	ADJ
ajlsi-2696	16	30	,	,	PUNCT
ajlsi-2696	16	31	non	non	ADJ
ajlsi-2696	16	32	-	-	ADJ
ajlsi-2696	16	33	communicable	communicable	ADJ
ajlsi-2696	16	34	,	,	PUNCT
ajlsi-2696	16	35	immune	immune	NOUN
ajlsi-2696	16	36	-	-	PUNCT
ajlsi-2696	16	37	mediated	mediate	VERB
ajlsi-2696	16	38	inflammatory	inflammatory	ADJ
ajlsi-2696	16	39	skin	skin	NOUN
ajlsi-2696	16	40	condition	condition	NOUN
ajlsi-2696	16	41	that	that	PRON
ajlsi-2696	16	42	mostly	mostly	ADV
ajlsi-2696	16	43	affects	affect	VERB
ajlsi-2696	16	44	children	child	NOUN
ajlsi-2696	16	45	.	.	PUNCT
ajlsi-2696	17	1	it	it	PRON
ajlsi-2696	17	2	ranks	rank	VERB
ajlsi-2696	17	3	first	first	ADV
ajlsi-2696	17	4	among	among	ADP
ajlsi-2696	17	5	all	all	DET
ajlsi-2696	17	6	skin	skin	NOUN
ajlsi-2696	17	7	illnesses	illness	NOUN
ajlsi-2696	17	8	and	and	CCONJ
ajlsi-2696	17	9	15th	15th	ADJ
ajlsi-2696	17	10	among	among	ADP
ajlsi-2696	17	11	nonfatal	nonfatal	ADJ
ajlsi-2696	17	12	diseases	disease	NOUN
ajlsi-2696	17	13	(	(	PUNCT
ajlsi-2696	17	14	rusiñol	rusiñol	NOUN
ajlsi-2696	17	15	&	&	CCONJ
ajlsi-2696	17	16	puig	puig	PROPN
ajlsi-2696	17	17	,	,	PUNCT
ajlsi-2696	17	18	2024	2024	NUM
ajlsi-2696	17	19	)	)	PUNCT
ajlsi-2696	17	20	.	.	PUNCT
ajlsi-2696	18	1	it	it	PRON
ajlsi-2696	18	2	typically	typically	ADV
ajlsi-2696	18	3	manifests	manifest	VERB
ajlsi-2696	18	4	within	within	ADP
ajlsi-2696	18	5	the	the	DET
ajlsi-2696	18	6	first	first	ADJ
ajlsi-2696	18	7	six	six	NUM
ajlsi-2696	18	8	months	month	NOUN
ajlsi-2696	18	9	of	of	ADP
ajlsi-2696	18	10	life	life	NOUN
ajlsi-2696	18	11	.	.	PUNCT
ajlsi-2696	19	1	it	it	PRON
ajlsi-2696	19	2	harms	harm	VERB
ajlsi-2696	19	3	general	general	ADJ
ajlsi-2696	19	4	health	health	NOUN
ajlsi-2696	19	5	and	and	CCONJ
ajlsi-2696	19	6	is	be	AUX
ajlsi-2696	19	7	linked	link	VERB
ajlsi-2696	19	8	to	to	ADP
ajlsi-2696	19	9	a	a	DET
ajlsi-2696	19	10	higher	high	ADJ
ajlsi-2696	19	11	occurrence	occurrence	NOUN
ajlsi-2696	19	12	of	of	ADP
ajlsi-2696	19	13	mental	mental	ADJ
ajlsi-2696	19	14	health	health	NOUN
ajlsi-2696	19	15	conditions	condition	NOUN
ajlsi-2696	19	16	and	and	CCONJ
ajlsi-2696	19	17	symptoms	symptom	NOUN
ajlsi-2696	19	18	,	,	PUNCT
ajlsi-2696	19	19	including	include	VERB
ajlsi-2696	19	20	anxiety	anxiety	NOUN
ajlsi-2696	19	21	,	,	PUNCT
ajlsi-2696	19	22	depression	depression	NOUN
ajlsi-2696	19	23	,	,	PUNCT
ajlsi-2696	19	24	hyperactivity	hyperactivity	NOUN
ajlsi-2696	19	25	,	,	PUNCT
ajlsi-2696	19	26	sleep	sleep	NOUN
ajlsi-2696	19	27	problems	problem	NOUN
ajlsi-2696	19	28	,	,	PUNCT
ajlsi-2696	19	29	asthma	asthma	NOUN
ajlsi-2696	19	30	,	,	PUNCT
ajlsi-2696	19	31	hay	hay	NOUN
ajlsi-2696	19	32	fever	fever	NOUN
ajlsi-2696	19	33	,	,	PUNCT
ajlsi-2696	19	34	cardiovascular	cardiovascular	ADJ
ajlsi-2696	19	35	disease	disease	NOUN
ajlsi-2696	19	36	,	,	PUNCT
ajlsi-2696	19	37	stroke	stroke	NOUN
ajlsi-2696	19	38	,	,	PUNCT
ajlsi-2696	19	39	and	and	CCONJ
ajlsi-2696	19	40	obesity	obesity	NOUN
ajlsi-2696	19	41	(	(	PUNCT
ajlsi-2696	19	42	chovatiya	chovatiya	PROPN
ajlsi-2696	19	43	&	&	CCONJ
ajlsi-2696	19	44	silverberg	silverberg	PROPN
ajlsi-2696	19	45	,	,	PUNCT
ajlsi-2696	19	46	2019	2019	NUM
ajlsi-2696	19	47	;	;	PUNCT
ajlsi-2696	19	48	nicholas	nicholas	PROPN
ajlsi-2696	19	49	et	et	PROPN
ajlsi-2696	19	50	al	al	PROPN
ajlsi-2696	19	51	.	.	PROPN
ajlsi-2696	19	52	,	,	PUNCT
ajlsi-2696	19	53	2022	2022	NUM
ajlsi-2696	19	54	;	;	PUNCT
ajlsi-2696	19	55	xu	xu	PROPN
ajlsi-2696	19	56	et	et	PROPN
ajlsi-2696	19	57	al	al	PROPN
ajlsi-2696	19	58	.	.	PROPN
ajlsi-2696	19	59	,	,	PUNCT
ajlsi-2696	19	60	2019	2019	NUM
ajlsi-2696	19	61	)	)	PUNCT
ajlsi-2696	19	62	.	.	PUNCT
ajlsi-2696	20	1	it	it	PRON
ajlsi-2696	20	2	is	be	AUX
ajlsi-2696	20	3	caused	cause	VERB
ajlsi-2696	20	4	by	by	ADP
ajlsi-2696	20	5	changes	change	NOUN
ajlsi-2696	20	6	in	in	ADP
ajlsi-2696	20	7	the	the	DET
ajlsi-2696	20	8	skin	skin	NOUN
ajlsi-2696	20	9	microbiotaimmune	microbiotaimmune	NOUN
ajlsi-2696	20	10	system	system	NOUN
ajlsi-2696	20	11	hyperactivity	hyperactivity	NOUN
ajlsi-2696	20	12	,	,	PUNCT
ajlsi-2696	20	13	sensitivity	sensitivity	NOUN
ajlsi-2696	20	14	to	to	ADP
ajlsi-2696	20	15	immunoglobulin	immunoglobulin	NOUN
ajlsi-2696	20	16	e	e	NOUN
ajlsi-2696	20	17	,	,	PUNCT
ajlsi-2696	20	18	neuro	neuro	NOUN
ajlsi-2696	20	19	-	-	PUNCT
ajlsi-2696	20	20	inflammation	inflammation	NOUN
ajlsi-2696	20	21	(	(	PUNCT
ajlsi-2696	20	22	mandlik	mandlik	NOUN
ajlsi-2696	20	23	&	&	CCONJ
ajlsi-2696	20	24	mandlik	mandlik	NOUN
ajlsi-2696	20	25	,	,	PUNCT
ajlsi-2696	20	26	2021	2021	NUM
ajlsi-2696	20	27	)	)	PUNCT
ajlsi-2696	20	28	,	,	PUNCT
ajlsi-2696	20	29	environmental	environmental	ADJ
ajlsi-2696	20	30	variables	variable	NOUN
ajlsi-2696	20	31	,	,	PUNCT
ajlsi-2696	20	32	and	and	CCONJ
ajlsi-2696	20	33	hereditary	hereditary	ADJ
ajlsi-2696	20	34	predisposition	predisposition	NOUN
ajlsi-2696	20	35	.	.	PUNCT
ajlsi-2696	21	1	(	(	PUNCT
ajlsi-2696	21	2	grobe	grobe	PROPN
ajlsi-2696	21	3	et	et	PROPN
ajlsi-2696	21	4	al	al	PROPN
ajlsi-2696	21	5	.	.	PROPN
ajlsi-2696	21	6	,	,	PUNCT
ajlsi-2696	21	7	2019	2019	NUM
ajlsi-2696	21	8	;	;	PUNCT
ajlsi-2696	21	9	mehta	mehta	PROPN
ajlsi-2696	21	10	&	&	CCONJ
ajlsi-2696	21	11	fulmali	fulmali	PROPN
ajlsi-2696	21	12	,	,	PUNCT
ajlsi-2696	21	13	2022	2022	NUM
ajlsi-2696	21	14	)	)	PUNCT
ajlsi-2696	21	15	.	.	PUNCT
ajlsi-2696	22	1	the	the	DET
ajlsi-2696	22	2	intricate	intricate	ADJ
ajlsi-2696	22	3	interactions	interaction	NOUN
ajlsi-2696	22	4	between	between	ADP
ajlsi-2696	22	5	itch	itch	NOUN
ajlsi-2696	22	6	,	,	PUNCT
ajlsi-2696	22	7	inflammation	inflammation	NOUN
ajlsi-2696	22	8	,	,	PUNCT
ajlsi-2696	22	9	and	and	CCONJ
ajlsi-2696	22	10	barrier	barrier	NOUN
ajlsi-2696	22	11	failure	failure	NOUN
ajlsi-2696	22	12	play	play	VERB
ajlsi-2696	22	13	a	a	DET
ajlsi-2696	22	14	crucial	crucial	ADJ
ajlsi-2696	22	15	role	role	NOUN
ajlsi-2696	22	16	in	in	ADP
ajlsi-2696	22	17	this	this	DET
ajlsi-2696	22	18	condition	condition	NOUN
ajlsi-2696	22	19	’s	’s	PART
ajlsi-2696	22	20	onset	onset	NOUN
ajlsi-2696	22	21	,	,	PUNCT
ajlsi-2696	22	22	progression	progression	NOUN
ajlsi-2696	22	23	,	,	PUNCT
ajlsi-2696	22	24	and	and	CCONJ
ajlsi-2696	22	25	chronicity	chronicity	NOUN
ajlsi-2696	22	26	,	,	PUNCT
ajlsi-2696	22	27	even	even	ADV
ajlsi-2696	22	28	though	though	SCONJ
ajlsi-2696	22	29	the	the	DET
ajlsi-2696	22	30	pathophysiological	pathophysiological	ADJ
ajlsi-2696	22	31	mechanisms	mechanism	NOUN
ajlsi-2696	22	32	are	be	AUX
ajlsi-2696	22	33	yet	yet	ADV
ajlsi-2696	22	34	unknown	unknown	ADJ
ajlsi-2696	22	35	.	.	PUNCT
ajlsi-2696	23	1	skin	skin	NOUN
ajlsi-2696	23	2	inflammation	inflammation	NOUN
ajlsi-2696	23	3	that	that	PRON
ajlsi-2696	23	4	is	be	AUX
ajlsi-2696	23	5	aggravated	aggravate	VERB
ajlsi-2696	23	6	by	by	ADP
ajlsi-2696	23	7	filaggrin	filaggrin	NOUN
ajlsi-2696	23	8	abnormalities	abnormality	NOUN
ajlsi-2696	23	9	,	,	PUNCT
ajlsi-2696	23	10	intercellular	intercellular	ADJ
ajlsi-2696	23	11	lipids	lipid	NOUN
ajlsi-2696	23	12	,	,	PUNCT
ajlsi-2696	23	13	and	and	CCONJ
ajlsi-2696	23	14	tight	tight	ADJ
ajlsi-2696	23	15	junctions	junction	NOUN
ajlsi-2696	23	16	is	be	AUX
ajlsi-2696	23	17	the	the	DET
ajlsi-2696	23	18	hallmark	hallmark	NOUN
ajlsi-2696	23	19	of	of	ADP
ajlsi-2696	23	20	type	type	NOUN
ajlsi-2696	23	21	2	2	NUM
ajlsi-2696	23	22	immune	immune	ADJ
ajlsi-2696	23	23	deviation	deviation	NOUN
ajlsi-2696	23	24	.	.	PUNCT
ajlsi-2696	24	1	these	these	DET
ajlsi-2696	24	2	abnormalities	abnormality	NOUN
ajlsi-2696	24	3	lead	lead	VERB
ajlsi-2696	24	4	to	to	ADP
ajlsi-2696	24	5	barrier	barrier	NOUN
ajlsi-2696	24	6	disruption	disruption	NOUN
ajlsi-2696	24	7	in	in	ADP
ajlsi-2696	24	8	the	the	DET
ajlsi-2696	24	9	skin	skin	NOUN
ajlsi-2696	24	10	,	,	PUNCT
ajlsi-2696	24	11	producing	produce	VERB
ajlsi-2696	24	12	thymic	thymic	ADJ
ajlsi-2696	24	13	stromal	stromal	ADJ
ajlsi-2696	24	14	lymphopoietin	lymphopoietin	NOUN
ajlsi-2696	24	15	,	,	PUNCT
ajlsi-2696	24	16	interleukin	interleukin	NOUN
ajlsi-2696	24	17	(	(	PUNCT
ajlsi-2696	24	18	il)-25	il)-25	PROPN
ajlsi-2696	24	19	,	,	PUNCT
ajlsi-2696	24	20	and	and	CCONJ
ajlsi-2696	24	21	il-33	il-33	NUM
ajlsi-2696	24	22	.	.	PUNCT
ajlsi-2696	25	1	subsequently	subsequently	ADV
ajlsi-2696	25	2	,	,	PUNCT
ajlsi-2696	25	3	this	this	DET
ajlsi-2696	25	4	inflammation	inflammation	NOUN
ajlsi-2696	25	5	intensifies	intensify	VERB
ajlsi-2696	25	6	the	the	DET
ajlsi-2696	25	7	breakdown	breakdown	NOUN
ajlsi-2696	25	8	of	of	ADP
ajlsi-2696	25	9	the	the	DET
ajlsi-2696	25	10	epidermal	epidermal	ADJ
ajlsi-2696	25	11	barrier	barrier	NOUN
ajlsi-2696	25	12	by	by	ADP
ajlsi-2696	25	13	suppressing	suppress	VERB
ajlsi-2696	25	14	filaggrin	filaggrin	ADJ
ajlsi-2696	25	15	expression	expression	NOUN
ajlsi-2696	25	16	in	in	ADP
ajlsi-2696	25	17	keratinocytes	keratinocyte	NOUN
ajlsi-2696	25	18	.	.	PUNCT
ajlsi-2696	26	1	moreover	moreover	ADV
ajlsi-2696	26	2	,	,	PUNCT
ajlsi-2696	26	3	various	various	ADJ
ajlsi-2696	26	4	pruritogens	pruritogen	NOUN
ajlsi-2696	26	5	and	and	CCONJ
ajlsi-2696	26	6	itch	itch	NOUN
ajlsi-2696	26	7	mediators	mediator	NOUN
ajlsi-2696	26	8	generated	generate	VERB
ajlsi-2696	26	9	during	during	ADP
ajlsi-2696	26	10	this	this	DET
ajlsi-2696	26	11	inflammatory	inflammatory	ADJ
ajlsi-2696	26	12	process	process	NOUN
ajlsi-2696	26	13	can	can	AUX
ajlsi-2696	26	14	directly	directly	ADV
ajlsi-2696	26	15	affect	affect	VERB
ajlsi-2696	26	16	sensory	sensory	ADJ
ajlsi-2696	26	17	nerves	nerve	NOUN
ajlsi-2696	26	18	and	and	CCONJ
ajlsi-2696	26	19	induce	induce	VERB
ajlsi-2696	26	20	itching	itching	NOUN
ajlsi-2696	26	21	(	(	PUNCT
ajlsi-2696	26	22	kim	kim	PROPN
ajlsi-2696	26	23	et	et	PROPN
ajlsi-2696	26	24	al	al	PROPN
ajlsi-2696	26	25	.	.	PROPN
ajlsi-2696	26	26	,	,	PUNCT
ajlsi-2696	26	27	2019	2019	NUM
ajlsi-2696	26	28	;	;	PUNCT
ajlsi-2696	26	29	nakahara	nakahara	PROPN
ajlsi-2696	26	30	et	et	PROPN
ajlsi-2696	26	31	al	al	PROPN
ajlsi-2696	26	32	.	.	PROPN
ajlsi-2696	26	33	,	,	PUNCT
ajlsi-2696	26	34	2021	2021	NUM
ajlsi-2696	26	35	)	)	PUNCT
ajlsi-2696	26	36	.	.	PUNCT
ajlsi-2696	27	1	while	while	SCONJ
ajlsi-2696	27	2	in	in	ADP
ajlsi-2696	27	3	some	some	DET
ajlsi-2696	27	4	children	child	NOUN
ajlsi-2696	27	5	,	,	PUNCT
ajlsi-2696	27	6	food	food	NOUN
ajlsi-2696	27	7	allergies	allergy	NOUN
ajlsi-2696	27	8	are	be	AUX
ajlsi-2696	27	9	closely	closely	ADV
ajlsi-2696	27	10	associated	associate	VERB
ajlsi-2696	27	11	with	with	ADP
ajlsi-2696	27	12	ad	ad	NOUN
ajlsi-2696	27	13	,	,	PUNCT
ajlsi-2696	27	14	30	30	NUM
ajlsi-2696	27	15	%	%	NOUN
ajlsi-2696	27	16	of	of	ADP
ajlsi-2696	27	17	these	these	DET
ajlsi-2696	27	18	children	child	NOUN
ajlsi-2696	27	19	experience	experience	VERB
ajlsi-2696	27	20	symptoms	symptom	NOUN
ajlsi-2696	27	21	such	such	ADJ
ajlsi-2696	27	22	as	as	ADP
ajlsi-2696	27	23	rash	rash	NOUN
ajlsi-2696	27	24	,	,	PUNCT
ajlsi-2696	27	25	itching	itching	NOUN
ajlsi-2696	27	26	,	,	PUNCT
ajlsi-2696	27	27	leaking	leaking	NOUN
ajlsi-2696	27	28	,	,	PUNCT
ajlsi-2696	27	29	and	and	CCONJ
ajlsi-2696	27	30	dry	dry	ADJ
ajlsi-2696	27	31	,	,	PUNCT
ajlsi-2696	27	32	cracked	crack	VERB
ajlsi-2696	27	33	skin	skin	NOUN
ajlsi-2696	27	34	.	.	PUNCT
ajlsi-2696	28	1	smaller	small	ADJ
ajlsi-2696	28	2	kids	kid	NOUN
ajlsi-2696	28	3	show	show	VERB
ajlsi-2696	28	4	intolerance	intolerance	NOUN
ajlsi-2696	28	5	to	to	ADP
ajlsi-2696	28	6	some	some	DET
ajlsi-2696	28	7	foods	food	NOUN
ajlsi-2696	28	8	.	.	PUNCT
ajlsi-2696	29	1	red	red	ADJ
ajlsi-2696	29	2	,	,	PUNCT
ajlsi-2696	29	3	weepy	weepy	ADJ
ajlsi-2696	29	4	,	,	PUNCT
ajlsi-2696	29	5	crusty	crusty	ADJ
ajlsi-2696	29	6	,	,	PUNCT
ajlsi-2696	29	7	itchy	itchy	ADJ
ajlsi-2696	29	8	,	,	PUNCT
ajlsi-2696	29	9	and	and	CCONJ
ajlsi-2696	29	10	flaky	flaky	ADJ
ajlsi-2696	29	11	skin	skin	NOUN
ajlsi-2696	29	12	patches	patch	NOUN
ajlsi-2696	29	13	that	that	PRON
ajlsi-2696	29	14	typically	typically	ADV
ajlsi-2696	29	15	form	form	VERB
ajlsi-2696	29	16	in	in	ADP
ajlsi-2696	29	17	oval	oval	NOUN
ajlsi-2696	29	18	or	or	CCONJ
ajlsi-2696	29	19	circular	circular	ADJ
ajlsi-2696	29	20	forms	form	NOUN
ajlsi-2696	29	21	are	be	AUX
ajlsi-2696	29	22	its	its	PRON
ajlsi-2696	29	23	defining	define	VERB
ajlsi-2696	29	24	feature	feature	NOUN
ajlsi-2696	29	25	(	(	PUNCT
ajlsi-2696	29	26	rusiñol	rusiñol	NOUN
ajlsi-2696	29	27	&	&	CCONJ
ajlsi-2696	29	28	puig	puig	PROPN
ajlsi-2696	29	29	,	,	PUNCT
ajlsi-2696	29	30	2024	2024	NUM
ajlsi-2696	29	31	)	)	PUNCT
ajlsi-2696	29	32	.	.	PUNCT
ajlsi-2696	30	1	age	age	NOUN
ajlsi-2696	30	2	-	-	PUNCT
ajlsi-2696	30	3	related	relate	VERB
ajlsi-2696	30	4	symptom	symptom	NOUN
ajlsi-2696	30	5	variations	variation	NOUN
ajlsi-2696	30	6	include	include	VERB
ajlsi-2696	30	7	red	red	ADJ
ajlsi-2696	30	8	rash	rash	NOUN
ajlsi-2696	30	9	in	in	ADP
ajlsi-2696	30	10	infants	infant	NOUN
ajlsi-2696	30	11	,	,	PUNCT
ajlsi-2696	30	12	thickened	thicken	VERB
ajlsi-2696	30	13	rash	rash	NOUN
ajlsi-2696	30	14	in	in	ADP
ajlsi-2696	30	15	children	child	NOUN
ajlsi-2696	30	16	,	,	PUNCT
ajlsi-2696	30	17	and	and	CCONJ
ajlsi-2696	30	18	scaly	scaly	NOUN
ajlsi-2696	30	19	rash	rash	NOUN
ajlsi-2696	30	20	in	in	ADP
ajlsi-2696	30	21	teens	teen	NOUN
ajlsi-2696	30	22	and	and	CCONJ
ajlsi-2696	30	23	adults	adult	NOUN
ajlsi-2696	30	24	.	.	PUNCT
ajlsi-2696	31	1	common	common	ADJ
ajlsi-2696	31	2	1	1	NUM
ajlsi-2696	31	3	pediatric	pediatric	ADJ
ajlsi-2696	31	4	specialist	specialist	NOUN
ajlsi-2696	31	5	in	in	ADP
ajlsi-2696	31	6	uae	uae	PROPN
ajlsi-2696	31	7	2	2	NUM
ajlsi-2696	31	8	dermatology	dermatology	NOUN
ajlsi-2696	31	9	specialist	specialist	NOUN
ajlsi-2696	31	10	in	in	ADP
ajlsi-2696	31	11	uae	uae	PROPN
ajlsi-2696	31	12	*	*	PUNCT
ajlsi-2696	31	13	corresponding	correspond	VERB
ajlsi-2696	31	14	author	author	NOUN
ajlsi-2696	31	15	’s	’s	PART
ajlsi-2696	31	16	e	e	NOUN
ajlsi-2696	31	17	-	-	NOUN
ajlsi-2696	31	18	mail	mail	NOUN
ajlsi-2696	31	19	:	:	PUNCT
ajlsi-2696	31	20	dr_eh2412@yahoo.com	dr_eh2412@yahoo.com	X
ajlsi-2696	31	21	figure	figure	VERB
ajlsi-2696	31	22	1	1	NUM
ajlsi-2696	31	23	:	:	PUNCT
ajlsi-2696	31	24	conditions	condition	NOUN
ajlsi-2696	31	25	related	relate	VERB
ajlsi-2696	31	26	to	to	ADP
ajlsi-2696	31	27	atopic	atopic	NOUN
ajlsi-2696	31	28	dermatitis	dermatitis	PROPN
ajlsi-2696	31	29	pa	pa	PROPN
ajlsi-2696	31	30	ge	ge	PROPN
ajlsi-2696	31	31	62	62	NUM
ajlsi-2696	31	32	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	31	33	am	am	NOUN
ajlsi-2696	31	34	.	.	PUNCT
ajlsi-2696	32	1	j.	j.	PROPN
ajlsi-2696	32	2	life	life	PROPN
ajlsi-2696	32	3	sci	sci	PROPN
ajlsi-2696	32	4	.	.	PUNCT
ajlsi-2696	32	5	innov	innov	PROPN
ajlsi-2696	32	6	.	.	PUNCT
ajlsi-2696	33	1	3(1	3(1	NUM
ajlsi-2696	33	2	)	)	PUNCT
ajlsi-2696	33	3	61	61	NUM
ajlsi-2696	33	4	-	-	SYM
ajlsi-2696	33	5	68	68	NUM
ajlsi-2696	33	6	,	,	PUNCT
ajlsi-2696	33	7	2024	2024	NUM
ajlsi-2696	33	8	features	feature	NOUN
ajlsi-2696	33	9	include	include	VERB
ajlsi-2696	33	10	extra	extra	ADJ
ajlsi-2696	33	11	skin	skin	NOUN
ajlsi-2696	33	12	folds	fold	NOUN
ajlsi-2696	33	13	and	and	CCONJ
ajlsi-2696	33	14	darkening	darkening	NOUN
ajlsi-2696	33	15	(	(	PUNCT
ajlsi-2696	33	16	frazier	frazier	PROPN
ajlsi-2696	33	17	&	&	CCONJ
ajlsi-2696	33	18	bhardwaj	bhardwaj	PROPN
ajlsi-2696	33	19	,	,	PUNCT
ajlsi-2696	33	20	2020	2020	NUM
ajlsi-2696	33	21	;	;	PUNCT
ajlsi-2696	33	22	soares	soare	NOUN
ajlsi-2696	33	23	et	et	PROPN
ajlsi-2696	33	24	al	al	PROPN
ajlsi-2696	33	25	.	.	PROPN
ajlsi-2696	33	26	,	,	PUNCT
ajlsi-2696	33	27	2024	2024	NUM
ajlsi-2696	33	28	)	)	PUNCT
ajlsi-2696	33	29	.	.	PUNCT
ajlsi-2696	34	1	for	for	ADP
ajlsi-2696	34	2	patients	patient	NOUN
ajlsi-2696	34	3	with	with	ADP
ajlsi-2696	34	4	moderate	moderate	ADJ
ajlsi-2696	34	5	to	to	ADP
ajlsi-2696	34	6	severe	severe	ADJ
ajlsi-2696	34	7	types	type	NOUN
ajlsi-2696	34	8	of	of	ADP
ajlsi-2696	34	9	atopic	atopic	NOUN
ajlsi-2696	34	10	dermatitis	dermatitis	NOUN
ajlsi-2696	34	11	(	(	PUNCT
ajlsi-2696	34	12	ad	ad	NOUN
ajlsi-2696	34	13	)	)	PUNCT
ajlsi-2696	34	14	,	,	PUNCT
ajlsi-2696	34	15	biological	biological	ADJ
ajlsi-2696	34	16	therapies	therapy	NOUN
ajlsi-2696	34	17	are	be	AUX
ajlsi-2696	34	18	very	very	ADV
ajlsi-2696	34	19	important	important	ADJ
ajlsi-2696	34	20	.	.	PUNCT
ajlsi-2696	35	1	these	these	DET
ajlsi-2696	35	2	therapies	therapy	NOUN
ajlsi-2696	35	3	concentrate	concentrate	VERB
ajlsi-2696	35	4	on	on	ADP
ajlsi-2696	35	5	particular	particular	ADJ
ajlsi-2696	35	6	molecules	molecule	NOUN
ajlsi-2696	35	7	involved	involve	VERB
ajlsi-2696	35	8	in	in	ADP
ajlsi-2696	35	9	the	the	DET
ajlsi-2696	35	10	inflammatory	inflammatory	ADJ
ajlsi-2696	35	11	and	and	CCONJ
ajlsi-2696	35	12	immunological	immunological	ADJ
ajlsi-2696	35	13	responses	response	NOUN
ajlsi-2696	35	14	typical	typical	ADJ
ajlsi-2696	35	15	of	of	ADP
ajlsi-2696	35	16	ad	ad	NOUN
ajlsi-2696	35	17	.	.	PUNCT
ajlsi-2696	36	1	compared	compare	VERB
ajlsi-2696	36	2	to	to	ADP
ajlsi-2696	36	3	more	more	ADJ
ajlsi-2696	36	4	conventional	conventional	ADJ
ajlsi-2696	36	5	treatments	treatment	NOUN
ajlsi-2696	36	6	like	like	ADP
ajlsi-2696	36	7	corticosteroids	corticosteroid	NOUN
ajlsi-2696	36	8	or	or	CCONJ
ajlsi-2696	36	9	immunosuppressive	immunosuppressive	ADJ
ajlsi-2696	36	10	medications	medication	NOUN
ajlsi-2696	36	11	,	,	PUNCT
ajlsi-2696	36	12	biological	biological	ADJ
ajlsi-2696	36	13	therapies	therapy	NOUN
ajlsi-2696	36	14	like	like	ADP
ajlsi-2696	36	15	monoclonal	monoclonal	NOUN
ajlsi-2696	36	16	antibodies	antibody	NOUN
ajlsi-2696	36	17	like	like	ADP
ajlsi-2696	36	18	dupilumab	dupilumab	NOUN
ajlsi-2696	36	19	and	and	CCONJ
ajlsi-2696	36	20	tralokinumab	tralokinumab	NOUN
ajlsi-2696	36	21	provide	provide	VERB
ajlsi-2696	36	22	a	a	DET
ajlsi-2696	36	23	more	more	ADV
ajlsi-2696	36	24	tailored	tailor	VERB
ajlsi-2696	36	25	approach	approach	NOUN
ajlsi-2696	36	26	by	by	ADP
ajlsi-2696	36	27	concentrating	concentrate	VERB
ajlsi-2696	36	28	on	on	ADP
ajlsi-2696	36	29	particular	particular	ADJ
ajlsi-2696	36	30	molecular	molecular	ADJ
ajlsi-2696	36	31	targets	target	NOUN
ajlsi-2696	36	32	(	(	PUNCT
ajlsi-2696	36	33	deleanu	deleanu	NOUN
ajlsi-2696	36	34	&	&	CCONJ
ajlsi-2696	36	35	nedelea	nedelea	NOUN
ajlsi-2696	36	36	,	,	PUNCT
ajlsi-2696	36	37	2019	2019	NUM
ajlsi-2696	36	38	)	)	PUNCT
ajlsi-2696	36	39	.	.	PUNCT
ajlsi-2696	37	1	new	new	ADJ
ajlsi-2696	37	2	insights	insight	NOUN
ajlsi-2696	37	3	into	into	ADP
ajlsi-2696	37	4	the	the	DET
ajlsi-2696	37	5	immunopathology	immunopathology	NOUN
ajlsi-2696	37	6	of	of	ADP
ajlsi-2696	37	7	ad	ad	NOUN
ajlsi-2696	37	8	have	have	AUX
ajlsi-2696	37	9	made	make	VERB
ajlsi-2696	37	10	it	it	PRON
ajlsi-2696	37	11	possible	possible	ADJ
ajlsi-2696	37	12	to	to	PART
ajlsi-2696	37	13	identify	identify	VERB
ajlsi-2696	37	14	therapeutic	therapeutic	ADJ
ajlsi-2696	37	15	molecular	molecular	ADJ
ajlsi-2696	37	16	targets	target	NOUN
ajlsi-2696	37	17	for	for	ADP
ajlsi-2696	37	18	innovative	innovative	ADJ
ajlsi-2696	37	19	biological	biological	ADJ
ajlsi-2696	37	20	therapies	therapy	NOUN
ajlsi-2696	37	21	.	.	PUNCT
ajlsi-2696	38	1	by	by	ADP
ajlsi-2696	38	2	modifying	modify	VERB
ajlsi-2696	38	3	the	the	DET
ajlsi-2696	38	4	immune	immune	ADJ
ajlsi-2696	38	5	response	response	NOUN
ajlsi-2696	38	6	and	and	CCONJ
ajlsi-2696	38	7	inflammatory	inflammatory	ADJ
ajlsi-2696	38	8	pathways	pathway	NOUN
ajlsi-2696	38	9	,	,	PUNCT
ajlsi-2696	38	10	these	these	DET
ajlsi-2696	38	11	treatments	treatment	NOUN
ajlsi-2696	38	12	;	;	PUNCT
ajlsi-2696	38	13	including	include	VERB
ajlsi-2696	38	14	“	"	PUNCT
ajlsi-2696	38	15	il-4	il-4	NOUN
ajlsi-2696	38	16	/	/	SYM
ajlsi-2696	38	17	il-13	il-13	PRON
ajlsi-2696	38	18	”	"	PUNCT
ajlsi-2696	38	19	inhibitors	inhibitor	NOUN
ajlsi-2696	38	20	,	,	PUNCT
ajlsi-2696	38	21	jak	jak	PROPN
ajlsi-2696	38	22	inhibitors	inhibitor	NOUN
ajlsi-2696	38	23	,	,	PUNCT
ajlsi-2696	38	24	and	and	CCONJ
ajlsi-2696	38	25	“	"	PUNCT
ajlsi-2696	38	26	il-13	il-13	ADP
ajlsi-2696	38	27	inhibitors	inhibitor	NOUN
ajlsi-2696	38	28	”	"	PUNCT
ajlsi-2696	38	29	have	have	AUX
ajlsi-2696	38	30	demonstrated	demonstrate	VERB
ajlsi-2696	38	31	notable	notable	ADJ
ajlsi-2696	38	32	success	success	NOUN
ajlsi-2696	38	33	in	in	ADP
ajlsi-2696	38	34	treating	treat	VERB
ajlsi-2696	38	35	ad	ad	NOUN
ajlsi-2696	38	36	.	.	PUNCT
ajlsi-2696	39	1	furthermore	furthermore	ADV
ajlsi-2696	39	2	,	,	PUNCT
ajlsi-2696	39	3	the	the	DET
ajlsi-2696	39	4	fda	fda	PROPN
ajlsi-2696	39	5	has	have	AUX
ajlsi-2696	39	6	approved	approve	VERB
ajlsi-2696	39	7	biologics	biologic	NOUN
ajlsi-2696	39	8	like	like	ADP
ajlsi-2696	39	9	dupilumab	dupilumab	NOUN
ajlsi-2696	39	10	for	for	ADP
ajlsi-2696	39	11	treating	treat	VERB
ajlsi-2696	39	12	moderate	moderate	ADJ
ajlsi-2696	39	13	-	-	PUNCT
ajlsi-2696	39	14	to	to	ADP
ajlsi-2696	39	15	-	-	PUNCT
ajlsi-2696	39	16	severe	severe	ADJ
ajlsi-2696	39	17	ad	ad	NOUN
ajlsi-2696	39	18	,	,	PUNCT
ajlsi-2696	39	19	demonstrating	demonstrate	VERB
ajlsi-2696	39	20	their	their	PRON
ajlsi-2696	39	21	efficacy	efficacy	NOUN
ajlsi-2696	39	22	in	in	ADP
ajlsi-2696	39	23	enhancing	enhance	VERB
ajlsi-2696	39	24	patients	patient	NOUN
ajlsi-2696	39	25	’	'	PUNCT
ajlsi-2696	39	26	quality	quality	NOUN
ajlsi-2696	39	27	of	of	ADP
ajlsi-2696	39	28	life	life	NOUN
ajlsi-2696	39	29	and	and	CCONJ
ajlsi-2696	39	30	symptom	symptom	NOUN
ajlsi-2696	39	31	relief	relief	NOUN
ajlsi-2696	39	32	(	(	PUNCT
ajlsi-2696	39	33	zhou	zhou	X
ajlsi-2696	39	34	et	et	PROPN
ajlsi-2696	39	35	al	al	PROPN
ajlsi-2696	39	36	.	.	PROPN
ajlsi-2696	39	37	,	,	PUNCT
ajlsi-2696	39	38	2021	2021	NUM
ajlsi-2696	39	39	)	)	PUNCT
ajlsi-2696	39	40	.	.	PUNCT
ajlsi-2696	40	1	it	it	PRON
ajlsi-2696	40	2	provides	provide	VERB
ajlsi-2696	40	3	a	a	DET
ajlsi-2696	40	4	more	more	ADV
ajlsi-2696	40	5	focused	focused	ADJ
ajlsi-2696	40	6	and	and	CCONJ
ajlsi-2696	40	7	targeted	target	VERB
ajlsi-2696	40	8	approach	approach	NOUN
ajlsi-2696	40	9	.	.	PUNCT
ajlsi-2696	41	1	research	research	NOUN
ajlsi-2696	41	2	has	have	AUX
ajlsi-2696	41	3	indicated	indicate	VERB
ajlsi-2696	41	4	that	that	SCONJ
ajlsi-2696	41	5	biological	biological	ADJ
ajlsi-2696	41	6	treatments	treatment	NOUN
ajlsi-2696	41	7	are	be	AUX
ajlsi-2696	41	8	a	a	DET
ajlsi-2696	41	9	useful	useful	ADJ
ajlsi-2696	41	10	means	mean	NOUN
ajlsi-2696	41	11	of	of	ADP
ajlsi-2696	41	12	alleviating	alleviate	VERB
ajlsi-2696	41	13	symptoms	symptom	NOUN
ajlsi-2696	41	14	.	.	PUNCT
ajlsi-2696	42	1	furthermore	furthermore	ADV
ajlsi-2696	42	2	,	,	PUNCT
ajlsi-2696	42	3	biologics	biologic	NOUN
ajlsi-2696	42	4	have	have	AUX
ajlsi-2696	42	5	demonstrated	demonstrate	VERB
ajlsi-2696	42	6	a	a	DET
ajlsi-2696	42	7	quick	quick	ADJ
ajlsi-2696	42	8	start	start	NOUN
ajlsi-2696	42	9	of	of	ADP
ajlsi-2696	42	10	action	action	NOUN
ajlsi-2696	42	11	,	,	PUNCT
ajlsi-2696	42	12	offering	offer	VERB
ajlsi-2696	42	13	immediate	immediate	ADJ
ajlsi-2696	42	14	relief	relief	NOUN
ajlsi-2696	42	15	to	to	ADP
ajlsi-2696	42	16	patients	patient	NOUN
ajlsi-2696	42	17	who	who	PRON
ajlsi-2696	42	18	have	have	AUX
ajlsi-2696	42	19	not	not	PART
ajlsi-2696	42	20	responded	respond	VERB
ajlsi-2696	42	21	well	well	ADV
ajlsi-2696	42	22	to	to	ADP
ajlsi-2696	42	23	traditional	traditional	ADJ
ajlsi-2696	42	24	therapy	therapy	NOUN
ajlsi-2696	42	25	.	.	PUNCT
ajlsi-2696	43	1	clinical	clinical	ADJ
ajlsi-2696	43	2	trials	trial	NOUN
ajlsi-2696	43	3	and	and	CCONJ
ajlsi-2696	43	4	real	real	ADJ
ajlsi-2696	43	5	-	-	PUNCT
ajlsi-2696	43	6	world	world	NOUN
ajlsi-2696	43	7	applications	application	NOUN
ajlsi-2696	43	8	have	have	AUX
ajlsi-2696	43	9	provided	provide	VERB
ajlsi-2696	43	10	strong	strong	ADJ
ajlsi-2696	43	11	evidence	evidence	NOUN
ajlsi-2696	43	12	for	for	ADP
ajlsi-2696	43	13	the	the	DET
ajlsi-2696	43	14	safety	safety	NOUN
ajlsi-2696	43	15	and	and	CCONJ
ajlsi-2696	43	16	effectiveness	effectiveness	NOUN
ajlsi-2696	43	17	of	of	ADP
ajlsi-2696	43	18	biological	biological	ADJ
ajlsi-2696	43	19	therapy	therapy	NOUN
ajlsi-2696	43	20	(	(	PUNCT
ajlsi-2696	43	21	caffarelli	caffarelli	PROPN
ajlsi-2696	43	22	et	et	PROPN
ajlsi-2696	43	23	al	al	PROPN
ajlsi-2696	43	24	.	.	PROPN
ajlsi-2696	43	25	,	,	PUNCT
ajlsi-2696	43	26	2023	2023	NUM
ajlsi-2696	43	27	;	;	PUNCT
ajlsi-2696	43	28	montes	monte	NOUN
ajlsi-2696	43	29	-	-	NOUN
ajlsi-2696	43	30	torres	torre	VERB
ajlsi-2696	43	31	et	et	PROPN
ajlsi-2696	43	32	al	al	PROPN
ajlsi-2696	43	33	.	.	PROPN
ajlsi-2696	43	34	,	,	PUNCT
ajlsi-2696	43	35	2015	2015	NUM
ajlsi-2696	43	36	)	)	PUNCT
ajlsi-2696	43	37	.	.	PUNCT
ajlsi-2696	44	1	the	the	DET
ajlsi-2696	44	2	present	present	ADJ
ajlsi-2696	44	3	research	research	NOUN
ajlsi-2696	44	4	paper	paper	NOUN
ajlsi-2696	44	5	aimed	aim	VERB
ajlsi-2696	44	6	to	to	PART
ajlsi-2696	44	7	evaluate	evaluate	VERB
ajlsi-2696	44	8	and	and	CCONJ
ajlsi-2696	44	9	compare	compare	VERB
ajlsi-2696	44	10	the	the	DET
ajlsi-2696	44	11	efficacy	efficacy	NOUN
ajlsi-2696	44	12	,	,	PUNCT
ajlsi-2696	44	13	optimal	optimal	ADJ
ajlsi-2696	44	14	dosage	dosage	NOUN
ajlsi-2696	44	15	,	,	PUNCT
ajlsi-2696	44	16	and	and	CCONJ
ajlsi-2696	44	17	frequency	frequency	NOUN
ajlsi-2696	44	18	of	of	ADP
ajlsi-2696	44	19	administration	administration	NOUN
ajlsi-2696	44	20	of	of	ADP
ajlsi-2696	44	21	biological	biological	ADJ
ajlsi-2696	44	22	treatment	treatment	NOUN
ajlsi-2696	44	23	such	such	ADJ
ajlsi-2696	44	24	as	as	ADP
ajlsi-2696	44	25	monoclonal	monoclonal	NOUN
ajlsi-2696	44	26	antibody	antibody	NOUN
ajlsi-2696	44	27	dupilumab	dupilumab	NOUN
ajlsi-2696	44	28	with	with	ADP
ajlsi-2696	44	29	standard	standard	ADJ
ajlsi-2696	44	30	treatment	treatment	NOUN
ajlsi-2696	44	31	options	option	NOUN
ajlsi-2696	44	32	,	,	PUNCT
ajlsi-2696	44	33	including	include	VERB
ajlsi-2696	44	34	antibiotics	antibiotic	NOUN
ajlsi-2696	44	35	,	,	PUNCT
ajlsi-2696	44	36	corticosteroids	corticosteroid	NOUN
ajlsi-2696	44	37	,	,	PUNCT
ajlsi-2696	44	38	immunosuppressants	immunosuppressant	NOUN
ajlsi-2696	44	39	such	such	ADJ
ajlsi-2696	44	40	as	as	ADP
ajlsi-2696	44	41	cyclosporine	cyclosporine	NOUN
ajlsi-2696	44	42	,	,	PUNCT
ajlsi-2696	44	43	mycophenolate	mycophenolate	PROPN
ajlsi-2696	44	44	,	,	PUNCT
ajlsi-2696	44	45	tacrolimus	tacrolimus	NOUN
ajlsi-2696	44	46	,	,	PUNCT
ajlsi-2696	44	47	and	and	CCONJ
ajlsi-2696	44	48	azathioprine	azathioprine	ADJ
ajlsi-2696	44	49	,	,	PUNCT
ajlsi-2696	44	50	histamines	histamine	NOUN
ajlsi-2696	44	51	,	,	PUNCT
ajlsi-2696	44	52	and	and	CCONJ
ajlsi-2696	44	53	demards	demards	ADV
ajlsi-2696	44	54	like	like	INTJ
ajlsi-2696	44	55	methotrexate	methotrexate	VERB
ajlsi-2696	44	56	in	in	ADP
ajlsi-2696	44	57	the	the	DET
ajlsi-2696	44	58	management	management	NOUN
ajlsi-2696	44	59	of	of	ADP
ajlsi-2696	44	60	atopic	atopic	NOUN
ajlsi-2696	44	61	dermatitis	dermatitis	NOUN
ajlsi-2696	44	62	in	in	ADP
ajlsi-2696	44	63	pediatric	pediatric	ADJ
ajlsi-2696	44	64	patients	patient	NOUN
ajlsi-2696	44	65	.	.	PUNCT
ajlsi-2696	45	1	methods	method	NOUN
ajlsi-2696	45	2	and	and	CCONJ
ajlsi-2696	45	3	clinical	clinical	ADJ
ajlsi-2696	45	4	trials	trial	NOUN
ajlsi-2696	45	5	the	the	DET
ajlsi-2696	45	6	research	research	NOUN
ajlsi-2696	45	7	study	study	NOUN
ajlsi-2696	45	8	on	on	ADP
ajlsi-2696	45	9	“	"	PUNCT
ajlsi-2696	45	10	revolutionizing	revolutionize	VERB
ajlsi-2696	45	11	pediatric	pediatric	ADJ
ajlsi-2696	45	12	dermatology	dermatology	NOUN
ajlsi-2696	45	13	:	:	PUNCT
ajlsi-2696	45	14	dupilumab	dupilumab	NOUN
ajlsi-2696	45	15	’s	’s	PART
ajlsi-2696	45	16	impact	impact	NOUN
ajlsi-2696	45	17	on	on	ADP
ajlsi-2696	45	18	atopic	atopic	NOUN
ajlsi-2696	45	19	dermatitis	dermatitis	NOUN
ajlsi-2696	45	20	in	in	ADP
ajlsi-2696	45	21	kids	kid	NOUN
ajlsi-2696	45	22	”	"	PUNCT
ajlsi-2696	45	23	was	be	AUX
ajlsi-2696	45	24	conducted	conduct	VERB
ajlsi-2696	45	25	by	by	ADP
ajlsi-2696	45	26	employing	employ	VERB
ajlsi-2696	45	27	the	the	DET
ajlsi-2696	45	28	approved	approve	VERB
ajlsi-2696	45	29	clinical	clinical	ADJ
ajlsi-2696	45	30	trials	trial	NOUN
ajlsi-2696	45	31	studies	study	NOUN
ajlsi-2696	45	32	of	of	ADP
ajlsi-2696	45	33	“	"	PUNCT
ajlsi-2696	45	34	united	united	PROPN
ajlsi-2696	45	35	states	states	PROPN
ajlsi-2696	45	36	-	-	PUNCT
ajlsi-2696	45	37	food	food	NOUN
ajlsi-2696	45	38	&	&	CCONJ
ajlsi-2696	45	39	drug	drug	PROPN
ajlsi-2696	45	40	administration	administration	PROPN
ajlsi-2696	45	41	(	(	PUNCT
ajlsi-2696	45	42	fda	fda	PROPN
ajlsi-2696	45	43	)	)	PUNCT
ajlsi-2696	45	44	”	"	PUNCT
ajlsi-2696	45	45	among	among	ADP
ajlsi-2696	45	46	individuals	individual	NOUN
ajlsi-2696	45	47	of	of	ADP
ajlsi-2696	45	48	different	different	ADJ
ajlsi-2696	45	49	ages	age	NOUN
ajlsi-2696	45	50	,	,	PUNCT
ajlsi-2696	45	51	ethnicity	ethnicity	NOUN
ajlsi-2696	45	52	,	,	PUNCT
ajlsi-2696	45	53	genders	gender	NOUN
ajlsi-2696	45	54	and	and	CCONJ
ajlsi-2696	45	55	health	health	NOUN
ajlsi-2696	45	56	status	status	NOUN
ajlsi-2696	45	57	.	.	PUNCT
ajlsi-2696	46	1	biological	biological	ADJ
ajlsi-2696	46	2	treatment	treatment	NOUN
ajlsi-2696	46	3	options	option	NOUN
ajlsi-2696	46	4	efficiency	efficiency	NOUN
ajlsi-2696	46	5	of	of	ADP
ajlsi-2696	46	6	biological	biological	ADJ
ajlsi-2696	46	7	treatment	treatment	NOUN
ajlsi-2696	46	8	systemic	systemic	ADJ
ajlsi-2696	46	9	non	non	ADJ
ajlsi-2696	46	10	-	-	ADJ
ajlsi-2696	46	11	biological	biological	ADJ
ajlsi-2696	46	12	therapies	therapy	NOUN
ajlsi-2696	46	13	,	,	PUNCT
ajlsi-2696	46	14	such	such	ADJ
ajlsi-2696	46	15	as	as	ADP
ajlsi-2696	46	16	oral	oral	ADJ
ajlsi-2696	46	17	corticosteroids	corticosteroid	NOUN
ajlsi-2696	46	18	,	,	PUNCT
ajlsi-2696	46	19	cyclosporine	cyclosporine	NOUN
ajlsi-2696	46	20	,	,	PUNCT
ajlsi-2696	46	21	methotrexate	methotrexate	NOUN
ajlsi-2696	46	22	,	,	PUNCT
ajlsi-2696	46	23	azathioprine	azathioprine	NOUN
ajlsi-2696	46	24	,	,	PUNCT
ajlsi-2696	46	25	and	and	CCONJ
ajlsi-2696	46	26	mycophenolic	mycophenolic	ADJ
ajlsi-2696	46	27	acid	acid	NOUN
ajlsi-2696	46	28	,	,	PUNCT
ajlsi-2696	46	29	effectively	effectively	ADV
ajlsi-2696	46	30	manage	manage	VERB
ajlsi-2696	46	31	moderate	moderate	ADJ
ajlsi-2696	46	32	to	to	ADP
ajlsi-2696	46	33	severe	severe	ADJ
ajlsi-2696	46	34	atopic	atopic	NOUN
ajlsi-2696	46	35	dermatitis	dermatitis	NOUN
ajlsi-2696	46	36	(	(	PUNCT
ajlsi-2696	46	37	paolino	paolino	PROPN
ajlsi-2696	46	38	et	et	PROPN
ajlsi-2696	46	39	al	al	PROPN
ajlsi-2696	46	40	.	.	PROPN
ajlsi-2696	46	41	,	,	PUNCT
ajlsi-2696	46	42	2023	2023	NUM
ajlsi-2696	46	43	)	)	PUNCT
ajlsi-2696	46	44	.	.	PUNCT
ajlsi-2696	47	1	nonbiological	nonbiological	ADJ
ajlsi-2696	47	2	systemic	systemic	ADJ
ajlsi-2696	47	3	therapy	therapy	NOUN
ajlsi-2696	47	4	for	for	ADP
ajlsi-2696	47	5	atopic	atopic	NOUN
ajlsi-2696	47	6	dermatitis	dermatitis	NOUN
ajlsi-2696	47	7	may	may	AUX
ajlsi-2696	47	8	not	not	PART
ajlsi-2696	47	9	be	be	AUX
ajlsi-2696	47	10	as	as	ADV
ajlsi-2696	47	11	effective	effective	ADJ
ajlsi-2696	47	12	at	at	ADP
ajlsi-2696	47	13	controlling	control	VERB
ajlsi-2696	47	14	symptoms	symptom	NOUN
ajlsi-2696	47	15	and	and	CCONJ
ajlsi-2696	47	16	preventing	prevent	VERB
ajlsi-2696	47	17	exacerbations	exacerbation	NOUN
ajlsi-2696	47	18	as	as	SCONJ
ajlsi-2696	47	19	biological	biological	ADJ
ajlsi-2696	47	20	treatments	treatment	NOUN
ajlsi-2696	47	21	are	be	AUX
ajlsi-2696	47	22	(	(	PUNCT
ajlsi-2696	47	23	ferrucci	ferrucci	NOUN
ajlsi-2696	47	24	et	et	PROPN
ajlsi-2696	47	25	al	al	PROPN
ajlsi-2696	47	26	.	.	PROPN
ajlsi-2696	47	27	,	,	PUNCT
ajlsi-2696	47	28	2023	2023	NUM
ajlsi-2696	47	29	)	)	PUNCT
ajlsi-2696	47	30	.	.	PUNCT
ajlsi-2696	48	1	meanwhile	meanwhile	ADV
ajlsi-2696	48	2	,	,	PUNCT
ajlsi-2696	48	3	biological	biological	ADJ
ajlsi-2696	48	4	therapies	therapy	NOUN
ajlsi-2696	48	5	,	,	PUNCT
ajlsi-2696	48	6	including	include	VERB
ajlsi-2696	48	7	dupilumab	dupilumab	NOUN
ajlsi-2696	48	8	,	,	PUNCT
ajlsi-2696	48	9	omalizumab	omalizumab	NOUN
ajlsi-2696	48	10	,	,	PUNCT
ajlsi-2696	48	11	and	and	CCONJ
ajlsi-2696	48	12	ustekinumab	ustekinumab	NOUN
ajlsi-2696	48	13	,	,	PUNCT
ajlsi-2696	48	14	offer	offer	VERB
ajlsi-2696	48	15	a	a	DET
ajlsi-2696	48	16	more	more	ADV
ajlsi-2696	48	17	targeted	target	VERB
ajlsi-2696	48	18	approach	approach	NOUN
ajlsi-2696	48	19	focusing	focus	VERB
ajlsi-2696	48	20	on	on	ADP
ajlsi-2696	48	21	molecules	molecule	NOUN
ajlsi-2696	48	22	linked	link	VERB
ajlsi-2696	48	23	to	to	ADP
ajlsi-2696	48	24	the	the	DET
ajlsi-2696	48	25	immune	immune	ADJ
ajlsi-2696	48	26	response	response	NOUN
ajlsi-2696	48	27	and	and	CCONJ
ajlsi-2696	48	28	inflammatory	inflammatory	ADJ
ajlsi-2696	48	29	processes	process	NOUN
ajlsi-2696	48	30	in	in	ADP
ajlsi-2696	48	31	ad	ad	NOUN
ajlsi-2696	48	32	.	.	PUNCT
ajlsi-2696	49	1	these	these	DET
ajlsi-2696	49	2	biologics	biologic	NOUN
ajlsi-2696	49	3	have	have	AUX
ajlsi-2696	49	4	shown	show	VERB
ajlsi-2696	49	5	a	a	DET
ajlsi-2696	49	6	significant	significant	ADJ
ajlsi-2696	49	7	improvement	improvement	NOUN
ajlsi-2696	49	8	in	in	ADP
ajlsi-2696	49	9	symptoms	symptom	NOUN
ajlsi-2696	49	10	and	and	CCONJ
ajlsi-2696	49	11	quality	quality	NOUN
ajlsi-2696	49	12	of	of	ADP
ajlsi-2696	49	13	life	life	NOUN
ajlsi-2696	49	14	for	for	ADP
ajlsi-2696	49	15	those	those	PRON
ajlsi-2696	49	16	with	with	ADP
ajlsi-2696	49	17	moderate	moderate	ADJ
ajlsi-2696	49	18	to	to	ADP
ajlsi-2696	49	19	severe	severe	ADJ
ajlsi-2696	49	20	ad	ad	NOUN
ajlsi-2696	49	21	(	(	PUNCT
ajlsi-2696	49	22	chu	chu	PROPN
ajlsi-2696	49	23	et	et	PROPN
ajlsi-2696	49	24	al	al	PROPN
ajlsi-2696	49	25	.	.	PROPN
ajlsi-2696	49	26	,	,	PUNCT
ajlsi-2696	49	27	2023	2023	NUM
ajlsi-2696	49	28	)	)	PUNCT
ajlsi-2696	49	29	and	and	CCONJ
ajlsi-2696	49	30	disease	disease	NOUN
ajlsi-2696	49	31	control	control	NOUN
ajlsi-2696	49	32	by	by	ADP
ajlsi-2696	49	33	targeting	target	VERB
ajlsi-2696	49	34	key	key	ADJ
ajlsi-2696	49	35	pathways	pathway	NOUN
ajlsi-2696	49	36	involved	involve	VERB
ajlsi-2696	49	37	in	in	ADP
ajlsi-2696	49	38	ad	ad	NOUN
ajlsi-2696	49	39	pathogenesis	pathogenesis	NOUN
ajlsi-2696	49	40	,	,	PUNCT
ajlsi-2696	49	41	such	such	ADJ
ajlsi-2696	49	42	as	as	ADP
ajlsi-2696	49	43	th2	th2	PROPN
ajlsi-2696	49	44	,	,	PUNCT
ajlsi-2696	49	45	th22	th22	PROPN
ajlsi-2696	49	46	,	,	PUNCT
ajlsi-2696	49	47	th17	th17	PROPN
ajlsi-2696	49	48	/	/	SYM
ajlsi-2696	49	49	il-23	il-23	NOUN
ajlsi-2696	49	50	,	,	PUNCT
ajlsi-2696	49	51	and	and	CCONJ
ajlsi-2696	49	52	ige	ige	PROPN
ajlsi-2696	49	53	.	.	PROPN
ajlsi-2696	49	54	monoclonal	monoclonal	NOUN
ajlsi-2696	49	55	antibody	antibody	NOUN
ajlsi-2696	49	56	dupilumab	dupilumab	NOUN
ajlsi-2696	49	57	dupilumab	dupilumab	NOUN
ajlsi-2696	49	58	obstructs	obstruct	VERB
ajlsi-2696	49	59	the	the	DET
ajlsi-2696	49	60	signalling	signal	VERB
ajlsi-2696	49	61	pathways	pathway	NOUN
ajlsi-2696	49	62	for	for	ADP
ajlsi-2696	49	63	interleukin	interleukin	NOUN
ajlsi-2696	49	64	13	13	NUM
ajlsi-2696	49	65	(	(	PUNCT
ajlsi-2696	49	66	il-13	il-13	NUM
ajlsi-2696	49	67	)	)	PUNCT
ajlsi-2696	49	68	and	and	CCONJ
ajlsi-2696	49	69	4	4	NUM
ajlsi-2696	49	70	(	(	PUNCT
ajlsi-2696	49	71	il-4	il-4	NOUN
ajlsi-2696	49	72	)	)	PUNCT
ajlsi-2696	49	73	.	.	PUNCT
ajlsi-2696	50	1	attaching	attach	VERB
ajlsi-2696	50	2	to	to	ADP
ajlsi-2696	50	3	the	the	DET
ajlsi-2696	50	4	alpha	alpha	ADJ
ajlsi-2696	50	5	subunit	subunit	NOUN
ajlsi-2696	50	6	of	of	ADP
ajlsi-2696	50	7	the	the	DET
ajlsi-2696	50	8	interleukin-4	interleukin-4	NOUN
ajlsi-2696	50	9	receptor	receptor	NOUN
ajlsi-2696	50	10	(	(	PUNCT
ajlsi-2696	50	11	il-4rα	il-4rα	NOUN
ajlsi-2696	50	12	)	)	PUNCT
ajlsi-2696	50	13	,	,	PUNCT
ajlsi-2696	50	14	this	this	DET
ajlsi-2696	50	15	method	method	NOUN
ajlsi-2696	50	16	of	of	ADP
ajlsi-2696	50	17	action	action	NOUN
ajlsi-2696	50	18	functions	function	NOUN
ajlsi-2696	50	19	as	as	ADP
ajlsi-2696	50	20	a	a	DET
ajlsi-2696	50	21	receptor	receptor	NOUN
ajlsi-2696	50	22	antagonist	antagonist	NOUN
ajlsi-2696	50	23	.	.	PUNCT
ajlsi-2696	51	1	dupilumab	dupilumab	NOUN
ajlsi-2696	51	2	specifically	specifically	ADV
ajlsi-2696	51	3	targets	target	VERB
ajlsi-2696	51	4	two	two	NUM
ajlsi-2696	51	5	important	important	ADJ
ajlsi-2696	51	6	cytokines	cytokine	NOUN
ajlsi-2696	51	7	involved	involve	VERB
ajlsi-2696	51	8	in	in	ADP
ajlsi-2696	51	9	asthma	asthma	NOUN
ajlsi-2696	51	10	and	and	CCONJ
ajlsi-2696	51	11	atopic	atopic	NOUN
ajlsi-2696	51	12	dermatitis	dermatitis	NOUN
ajlsi-2696	51	13	inflammation	inflammation	NOUN
ajlsi-2696	51	14	:	:	PUNCT
ajlsi-2696	51	15	“	"	PUNCT
ajlsi-2696	51	16	il-4	il-4	X
ajlsi-2696	51	17	and	and	CCONJ
ajlsi-2696	51	18	il-13	il-13	PRON
ajlsi-2696	51	19	”	"	PUNCT
ajlsi-2696	51	20	intracellular	intracellular	ADJ
ajlsi-2696	51	21	signalling	signalling	NOUN
ajlsi-2696	51	22	.	.	PUNCT
ajlsi-2696	52	1	the	the	DET
ajlsi-2696	52	2	simultaneous	simultaneous	ADJ
ajlsi-2696	52	3	inhibition	inhibition	NOUN
ajlsi-2696	52	4	of	of	ADP
ajlsi-2696	52	5	“	"	PUNCT
ajlsi-2696	52	6	il-4	il-4	X
ajlsi-2696	52	7	and	and	CCONJ
ajlsi-2696	52	8	il-13	il-13	ADV
ajlsi-2696	52	9	”	"	PUNCT
ajlsi-2696	52	10	signaling	signal	VERB
ajlsi-2696	52	11	enhances	enhance	NOUN
ajlsi-2696	52	12	skin	skin	NOUN
ajlsi-2696	52	13	barrier	barrier	NOUN
ajlsi-2696	52	14	function	function	NOUN
ajlsi-2696	52	15	,	,	PUNCT
ajlsi-2696	52	16	reduces	reduce	VERB
ajlsi-2696	52	17	type	type	NOUN
ajlsi-2696	52	18	2	2	NUM
ajlsi-2696	52	19	inflammation	inflammation	NOUN
ajlsi-2696	52	20	,	,	PUNCT
ajlsi-2696	52	21	reduces	reduce	VERB
ajlsi-2696	52	22	itching	itching	NOUN
ajlsi-2696	52	23	,	,	PUNCT
ajlsi-2696	52	24	and	and	CCONJ
ajlsi-2696	52	25	improves	improve	VERB
ajlsi-2696	52	26	skin	skin	NOUN
ajlsi-2696	52	27	lesions	lesion	NOUN
ajlsi-2696	52	28	in	in	ADP
ajlsi-2696	52	29	people	people	NOUN
ajlsi-2696	52	30	with	with	ADP
ajlsi-2696	52	31	atopic	atopic	NOUN
ajlsi-2696	52	32	dermatitis	dermatitis	NOUN
ajlsi-2696	52	33	.	.	PUNCT
ajlsi-2696	53	1	(	(	PUNCT
ajlsi-2696	53	2	kraft	kraft	NOUN
ajlsi-2696	53	3	&	&	CCONJ
ajlsi-2696	53	4	worm	worm	NOUN
ajlsi-2696	53	5	,	,	PUNCT
ajlsi-2696	53	6	2017	2017	NUM
ajlsi-2696	53	7	)	)	PUNCT
ajlsi-2696	53	8	.	.	PUNCT
ajlsi-2696	54	1	dupilumab	dupilumab	NOUN
ajlsi-2696	54	2	significantly	significantly	ADV
ajlsi-2696	54	3	enhances	enhance	VERB
ajlsi-2696	54	4	clinical	clinical	ADJ
ajlsi-2696	54	5	scores	score	NOUN
ajlsi-2696	54	6	and	and	CCONJ
ajlsi-2696	54	7	symptoms	symptom	NOUN
ajlsi-2696	54	8	in	in	ADP
ajlsi-2696	54	9	children	child	NOUN
ajlsi-2696	54	10	with	with	ADP
ajlsi-2696	54	11	severe	severe	ADJ
ajlsi-2696	54	12	atopic	atopic	NOUN
ajlsi-2696	54	13	dermatitis	dermatitis	NOUN
ajlsi-2696	54	14	aged	age	VERB
ajlsi-2696	54	15	6	6	NUM
ajlsi-2696	54	16	-	-	SYM
ajlsi-2696	54	17	11	11	NUM
ajlsi-2696	54	18	years	year	NOUN
ajlsi-2696	54	19	,	,	PUNCT
ajlsi-2696	54	20	improving	improve	VERB
ajlsi-2696	54	21	their	their	PRON
ajlsi-2696	54	22	quality	quality	NOUN
ajlsi-2696	54	23	of	of	ADP
ajlsi-2696	54	24	life	life	NOUN
ajlsi-2696	54	25	and	and	CCONJ
ajlsi-2696	54	26	smoother	smooth	ADJ
ajlsi-2696	54	27	skin	skin	NOUN
ajlsi-2696	54	28	(	(	PUNCT
ajlsi-2696	54	29	berna	berna	PROPN
ajlsi-2696	54	30	-	-	PUNCT
ajlsi-2696	54	31	rico	rico	PROPN
ajlsi-2696	54	32	et	et	PROPN
ajlsi-2696	54	33	al	al	PROPN
ajlsi-2696	54	34	.	.	PROPN
ajlsi-2696	54	35	,	,	PUNCT
ajlsi-2696	54	36	2023	2023	NUM
ajlsi-2696	54	37	;	;	PUNCT
ajlsi-2696	54	38	cork	cork	NOUN
ajlsi-2696	54	39	et	et	NOUN
ajlsi-2696	54	40	al	al	PROPN
ajlsi-2696	54	41	.	.	PROPN
ajlsi-2696	54	42	,	,	PUNCT
ajlsi-2696	54	43	2024	2024	NUM
ajlsi-2696	54	44	)	)	PUNCT
ajlsi-2696	54	45	.	.	PUNCT
ajlsi-2696	55	1	the	the	DET
ajlsi-2696	55	2	recommended	recommend	VERB
ajlsi-2696	55	3	dosages	dosage	NOUN
ajlsi-2696	55	4	and	and	CCONJ
ajlsi-2696	55	5	frequency	frequency	NOUN
ajlsi-2696	55	6	of	of	ADP
ajlsi-2696	55	7	dupilumab	dupilumab	NOUN
ajlsi-2696	55	8	for	for	ADP
ajlsi-2696	55	9	children	child	NOUN
ajlsi-2696	55	10	with	with	ADP
ajlsi-2696	55	11	atopic	atopic	NOUN
ajlsi-2696	55	12	dermatitis	dermatitis	NOUN
ajlsi-2696	55	13	are	be	AUX
ajlsi-2696	55	14	weight	weight	NOUN
ajlsi-2696	55	15	-	-	PUNCT
ajlsi-2696	55	16	based	base	VERB
ajlsi-2696	55	17	and	and	CCONJ
ajlsi-2696	55	18	range	range	VERB
ajlsi-2696	55	19	from	from	ADP
ajlsi-2696	55	20	200	200	NUM
ajlsi-2696	55	21	mg	mg	NOUN
ajlsi-2696	55	22	to	to	ADP
ajlsi-2696	55	23	300	300	NUM
ajlsi-2696	55	24	mg	mg	NOUN
ajlsi-2696	55	25	for	for	ADP
ajlsi-2696	55	26	children	child	NOUN
ajlsi-2696	55	27	weighing	weigh	VERB
ajlsi-2696	55	28	15	15	NUM
ajlsi-2696	55	29	to	to	PART
ajlsi-2696	55	30	30	30	NUM
ajlsi-2696	55	31	kg	kg	NOUN
ajlsi-2696	55	32	,	,	PUNCT
ajlsi-2696	55	33	30	30	NUM
ajlsi-2696	55	34	to	to	PART
ajlsi-2696	55	35	40	40	NUM
ajlsi-2696	55	36	kg	kg	NOUN
ajlsi-2696	55	37	,	,	PUNCT
ajlsi-2696	55	38	and	and	CCONJ
ajlsi-2696	55	39	40	40	NUM
ajlsi-2696	55	40	kg	kg	NOUN
ajlsi-2696	55	41	or	or	CCONJ
ajlsi-2696	55	42	more	more	ADJ
ajlsi-2696	55	43	(	(	PUNCT
ajlsi-2696	55	44	berna	berna	PROPN
ajlsi-2696	55	45	-	-	PUNCT
ajlsi-2696	55	46	rico	rico	PROPN
ajlsi-2696	55	47	et	et	PROPN
ajlsi-2696	55	48	al	al	PROPN
ajlsi-2696	55	49	.	.	PROPN
ajlsi-2696	55	50	,	,	PUNCT
ajlsi-2696	55	51	2023	2023	NUM
ajlsi-2696	55	52	;	;	PUNCT
ajlsi-2696	55	53	cork	cork	NOUN
ajlsi-2696	55	54	et	et	NOUN
ajlsi-2696	55	55	al	al	PROPN
ajlsi-2696	55	56	.	.	PROPN
ajlsi-2696	55	57	,	,	PUNCT
ajlsi-2696	55	58	2024	2024	NUM
ajlsi-2696	55	59	;	;	PUNCT
ajlsi-2696	55	60	kamal	kamal	PROPN
ajlsi-2696	55	61	et	et	PROPN
ajlsi-2696	55	62	al	al	PROPN
ajlsi-2696	55	63	.	.	PROPN
ajlsi-2696	55	64	,	,	PUNCT
ajlsi-2696	55	65	2021	2021	NUM
ajlsi-2696	55	66	)	)	PUNCT
ajlsi-2696	55	67	.	.	PUNCT
ajlsi-2696	56	1	comparison	comparison	NOUN
ajlsi-2696	56	2	with	with	ADP
ajlsi-2696	56	3	other	other	ADJ
ajlsi-2696	56	4	treatment	treatment	NOUN
ajlsi-2696	56	5	modalities	modality	NOUN
ajlsi-2696	56	6	antibiotics	antibiotic	NOUN
ajlsi-2696	56	7	for	for	ADP
ajlsi-2696	56	8	atopic	atopic	NOUN
ajlsi-2696	56	9	dermatitis	dermatitis	NOUN
ajlsi-2696	56	10	since	since	SCONJ
ajlsi-2696	56	11	secondary	secondary	ADJ
ajlsi-2696	56	12	skin	skin	NOUN
ajlsi-2696	56	13	infections	infection	NOUN
ajlsi-2696	56	14	frequently	frequently	ADV
ajlsi-2696	56	15	arise	arise	VERB
ajlsi-2696	56	16	in	in	ADP
ajlsi-2696	56	17	ad	ad	NOUN
ajlsi-2696	56	18	patients	patient	NOUN
ajlsi-2696	56	19	,	,	PUNCT
ajlsi-2696	56	20	antibiotics	antibiotic	NOUN
ajlsi-2696	56	21	,	,	PUNCT
ajlsi-2696	56	22	including	include	VERB
ajlsi-2696	56	23	cephalexin	cephalexin	PROPN
ajlsi-2696	56	24	,	,	PUNCT
ajlsi-2696	56	25	clindamycin	clindamycin	NOUN
ajlsi-2696	56	26	,	,	PUNCT
ajlsi-2696	56	27	doxycycline	doxycycline	NOUN
ajlsi-2696	56	28	,	,	PUNCT
ajlsi-2696	56	29	azithromycin	azithromycin	PROPN
ajlsi-2696	56	30	and	and	CCONJ
ajlsi-2696	56	31	amoxicillin	amoxicillin	PROPN
ajlsi-2696	56	32	/	/	SYM
ajlsi-2696	56	33	clavulanic	clavulanic	NOUN
ajlsi-2696	56	34	acid	acid	NOUN
ajlsi-2696	56	35	,	,	PUNCT
ajlsi-2696	56	36	are	be	AUX
ajlsi-2696	56	37	frequently	frequently	ADV
ajlsi-2696	56	38	used	use	VERB
ajlsi-2696	56	39	to	to	PART
ajlsi-2696	56	40	manage	manage	VERB
ajlsi-2696	56	41	ad	ad	NOUN
ajlsi-2696	56	42	.	.	PUNCT
ajlsi-2696	57	1	in	in	ADP
ajlsi-2696	57	2	eczematous	eczematous	ADJ
ajlsi-2696	57	3	lesions	lesion	NOUN
ajlsi-2696	57	4	of	of	ADP
ajlsi-2696	57	5	atopic	atopic	NOUN
ajlsi-2696	57	6	patients	patient	NOUN
ajlsi-2696	57	7	,	,	PUNCT
ajlsi-2696	57	8	staphylococcus	staphylococcus	NOUN
ajlsi-2696	57	9	aureus	aureus	NOUN
ajlsi-2696	57	10	colonization	colonization	NOUN
ajlsi-2696	57	11	is	be	AUX
ajlsi-2696	57	12	common	common	ADJ
ajlsi-2696	57	13	.	.	PUNCT
ajlsi-2696	58	1	it	it	PRON
ajlsi-2696	58	2	releases	release	VERB
ajlsi-2696	58	3	superantigens	superantigen	NOUN
ajlsi-2696	58	4	and	and	CCONJ
ajlsi-2696	58	5	exotoxins	exotoxin	NOUN
ajlsi-2696	58	6	that	that	PRON
ajlsi-2696	58	7	prolong	prolong	VERB
ajlsi-2696	58	8	inflammatory	inflammatory	ADJ
ajlsi-2696	58	9	reactions	reaction	NOUN
ajlsi-2696	58	10	and	and	CCONJ
ajlsi-2696	58	11	worsen	worsen	VERB
ajlsi-2696	58	12	symptoms	symptom	NOUN
ajlsi-2696	58	13	.	.	PUNCT
ajlsi-2696	59	1	patients	patient	NOUN
ajlsi-2696	59	2	with	with	ADP
ajlsi-2696	59	3	ad	ad	NOUN
ajlsi-2696	59	4	are	be	AUX
ajlsi-2696	59	5	often	often	ADV
ajlsi-2696	59	6	offered	offer	VERB
ajlsi-2696	59	7	topical	topical	ADJ
ajlsi-2696	59	8	antibiotics	antibiotic	NOUN
ajlsi-2696	59	9	such	such	ADJ
ajlsi-2696	59	10	as	as	ADP
ajlsi-2696	59	11	gentamicin	gentamicin	NOUN
ajlsi-2696	59	12	,	,	PUNCT
ajlsi-2696	59	13	fusidic	fusidic	ADJ
ajlsi-2696	59	14	acid	acid	NOUN
ajlsi-2696	59	15	,	,	PUNCT
ajlsi-2696	59	16	and	and	CCONJ
ajlsi-2696	59	17	mupirocin	mupirocin	NOUN
ajlsi-2696	59	18	for	for	ADP
ajlsi-2696	59	19	mild	mild	ADJ
ajlsi-2696	59	20	to	to	AUX
ajlsi-2696	59	21	moderate	moderate	ADJ
ajlsi-2696	59	22	secondary	secondary	ADJ
ajlsi-2696	59	23	infections	infection	NOUN
ajlsi-2696	59	24	(	(	PUNCT
ajlsi-2696	59	25	neri	neri	NOUN
ajlsi-2696	59	26	,	,	PUNCT
ajlsi-2696	59	27	2015	2015	NUM
ajlsi-2696	59	28	)	)	PUNCT
ajlsi-2696	59	29	.	.	PUNCT
ajlsi-2696	60	1	cephalexin	cephalexin	PROPN
ajlsi-2696	60	2	is	be	AUX
ajlsi-2696	60	3	a	a	DET
ajlsi-2696	60	4	first	first	ADJ
ajlsi-2696	60	5	-	-	PUNCT
ajlsi-2696	60	6	generation	generation	NOUN
ajlsi-2696	60	7	cephalosporin	cephalosporin	NOUN
ajlsi-2696	60	8	used	use	VERB
ajlsi-2696	60	9	to	to	PART
ajlsi-2696	60	10	treat	treat	VERB
ajlsi-2696	60	11	staphylococcus	staphylococcus	NOUN
ajlsi-2696	60	12	aureus	aureus	NOUN
ajlsi-2696	60	13	-	-	PUNCT
ajlsi-2696	60	14	related	relate	VERB
ajlsi-2696	60	15	skin	skin	NOUN
ajlsi-2696	60	16	infections	infection	NOUN
ajlsi-2696	60	17	in	in	ADP
ajlsi-2696	60	18	atopic	atopic	NOUN
ajlsi-2696	60	19	dermatitis	dermatitis	NOUN
ajlsi-2696	60	20	,	,	PUNCT
ajlsi-2696	60	21	particularly	particularly	ADV
ajlsi-2696	60	22	in	in	ADP
ajlsi-2696	60	23	those	those	PRON
ajlsi-2696	60	24	with	with	ADP
ajlsi-2696	60	25	colonized	colonized	ADJ
ajlsi-2696	60	26	staphylococcus	staphylococcus	NOUN
ajlsi-2696	60	27	aureus	aureus	NOUN
ajlsi-2696	60	28	.	.	PUNCT
ajlsi-2696	61	1	its	its	PRON
ajlsi-2696	61	2	bactericidal	bactericidal	ADJ
ajlsi-2696	61	3	activity	activity	NOUN
ajlsi-2696	61	4	supports	support	VERB
ajlsi-2696	61	5	its	its	PRON
ajlsi-2696	61	6	use	use	NOUN
ajlsi-2696	61	7	in	in	ADP
ajlsi-2696	61	8	treating	treat	VERB
ajlsi-2696	61	9	atopic	atopic	NOUN
ajlsi-2696	61	10	dermatitis	dermatitis	NOUN
ajlsi-2696	61	11	,	,	PUNCT
ajlsi-2696	61	12	prophylaxis	prophylaxis	NOUN
ajlsi-2696	61	13	,	,	PUNCT
ajlsi-2696	61	14	and	and	CCONJ
ajlsi-2696	61	15	minor	minor	ADJ
ajlsi-2696	61	16	procedures	procedure	NOUN
ajlsi-2696	61	17	(	(	PUNCT
ajlsi-2696	61	18	class	class	NOUN
ajlsi-2696	61	19	et	et	PROPN
ajlsi-2696	61	20	al	al	PROPN
ajlsi-2696	61	21	.	.	PROPN
ajlsi-2696	61	22	,	,	PUNCT
ajlsi-2696	61	23	2022	2022	NUM
ajlsi-2696	61	24	;	;	PUNCT
ajlsi-2696	61	25	rist	rist	PROPN
ajlsi-2696	61	26	et	et	PROPN
ajlsi-2696	61	27	al	al	PROPN
ajlsi-2696	61	28	.	.	PROPN
ajlsi-2696	61	29	,	,	PUNCT
ajlsi-2696	61	30	2002	2002	NUM
ajlsi-2696	61	31	)	)	PUNCT
ajlsi-2696	61	32	.	.	PUNCT
ajlsi-2696	62	1	clindamycin	clindamycin	NOUN
ajlsi-2696	62	2	a	a	DET
ajlsi-2696	62	3	lincosamide	lincosamide	NOUN
ajlsi-2696	62	4	antibiotic	antibiotic	ADJ
ajlsi-2696	62	5	,	,	PUNCT
ajlsi-2696	62	6	is	be	AUX
ajlsi-2696	62	7	used	use	VERB
ajlsi-2696	62	8	to	to	PART
ajlsi-2696	62	9	treat	treat	VERB
ajlsi-2696	62	10	severe	severe	ADJ
ajlsi-2696	62	11	skin	skin	NOUN
ajlsi-2696	62	12	and	and	CCONJ
ajlsi-2696	62	13	pa	pa	PROPN
ajlsi-2696	62	14	ge	ge	PROPN
ajlsi-2696	62	15	63	63	NUM
ajlsi-2696	62	16	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	62	17	am	am	NOUN
ajlsi-2696	62	18	.	.	PUNCT
ajlsi-2696	63	1	j.	j.	PROPN
ajlsi-2696	63	2	life	life	PROPN
ajlsi-2696	63	3	sci	sci	PROPN
ajlsi-2696	63	4	.	.	PUNCT
ajlsi-2696	63	5	innov	innov	PROPN
ajlsi-2696	63	6	.	.	PUNCT
ajlsi-2696	64	1	3(1	3(1	NUM
ajlsi-2696	64	2	)	)	PUNCT
ajlsi-2696	64	3	61	61	NUM
ajlsi-2696	64	4	-	-	SYM
ajlsi-2696	64	5	68	68	NUM
ajlsi-2696	64	6	,	,	PUNCT
ajlsi-2696	64	7	2024	2024	NUM
ajlsi-2696	64	8	soft	soft	ADJ
ajlsi-2696	64	9	tissue	tissue	NOUN
ajlsi-2696	64	10	infections	infection	NOUN
ajlsi-2696	64	11	caused	cause	VERB
ajlsi-2696	64	12	by	by	ADP
ajlsi-2696	64	13	staphylococcus	staphylococcus	NOUN
ajlsi-2696	64	14	aureus	aureus	NOUN
ajlsi-2696	64	15	.	.	PUNCT
ajlsi-2696	65	1	it	it	PRON
ajlsi-2696	65	2	works	work	VERB
ajlsi-2696	65	3	well	well	ADV
ajlsi-2696	65	4	against	against	ADP
ajlsi-2696	65	5	aerobic	aerobic	ADJ
ajlsi-2696	65	6	and	and	CCONJ
ajlsi-2696	65	7	anaerobic	anaerobic	ADJ
ajlsi-2696	65	8	bacteria	bacteria	NOUN
ajlsi-2696	65	9	,	,	PUNCT
ajlsi-2696	65	10	especially	especially	ADV
ajlsi-2696	65	11	in	in	ADP
ajlsi-2696	65	12	those	those	PRON
ajlsi-2696	65	13	with	with	ADP
ajlsi-2696	65	14	s.	s.	PROPN
ajlsi-2696	65	15	aureus	aureus	PROPN
ajlsi-2696	65	16	colonization	colonization	NOUN
ajlsi-2696	65	17	due	due	ADP
ajlsi-2696	65	18	to	to	ADP
ajlsi-2696	65	19	atopic	atopic	NOUN
ajlsi-2696	65	20	dermatitis	dermatitis	NOUN
ajlsi-2696	65	21	(	(	PUNCT
ajlsi-2696	65	22	coskey	coskey	PROPN
ajlsi-2696	65	23	,	,	PUNCT
ajlsi-2696	65	24	1978	1978	NUM
ajlsi-2696	65	25	;	;	PUNCT
ajlsi-2696	65	26	mose	mose	VERB
ajlsi-2696	65	27	et	et	PROPN
ajlsi-2696	65	28	al	al	PROPN
ajlsi-2696	65	29	.	.	PROPN
ajlsi-2696	65	30	,	,	PUNCT
ajlsi-2696	65	31	2022	2022	NUM
ajlsi-2696	65	32	)	)	PUNCT
ajlsi-2696	65	33	.	.	PUNCT
ajlsi-2696	66	1	doxycycline	doxycycline	VERB
ajlsi-2696	66	2	a	a	DET
ajlsi-2696	66	3	tetracycline	tetracycline	ADJ
ajlsi-2696	66	4	antibiotic	antibiotic	ADJ
ajlsi-2696	66	5	doxycycline	doxycycline	NOUN
ajlsi-2696	66	6	,	,	PUNCT
ajlsi-2696	66	7	has	have	AUX
ajlsi-2696	66	8	been	be	AUX
ajlsi-2696	66	9	investigated	investigate	VERB
ajlsi-2696	66	10	for	for	ADP
ajlsi-2696	66	11	treating	treat	VERB
ajlsi-2696	66	12	atopic	atopic	NOUN
ajlsi-2696	66	13	dermatitis	dermatitis	NOUN
ajlsi-2696	66	14	(	(	PUNCT
ajlsi-2696	66	15	ad	ad	NOUN
ajlsi-2696	66	16	)	)	PUNCT
ajlsi-2696	66	17	.	.	PUNCT
ajlsi-2696	67	1	doxycycline	doxycycline	NOUN
ajlsi-2696	67	2	may	may	AUX
ajlsi-2696	67	3	be	be	AUX
ajlsi-2696	67	4	able	able	ADJ
ajlsi-2696	67	5	to	to	PART
ajlsi-2696	67	6	treat	treat	VERB
ajlsi-2696	67	7	ad	ad	NOUN
ajlsi-2696	67	8	since	since	SCONJ
ajlsi-2696	67	9	research	research	NOUN
ajlsi-2696	67	10	indicates	indicate	VERB
ajlsi-2696	67	11	that	that	SCONJ
ajlsi-2696	67	12	it	it	PRON
ajlsi-2696	67	13	may	may	AUX
ajlsi-2696	67	14	include	include	VERB
ajlsi-2696	67	15	anti	anti	ADJ
ajlsi-2696	67	16	-	-	ADJ
ajlsi-2696	67	17	inflammatory	inflammatory	ADJ
ajlsi-2696	67	18	qualities	quality	NOUN
ajlsi-2696	67	19	and	and	CCONJ
ajlsi-2696	67	20	antibacterial	antibacterial	ADJ
ajlsi-2696	67	21	benefits	benefit	NOUN
ajlsi-2696	67	22	.	.	PUNCT
ajlsi-2696	68	1	doxycycline	doxycycline	PROPN
ajlsi-2696	68	2	may	may	AUX
ajlsi-2696	68	3	have	have	VERB
ajlsi-2696	68	4	a	a	DET
ajlsi-2696	68	5	role	role	NOUN
ajlsi-2696	68	6	in	in	ADP
ajlsi-2696	68	7	regulating	regulate	VERB
ajlsi-2696	68	8	the	the	DET
ajlsi-2696	68	9	immune	immune	ADJ
ajlsi-2696	68	10	response	response	NOUN
ajlsi-2696	68	11	in	in	ADP
ajlsi-2696	68	12	allergy	allergy	NOUN
ajlsi-2696	68	13	disorders	disorder	NOUN
ajlsi-2696	68	14	such	such	ADJ
ajlsi-2696	68	15	as	as	ADP
ajlsi-2696	68	16	ad	ad	NOUN
ajlsi-2696	68	17	.	.	PUNCT
ajlsi-2696	69	1	its	its	PRON
ajlsi-2696	69	2	use	use	NOUN
ajlsi-2696	69	3	has	have	AUX
ajlsi-2696	69	4	been	be	AUX
ajlsi-2696	69	5	widely	widely	ADV
ajlsi-2696	69	6	demonstrated	demonstrate	VERB
ajlsi-2696	69	7	to	to	PART
ajlsi-2696	69	8	reduce	reduce	VERB
ajlsi-2696	69	9	mast	mast	NOUN
ajlsi-2696	69	10	cell	cell	NOUN
ajlsi-2696	69	11	histamine	histamine	NOUN
ajlsi-2696	69	12	release	release	NOUN
ajlsi-2696	69	13	and	and	CCONJ
ajlsi-2696	69	14	asthmatic	asthmatic	ADJ
ajlsi-2696	69	15	patients	patient	NOUN
ajlsi-2696	69	16	’	'	PUNCT
ajlsi-2696	69	17	levels	level	NOUN
ajlsi-2696	69	18	of	of	ADP
ajlsi-2696	69	19	immunoglobulin	immunoglobulin	NOUN
ajlsi-2696	69	20	e	e	PROPN
ajlsi-2696	69	21	(	(	PUNCT
ajlsi-2696	69	22	ige	ige	PROPN
ajlsi-2696	69	23	)	)	PUNCT
ajlsi-2696	69	24	for	for	ADP
ajlsi-2696	69	25	skin	skin	NOUN
ajlsi-2696	69	26	disorders	disorder	NOUN
ajlsi-2696	69	27	such	such	ADJ
ajlsi-2696	69	28	as	as	ADP
ajlsi-2696	69	29	rosacea	rosacea	NOUN
ajlsi-2696	69	30	,	,	PUNCT
ajlsi-2696	69	31	acne	acne	NOUN
ajlsi-2696	69	32	,	,	PUNCT
ajlsi-2696	69	33	and	and	CCONJ
ajlsi-2696	69	34	perioral	perioral	PROPN
ajlsi-2696	69	35	dermatitis	dermatitis	NOUN
ajlsi-2696	69	36	(	(	PUNCT
ajlsi-2696	69	37	bohannon	bohannon	PROPN
ajlsi-2696	69	38	et	et	PROPN
ajlsi-2696	69	39	al	al	PROPN
ajlsi-2696	69	40	.	.	PROPN
ajlsi-2696	69	41	,	,	PUNCT
ajlsi-2696	69	42	2020	2020	NUM
ajlsi-2696	69	43	;	;	PUNCT
ajlsi-2696	69	44	hulme	hulme	NOUN
ajlsi-2696	69	45	,	,	PUNCT
ajlsi-2696	69	46	2023	2023	NUM
ajlsi-2696	69	47	)	)	PUNCT
ajlsi-2696	69	48	;	;	PUNCT
ajlsi-2696	69	49	it	it	PRON
ajlsi-2696	69	50	also	also	ADV
ajlsi-2696	69	51	functions	function	VERB
ajlsi-2696	69	52	by	by	ADP
ajlsi-2696	69	53	destabilizing	destabilizing	ADJ
ajlsi-2696	69	54	nitric	nitric	ADJ
ajlsi-2696	69	55	oxide	oxide	NOUN
ajlsi-2696	69	56	synthase	synthase	NOUN
ajlsi-2696	69	57	(	(	PUNCT
ajlsi-2696	69	58	nos	nos	NOUN
ajlsi-2696	69	59	)	)	PUNCT
ajlsi-2696	69	60	,	,	PUNCT
ajlsi-2696	69	61	which	which	PRON
ajlsi-2696	69	62	can	can	AUX
ajlsi-2696	69	63	reduce	reduce	VERB
ajlsi-2696	69	64	inflammation	inflammation	NOUN
ajlsi-2696	69	65	and	and	CCONJ
ajlsi-2696	69	66	improve	improve	VERB
ajlsi-2696	69	67	symptoms	symptom	NOUN
ajlsi-2696	69	68	of	of	ADP
ajlsi-2696	69	69	atopic	atopic	NOUN
ajlsi-2696	69	70	dermatitis	dermatitis	NOUN
ajlsi-2696	69	71	by	by	ADP
ajlsi-2696	69	72	increasing	increase	VERB
ajlsi-2696	69	73	degradation	degradation	NOUN
ajlsi-2696	69	74	.	.	PUNCT
ajlsi-2696	70	1	it	it	PRON
ajlsi-2696	70	2	is	be	AUX
ajlsi-2696	70	3	frequently	frequently	ADV
ajlsi-2696	70	4	used	use	VERB
ajlsi-2696	70	5	to	to	PART
ajlsi-2696	70	6	treat	treat	VERB
ajlsi-2696	70	7	skin	skin	NOUN
ajlsi-2696	70	8	conditions	condition	NOUN
ajlsi-2696	70	9	such	such	ADJ
ajlsi-2696	70	10	perioral	perioral	ADJ
ajlsi-2696	70	11	dermatitis	dermatitis	NOUN
ajlsi-2696	70	12	,	,	PUNCT
ajlsi-2696	70	13	acne	acne	NOUN
ajlsi-2696	70	14	,	,	PUNCT
ajlsi-2696	70	15	and	and	CCONJ
ajlsi-2696	70	16	rosacea	rosacea	PROPN
ajlsi-2696	70	17	.	.	PUNCT
ajlsi-2696	71	1	(	(	PUNCT
ajlsi-2696	71	2	bohannon	bohannon	PROPN
ajlsi-2696	71	3	et	et	PROPN
ajlsi-2696	71	4	al	al	PROPN
ajlsi-2696	71	5	.	.	PROPN
ajlsi-2696	71	6	,	,	PUNCT
ajlsi-2696	71	7	2020	2020	NUM
ajlsi-2696	71	8	)	)	PUNCT
ajlsi-2696	71	9	.	.	PUNCT
ajlsi-2696	72	1	effectiveness	effectiveness	NOUN
ajlsi-2696	72	2	and	and	CCONJ
ajlsi-2696	72	3	limitations	limitation	NOUN
ajlsi-2696	72	4	children	child	NOUN
ajlsi-2696	72	5	who	who	PRON
ajlsi-2696	72	6	were	be	AUX
ajlsi-2696	72	7	exposed	expose	VERB
ajlsi-2696	72	8	to	to	ADP
ajlsi-2696	72	9	antibiotics	antibiotic	NOUN
ajlsi-2696	72	10	in	in	ADP
ajlsi-2696	72	11	their	their	PRON
ajlsi-2696	72	12	early	early	ADJ
ajlsi-2696	72	13	years	year	NOUN
ajlsi-2696	72	14	had	have	VERB
ajlsi-2696	72	15	a	a	DET
ajlsi-2696	72	16	higher	high	ADJ
ajlsi-2696	72	17	chance	chance	NOUN
ajlsi-2696	72	18	of	of	ADP
ajlsi-2696	72	19	acquiring	acquire	VERB
ajlsi-2696	72	20	adverse	adverse	ADJ
ajlsi-2696	72	21	events	event	NOUN
ajlsi-2696	72	22	.	.	PUNCT
ajlsi-2696	73	1	irrational	irrational	ADJ
ajlsi-2696	73	2	and	and	CCONJ
ajlsi-2696	73	3	direct	direct	ADJ
ajlsi-2696	73	4	use	use	NOUN
ajlsi-2696	73	5	of	of	ADP
ajlsi-2696	73	6	broad	broad	ADJ
ajlsi-2696	73	7	-	-	PUNCT
ajlsi-2696	73	8	spectrum	spectrum	NOUN
ajlsi-2696	73	9	antibiotics	antibiotic	NOUN
ajlsi-2696	73	10	increases	increase	VERB
ajlsi-2696	73	11	susceptibility	susceptibility	NOUN
ajlsi-2696	73	12	to	to	ADP
ajlsi-2696	73	13	infections	infection	NOUN
ajlsi-2696	73	14	and	and	CCONJ
ajlsi-2696	73	15	resistance	resistance	NOUN
ajlsi-2696	73	16	rates	rate	NOUN
ajlsi-2696	73	17	,	,	PUNCT
ajlsi-2696	73	18	potentially	potentially	ADV
ajlsi-2696	73	19	leading	lead	VERB
ajlsi-2696	73	20	to	to	ADP
ajlsi-2696	73	21	fatal	fatal	ADJ
ajlsi-2696	73	22	diseases	disease	NOUN
ajlsi-2696	73	23	.	.	PUNCT
ajlsi-2696	74	1	the	the	DET
ajlsi-2696	74	2	relative	relative	ADJ
ajlsi-2696	74	3	efficacy	efficacy	NOUN
ajlsi-2696	74	4	of	of	ADP
ajlsi-2696	74	5	antibiotics	antibiotic	NOUN
ajlsi-2696	74	6	and	and	CCONJ
ajlsi-2696	74	7	biological	biological	ADJ
ajlsi-2696	74	8	treatment	treatment	NOUN
ajlsi-2696	74	9	for	for	ADP
ajlsi-2696	74	10	pediatric	pediatric	ADJ
ajlsi-2696	74	11	atopic	atopic	NOUN
ajlsi-2696	74	12	dermatitis	dermatitis	NOUN
ajlsi-2696	74	13	depends	depend	VERB
ajlsi-2696	74	14	on	on	ADP
ajlsi-2696	74	15	the	the	DET
ajlsi-2696	74	16	particular	particular	ADJ
ajlsi-2696	74	17	circumstances	circumstance	NOUN
ajlsi-2696	74	18	and	and	CCONJ
ajlsi-2696	74	19	degree	degree	NOUN
ajlsi-2696	74	20	of	of	ADP
ajlsi-2696	74	21	the	the	DET
ajlsi-2696	74	22	ailment	ailment	NOUN
ajlsi-2696	74	23	.	.	PUNCT
ajlsi-2696	75	1	although	although	SCONJ
ajlsi-2696	75	2	they	they	PRON
ajlsi-2696	75	3	have	have	VERB
ajlsi-2696	75	4	a	a	DET
ajlsi-2696	75	5	limited	limited	ADJ
ajlsi-2696	75	6	effect	effect	NOUN
ajlsi-2696	75	7	in	in	ADP
ajlsi-2696	75	8	treating	treat	VERB
ajlsi-2696	75	9	the	the	DET
ajlsi-2696	75	10	underlying	underlie	VERB
ajlsi-2696	75	11	inflammation	inflammation	NOUN
ajlsi-2696	75	12	of	of	ADP
ajlsi-2696	75	13	atopic	atopic	NOUN
ajlsi-2696	75	14	dermatitis	dermatitis	NOUN
ajlsi-2696	75	15	,	,	PUNCT
ajlsi-2696	75	16	antibiotics	antibiotic	NOUN
ajlsi-2696	75	17	are	be	AUX
ajlsi-2696	75	18	frequently	frequently	ADV
ajlsi-2696	75	19	used	use	VERB
ajlsi-2696	75	20	to	to	PART
ajlsi-2696	75	21	treat	treat	VERB
ajlsi-2696	75	22	infections	infection	NOUN
ajlsi-2696	75	23	that	that	PRON
ajlsi-2696	75	24	may	may	AUX
ajlsi-2696	75	25	worsen	worsen	VERB
ajlsi-2696	75	26	the	the	DET
ajlsi-2696	75	27	symptoms	symptom	NOUN
ajlsi-2696	75	28	of	of	ADP
ajlsi-2696	75	29	atopic	atopic	NOUN
ajlsi-2696	75	30	dermatitis	dermatitis	NOUN
ajlsi-2696	75	31	.	.	PUNCT
ajlsi-2696	76	1	according	accord	VERB
ajlsi-2696	76	2	to	to	ADP
ajlsi-2696	76	3	research	research	NOUN
ajlsi-2696	76	4	,	,	PUNCT
ajlsi-2696	76	5	antibiotics	antibiotic	NOUN
ajlsi-2696	76	6	may	may	AUX
ajlsi-2696	76	7	not	not	PART
ajlsi-2696	76	8	significantly	significantly	ADV
ajlsi-2696	76	9	help	help	VERB
ajlsi-2696	76	10	children	child	NOUN
ajlsi-2696	76	11	with	with	ADP
ajlsi-2696	76	12	minor	minor	ADJ
ajlsi-2696	76	13	eczema	eczema	NOUN
ajlsi-2696	76	14	infections	infection	NOUN
ajlsi-2696	76	15	,	,	PUNCT
ajlsi-2696	76	16	and	and	CCONJ
ajlsi-2696	76	17	they	they	PRON
ajlsi-2696	76	18	may	may	AUX
ajlsi-2696	76	19	even	even	ADV
ajlsi-2696	76	20	increase	increase	VERB
ajlsi-2696	76	21	skin	skin	NOUN
ajlsi-2696	76	22	sensitivity	sensitivity	NOUN
ajlsi-2696	76	23	and	and	CCONJ
ajlsi-2696	76	24	resistance(choi	resistance(choi	PROPN
ajlsi-2696	76	25	et	et	PROPN
ajlsi-2696	76	26	al	al	PROPN
ajlsi-2696	76	27	.	.	PROPN
ajlsi-2696	76	28	,	,	PUNCT
ajlsi-2696	76	29	2020	2020	NUM
ajlsi-2696	76	30	;	;	PUNCT
ajlsi-2696	76	31	li	li	PROPN
ajlsi-2696	76	32	et	et	PROPN
ajlsi-2696	76	33	al	al	PROPN
ajlsi-2696	76	34	.	.	PROPN
ajlsi-2696	76	35	,	,	PUNCT
ajlsi-2696	76	36	2021	2021	NUM
ajlsi-2696	76	37	;	;	PUNCT
ajlsi-2696	76	38	mubanga	mubanga	ADV
ajlsi-2696	76	39	et	et	PROPN
ajlsi-2696	76	40	al	al	PROPN
ajlsi-2696	76	41	.	.	PROPN
ajlsi-2696	76	42	,	,	PUNCT
ajlsi-2696	76	43	2021	2021	NUM
ajlsi-2696	76	44	)	)	PUNCT
ajlsi-2696	76	45	.	.	PUNCT
ajlsi-2696	77	1	corticosteroids	corticosteroid	NOUN
ajlsi-2696	77	2	in	in	ADP
ajlsi-2696	77	3	atopic	atopic	NOUN
ajlsi-2696	77	4	dermatitis	dermatitis	NOUN
ajlsi-2696	77	5	management	management	NOUN
ajlsi-2696	77	6	depending	depend	VERB
ajlsi-2696	77	7	on	on	ADP
ajlsi-2696	77	8	the	the	DET
ajlsi-2696	77	9	severity	severity	NOUN
ajlsi-2696	77	10	of	of	ADP
ajlsi-2696	77	11	the	the	DET
ajlsi-2696	77	12	ailment	ailment	NOUN
ajlsi-2696	77	13	,	,	PUNCT
ajlsi-2696	77	14	different	different	ADJ
ajlsi-2696	77	15	dosages	dosage	NOUN
ajlsi-2696	77	16	and	and	CCONJ
ajlsi-2696	77	17	potencies	potency	NOUN
ajlsi-2696	77	18	of	of	ADP
ajlsi-2696	77	19	corticosteroids	corticosteroid	NOUN
ajlsi-2696	77	20	,	,	PUNCT
ajlsi-2696	77	21	such	such	ADJ
ajlsi-2696	77	22	as	as	ADP
ajlsi-2696	77	23	hydrocortisone	hydrocortisone	PROPN
ajlsi-2696	77	24	,	,	PUNCT
ajlsi-2696	77	25	fluticasone	fluticasone	PROPN
ajlsi-2696	77	26	,	,	PUNCT
ajlsi-2696	77	27	betamethasone	betamethasone	NOUN
ajlsi-2696	77	28	valerate	valerate	NOUN
ajlsi-2696	77	29	,	,	PUNCT
ajlsi-2696	77	30	and	and	CCONJ
ajlsi-2696	77	31	tacrolimus	tacrolimus	NOUN
ajlsi-2696	77	32	,	,	PUNCT
ajlsi-2696	77	33	are	be	AUX
ajlsi-2696	77	34	frequently	frequently	ADV
ajlsi-2696	77	35	given	give	VERB
ajlsi-2696	77	36	to	to	PART
ajlsi-2696	77	37	treat	treat	VERB
ajlsi-2696	77	38	atopic	atopic	NOUN
ajlsi-2696	77	39	dermatitis	dermatitis	NOUN
ajlsi-2696	77	40	(	(	PUNCT
ajlsi-2696	77	41	drucker	drucker	NOUN
ajlsi-2696	77	42	et	et	PROPN
ajlsi-2696	77	43	al	al	PROPN
ajlsi-2696	77	44	.	.	PROPN
ajlsi-2696	77	45	,	,	PUNCT
ajlsi-2696	77	46	2018	2018	NUM
ajlsi-2696	77	47	;	;	PUNCT
ajlsi-2696	77	48	stacey	stacey	PROPN
ajlsi-2696	77	49	&	&	CCONJ
ajlsi-2696	77	50	mceleney	mceleney	PROPN
ajlsi-2696	77	51	,	,	PUNCT
ajlsi-2696	77	52	2021	2021	NUM
ajlsi-2696	77	53	)	)	PUNCT
ajlsi-2696	77	54	.	.	PUNCT
ajlsi-2696	78	1	hydrocortisone	hydrocortisone	PROPN
ajlsi-2696	78	2	hydrocortisone	hydrocortisone	PROPN
ajlsi-2696	78	3	is	be	AUX
ajlsi-2696	78	4	frequently	frequently	ADV
ajlsi-2696	78	5	used	use	VERB
ajlsi-2696	78	6	for	for	ADP
ajlsi-2696	78	7	the	the	DET
ajlsi-2696	78	8	treatment	treatment	NOUN
ajlsi-2696	78	9	of	of	ADP
ajlsi-2696	78	10	atopic	atopic	NOUN
ajlsi-2696	78	11	dermatitis	dermatitis	NOUN
ajlsi-2696	78	12	in	in	ADP
ajlsi-2696	78	13	a	a	DET
ajlsi-2696	78	14	variety	variety	NOUN
ajlsi-2696	78	15	of	of	ADP
ajlsi-2696	78	16	dosages	dosage	NOUN
ajlsi-2696	78	17	and	and	CCONJ
ajlsi-2696	78	18	formulations	formulation	NOUN
ajlsi-2696	78	19	.	.	PUNCT
ajlsi-2696	79	1	hydrocortisone	hydrocortisone	PROPN
ajlsi-2696	79	2	comes	come	VERB
ajlsi-2696	79	3	in	in	ADP
ajlsi-2696	79	4	various	various	ADJ
ajlsi-2696	79	5	formulations	formulation	NOUN
ajlsi-2696	79	6	for	for	ADP
ajlsi-2696	79	7	atopic	atopic	NOUN
ajlsi-2696	79	8	dermatitis	dermatitis	NOUN
ajlsi-2696	79	9	,	,	PUNCT
ajlsi-2696	79	10	with	with	ADP
ajlsi-2696	79	11	concentrations	concentration	NOUN
ajlsi-2696	79	12	ranging	range	VERB
ajlsi-2696	79	13	from	from	ADP
ajlsi-2696	79	14	0.1	0.1	NUM
ajlsi-2696	79	15	%	%	NOUN
ajlsi-2696	79	16	to	to	ADP
ajlsi-2696	79	17	2.5	2.5	NUM
ajlsi-2696	79	18	%	%	NOUN
ajlsi-2696	79	19	.	.	PUNCT
ajlsi-2696	80	1	these	these	DET
ajlsi-2696	80	2	formulations	formulation	NOUN
ajlsi-2696	80	3	include	include	VERB
ajlsi-2696	80	4	creams	cream	NOUN
ajlsi-2696	80	5	,	,	PUNCT
ajlsi-2696	80	6	lotions	lotion	NOUN
ajlsi-2696	80	7	,	,	PUNCT
ajlsi-2696	80	8	gels	gel	NOUN
ajlsi-2696	80	9	,	,	PUNCT
ajlsi-2696	80	10	solutions	solution	NOUN
ajlsi-2696	80	11	,	,	PUNCT
ajlsi-2696	80	12	and	and	CCONJ
ajlsi-2696	80	13	ointments	ointment	NOUN
ajlsi-2696	80	14	.	.	PUNCT
ajlsi-2696	81	1	lower	low	ADJ
ajlsi-2696	81	2	potency	potency	NOUN
ajlsi-2696	81	3	hydrocortisone	hydrocortisone	NOUN
ajlsi-2696	81	4	formulations	formulation	NOUN
ajlsi-2696	81	5	“	"	PUNCT
ajlsi-2696	81	6	(	(	PUNCT
ajlsi-2696	81	7	class	class	NOUN
ajlsi-2696	81	8	vi	vi	PROPN
ajlsi-2696	81	9	or	or	CCONJ
ajlsi-2696	81	10	vii	vii	PROPN
ajlsi-2696	81	11	)	)	PUNCT
ajlsi-2696	81	12	,	,	PUNCT
ajlsi-2696	81	13	such	such	ADJ
ajlsi-2696	81	14	as	as	ADP
ajlsi-2696	81	15	1	1	NUM
ajlsi-2696	81	16	%	%	NOUN
ajlsi-2696	81	17	cream	cream	NOUN
ajlsi-2696	81	18	”	"	PUNCT
ajlsi-2696	81	19	or	or	CCONJ
ajlsi-2696	81	20	ointment	ointment	NOUN
ajlsi-2696	81	21	,	,	PUNCT
ajlsi-2696	81	22	are	be	AUX
ajlsi-2696	81	23	usually	usually	ADV
ajlsi-2696	81	24	used	use	VERB
ajlsi-2696	81	25	for	for	ADP
ajlsi-2696	81	26	infants	infant	NOUN
ajlsi-2696	81	27	and	and	CCONJ
ajlsi-2696	81	28	children	child	NOUN
ajlsi-2696	81	29	with	with	ADP
ajlsi-2696	81	30	atopic	atopic	NOUN
ajlsi-2696	81	31	dermatitis	dermatitis	NOUN
ajlsi-2696	81	32	.	.	PUNCT
ajlsi-2696	82	1	these	these	DET
ajlsi-2696	82	2	formulations	formulation	NOUN
ajlsi-2696	82	3	are	be	AUX
ajlsi-2696	82	4	administered	administer	VERB
ajlsi-2696	82	5	twice	twice	DET
ajlsi-2696	82	6	a	a	DET
ajlsi-2696	82	7	day	day	NOUN
ajlsi-2696	82	8	to	to	PART
ajlsi-2696	82	9	reduce	reduce	VERB
ajlsi-2696	82	10	inflammation	inflammation	NOUN
ajlsi-2696	82	11	and	and	CCONJ
ajlsi-2696	82	12	itch	itch	NOUN
ajlsi-2696	82	13	.	.	PUNCT
ajlsi-2696	83	1	low	low	ADJ
ajlsi-2696	83	2	-	-	PUNCT
ajlsi-2696	83	3	potency	potency	NOUN
ajlsi-2696	83	4	steroids	steroid	NOUN
ajlsi-2696	83	5	should	should	AUX
ajlsi-2696	83	6	be	be	AUX
ajlsi-2696	83	7	used	use	VERB
ajlsi-2696	83	8	for	for	ADP
ajlsi-2696	83	9	maintenance	maintenance	NOUN
ajlsi-2696	83	10	in	in	ADP
ajlsi-2696	83	11	cases	case	NOUN
ajlsi-2696	83	12	of	of	ADP
ajlsi-2696	83	13	mild	mild	ADJ
ajlsi-2696	83	14	atopic	atopic	NOUN
ajlsi-2696	83	15	dermatitis	dermatitis	NOUN
ajlsi-2696	83	16	after	after	SCONJ
ajlsi-2696	83	17	intermediatepotency	intermediatepotency	NOUN
ajlsi-2696	83	18	steroids	steroid	NOUN
ajlsi-2696	83	19	(	(	PUNCT
ajlsi-2696	83	20	class	class	NOUN
ajlsi-2696	83	21	iii	iii	PROPN
ajlsi-2696	83	22	,	,	PUNCT
ajlsi-2696	83	23	iv	iv	NOUN
ajlsi-2696	83	24	,	,	PUNCT
ajlsi-2696	83	25	and	and	CCONJ
ajlsi-2696	83	26	v	v	NOUN
ajlsi-2696	83	27	)	)	PUNCT
ajlsi-2696	83	28	are	be	AUX
ajlsi-2696	83	29	taken	take	VERB
ajlsi-2696	83	30	for	for	ADP
ajlsi-2696	83	31	short	short	ADJ
ajlsi-2696	83	32	periods	period	NOUN
ajlsi-2696	83	33	to	to	PART
ajlsi-2696	83	34	control	control	VERB
ajlsi-2696	83	35	flare	flare	NOUN
ajlsi-2696	83	36	-	-	PUNCT
ajlsi-2696	83	37	ups	up	NOUN
ajlsi-2696	83	38	in	in	ADP
ajlsi-2696	83	39	severe	severe	ADJ
ajlsi-2696	83	40	atopic	atopic	NOUN
ajlsi-2696	83	41	dermatitis	dermatitis	NOUN
ajlsi-2696	83	42	cases	case	NOUN
ajlsi-2696	83	43	in	in	ADP
ajlsi-2696	83	44	teenagers	teenager	NOUN
ajlsi-2696	83	45	(	(	PUNCT
ajlsi-2696	83	46	haeck	haeck	NOUN
ajlsi-2696	83	47	et	et	PROPN
ajlsi-2696	83	48	al	al	PROPN
ajlsi-2696	83	49	.	.	PROPN
ajlsi-2696	83	50	,	,	PUNCT
ajlsi-2696	83	51	2011	2011	NUM
ajlsi-2696	83	52	)	)	PUNCT
ajlsi-2696	83	53	,	,	PUNCT
ajlsi-2696	83	54	while	while	SCONJ
ajlsi-2696	83	55	their	their	PRON
ajlsi-2696	83	56	excessive	excessive	ADJ
ajlsi-2696	83	57	strength	strength	NOUN
ajlsi-2696	83	58	may	may	AUX
ajlsi-2696	83	59	result	result	VERB
ajlsi-2696	83	60	in	in	ADP
ajlsi-2696	83	61	negative	negative	ADJ
ajlsi-2696	83	62	side	side	ADJ
ajlsi-2696	83	63	effects	effect	NOUN
ajlsi-2696	83	64	such	such	ADJ
ajlsi-2696	83	65	as	as	ADP
ajlsi-2696	83	66	folliculitis	folliculitis	NOUN
ajlsi-2696	83	67	,	,	PUNCT
ajlsi-2696	83	68	dermatitis	dermatitis	NOUN
ajlsi-2696	83	69	,	,	PUNCT
ajlsi-2696	83	70	acne	acne	NOUN
ajlsi-2696	83	71	,	,	PUNCT
ajlsi-2696	83	72	atrophy	atrophy	NOUN
ajlsi-2696	83	73	of	of	ADP
ajlsi-2696	83	74	the	the	DET
ajlsi-2696	83	75	skin	skin	NOUN
ajlsi-2696	83	76	,	,	PUNCT
ajlsi-2696	83	77	itchiness	itchiness	NOUN
ajlsi-2696	83	78	,	,	PUNCT
ajlsi-2696	83	79	changes	change	NOUN
ajlsi-2696	83	80	in	in	ADP
ajlsi-2696	83	81	pigmentation	pigmentation	NOUN
ajlsi-2696	83	82	,	,	PUNCT
ajlsi-2696	83	83	and	and	CCONJ
ajlsi-2696	83	84	inhibition	inhibition	NOUN
ajlsi-2696	83	85	of	of	ADP
ajlsi-2696	83	86	the	the	DET
ajlsi-2696	83	87	hypothalamic	hypothalamic	ADJ
ajlsi-2696	83	88	-	-	PUNCT
ajlsi-2696	83	89	pituitary	pituitary	ADJ
ajlsi-2696	83	90	-	-	PUNCT
ajlsi-2696	83	91	adrenal	adrenal	ADJ
ajlsi-2696	83	92	axis	axis	NOUN
ajlsi-2696	83	93	(	(	PUNCT
ajlsi-2696	83	94	axon	axon	NOUN
ajlsi-2696	83	95	et	et	PROPN
ajlsi-2696	83	96	al	al	PROPN
ajlsi-2696	83	97	.	.	PROPN
ajlsi-2696	83	98	,	,	PUNCT
ajlsi-2696	83	99	2021	2021	NUM
ajlsi-2696	83	100	)	)	PUNCT
ajlsi-2696	83	101	.	.	PUNCT
ajlsi-2696	84	1	fluticasone	fluticasone	PROPN
ajlsi-2696	84	2	a	a	DET
ajlsi-2696	84	3	corticosteroid	corticosteroid	NOUN
ajlsi-2696	84	4	,	,	PUNCT
ajlsi-2696	84	5	is	be	AUX
ajlsi-2696	84	6	available	available	ADJ
ajlsi-2696	84	7	in	in	ADP
ajlsi-2696	84	8	several	several	ADJ
ajlsi-2696	84	9	formulations	formulation	NOUN
ajlsi-2696	84	10	and	and	CCONJ
ajlsi-2696	84	11	doses	dose	NOUN
ajlsi-2696	84	12	ranging	range	VERB
ajlsi-2696	84	13	from	from	ADP
ajlsi-2696	84	14	0.05	0.05	NUM
ajlsi-2696	84	15	%	%	NOUN
ajlsi-2696	84	16	to	to	ADP
ajlsi-2696	84	17	2.5	2.5	NUM
ajlsi-2696	84	18	%	%	NOUN
ajlsi-2696	84	19	.	.	PUNCT
ajlsi-2696	85	1	it	it	PRON
ajlsi-2696	85	2	is	be	AUX
ajlsi-2696	85	3	used	use	VERB
ajlsi-2696	85	4	in	in	ADP
ajlsi-2696	85	5	atopic	atopic	NOUN
ajlsi-2696	85	6	dermatitis	dermatitis	NOUN
ajlsi-2696	85	7	to	to	PART
ajlsi-2696	85	8	reduce	reduce	VERB
ajlsi-2696	85	9	inflammation	inflammation	NOUN
ajlsi-2696	85	10	and	and	CCONJ
ajlsi-2696	85	11	symptoms	symptom	NOUN
ajlsi-2696	85	12	by	by	ADP
ajlsi-2696	85	13	suppressing	suppress	VERB
ajlsi-2696	85	14	the	the	DET
ajlsi-2696	85	15	release	release	NOUN
ajlsi-2696	85	16	of	of	ADP
ajlsi-2696	85	17	inflammatory	inflammatory	ADJ
ajlsi-2696	85	18	mediators	mediator	NOUN
ajlsi-2696	85	19	(	(	PUNCT
ajlsi-2696	85	20	dhamija	dhamija	VERB
ajlsi-2696	85	21	et	et	PROPN
ajlsi-2696	85	22	al	al	PROPN
ajlsi-2696	85	23	.	.	PROPN
ajlsi-2696	85	24	,	,	PUNCT
ajlsi-2696	85	25	2024	2024	NUM
ajlsi-2696	85	26	)	)	PUNCT
ajlsi-2696	85	27	.	.	PUNCT
ajlsi-2696	86	1	on	on	ADP
ajlsi-2696	86	2	the	the	DET
ajlsi-2696	86	3	other	other	ADJ
ajlsi-2696	86	4	hand	hand	NOUN
ajlsi-2696	86	5	,	,	PUNCT
ajlsi-2696	86	6	a	a	DET
ajlsi-2696	86	7	variety	variety	NOUN
ajlsi-2696	86	8	of	of	ADP
ajlsi-2696	86	9	negative	negative	ADJ
ajlsi-2696	86	10	side	side	NOUN
ajlsi-2696	86	11	effects	effect	NOUN
ajlsi-2696	86	12	might	might	AUX
ajlsi-2696	86	13	occur	occur	VERB
ajlsi-2696	86	14	,	,	PUNCT
ajlsi-2696	86	15	such	such	ADJ
ajlsi-2696	86	16	as	as	ADP
ajlsi-2696	86	17	increased	increase	VERB
ajlsi-2696	86	18	hair	hair	NOUN
ajlsi-2696	86	19	growth	growth	NOUN
ajlsi-2696	86	20	,	,	PUNCT
ajlsi-2696	86	21	dizziness	dizziness	NOUN
ajlsi-2696	86	22	,	,	PUNCT
ajlsi-2696	86	23	rash	rash	ADJ
ajlsi-2696	86	24	,	,	PUNCT
ajlsi-2696	86	25	itching	itching	NOUN
ajlsi-2696	86	26	,	,	PUNCT
ajlsi-2696	86	27	and	and	CCONJ
ajlsi-2696	86	28	redness	redness	NOUN
ajlsi-2696	86	29	of	of	ADP
ajlsi-2696	86	30	the	the	DET
ajlsi-2696	86	31	treated	treat	VERB
ajlsi-2696	86	32	area	area	NOUN
ajlsi-2696	86	33	of	of	ADP
ajlsi-2696	86	34	skin	skin	NOUN
ajlsi-2696	86	35	.	.	PUNCT
ajlsi-2696	87	1	hives	hive	NOUN
ajlsi-2696	87	2	,	,	PUNCT
ajlsi-2696	87	3	breathing	breathe	VERB
ajlsi-2696	87	4	difficulties	difficulty	NOUN
ajlsi-2696	87	5	,	,	PUNCT
ajlsi-2696	87	6	swelling	swell	VERB
ajlsi-2696	87	7	of	of	ADP
ajlsi-2696	87	8	the	the	DET
ajlsi-2696	87	9	lips	lip	NOUN
ajlsi-2696	87	10	,	,	PUNCT
ajlsi-2696	87	11	tongue	tongue	NOUN
ajlsi-2696	87	12	,	,	PUNCT
ajlsi-2696	87	13	or	or	CCONJ
ajlsi-2696	87	14	throat	throat	NOUN
ajlsi-2696	87	15	,	,	PUNCT
ajlsi-2696	87	16	skin	skin	NOUN
ajlsi-2696	87	17	pain	pain	NOUN
ajlsi-2696	87	18	,	,	PUNCT
ajlsi-2696	87	19	tenderness	tenderness	NOUN
ajlsi-2696	87	20	,	,	PUNCT
ajlsi-2696	87	21	or	or	CCONJ
ajlsi-2696	87	22	swelling	swell	VERB
ajlsi-2696	87	23	,	,	PUNCT
ajlsi-2696	87	24	wounds	wound	NOUN
ajlsi-2696	87	25	that	that	PRON
ajlsi-2696	87	26	do	do	AUX
ajlsi-2696	87	27	not	not	PART
ajlsi-2696	87	28	heal	heal	VERB
ajlsi-2696	87	29	,	,	PUNCT
ajlsi-2696	87	30	severe	severe	ADJ
ajlsi-2696	87	31	skin	skin	NOUN
ajlsi-2696	87	32	irritation	irritation	NOUN
ajlsi-2696	87	33	,	,	PUNCT
ajlsi-2696	87	34	or	or	CCONJ
ajlsi-2696	87	35	signs	sign	NOUN
ajlsi-2696	87	36	of	of	ADP
ajlsi-2696	87	37	systemic	systemic	ADJ
ajlsi-2696	87	38	absorption	absorption	NOUN
ajlsi-2696	87	39	such	such	ADJ
ajlsi-2696	87	40	as	as	ADP
ajlsi-2696	87	41	weight	weight	NOUN
ajlsi-2696	87	42	gain	gain	NOUN
ajlsi-2696	87	43	,	,	PUNCT
ajlsi-2696	87	44	thinning	thinning	NOUN
ajlsi-2696	87	45	or	or	CCONJ
ajlsi-2696	87	46	discolored	discolored	ADJ
ajlsi-2696	87	47	skin	skin	NOUN
ajlsi-2696	87	48	,	,	PUNCT
ajlsi-2696	87	49	increased	increase	VERB
ajlsi-2696	87	50	body	body	NOUN
ajlsi-2696	87	51	hair	hair	NOUN
ajlsi-2696	87	52	,	,	PUNCT
ajlsi-2696	87	53	nausea	nausea	NOUN
ajlsi-2696	87	54	,	,	PUNCT
ajlsi-2696	87	55	diarrhoea	diarrhoea	NOUN
ajlsi-2696	87	56	,	,	PUNCT
ajlsi-2696	87	57	fatigue	fatigue	NOUN
ajlsi-2696	87	58	,	,	PUNCT
ajlsi-2696	87	59	mood	mood	NOUN
ajlsi-2696	87	60	swings	swing	NOUN
ajlsi-2696	87	61	,	,	PUNCT
ajlsi-2696	87	62	menstrual	menstrual	ADJ
ajlsi-2696	87	63	changes	change	NOUN
ajlsi-2696	87	64	,	,	PUNCT
ajlsi-2696	87	65	and	and	CCONJ
ajlsi-2696	87	66	sexual	sexual	ADJ
ajlsi-2696	87	67	changes	change	NOUN
ajlsi-2696	87	68	,	,	PUNCT
ajlsi-2696	87	69	as	as	ADV
ajlsi-2696	87	70	well	well	ADV
ajlsi-2696	87	71	as	as	ADP
ajlsi-2696	87	72	severe	severe	ADJ
ajlsi-2696	87	73	headaches	headache	NOUN
ajlsi-2696	87	74	,	,	PUNCT
ajlsi-2696	87	75	confusion	confusion	NOUN
ajlsi-2696	87	76	,	,	PUNCT
ajlsi-2696	87	77	muscle	muscle	NOUN
ajlsi-2696	87	78	weakness	weakness	NOUN
ajlsi-2696	87	79	,	,	PUNCT
ajlsi-2696	87	80	vision	vision	NOUN
ajlsi-2696	87	81	abnormalities	abnormality	NOUN
ajlsi-2696	87	82	,	,	PUNCT
ajlsi-2696	87	83	heart	heart	NOUN
ajlsi-2696	87	84	symptoms	symptom	NOUN
ajlsi-2696	87	85	,	,	PUNCT
ajlsi-2696	87	86	or	or	CCONJ
ajlsi-2696	87	87	serious	serious	ADJ
ajlsi-2696	87	88	allergic	allergic	ADJ
ajlsi-2696	87	89	reactions	reaction	NOUN
ajlsi-2696	87	90	are	be	AUX
ajlsi-2696	87	91	examples	example	NOUN
ajlsi-2696	87	92	of	of	ADP
ajlsi-2696	87	93	serious	serious	ADJ
ajlsi-2696	87	94	side	side	NOUN
ajlsi-2696	87	95	effects	effect	NOUN
ajlsi-2696	87	96	that	that	PRON
ajlsi-2696	87	97	can	can	AUX
ajlsi-2696	87	98	occur	occur	VERB
ajlsi-2696	87	99	.	.	PUNCT
ajlsi-2696	88	1	(	(	PUNCT
ajlsi-2696	88	2	berth	berth	NOUN
ajlsi-2696	88	3	-	-	PUNCT
ajlsi-2696	88	4	jones	jones	NOUN
ajlsi-2696	88	5	et	et	PROPN
ajlsi-2696	88	6	al	al	PROPN
ajlsi-2696	88	7	.	.	PROPN
ajlsi-2696	88	8	,	,	PUNCT
ajlsi-2696	88	9	2003	2003	NUM
ajlsi-2696	88	10	;	;	PUNCT
ajlsi-2696	88	11	harvey	harvey	PROPN
ajlsi-2696	88	12	et	et	PROPN
ajlsi-2696	88	13	al	al	PROPN
ajlsi-2696	88	14	.	.	PROPN
ajlsi-2696	88	15	,	,	PUNCT
ajlsi-2696	88	16	2023	2023	NUM
ajlsi-2696	88	17	)	)	PUNCT
ajlsi-2696	88	18	.	.	PUNCT
ajlsi-2696	89	1	betamethasone	betamethasone	PROPN
ajlsi-2696	89	2	valerate	valerate	VERB
ajlsi-2696	89	3	0.1	0.1	NUM
ajlsi-2696	89	4	%	%	NOUN
ajlsi-2696	89	5	twice	twice	ADV
ajlsi-2696	89	6	daily	daily	ADV
ajlsi-2696	89	7	for	for	ADP
ajlsi-2696	89	8	three	three	NUM
ajlsi-2696	89	9	to	to	PART
ajlsi-2696	89	10	five	five	NUM
ajlsi-2696	89	11	days	day	NOUN
ajlsi-2696	89	12	.	.	PUNCT
ajlsi-2696	90	1	the	the	DET
ajlsi-2696	90	2	corticosteroid	corticosteroid	ADJ
ajlsi-2696	90	3	betamethasone	betamethasone	NOUN
ajlsi-2696	90	4	can	can	AUX
ajlsi-2696	90	5	efficiently	efficiently	ADV
ajlsi-2696	90	6	manage	manage	VERB
ajlsi-2696	90	7	children	child	NOUN
ajlsi-2696	90	8	’s	’s	PART
ajlsi-2696	90	9	eczema	eczema	PROPN
ajlsi-2696	90	10	flare	flare	NOUN
ajlsi-2696	90	11	-	-	PUNCT
ajlsi-2696	90	12	ups	up	NOUN
ajlsi-2696	90	13	,	,	PUNCT
ajlsi-2696	90	14	which	which	PRON
ajlsi-2696	90	15	enhances	enhance	VERB
ajlsi-2696	90	16	skin	skin	NOUN
ajlsi-2696	90	17	barrier	barrier	NOUN
ajlsi-2696	90	18	function	function	NOUN
ajlsi-2696	90	19	and	and	CCONJ
ajlsi-2696	90	20	reduces	reduce	VERB
ajlsi-2696	90	21	skin	skin	NOUN
ajlsi-2696	90	22	inflammatory	inflammatory	ADJ
ajlsi-2696	90	23	responses	response	NOUN
ajlsi-2696	90	24	(	(	PUNCT
ajlsi-2696	90	25	subramanian	subramanian	PROPN
ajlsi-2696	90	26	et	et	PROPN
ajlsi-2696	90	27	al	al	PROPN
ajlsi-2696	90	28	.	.	PROPN
ajlsi-2696	90	29	,	,	PUNCT
ajlsi-2696	90	30	2018	2018	NUM
ajlsi-2696	90	31	)	)	PUNCT
ajlsi-2696	90	32	.	.	PUNCT
ajlsi-2696	91	1	topical	topical	ADJ
ajlsi-2696	91	2	&	&	CCONJ
ajlsi-2696	91	3	oral	oral	ADJ
ajlsi-2696	91	4	corticosteroids	corticosteroid	NOUN
ajlsi-2696	91	5	effectiveness	effectiveness	NOUN
ajlsi-2696	91	6	in	in	ADP
ajlsi-2696	91	7	comparison	comparison	NOUN
ajlsi-2696	91	8	with	with	ADP
ajlsi-2696	91	9	dupilumab	dupilumab	NOUN
ajlsi-2696	91	10	-	-	PUNCT
ajlsi-2696	91	11	fda	fda	PROPN
ajlsi-2696	91	12	it	it	PRON
ajlsi-2696	91	13	has	have	AUX
ajlsi-2696	91	14	been	be	AUX
ajlsi-2696	91	15	shown	show	VERB
ajlsi-2696	91	16	that	that	DET
ajlsi-2696	91	17	dupilumab	dupilumab	NOUN
ajlsi-2696	91	18	(	(	PUNCT
ajlsi-2696	91	19	dupixent	dupixent	NOUN
ajlsi-2696	91	20	)	)	PUNCT
ajlsi-2696	91	21	can	can	AUX
ajlsi-2696	91	22	be	be	AUX
ajlsi-2696	91	23	used	use	VERB
ajlsi-2696	91	24	with	with	ADP
ajlsi-2696	91	25	or	or	CCONJ
ajlsi-2696	91	26	without	without	ADP
ajlsi-2696	91	27	topical	topical	ADJ
ajlsi-2696	91	28	corticosteroids	corticosteroid	NOUN
ajlsi-2696	91	29	in	in	ADP
ajlsi-2696	91	30	the	the	DET
ajlsi-2696	91	31	treatment	treatment	NOUN
ajlsi-2696	91	32	of	of	ADP
ajlsi-2696	91	33	disorders	disorder	NOUN
ajlsi-2696	91	34	like	like	ADP
ajlsi-2696	91	35	atopic	atopic	NOUN
ajlsi-2696	91	36	dermatitis	dermatitis	NOUN
ajlsi-2696	91	37	based	base	VERB
ajlsi-2696	91	38	on	on	ADP
ajlsi-2696	91	39	the	the	DET
ajlsi-2696	91	40	information	information	NOUN
ajlsi-2696	91	41	from	from	ADP
ajlsi-2696	91	42	the	the	DET
ajlsi-2696	91	43	sources	source	NOUN
ajlsi-2696	91	44	that	that	PRON
ajlsi-2696	91	45	have	have	AUX
ajlsi-2696	91	46	been	be	AUX
ajlsi-2696	91	47	presented	present	VERB
ajlsi-2696	91	48	,	,	PUNCT
ajlsi-2696	91	49	including	include	VERB
ajlsi-2696	91	50	the	the	DET
ajlsi-2696	91	51	fda	fda	PROPN
ajlsi-2696	91	52	clinical	clinical	ADJ
ajlsi-2696	91	53	trials	trial	NOUN
ajlsi-2696	91	54	and	and	CCONJ
ajlsi-2696	91	55	reviews	review	NOUN
ajlsi-2696	91	56	on	on	ADP
ajlsi-2696	91	57	the	the	DET
ajlsi-2696	91	58	drug	drug	NOUN
ajlsi-2696	91	59	.	.	PUNCT
ajlsi-2696	92	1	dupilumab	dupilumab	NOUN
ajlsi-2696	92	2	is	be	AUX
ajlsi-2696	92	3	a	a	DET
ajlsi-2696	92	4	useful	useful	ADJ
ajlsi-2696	92	5	therapeutic	therapeutic	ADJ
ajlsi-2696	92	6	option	option	NOUN
ajlsi-2696	92	7	for	for	ADP
ajlsi-2696	92	8	moderate	moderate	ADJ
ajlsi-2696	92	9	-	-	PUNCT
ajlsi-2696	92	10	to	to	ADP
ajlsi-2696	92	11	-	-	PUNCT
ajlsi-2696	92	12	severe	severe	ADJ
ajlsi-2696	92	13	atopic	atopic	NOUN
ajlsi-2696	92	14	dermatitis	dermatitis	NOUN
ajlsi-2696	92	15	since	since	SCONJ
ajlsi-2696	92	16	clinical	clinical	ADJ
ajlsi-2696	92	17	trials	trial	NOUN
ajlsi-2696	92	18	have	have	AUX
ajlsi-2696	92	19	demonstrated	demonstrate	VERB
ajlsi-2696	92	20	that	that	SCONJ
ajlsi-2696	92	21	adding	add	VERB
ajlsi-2696	92	22	it	it	PRON
ajlsi-2696	92	23	to	to	ADP
ajlsi-2696	92	24	topical	topical	ADJ
ajlsi-2696	92	25	corticosteroids	corticosteroid	NOUN
ajlsi-2696	92	26	has	have	AUX
ajlsi-2696	92	27	significantly	significantly	ADV
ajlsi-2696	92	28	improved	improve	VERB
ajlsi-2696	92	29	patient	patient	NOUN
ajlsi-2696	92	30	-	-	PUNCT
ajlsi-2696	92	31	reported	report	VERB
ajlsi-2696	92	32	symptoms	symptom	NOUN
ajlsi-2696	92	33	and	and	CCONJ
ajlsi-2696	92	34	quality	quality	NOUN
ajlsi-2696	92	35	of	of	ADP
ajlsi-2696	92	36	life	life	NOUN
ajlsi-2696	92	37	.	.	PUNCT
ajlsi-2696	93	1	according	accord	VERB
ajlsi-2696	93	2	to	to	ADP
ajlsi-2696	93	3	a	a	DET
ajlsi-2696	93	4	study	study	NOUN
ajlsi-2696	93	5	,	,	PUNCT
ajlsi-2696	93	6	dupilumab	dupilumab	NOUN
ajlsi-2696	93	7	is	be	AUX
ajlsi-2696	93	8	far	far	ADV
ajlsi-2696	93	9	more	more	ADV
ajlsi-2696	93	10	effective	effective	ADJ
ajlsi-2696	93	11	than	than	ADP
ajlsi-2696	93	12	a	a	DET
ajlsi-2696	93	13	placebo	placebo	NOUN
ajlsi-2696	93	14	in	in	ADP
ajlsi-2696	93	15	relieving	relieve	VERB
ajlsi-2696	93	16	the	the	DET
ajlsi-2696	93	17	condition	condition	NOUN
ajlsi-2696	93	18	of	of	ADP
ajlsi-2696	93	19	individuals	individual	NOUN
ajlsi-2696	93	20	with	with	ADP
ajlsi-2696	93	21	atopic	atopic	NOUN
ajlsi-2696	93	22	dermatitis	dermatitis	NOUN
ajlsi-2696	93	23	when	when	SCONJ
ajlsi-2696	93	24	used	use	VERB
ajlsi-2696	93	25	in	in	ADP
ajlsi-2696	93	26	conjunction	conjunction	NOUN
ajlsi-2696	93	27	with	with	ADP
ajlsi-2696	93	28	topical	topical	ADJ
ajlsi-2696	93	29	corticosteroids	corticosteroid	NOUN
ajlsi-2696	93	30	.	.	PUNCT
ajlsi-2696	94	1	these	these	DET
ajlsi-2696	94	2	trial	trial	NOUN
ajlsi-2696	94	3	studies	study	NOUN
ajlsi-2696	94	4	have	have	AUX
ajlsi-2696	94	5	demonstrated	demonstrate	VERB
ajlsi-2696	94	6	the	the	DET
ajlsi-2696	94	7	advantages	advantage	NOUN
ajlsi-2696	94	8	of	of	ADP
ajlsi-2696	94	9	using	use	VERB
ajlsi-2696	94	10	dupilumab	dupilumab	NOUN
ajlsi-2696	94	11	with	with	ADP
ajlsi-2696	94	12	topical	topical	ADJ
ajlsi-2696	94	13	corticosteroids	corticosteroid	NOUN
ajlsi-2696	94	14	,	,	PUNCT
ajlsi-2696	94	15	highlighting	highlight	VERB
ajlsi-2696	94	16	the	the	DET
ajlsi-2696	94	17	drug	drug	NOUN
ajlsi-2696	94	18	’s	’s	PART
ajlsi-2696	94	19	efficacy	efficacy	NOUN
ajlsi-2696	94	20	in	in	ADP
ajlsi-2696	94	21	treating	treat	VERB
ajlsi-2696	94	22	atopic	atopic	NOUN
ajlsi-2696	94	23	dermatitis	dermatitis	NOUN
ajlsi-2696	94	24	and	and	CCONJ
ajlsi-2696	94	25	minimizing	minimize	VERB
ajlsi-2696	94	26	the	the	DET
ajlsi-2696	94	27	need	need	NOUN
ajlsi-2696	94	28	for	for	ADP
ajlsi-2696	94	29	corticosteroids	corticosteroid	NOUN
ajlsi-2696	94	30	pa	pa	PROPN
ajlsi-2696	94	31	ge	ge	PROPN
ajlsi-2696	94	32	64	64	NUM
ajlsi-2696	94	33	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	94	34	am	am	NOUN
ajlsi-2696	94	35	.	.	PUNCT
ajlsi-2696	95	1	j.	j.	PROPN
ajlsi-2696	95	2	life	life	PROPN
ajlsi-2696	95	3	sci	sci	PROPN
ajlsi-2696	95	4	.	.	PUNCT
ajlsi-2696	95	5	innov	innov	PROPN
ajlsi-2696	95	6	.	.	PUNCT
ajlsi-2696	96	1	3(1	3(1	NUM
ajlsi-2696	96	2	)	)	PUNCT
ajlsi-2696	96	3	61	61	NUM
ajlsi-2696	96	4	-	-	SYM
ajlsi-2696	96	5	68	68	NUM
ajlsi-2696	96	6	,	,	PUNCT
ajlsi-2696	96	7	2024	2024	NUM
ajlsi-2696	96	8	alone	alone	ADV
ajlsi-2696	96	9	.	.	PUNCT
ajlsi-2696	97	1	consequently	consequently	ADV
ajlsi-2696	97	2	,	,	PUNCT
ajlsi-2696	97	3	dupilumab	dupilumab	NOUN
ajlsi-2696	97	4	combined	combine	VERB
ajlsi-2696	97	5	with	with	ADP
ajlsi-2696	97	6	topical	topical	ADJ
ajlsi-2696	97	7	corticosteroids	corticosteroid	NOUN
ajlsi-2696	97	8	is	be	AUX
ajlsi-2696	97	9	a	a	DET
ajlsi-2696	97	10	beneficial	beneficial	ADJ
ajlsi-2696	97	11	therapeutic	therapeutic	ADJ
ajlsi-2696	97	12	strategy	strategy	NOUN
ajlsi-2696	97	13	for	for	ADP
ajlsi-2696	97	14	diseases	disease	NOUN
ajlsi-2696	97	15	like	like	ADP
ajlsi-2696	97	16	atopic	atopic	NOUN
ajlsi-2696	97	17	dermatitis	dermatitis	NOUN
ajlsi-2696	97	18	,	,	PUNCT
ajlsi-2696	97	19	providing	provide	VERB
ajlsi-2696	97	20	patients	patient	NOUN
ajlsi-2696	97	21	with	with	ADP
ajlsi-2696	97	22	better	well	ADJ
ajlsi-2696	97	23	results	result	NOUN
ajlsi-2696	97	24	and	and	CCONJ
ajlsi-2696	97	25	a	a	DET
ajlsi-2696	97	26	higher	high	ADJ
ajlsi-2696	97	27	quality	quality	NOUN
ajlsi-2696	97	28	of	of	ADP
ajlsi-2696	97	29	life	life	NOUN
ajlsi-2696	97	30	,	,	PUNCT
ajlsi-2696	97	31	according	accord	VERB
ajlsi-2696	97	32	to	to	ADP
ajlsi-2696	97	33	data	datum	NOUN
ajlsi-2696	97	34	from	from	ADP
ajlsi-2696	97	35	fda	fda	PROPN
ajlsi-2696	97	36	clinical	clinical	ADJ
ajlsi-2696	97	37	trials	trial	NOUN
ajlsi-2696	97	38	and	and	CCONJ
ajlsi-2696	97	39	reviews	review	NOUN
ajlsi-2696	97	40	(	(	PUNCT
ajlsi-2696	97	41	fda	fda	PROPN
ajlsi-2696	97	42	,	,	PUNCT
ajlsi-2696	97	43	2017	2017	NUM
ajlsi-2696	97	44	)	)	PUNCT
ajlsi-2696	97	45	.	.	PUNCT
ajlsi-2696	98	1	immunosuppressant	immunosuppressant	PROPN
ajlsi-2696	98	2	’s	’s	PART
ajlsi-2696	98	3	cyclosporine	cyclosporine	VERB
ajlsi-2696	98	4	a	a	DET
ajlsi-2696	98	5	calcineurin	calcineurin	ADJ
ajlsi-2696	98	6	inhibitor	inhibitor	NOUN
ajlsi-2696	98	7	,	,	PUNCT
ajlsi-2696	98	8	targets	target	VERB
ajlsi-2696	98	9	t	t	NOUN
ajlsi-2696	98	10	cells	cell	NOUN
ajlsi-2696	98	11	specifically	specifically	ADV
ajlsi-2696	98	12	,	,	PUNCT
ajlsi-2696	98	13	inhibiting	inhibit	VERB
ajlsi-2696	98	14	the	the	DET
ajlsi-2696	98	15	transcription	transcription	NOUN
ajlsi-2696	98	16	of	of	ADP
ajlsi-2696	98	17	the	the	DET
ajlsi-2696	98	18	interleukin	interleukin	NOUN
ajlsi-2696	98	19	2	2	NUM
ajlsi-2696	98	20	gene	gene	NOUN
ajlsi-2696	98	21	,	,	PUNCT
ajlsi-2696	98	22	modifying	modify	VERB
ajlsi-2696	98	23	the	the	DET
ajlsi-2696	98	24	immune	immune	ADJ
ajlsi-2696	98	25	response	response	NOUN
ajlsi-2696	98	26	,	,	PUNCT
ajlsi-2696	98	27	and	and	CCONJ
ajlsi-2696	98	28	lowering	lower	VERB
ajlsi-2696	98	29	inflammation	inflammation	NOUN
ajlsi-2696	98	30	in	in	ADP
ajlsi-2696	98	31	diseases	disease	NOUN
ajlsi-2696	98	32	such	such	ADJ
ajlsi-2696	98	33	as	as	ADP
ajlsi-2696	98	34	atopic	atopic	NOUN
ajlsi-2696	98	35	dermatitis	dermatitis	NOUN
ajlsi-2696	98	36	,	,	PUNCT
ajlsi-2696	98	37	typically	typically	ADV
ajlsi-2696	98	38	administered	administer	VERB
ajlsi-2696	98	39	at	at	ADP
ajlsi-2696	98	40	a	a	DET
ajlsi-2696	98	41	dose	dose	NOUN
ajlsi-2696	98	42	of	of	ADP
ajlsi-2696	98	43	“	"	PUNCT
ajlsi-2696	98	44	5	5	NUM
ajlsi-2696	98	45	mg	mg	PROPN
ajlsi-2696	98	46	/	/	SYM
ajlsi-2696	98	47	kg	kg	PROPN
ajlsi-2696	98	48	/	/	SYM
ajlsi-2696	98	49	day	day	NOUN
ajlsi-2696	98	50	”	"	PUNCT
ajlsi-2696	98	51	and	and	CCONJ
ajlsi-2696	98	52	available	available	ADJ
ajlsi-2696	98	53	in	in	ADP
ajlsi-2696	98	54	multiple	multiple	ADJ
ajlsi-2696	98	55	forms	form	NOUN
ajlsi-2696	98	56	,	,	PUNCT
ajlsi-2696	98	57	including	include	VERB
ajlsi-2696	98	58	intravenous	intravenous	ADJ
ajlsi-2696	98	59	formulations	formulation	NOUN
ajlsi-2696	98	60	,	,	PUNCT
ajlsi-2696	98	61	oral	oral	ADJ
ajlsi-2696	98	62	solutions	solution	NOUN
ajlsi-2696	98	63	,	,	PUNCT
ajlsi-2696	98	64	and	and	CCONJ
ajlsi-2696	98	65	gelatin	gelatin	NOUN
ajlsi-2696	98	66	capsules	capsule	NOUN
ajlsi-2696	98	67	(	(	PUNCT
ajlsi-2696	98	68	amber	amber	PROPN
ajlsi-2696	98	69	&	&	CCONJ
ajlsi-2696	98	70	tabassum	tabassum	PROPN
ajlsi-2696	98	71	,	,	PUNCT
ajlsi-2696	98	72	2020	2020	NUM
ajlsi-2696	98	73	;	;	PUNCT
ajlsi-2696	98	74	antti	antti	PROPN
ajlsi-2696	98	75	et	et	PROPN
ajlsi-2696	98	76	al	al	PROPN
ajlsi-2696	98	77	.	.	PROPN
ajlsi-2696	98	78	,	,	PUNCT
ajlsi-2696	98	79	2021	2021	NUM
ajlsi-2696	98	80	;	;	PUNCT
ajlsi-2696	98	81	megna	megna	PROPN
ajlsi-2696	98	82	et	et	PROPN
ajlsi-2696	98	83	al	al	PROPN
ajlsi-2696	98	84	.	.	PROPN
ajlsi-2696	98	85	,	,	PUNCT
ajlsi-2696	98	86	2017	2017	NUM
ajlsi-2696	98	87	;	;	PUNCT
ajlsi-2696	98	88	rajagopalan	rajagopalan	VERB
ajlsi-2696	98	89	et	et	PROPN
ajlsi-2696	98	90	al	al	PROPN
ajlsi-2696	98	91	.	.	PROPN
ajlsi-2696	98	92	,	,	PUNCT
ajlsi-2696	98	93	2022	2022	NUM
ajlsi-2696	98	94	)	)	PUNCT
ajlsi-2696	98	95	.	.	PUNCT
ajlsi-2696	99	1	mycophenolate	mycophenolate	PROPN
ajlsi-2696	99	2	based	base	VERB
ajlsi-2696	99	3	on	on	ADP
ajlsi-2696	99	4	numerous	numerous	ADJ
ajlsi-2696	99	5	investigations	investigation	NOUN
ajlsi-2696	99	6	and	and	CCONJ
ajlsi-2696	99	7	clinical	clinical	ADJ
ajlsi-2696	99	8	trials	trial	NOUN
ajlsi-2696	99	9	,	,	PUNCT
ajlsi-2696	99	10	mycophenolate	mycophenolate	PROPN
ajlsi-2696	99	11	mofetil	mofetil	PROPN
ajlsi-2696	99	12	(	(	PUNCT
ajlsi-2696	99	13	mmf	mmf	NOUN
ajlsi-2696	99	14	)	)	PUNCT
ajlsi-2696	99	15	has	have	AUX
ajlsi-2696	99	16	demonstrated	demonstrate	VERB
ajlsi-2696	99	17	promising	promise	VERB
ajlsi-2696	99	18	outcomes	outcome	NOUN
ajlsi-2696	99	19	in	in	ADP
ajlsi-2696	99	20	treating	treat	VERB
ajlsi-2696	99	21	atopic	atopic	NOUN
ajlsi-2696	99	22	dermatitis	dermatitis	NOUN
ajlsi-2696	99	23	.	.	PUNCT
ajlsi-2696	100	1	studies	study	NOUN
ajlsi-2696	100	2	showed	show	VERB
ajlsi-2696	100	3	that	that	SCONJ
ajlsi-2696	100	4	mmf	mmf	NOUN
ajlsi-2696	100	5	is	be	AUX
ajlsi-2696	100	6	useful	useful	ADJ
ajlsi-2696	100	7	in	in	ADP
ajlsi-2696	100	8	treating	treat	VERB
ajlsi-2696	100	9	moderate	moderate	ADJ
ajlsi-2696	100	10	to	to	ADP
ajlsi-2696	100	11	severe	severe	ADJ
ajlsi-2696	100	12	ad	ad	NOUN
ajlsi-2696	100	13	among	among	ADP
ajlsi-2696	100	14	individuals	individual	NOUN
ajlsi-2696	100	15	who	who	PRON
ajlsi-2696	100	16	did	do	AUX
ajlsi-2696	100	17	not	not	PART
ajlsi-2696	100	18	respond	respond	VERB
ajlsi-2696	100	19	to	to	ADP
ajlsi-2696	100	20	conventional	conventional	ADJ
ajlsi-2696	100	21	treatments	treatment	NOUN
ajlsi-2696	100	22	;	;	PUNCT
ajlsi-2696	100	23	there	there	PRON
ajlsi-2696	100	24	was	be	VERB
ajlsi-2696	100	25	a	a	DET
ajlsi-2696	100	26	notable	notable	ADJ
ajlsi-2696	100	27	improvement	improvement	NOUN
ajlsi-2696	100	28	in	in	ADP
ajlsi-2696	100	29	the	the	DET
ajlsi-2696	100	30	severity	severity	NOUN
ajlsi-2696	100	31	of	of	ADP
ajlsi-2696	100	32	the	the	DET
ajlsi-2696	100	33	illness	illness	NOUN
ajlsi-2696	100	34	.	.	PUNCT
ajlsi-2696	101	1	mmf	mmf	NOUN
ajlsi-2696	101	2	significantly	significantly	ADV
ajlsi-2696	101	3	reduced	reduce	VERB
ajlsi-2696	101	4	the	the	DET
ajlsi-2696	101	5	scorad	scorad	PROPN
ajlsi-2696	101	6	index	index	NOUN
ajlsi-2696	101	7	,	,	PUNCT
ajlsi-2696	101	8	a	a	DET
ajlsi-2696	101	9	gauge	gauge	NOUN
ajlsi-2696	101	10	of	of	ADP
ajlsi-2696	101	11	the	the	DET
ajlsi-2696	101	12	severity	severity	NOUN
ajlsi-2696	101	13	of	of	ADP
ajlsi-2696	101	14	ad	ad	NOUN
ajlsi-2696	101	15	,	,	PUNCT
ajlsi-2696	101	16	within	within	ADP
ajlsi-2696	101	17	a	a	DET
ajlsi-2696	101	18	few	few	ADJ
ajlsi-2696	101	19	weeks	week	NOUN
ajlsi-2696	101	20	of	of	ADP
ajlsi-2696	101	21	treatment	treatment	NOUN
ajlsi-2696	101	22	;	;	PUNCT
ajlsi-2696	101	23	it	it	PRON
ajlsi-2696	101	24	may	may	AUX
ajlsi-2696	101	25	be	be	AUX
ajlsi-2696	101	26	a	a	DET
ajlsi-2696	101	27	useful	useful	ADJ
ajlsi-2696	101	28	substitute	substitute	NOUN
ajlsi-2696	101	29	for	for	ADP
ajlsi-2696	101	30	people	people	NOUN
ajlsi-2696	101	31	with	with	ADP
ajlsi-2696	101	32	severe	severe	ADJ
ajlsi-2696	101	33	or	or	CCONJ
ajlsi-2696	101	34	refractory	refractory	NOUN
ajlsi-2696	101	35	types	type	NOUN
ajlsi-2696	101	36	of	of	ADP
ajlsi-2696	101	37	ad	ad	NOUN
ajlsi-2696	101	38	because	because	SCONJ
ajlsi-2696	101	39	of	of	ADP
ajlsi-2696	101	40	fewer	few	ADJ
ajlsi-2696	101	41	risks	risk	NOUN
ajlsi-2696	101	42	of	of	ADP
ajlsi-2696	101	43	causing	cause	VERB
ajlsi-2696	101	44	adverse	adverse	ADJ
ajlsi-2696	101	45	effects	effect	NOUN
ajlsi-2696	101	46	than	than	ADP
ajlsi-2696	101	47	other	other	ADJ
ajlsi-2696	101	48	longterm	longterm	ADJ
ajlsi-2696	101	49	therapies	therapy	NOUN
ajlsi-2696	101	50	for	for	ADP
ajlsi-2696	101	51	the	the	DET
ajlsi-2696	101	52	disease	disease	NOUN
ajlsi-2696	101	53	(	(	PUNCT
ajlsi-2696	101	54	phan	phan	PROPN
ajlsi-2696	101	55	&	&	CCONJ
ajlsi-2696	101	56	smith	smith	PROPN
ajlsi-2696	101	57	,	,	PUNCT
ajlsi-2696	101	58	2020	2020	NUM
ajlsi-2696	101	59	)	)	PUNCT
ajlsi-2696	101	60	.	.	PUNCT
ajlsi-2696	102	1	azathioprine	azathioprine	PROPN
ajlsi-2696	102	2	immunosuppressive	immunosuppressive	ADJ
ajlsi-2696	102	3	drugs	drug	NOUN
ajlsi-2696	102	4	like	like	ADP
ajlsi-2696	102	5	azathioprine	azathioprine	NOUN
ajlsi-2696	102	6	prevent	prevent	VERB
ajlsi-2696	102	7	the	the	DET
ajlsi-2696	102	8	manufacture	manufacture	NOUN
ajlsi-2696	102	9	of	of	ADP
ajlsi-2696	102	10	purines	purine	NOUN
ajlsi-2696	102	11	,	,	PUNCT
ajlsi-2696	102	12	which	which	PRON
ajlsi-2696	102	13	impacts	impact	VERB
ajlsi-2696	102	14	lymphocytes	lymphocyte	NOUN
ajlsi-2696	102	15	and	and	CCONJ
ajlsi-2696	102	16	helps	help	VERB
ajlsi-2696	102	17	regulate	regulate	VERB
ajlsi-2696	102	18	the	the	DET
ajlsi-2696	102	19	immune	immune	ADJ
ajlsi-2696	102	20	system	system	NOUN
ajlsi-2696	102	21	in	in	ADP
ajlsi-2696	102	22	atopic	atopic	NOUN
ajlsi-2696	102	23	dermatitis	dermatitis	NOUN
ajlsi-2696	102	24	(	(	PUNCT
ajlsi-2696	102	25	ad	ad	NOUN
ajlsi-2696	102	26	)	)	PUNCT
ajlsi-2696	102	27	by	by	ADP
ajlsi-2696	102	28	lowering	lower	VERB
ajlsi-2696	102	29	inflammation	inflammation	NOUN
ajlsi-2696	102	30	and	and	CCONJ
ajlsi-2696	102	31	managing	manage	VERB
ajlsi-2696	102	32	symptoms	symptom	NOUN
ajlsi-2696	102	33	.	.	PUNCT
ajlsi-2696	103	1	the	the	DET
ajlsi-2696	103	2	recommended	recommend	VERB
ajlsi-2696	103	3	daily	daily	ADJ
ajlsi-2696	103	4	dose	dose	NOUN
ajlsi-2696	103	5	of	of	ADP
ajlsi-2696	103	6	azathioprine	azathioprine	PROPN
ajlsi-2696	103	7	for	for	ADP
ajlsi-2696	103	8	ad	ad	NOUN
ajlsi-2696	103	9	is	be	AUX
ajlsi-2696	103	10	1	1	NUM
ajlsi-2696	103	11	-	-	SYM
ajlsi-2696	103	12	2.5	2.5	NUM
ajlsi-2696	103	13	mg	mg	PROPN
ajlsi-2696	103	14	/	/	SYM
ajlsi-2696	103	15	kg	kg	PROPN
ajlsi-2696	103	16	,	,	PUNCT
ajlsi-2696	103	17	with	with	ADP
ajlsi-2696	103	18	adjustments	adjustment	NOUN
ajlsi-2696	103	19	based	base	VERB
ajlsi-2696	103	20	on	on	ADP
ajlsi-2696	103	21	individual	individual	ADJ
ajlsi-2696	103	22	patient	patient	ADJ
ajlsi-2696	103	23	response	response	NOUN
ajlsi-2696	103	24	and	and	CCONJ
ajlsi-2696	103	25	tolerance	tolerance	NOUN
ajlsi-2696	103	26	.	.	PUNCT
ajlsi-2696	104	1	it	it	PRON
ajlsi-2696	104	2	can	can	AUX
ajlsi-2696	104	3	cause	cause	VERB
ajlsi-2696	104	4	myelosuppression	myelosuppression	NOUN
ajlsi-2696	104	5	,	,	PUNCT
ajlsi-2696	104	6	increased	increase	VERB
ajlsi-2696	104	7	risk	risk	NOUN
ajlsi-2696	104	8	of	of	ADP
ajlsi-2696	104	9	infection	infection	NOUN
ajlsi-2696	104	10	,	,	PUNCT
ajlsi-2696	104	11	and	and	CCONJ
ajlsi-2696	104	12	gastrointestinal	gastrointestinal	ADJ
ajlsi-2696	104	13	problems	problem	NOUN
ajlsi-2696	104	14	.	.	PUNCT
ajlsi-2696	105	1	safety	safety	NOUN
ajlsi-2696	105	2	profile	profile	PROPN
ajlsi-2696	105	3	&	&	CCONJ
ajlsi-2696	105	4	clinical	clinical	ADJ
ajlsi-2696	105	5	trials	trial	NOUN
ajlsi-2696	105	6	of	of	ADP
ajlsi-2696	105	7	immunosuppressants	immunosuppressant	NOUN
ajlsi-2696	105	8	in	in	ADP
ajlsi-2696	105	9	comparison	comparison	NOUN
ajlsi-2696	105	10	with	with	ADP
ajlsi-2696	105	11	dupilumab	dupilumab	NOUN
ajlsi-2696	105	12	according	accord	VERB
ajlsi-2696	105	13	to	to	ADP
ajlsi-2696	105	14	the	the	DET
ajlsi-2696	105	15	information	information	NOUN
ajlsi-2696	105	16	provided	provide	VERB
ajlsi-2696	105	17	by	by	ADP
ajlsi-2696	105	18	the	the	DET
ajlsi-2696	105	19	sources	source	NOUN
ajlsi-2696	105	20	,	,	PUNCT
ajlsi-2696	105	21	including	include	VERB
ajlsi-2696	105	22	the	the	DET
ajlsi-2696	105	23	fda	fda	PROPN
ajlsi-2696	105	24	approvals	approval	NOUN
ajlsi-2696	105	25	and	and	CCONJ
ajlsi-2696	105	26	clinical	clinical	ADJ
ajlsi-2696	105	27	trials	trial	NOUN
ajlsi-2696	105	28	on	on	ADP
ajlsi-2696	105	29	the	the	DET
ajlsi-2696	105	30	drug	drug	NOUN
ajlsi-2696	105	31	,	,	PUNCT
ajlsi-2696	105	32	dupilumab	dupilumab	NOUN
ajlsi-2696	105	33	,	,	PUNCT
ajlsi-2696	105	34	also	also	ADV
ajlsi-2696	105	35	known	know	VERB
ajlsi-2696	105	36	as	as	ADP
ajlsi-2696	105	37	dupixent	dupixent	NOUN
ajlsi-2696	105	38	,	,	PUNCT
ajlsi-2696	105	39	has	have	AUX
ajlsi-2696	105	40	been	be	AUX
ajlsi-2696	105	41	the	the	DET
ajlsi-2696	105	42	subject	subject	NOUN
ajlsi-2696	105	43	of	of	ADP
ajlsi-2696	105	44	substantial	substantial	ADJ
ajlsi-2696	105	45	research	research	NOUN
ajlsi-2696	105	46	spanning	span	VERB
ajlsi-2696	105	47	over	over	ADP
ajlsi-2696	105	48	“	"	PUNCT
ajlsi-2696	105	49	60	60	NUM
ajlsi-2696	105	50	clinical	clinical	ADJ
ajlsi-2696	105	51	trials	trial	NOUN
ajlsi-2696	105	52	”	"	PUNCT
ajlsi-2696	105	53	involving	involve	VERB
ajlsi-2696	105	54	over	over	ADP
ajlsi-2696	105	55	“	"	PUNCT
ajlsi-2696	105	56	10,000	10,000	NUM
ajlsi-2696	105	57	”	"	PUNCT
ajlsi-2696	105	58	patients	patient	NOUN
ajlsi-2696	105	59	with	with	ADP
ajlsi-2696	105	60	various	various	ADJ
ajlsi-2696	105	61	chronic	chronic	ADJ
ajlsi-2696	105	62	conditions	condition	NOUN
ajlsi-2696	105	63	.	.	PUNCT
ajlsi-2696	106	1	for	for	ADP
ajlsi-2696	106	2	the	the	DET
ajlsi-2696	106	3	treatment	treatment	NOUN
ajlsi-2696	106	4	of	of	ADP
ajlsi-2696	106	5	disorders	disorder	NOUN
ajlsi-2696	106	6	such	such	ADJ
ajlsi-2696	106	7	as	as	ADP
ajlsi-2696	106	8	asthma	asthma	NOUN
ajlsi-2696	106	9	,	,	PUNCT
ajlsi-2696	106	10	atopic	atopic	NOUN
ajlsi-2696	106	11	dermatitis	dermatitis	NOUN
ajlsi-2696	106	12	,	,	PUNCT
ajlsi-2696	106	13	chronic	chronic	ADJ
ajlsi-2696	106	14	rhinosinusitis	rhinosinusitis	NOUN
ajlsi-2696	106	15	with	with	ADP
ajlsi-2696	106	16	nasal	nasal	ADJ
ajlsi-2696	106	17	polyposis	polyposis	NOUN
ajlsi-2696	106	18	,	,	PUNCT
ajlsi-2696	106	19	and	and	CCONJ
ajlsi-2696	106	20	eosinophilic	eosinophilic	ADJ
ajlsi-2696	106	21	esophagitis	esophagitis	NOUN
ajlsi-2696	106	22	,	,	PUNCT
ajlsi-2696	106	23	dupilumab	dupilumab	NOUN
ajlsi-2696	106	24	,	,	PUNCT
ajlsi-2696	106	25	a	a	DET
ajlsi-2696	106	26	completely	completely	ADV
ajlsi-2696	106	27	human	human	ADJ
ajlsi-2696	106	28	monoclonal	monoclonal	NOUN
ajlsi-2696	106	29	antibody	antibody	NOUN
ajlsi-2696	106	30	that	that	PRON
ajlsi-2696	106	31	inhibits	inhibit	VERB
ajlsi-2696	106	32	interleukin-4	interleukin-4	PROPN
ajlsi-2696	106	33	(	(	PUNCT
ajlsi-2696	106	34	il-4	il-4	NOUN
ajlsi-2696	106	35	)	)	PUNCT
ajlsi-2696	106	36	and	and	CCONJ
ajlsi-2696	106	37	interleukin-13	interleukin-13	PROPN
ajlsi-2696	106	38	(	(	PUNCT
ajlsi-2696	106	39	il-13	il-13	ADV
ajlsi-2696	106	40	)	)	PUNCT
ajlsi-2696	106	41	signaling	signal	VERB
ajlsi-2696	106	42	has	have	AUX
ajlsi-2696	106	43	demonstrated	demonstrate	VERB
ajlsi-2696	106	44	noteworthy	noteworthy	ADJ
ajlsi-2696	106	45	clinical	clinical	ADJ
ajlsi-2696	106	46	advantages	advantage	NOUN
ajlsi-2696	106	47	.	.	PUNCT
ajlsi-2696	107	1	dupilumab	dupilumab	NOUN
ajlsi-2696	107	2	’s	’s	PART
ajlsi-2696	107	3	effectiveness	effectiveness	NOUN
ajlsi-2696	107	4	in	in	ADP
ajlsi-2696	107	5	lowering	lower	VERB
ajlsi-2696	107	6	type	type	NOUN
ajlsi-2696	107	7	2	2	NUM
ajlsi-2696	107	8	inflammation	inflammation	NOUN
ajlsi-2696	107	9	,	,	PUNCT
ajlsi-2696	107	10	a	a	DET
ajlsi-2696	107	11	major	major	ADJ
ajlsi-2696	107	12	factor	factor	NOUN
ajlsi-2696	107	13	in	in	ADP
ajlsi-2696	107	14	many	many	ADJ
ajlsi-2696	107	15	illnesses	illness	NOUN
ajlsi-2696	107	16	,	,	PUNCT
ajlsi-2696	107	17	has	have	AUX
ajlsi-2696	107	18	been	be	AUX
ajlsi-2696	107	19	demonstrated	demonstrate	VERB
ajlsi-2696	107	20	by	by	ADP
ajlsi-2696	107	21	these	these	DET
ajlsi-2696	107	22	trials	trial	NOUN
ajlsi-2696	107	23	.	.	PUNCT
ajlsi-2696	108	1	specifically	specifically	ADV
ajlsi-2696	108	2	,	,	PUNCT
ajlsi-2696	108	3	the	the	DET
ajlsi-2696	108	4	fda	fda	PROPN
ajlsi-2696	108	5	has	have	AUX
ajlsi-2696	108	6	approved	approve	VERB
ajlsi-2696	108	7	dupilumab	dupilumab	NOUN
ajlsi-2696	108	8	for	for	ADP
ajlsi-2696	108	9	kids	kid	NOUN
ajlsi-2696	108	10	with	with	ADP
ajlsi-2696	108	11	eosinophilic	eosinophilic	ADJ
ajlsi-2696	108	12	esophagitis	esophagitis	NOUN
ajlsi-2696	108	13	aged	age	VERB
ajlsi-2696	108	14	one	one	NUM
ajlsi-2696	108	15	year	year	NOUN
ajlsi-2696	108	16	and	and	CCONJ
ajlsi-2696	108	17	older	old	ADJ
ajlsi-2696	108	18	,	,	PUNCT
ajlsi-2696	108	19	as	as	ADV
ajlsi-2696	108	20	well	well	ADV
ajlsi-2696	108	21	as	as	ADP
ajlsi-2696	108	22	kids	kid	NOUN
ajlsi-2696	108	23	with	with	ADP
ajlsi-2696	108	24	moderate	moderate	ADJ
ajlsi-2696	108	25	-	-	PUNCT
ajlsi-2696	108	26	to	to	ADP
ajlsi-2696	108	27	-	-	PUNCT
ajlsi-2696	108	28	severe	severe	ADJ
ajlsi-2696	108	29	atopic	atopic	NOUN
ajlsi-2696	108	30	dermatitis	dermatitis	NOUN
ajlsi-2696	108	31	aged	age	VERB
ajlsi-2696	108	32	six	six	NUM
ajlsi-2696	108	33	months	month	NOUN
ajlsi-2696	108	34	to	to	ADP
ajlsi-2696	108	35	five	five	NUM
ajlsi-2696	108	36	years	year	NOUN
ajlsi-2696	108	37	.	.	PUNCT
ajlsi-2696	109	1	(	(	PUNCT
ajlsi-2696	109	2	fda	fda	PROPN
ajlsi-2696	109	3	,	,	PUNCT
ajlsi-2696	109	4	2019	2019	NUM
ajlsi-2696	109	5	)	)	PUNCT
ajlsi-2696	109	6	.	.	PUNCT
ajlsi-2696	110	1	demards	demards	ADV
ajlsi-2696	110	2	(	(	PUNCT
ajlsi-2696	110	3	disease	disease	NOUN
ajlsi-2696	110	4	-	-	PUNCT
ajlsi-2696	110	5	modifying	modify	VERB
ajlsi-2696	110	6	anti	anti	ADJ
ajlsi-2696	110	7	-	-	ADJ
ajlsi-2696	110	8	rheumatic	rheumatic	ADJ
ajlsi-2696	110	9	drugs	drug	NOUN
ajlsi-2696	110	10	)	)	PUNCT
ajlsi-2696	110	11	methotrexate	methotrexate	NOUN
ajlsi-2696	110	12	inhibits	inhibit	VERB
ajlsi-2696	110	13	the	the	DET
ajlsi-2696	110	14	immune	immune	ADJ
ajlsi-2696	110	15	system	system	NOUN
ajlsi-2696	110	16	by	by	ADP
ajlsi-2696	110	17	inhibiting	inhibit	VERB
ajlsi-2696	110	18	dna	dna	ADJ
ajlsi-2696	110	19	synthesis	synthesis	NOUN
ajlsi-2696	110	20	and	and	CCONJ
ajlsi-2696	110	21	cell	cell	NOUN
ajlsi-2696	110	22	division	division	NOUN
ajlsi-2696	110	23	by	by	ADP
ajlsi-2696	110	24	blocking	block	VERB
ajlsi-2696	110	25	dihydrofolate	dihydrofolate	NOUN
ajlsi-2696	110	26	reductase	reductase	NOUN
ajlsi-2696	110	27	.	.	PUNCT
ajlsi-2696	111	1	for	for	ADP
ajlsi-2696	111	2	ad	ad	NOUN
ajlsi-2696	111	3	,	,	PUNCT
ajlsi-2696	111	4	methotrexate	methotrexate	NOUN
ajlsi-2696	111	5	is	be	AUX
ajlsi-2696	111	6	administered	administer	VERB
ajlsi-2696	111	7	at	at	ADP
ajlsi-2696	111	8	a	a	DET
ajlsi-2696	111	9	starting	starting	NOUN
ajlsi-2696	111	10	dose	dose	NOUN
ajlsi-2696	111	11	of	of	ADP
ajlsi-2696	111	12	10.3	10.3	NUM
ajlsi-2696	111	13	-	-	SYM
ajlsi-2696	111	14	2.6	2.6	NUM
ajlsi-2696	111	15	mg	mg	NUM
ajlsi-2696	111	16	/	/	SYM
ajlsi-2696	111	17	week	week	NOUN
ajlsi-2696	111	18	,	,	PUNCT
ajlsi-2696	111	19	which	which	PRON
ajlsi-2696	111	20	can	can	AUX
ajlsi-2696	111	21	be	be	AUX
ajlsi-2696	111	22	changed	change	VERB
ajlsi-2696	111	23	according	accord	VERB
ajlsi-2696	111	24	to	to	ADP
ajlsi-2696	111	25	the	the	DET
ajlsi-2696	111	26	patient	patient	NOUN
ajlsi-2696	111	27	’s	’s	PART
ajlsi-2696	111	28	tolerance	tolerance	NOUN
ajlsi-2696	111	29	and	and	CCONJ
ajlsi-2696	111	30	reaction	reaction	NOUN
ajlsi-2696	111	31	.	.	PUNCT
ajlsi-2696	112	1	weekly	weekly	ADJ
ajlsi-2696	112	2	increases	increase	NOUN
ajlsi-2696	112	3	are	be	AUX
ajlsi-2696	112	4	possible	possible	ADJ
ajlsi-2696	112	5	,	,	PUNCT
ajlsi-2696	112	6	with	with	ADP
ajlsi-2696	112	7	maintenance	maintenance	NOUN
ajlsi-2696	112	8	dosages	dosage	NOUN
ajlsi-2696	112	9	of	of	ADP
ajlsi-2696	112	10	about	about	ADP
ajlsi-2696	112	11	“	"	PUNCT
ajlsi-2696	112	12	11.7	11.7	NUM
ajlsi-2696	112	13	mg	mg	PROPN
ajlsi-2696	112	14	”	"	PUNCT
ajlsi-2696	112	15	(	(	PUNCT
ajlsi-2696	112	16	lee	lee	PROPN
ajlsi-2696	112	17	et	et	PROPN
ajlsi-2696	112	18	al	al	PROPN
ajlsi-2696	112	19	.	.	PROPN
ajlsi-2696	112	20	,	,	PUNCT
ajlsi-2696	112	21	2020	2020	NUM
ajlsi-2696	112	22	;	;	PUNCT
ajlsi-2696	112	23	shah	shah	PROPN
ajlsi-2696	112	24	et	et	PROPN
ajlsi-2696	112	25	al	al	PROPN
ajlsi-2696	112	26	.	.	PROPN
ajlsi-2696	112	27	,	,	PUNCT
ajlsi-2696	112	28	2018	2018	NUM
ajlsi-2696	112	29	)	)	PUNCT
ajlsi-2696	112	30	.	.	PUNCT
ajlsi-2696	113	1	comparison	comparison	NOUN
ajlsi-2696	113	2	with	with	ADP
ajlsi-2696	113	3	biological	biological	ADJ
ajlsi-2696	113	4	agents	agent	NOUN
ajlsi-2696	113	5	like	like	ADP
ajlsi-2696	113	6	dupilumab	dupilumab	NOUN
ajlsi-2696	113	7	on	on	ADP
ajlsi-2696	113	8	based	base	VERB
ajlsi-2696	113	9	on	on	ADP
ajlsi-2696	113	10	clinical	clinical	ADJ
ajlsi-2696	113	11	trials	trial	NOUN
ajlsi-2696	113	12	in	in	ADP
ajlsi-2696	113	13	individuals	individual	NOUN
ajlsi-2696	113	14	with	with	ADP
ajlsi-2696	113	15	moderate	moderate	ADJ
ajlsi-2696	113	16	to	to	ADP
ajlsi-2696	113	17	severe	severe	ADJ
ajlsi-2696	113	18	atopic	atopic	NOUN
ajlsi-2696	113	19	dermatitis	dermatitis	NOUN
ajlsi-2696	113	20	,	,	PUNCT
ajlsi-2696	113	21	dupilumab	dupilumab	NOUN
ajlsi-2696	113	22	has	have	AUX
ajlsi-2696	113	23	been	be	AUX
ajlsi-2696	113	24	demonstrated	demonstrate	VERB
ajlsi-2696	113	25	to	to	PART
ajlsi-2696	113	26	be	be	AUX
ajlsi-2696	113	27	more	more	ADV
ajlsi-2696	113	28	successful	successful	ADJ
ajlsi-2696	113	29	than	than	ADP
ajlsi-2696	113	30	methotrexate	methotrexate	VERB
ajlsi-2696	113	31	in	in	ADP
ajlsi-2696	113	32	reducing	reduce	VERB
ajlsi-2696	113	33	symptoms	symptom	NOUN
ajlsi-2696	113	34	and	and	CCONJ
ajlsi-2696	113	35	quality	quality	NOUN
ajlsi-2696	113	36	of	of	ADP
ajlsi-2696	113	37	life	life	NOUN
ajlsi-2696	113	38	.	.	PUNCT
ajlsi-2696	114	1	this	this	DET
ajlsi-2696	114	2	conclusion	conclusion	NOUN
ajlsi-2696	114	3	is	be	AUX
ajlsi-2696	114	4	based	base	VERB
ajlsi-2696	114	5	on	on	ADP
ajlsi-2696	114	6	fda	fda	PROPN
ajlsi-2696	114	7	clinical	clinical	ADJ
ajlsi-2696	114	8	trials	trial	NOUN
ajlsi-2696	114	9	and	and	CCONJ
ajlsi-2696	114	10	real	real	ADJ
ajlsi-2696	114	11	-	-	PUNCT
ajlsi-2696	114	12	world	world	NOUN
ajlsi-2696	114	13	analysis	analysis	NOUN
ajlsi-2696	114	14	comparing	compare	VERB
ajlsi-2696	114	15	the	the	DET
ajlsi-2696	114	16	two	two	NUM
ajlsi-2696	114	17	medications	medication	NOUN
ajlsi-2696	114	18	.	.	PUNCT
ajlsi-2696	115	1	when	when	SCONJ
ajlsi-2696	115	2	compared	compare	VERB
ajlsi-2696	115	3	to	to	ADP
ajlsi-2696	115	4	methotrexate	methotrexate	VERB
ajlsi-2696	115	5	,	,	PUNCT
ajlsi-2696	115	6	the	the	DET
ajlsi-2696	115	7	trials	trial	NOUN
ajlsi-2696	115	8	showed	show	VERB
ajlsi-2696	115	9	that	that	SCONJ
ajlsi-2696	115	10	dupilumab	dupilumab	NOUN
ajlsi-2696	115	11	improved	improve	VERB
ajlsi-2696	115	12	atopic	atopic	NOUN
ajlsi-2696	115	13	dermatitis	dermatitis	NOUN
ajlsi-2696	115	14	symptoms	symptom	NOUN
ajlsi-2696	115	15	and	and	CCONJ
ajlsi-2696	115	16	signs	sign	NOUN
ajlsi-2696	115	17	more	more	ADJ
ajlsi-2696	115	18	,	,	PUNCT
ajlsi-2696	115	19	and	and	CCONJ
ajlsi-2696	115	20	there	there	PRON
ajlsi-2696	115	21	were	be	VERB
ajlsi-2696	115	22	fewer	few	ADJ
ajlsi-2696	115	23	side	side	ADJ
ajlsi-2696	115	24	effects	effect	NOUN
ajlsi-2696	115	25	and	and	CCONJ
ajlsi-2696	115	26	treatment	treatment	NOUN
ajlsi-2696	115	27	discontinuations	discontinuation	NOUN
ajlsi-2696	115	28	.	.	PUNCT
ajlsi-2696	116	1	for	for	ADP
ajlsi-2696	116	2	treating	treat	VERB
ajlsi-2696	116	3	atopic	atopic	NOUN
ajlsi-2696	116	4	dermatitis	dermatitis	NOUN
ajlsi-2696	116	5	,	,	PUNCT
ajlsi-2696	116	6	dupilumab	dupilumab	NOUN
ajlsi-2696	116	7	is	be	AUX
ajlsi-2696	116	8	therefore	therefore	ADV
ajlsi-2696	116	9	thought	think	VERB
ajlsi-2696	116	10	to	to	PART
ajlsi-2696	116	11	be	be	AUX
ajlsi-2696	116	12	more	more	ADV
ajlsi-2696	116	13	effective	effective	ADJ
ajlsi-2696	116	14	and	and	CCONJ
ajlsi-2696	116	15	tolerable	tolerable	ADJ
ajlsi-2696	116	16	than	than	ADP
ajlsi-2696	116	17	methotrexate	methotrexate	NOUN
ajlsi-2696	116	18	,	,	PUNCT
ajlsi-2696	116	19	according	accord	VERB
ajlsi-2696	116	20	to	to	ADP
ajlsi-2696	116	21	data	datum	NOUN
ajlsi-2696	116	22	from	from	ADP
ajlsi-2696	116	23	fda	fda	PROPN
ajlsi-2696	116	24	clinical	clinical	ADJ
ajlsi-2696	116	25	studies	study	NOUN
ajlsi-2696	116	26	and	and	CCONJ
ajlsi-2696	116	27	real	real	ADJ
ajlsi-2696	116	28	-	-	PUNCT
ajlsi-2696	116	29	world	world	NOUN
ajlsi-2696	116	30	research	research	NOUN
ajlsi-2696	116	31	(	(	PUNCT
ajlsi-2696	116	32	fda	fda	PROPN
ajlsi-2696	116	33	,	,	PUNCT
ajlsi-2696	116	34	2017	2017	NUM
ajlsi-2696	116	35	)	)	PUNCT
ajlsi-2696	116	36	.	.	PUNCT
ajlsi-2696	117	1	histamines	histamine	NOUN
ajlsi-2696	117	2	in	in	ADP
ajlsi-2696	117	3	atopic	atopic	NOUN
ajlsi-2696	117	4	dermatitis	dermatitis	NOUN
ajlsi-2696	117	5	treatment	treatment	NOUN
ajlsi-2696	117	6	histamine	histamine	NOUN
ajlsi-2696	117	7	antagonists	antagonist	NOUN
ajlsi-2696	117	8	,	,	PUNCT
ajlsi-2696	117	9	which	which	PRON
ajlsi-2696	117	10	block	block	VERB
ajlsi-2696	117	11	h1	h1	NOUN
ajlsi-2696	117	12	and	and	CCONJ
ajlsi-2696	117	13	h4	h4	NOUN
ajlsi-2696	117	14	receptors	receptor	NOUN
ajlsi-2696	117	15	,	,	PUNCT
ajlsi-2696	117	16	reduce	reduce	VERB
ajlsi-2696	117	17	inflammation	inflammation	NOUN
ajlsi-2696	117	18	,	,	PUNCT
ajlsi-2696	117	19	nervous	nervous	ADJ
ajlsi-2696	117	20	irritability	irritability	NOUN
ajlsi-2696	117	21	,	,	PUNCT
ajlsi-2696	117	22	and	and	CCONJ
ajlsi-2696	117	23	itching	itch	VERB
ajlsi-2696	117	24	to	to	PART
ajlsi-2696	117	25	treat	treat	VERB
ajlsi-2696	117	26	the	the	DET
ajlsi-2696	117	27	symptoms	symptom	NOUN
ajlsi-2696	117	28	of	of	ADP
ajlsi-2696	117	29	atopic	atopic	NOUN
ajlsi-2696	117	30	dermatitis	dermatitis	NOUN
ajlsi-2696	117	31	(	(	PUNCT
ajlsi-2696	117	32	ad	ad	NOUN
ajlsi-2696	117	33	)	)	PUNCT
ajlsi-2696	117	34	.	.	PUNCT
ajlsi-2696	118	1	chronic	chronic	ADJ
ajlsi-2696	118	2	dermatitis	dermatitis	NOUN
ajlsi-2696	118	3	lesions	lesion	NOUN
ajlsi-2696	118	4	lessen	lessen	VERB
ajlsi-2696	118	5	pruritus	pruritus	PROPN
ajlsi-2696	118	6	and	and	CCONJ
ajlsi-2696	118	7	inflammatory	inflammatory	ADJ
ajlsi-2696	118	8	cytokines	cytokine	NOUN
ajlsi-2696	118	9	;	;	PUNCT
ajlsi-2696	118	10	in	in	ADP
ajlsi-2696	118	11	ad	ad	NOUN
ajlsi-2696	118	12	mice	mouse	NOUN
ajlsi-2696	118	13	models	model	NOUN
ajlsi-2696	118	14	,	,	PUNCT
ajlsi-2696	118	15	they	they	PRON
ajlsi-2696	118	16	have	have	VERB
ajlsi-2696	118	17	anti	anti	ADJ
ajlsi-2696	118	18	-	-	ADJ
ajlsi-2696	118	19	inflammatory	inflammatory	ADJ
ajlsi-2696	118	20	and	and	CCONJ
ajlsi-2696	118	21	anti	anti	ADJ
ajlsi-2696	118	22	-	-	ADJ
ajlsi-2696	118	23	pruritic	pruritic	ADJ
ajlsi-2696	118	24	properties	property	NOUN
ajlsi-2696	118	25	(	(	PUNCT
ajlsi-2696	118	26	albrecht	albrecht	PROPN
ajlsi-2696	118	27	&	&	CCONJ
ajlsi-2696	118	28	dittrich	dittrich	NOUN
ajlsi-2696	118	29	,	,	PUNCT
ajlsi-2696	118	30	2015	2015	NUM
ajlsi-2696	118	31	;	;	PUNCT
ajlsi-2696	118	32	ohsawa	ohsawa	PROPN
ajlsi-2696	118	33	&	&	CCONJ
ajlsi-2696	118	34	hirasawa	hirasawa	PROPN
ajlsi-2696	118	35	,	,	PUNCT
ajlsi-2696	118	36	2014	2014	NUM
ajlsi-2696	118	37	;	;	PUNCT
ajlsi-2696	118	38	schaper‐	schaper‐	NOUN
ajlsi-2696	118	39	gerhardt	gerhardt	PROPN
ajlsi-2696	118	40	et	et	PROPN
ajlsi-2696	118	41	al	al	PROPN
ajlsi-2696	118	42	.	.	PROPN
ajlsi-2696	118	43	,	,	PUNCT
ajlsi-2696	118	44	2020	2020	NUM
ajlsi-2696	118	45	)	)	PUNCT
ajlsi-2696	118	46	.	.	PUNCT
ajlsi-2696	119	1	histamine	histamine	NOUN
ajlsi-2696	119	2	antagonist	antagonist	NOUN
ajlsi-2696	119	3	’s	’s	PART
ajlsi-2696	119	4	comparison	comparison	NOUN
ajlsi-2696	119	5	with	with	ADP
ajlsi-2696	119	6	dupilumabfda	dupilumabfda	PROPN
ajlsi-2696	119	7	clinical	clinical	ADJ
ajlsi-2696	119	8	trials	trial	NOUN
ajlsi-2696	119	9	according	accord	VERB
ajlsi-2696	119	10	to	to	ADP
ajlsi-2696	119	11	fda	fda	PROPN
ajlsi-2696	119	12	clinical	clinical	ADJ
ajlsi-2696	119	13	trials	trial	NOUN
ajlsi-2696	119	14	,	,	PUNCT
ajlsi-2696	119	15	dupilumab	dupilumab	NOUN
ajlsi-2696	119	16	is	be	AUX
ajlsi-2696	119	17	superior	superior	ADJ
ajlsi-2696	119	18	to	to	ADP
ajlsi-2696	119	19	histamine	histamine	NOUN
ajlsi-2696	119	20	antagonists	antagonist	NOUN
ajlsi-2696	119	21	in	in	ADP
ajlsi-2696	119	22	treating	treat	VERB
ajlsi-2696	119	23	disorders	disorder	NOUN
ajlsi-2696	119	24	like	like	ADP
ajlsi-2696	119	25	atopic	atopic	NOUN
ajlsi-2696	119	26	dermatitis	dermatitis	NOUN
ajlsi-2696	119	27	and	and	CCONJ
ajlsi-2696	119	28	chronic	chronic	ADJ
ajlsi-2696	119	29	spontaneous	spontaneous	ADJ
ajlsi-2696	119	30	urticaria	urticaria	NOUN
ajlsi-2696	119	31	.	.	PUNCT
ajlsi-2696	120	1	atopic	atopic	NOUN
ajlsi-2696	120	2	dermatitis	dermatitis	NOUN
ajlsi-2696	120	3	patients	patient	NOUN
ajlsi-2696	120	4	with	with	ADP
ajlsi-2696	120	5	moderate	moderate	ADJ
ajlsi-2696	120	6	-	-	PUNCT
ajlsi-2696	120	7	to	to	ADP
ajlsi-2696	120	8	-	-	PUNCT
ajlsi-2696	120	9	severe	severe	ADJ
ajlsi-2696	120	10	ad	ad	NOUN
ajlsi-2696	120	11	have	have	AUX
ajlsi-2696	120	12	shown	show	VERB
ajlsi-2696	120	13	notable	notable	ADJ
ajlsi-2696	120	14	improvements	improvement	NOUN
ajlsi-2696	120	15	in	in	ADP
ajlsi-2696	120	16	their	their	PRON
ajlsi-2696	120	17	quality	quality	NOUN
ajlsi-2696	120	18	of	of	ADP
ajlsi-2696	120	19	life	life	NOUN
ajlsi-2696	120	20	and	and	CCONJ
ajlsi-2696	120	21	a	a	DET
ajlsi-2696	120	22	reduction	reduction	NOUN
ajlsi-2696	120	23	in	in	ADP
ajlsi-2696	120	24	the	the	DET
ajlsi-2696	120	25	severity	severity	NOUN
ajlsi-2696	120	26	of	of	ADP
ajlsi-2696	120	27	their	their	PRON
ajlsi-2696	120	28	condition	condition	NOUN
ajlsi-2696	120	29	after	after	ADP
ajlsi-2696	120	30	using	use	VERB
ajlsi-2696	120	31	dupilumab	dupilumab	NOUN
ajlsi-2696	120	32	,	,	PUNCT
ajlsi-2696	120	33	an	an	DET
ajlsi-2696	120	34	interleukin-4	interleukin-4	NUM
ajlsi-2696	120	35	receptor	receptor	NOUN
ajlsi-2696	120	36	alpha	alpha	NOUN
ajlsi-2696	120	37	antagonist	antagonist	NOUN
ajlsi-2696	120	38	.	.	PUNCT
ajlsi-2696	121	1	dupilumab	dupilumab	NOUN
ajlsi-2696	121	2	,	,	PUNCT
ajlsi-2696	121	3	on	on	ADP
ajlsi-2696	121	4	the	the	DET
ajlsi-2696	121	5	other	other	ADJ
ajlsi-2696	121	6	hand	hand	NOUN
ajlsi-2696	121	7	,	,	PUNCT
ajlsi-2696	121	8	may	may	AUX
ajlsi-2696	121	9	provide	provide	VERB
ajlsi-2696	121	10	a	a	DET
ajlsi-2696	121	11	more	more	ADV
ajlsi-2696	121	12	thorough	thorough	ADJ
ajlsi-2696	121	13	treatment	treatment	NOUN
ajlsi-2696	121	14	of	of	ADP
ajlsi-2696	121	15	the	the	DET
ajlsi-2696	121	16	disease	disease	NOUN
ajlsi-2696	121	17	’s	’s	PART
ajlsi-2696	121	18	underlying	underlie	VERB
ajlsi-2696	121	19	inflammatory	inflammatory	ADJ
ajlsi-2696	121	20	processes	process	NOUN
ajlsi-2696	121	21	than	than	ADP
ajlsi-2696	121	22	histamine	histamine	NOUN
ajlsi-2696	121	23	antagonists	antagonist	NOUN
ajlsi-2696	121	24	,	,	PUNCT
ajlsi-2696	121	25	which	which	PRON
ajlsi-2696	121	26	target	target	VERB
ajlsi-2696	121	27	histamine	histamine	NOUN
ajlsi-2696	121	28	receptors	receptor	NOUN
ajlsi-2696	121	29	to	to	PART
ajlsi-2696	121	30	relieve	relieve	VERB
ajlsi-2696	121	31	symptoms	symptom	NOUN
ajlsi-2696	121	32	like	like	ADP
ajlsi-2696	121	33	pruritus	pruritus	PROPN
ajlsi-2696	121	34	.	.	PUNCT
ajlsi-2696	122	1	dupilumab	dupilumab	NOUN
ajlsi-2696	122	2	is	be	AUX
ajlsi-2696	122	3	a	a	DET
ajlsi-2696	122	4	better	well	ADJ
ajlsi-2696	122	5	therapy	therapy	NOUN
ajlsi-2696	122	6	choice	choice	NOUN
ajlsi-2696	122	7	than	than	ADP
ajlsi-2696	122	8	histamine	histamine	NOUN
ajlsi-2696	122	9	antagonists	antagonist	NOUN
ajlsi-2696	122	10	for	for	ADP
ajlsi-2696	122	11	disorders	disorder	NOUN
ajlsi-2696	122	12	including	include	VERB
ajlsi-2696	122	13	atopic	atopic	NOUN
ajlsi-2696	122	14	dermatitis	dermatitis	NOUN
ajlsi-2696	122	15	and	and	CCONJ
ajlsi-2696	122	16	chronic	chronic	ADJ
ajlsi-2696	122	17	spontaneous	spontaneous	ADJ
ajlsi-2696	122	18	urticaria	urticaria	NOUN
ajlsi-2696	122	19	because	because	SCONJ
ajlsi-2696	122	20	of	of	ADP
ajlsi-2696	122	21	its	its	PRON
ajlsi-2696	122	22	demonstrated	demonstrate	VERB
ajlsi-2696	122	23	ability	ability	NOUN
ajlsi-2696	122	24	to	to	PART
ajlsi-2696	122	25	relieve	relieve	VERB
ajlsi-2696	122	26	signs	sign	NOUN
ajlsi-2696	122	27	and	and	CCONJ
ajlsi-2696	122	28	symptoms	symptom	NOUN
ajlsi-2696	122	29	of	of	ADP
ajlsi-2696	122	30	ad	ad	NOUN
ajlsi-2696	122	31	with	with	ADP
ajlsi-2696	122	32	a	a	DET
ajlsi-2696	122	33	tolerable	tolerable	ADJ
ajlsi-2696	122	34	safety	safety	NOUN
ajlsi-2696	122	35	profile	profile	NOUN
ajlsi-2696	122	36	(	(	PUNCT
ajlsi-2696	122	37	hon	hon	PROPN
ajlsi-2696	122	38	et	et	PROPN
ajlsi-2696	122	39	al	al	PROPN
ajlsi-2696	122	40	.	.	PROPN
ajlsi-2696	122	41	,	,	PUNCT
ajlsi-2696	122	42	2021	2021	NUM
ajlsi-2696	122	43	;	;	PUNCT
ajlsi-2696	122	44	clinical	clinical	ADJ
ajlsi-2696	122	45	trials	trial	NOUN
ajlsi-2696	122	46	2017	2017	NUM
ajlsi-2696	122	47	)	)	PUNCT
ajlsi-2696	122	48	.	.	PUNCT
ajlsi-2696	123	1	pa	pa	PROPN
ajlsi-2696	123	2	ge	ge	PROPN
ajlsi-2696	123	3	65	65	NUM
ajlsi-2696	123	4	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	123	5	am	am	NOUN
ajlsi-2696	123	6	.	.	PUNCT
ajlsi-2696	124	1	j.	j.	PROPN
ajlsi-2696	124	2	life	life	PROPN
ajlsi-2696	124	3	sci	sci	PROPN
ajlsi-2696	124	4	.	.	PUNCT
ajlsi-2696	124	5	innov	innov	PROPN
ajlsi-2696	124	6	.	.	PUNCT
ajlsi-2696	125	1	3(1	3(1	NUM
ajlsi-2696	125	2	)	)	PUNCT
ajlsi-2696	125	3	61	61	NUM
ajlsi-2696	125	4	-	-	SYM
ajlsi-2696	125	5	68	68	NUM
ajlsi-2696	125	6	,	,	PUNCT
ajlsi-2696	125	7	2024	2024	NUM
ajlsi-2696	125	8	tacrolimus	tacrolimus	NOUN
ajlsi-2696	125	9	as	as	ADP
ajlsi-2696	125	10	an	an	DET
ajlsi-2696	125	11	immunosuppressant	immunosuppressant	ADJ
ajlsi-2696	125	12	atopic	atopic	NOUN
ajlsi-2696	125	13	dermatitis	dermatitis	NOUN
ajlsi-2696	125	14	(	(	PUNCT
ajlsi-2696	125	15	ad	ad	NOUN
ajlsi-2696	125	16	)	)	PUNCT
ajlsi-2696	125	17	has	have	AUX
ajlsi-2696	125	18	found	find	VERB
ajlsi-2696	125	19	a	a	DET
ajlsi-2696	125	20	valuable	valuable	ADJ
ajlsi-2696	125	21	new	new	ADJ
ajlsi-2696	125	22	therapy	therapy	NOUN
ajlsi-2696	125	23	option	option	NOUN
ajlsi-2696	125	24	in	in	ADP
ajlsi-2696	125	25	tacrolimus	tacrolimus	NOUN
ajlsi-2696	125	26	,	,	PUNCT
ajlsi-2696	125	27	a	a	DET
ajlsi-2696	125	28	macrolide	macrolide	ADJ
ajlsi-2696	125	29	calcineurin	calcineurin	NOUN
ajlsi-2696	125	30	inhibitor	inhibitor	NOUN
ajlsi-2696	125	31	.	.	PUNCT
ajlsi-2696	126	1	it	it	PRON
ajlsi-2696	126	2	achieves	achieve	VERB
ajlsi-2696	126	3	its	its	PRON
ajlsi-2696	126	4	therapeutic	therapeutic	ADJ
ajlsi-2696	126	5	effects	effect	NOUN
ajlsi-2696	126	6	through	through	ADP
ajlsi-2696	126	7	immune	immune	ADJ
ajlsi-2696	126	8	response	response	NOUN
ajlsi-2696	126	9	modulation	modulation	NOUN
ajlsi-2696	126	10	and	and	CCONJ
ajlsi-2696	126	11	inhibition	inhibition	NOUN
ajlsi-2696	126	12	of	of	ADP
ajlsi-2696	126	13	inflammatory	inflammatory	ADJ
ajlsi-2696	126	14	processes	process	NOUN
ajlsi-2696	126	15	linked	link	VERB
ajlsi-2696	126	16	to	to	ADP
ajlsi-2696	126	17	ad	ad	NOUN
ajlsi-2696	126	18	progression	progression	NOUN
ajlsi-2696	126	19	.	.	PUNCT
ajlsi-2696	127	1	in	in	ADP
ajlsi-2696	127	2	the	the	DET
ajlsi-2696	127	3	treatment	treatment	NOUN
ajlsi-2696	127	4	of	of	ADP
ajlsi-2696	127	5	moderate	moderate	ADJ
ajlsi-2696	127	6	to	to	ADP
ajlsi-2696	127	7	severe	severe	ADJ
ajlsi-2696	127	8	ad	ad	NOUN
ajlsi-2696	127	9	,	,	PUNCT
ajlsi-2696	127	10	topical	topical	ADJ
ajlsi-2696	127	11	tacrolimus	tacrolimus	NOUN
ajlsi-2696	127	12	has	have	AUX
ajlsi-2696	127	13	demonstrated	demonstrate	VERB
ajlsi-2696	127	14	efficacy	efficacy	NOUN
ajlsi-2696	127	15	and	and	CCONJ
ajlsi-2696	127	16	safety	safety	NOUN
ajlsi-2696	127	17	,	,	PUNCT
ajlsi-2696	127	18	providing	provide	VERB
ajlsi-2696	127	19	a	a	DET
ajlsi-2696	127	20	non	non	ADJ
ajlsi-2696	127	21	-	-	ADJ
ajlsi-2696	127	22	corticosteroid	corticosteroid	ADJ
ajlsi-2696	127	23	option	option	NOUN
ajlsi-2696	127	24	.	.	PUNCT
ajlsi-2696	128	1	research	research	NOUN
ajlsi-2696	128	2	has	have	AUX
ajlsi-2696	128	3	shown	show	VERB
ajlsi-2696	128	4	that	that	SCONJ
ajlsi-2696	128	5	tacrolimus	tacrolimus	PROPN
ajlsi-2696	128	6	ointment	ointment	NOUN
ajlsi-2696	128	7	(	(	PUNCT
ajlsi-2696	128	8	available	available	ADJ
ajlsi-2696	128	9	in	in	ADP
ajlsi-2696	128	10	0.03	0.03	NUM
ajlsi-2696	128	11	%	%	NOUN
ajlsi-2696	128	12	and	and	CCONJ
ajlsi-2696	128	13	0.1	0.1	NUM
ajlsi-2696	128	14	%	%	NOUN
ajlsi-2696	128	15	concentrations	concentration	NOUN
ajlsi-2696	128	16	)	)	PUNCT
ajlsi-2696	128	17	is	be	AUX
ajlsi-2696	128	18	more	more	ADV
ajlsi-2696	128	19	effective	effective	ADJ
ajlsi-2696	128	20	in	in	ADP
ajlsi-2696	128	21	treating	treat	VERB
ajlsi-2696	128	22	ad	ad	NOUN
ajlsi-2696	128	23	than	than	ADP
ajlsi-2696	128	24	pimecrolimus	pimecrolimus	NOUN
ajlsi-2696	128	25	and	and	CCONJ
ajlsi-2696	128	26	moderate	moderate	ADJ
ajlsi-2696	128	27	corticosteroids	corticosteroid	NOUN
ajlsi-2696	128	28	.	.	PUNCT
ajlsi-2696	129	1	tacrolimus	tacrolimus	PROPN
ajlsi-2696	129	2	works	work	VERB
ajlsi-2696	129	3	by	by	ADP
ajlsi-2696	129	4	attaching	attach	VERB
ajlsi-2696	129	5	itself	itself	PRON
ajlsi-2696	129	6	to	to	ADP
ajlsi-2696	129	7	particular	particular	ADJ
ajlsi-2696	129	8	t	t	NOUN
ajlsi-2696	129	9	cell	cell	NOUN
ajlsi-2696	129	10	receptors	receptor	NOUN
ajlsi-2696	129	11	,	,	PUNCT
ajlsi-2696	129	12	which	which	PRON
ajlsi-2696	129	13	raises	raise	VERB
ajlsi-2696	129	14	intracellular	intracellular	ADJ
ajlsi-2696	129	15	calcium	calcium	NOUN
ajlsi-2696	129	16	levels	level	NOUN
ajlsi-2696	129	17	and	and	CCONJ
ajlsi-2696	129	18	inhibits	inhibit	VERB
ajlsi-2696	129	19	the	the	DET
ajlsi-2696	129	20	transcription	transcription	NOUN
ajlsi-2696	129	21	of	of	ADP
ajlsi-2696	129	22	cytokines	cytokine	NOUN
ajlsi-2696	129	23	such	such	ADJ
ajlsi-2696	129	24	as	as	ADP
ajlsi-2696	129	25	“	"	PUNCT
ajlsi-2696	129	26	il-2	il-2	NUM
ajlsi-2696	129	27	,	,	PUNCT
ajlsi-2696	129	28	il-4	il-4	PRON
ajlsi-2696	129	29	,	,	PUNCT
ajlsi-2696	129	30	and	and	CCONJ
ajlsi-2696	129	31	il-5	il-5	PRON
ajlsi-2696	129	32	”	"	PUNCT
ajlsi-2696	129	33	.	.	PUNCT
ajlsi-2696	130	1	clinical	clinical	ADJ
ajlsi-2696	130	2	studies	study	NOUN
ajlsi-2696	130	3	have	have	AUX
ajlsi-2696	130	4	demonstrated	demonstrate	VERB
ajlsi-2696	130	5	topical	topical	ADJ
ajlsi-2696	130	6	tacrolimus	tacrolimus	NOUN
ajlsi-2696	130	7	’s	’s	PART
ajlsi-2696	130	8	effectiveness	effectiveness	NOUN
ajlsi-2696	130	9	in	in	ADP
ajlsi-2696	130	10	lowering	lower	VERB
ajlsi-2696	130	11	ad	ad	NOUN
ajlsi-2696	130	12	severity	severity	NOUN
ajlsi-2696	130	13	ratings	rating	NOUN
ajlsi-2696	130	14	and	and	CCONJ
ajlsi-2696	130	15	improving	improve	VERB
ajlsi-2696	130	16	safety	safety	NOUN
ajlsi-2696	130	17	profiles	profile	NOUN
ajlsi-2696	130	18	with	with	ADP
ajlsi-2696	130	19	less	less	ADJ
ajlsi-2696	130	20	systemic	systemic	ADJ
ajlsi-2696	130	21	absorption	absorption	NOUN
ajlsi-2696	130	22	(	(	PUNCT
ajlsi-2696	130	23	martins	martin	NOUN
ajlsi-2696	130	24	et	et	NOUN
ajlsi-2696	130	25	al	al	PROPN
ajlsi-2696	130	26	.	.	PROPN
ajlsi-2696	130	27	,	,	PUNCT
ajlsi-2696	130	28	2015	2015	NUM
ajlsi-2696	130	29	;	;	PUNCT
ajlsi-2696	130	30	umar	umar	PROPN
ajlsi-2696	130	31	et	et	PROPN
ajlsi-2696	130	32	al	al	PROPN
ajlsi-2696	130	33	.	.	PROPN
ajlsi-2696	130	34	,	,	PUNCT
ajlsi-2696	130	35	2022	2022	NUM
ajlsi-2696	130	36	)	)	PUNCT
ajlsi-2696	130	37	.	.	PUNCT
ajlsi-2696	131	1	safety	safety	NOUN
ajlsi-2696	131	2	profile	profile	PROPN
ajlsi-2696	131	3	&	&	CCONJ
ajlsi-2696	131	4	clinical	clinical	ADJ
ajlsi-2696	131	5	trials	trial	NOUN
ajlsi-2696	131	6	in	in	ADP
ajlsi-2696	131	7	comparison	comparison	NOUN
ajlsi-2696	131	8	with	with	ADP
ajlsi-2696	131	9	dupilumab	dupilumab	NOUN
ajlsi-2696	131	10	compared	compare	VERB
ajlsi-2696	131	11	to	to	ADP
ajlsi-2696	131	12	tacrolimus	tacrolimus	NOUN
ajlsi-2696	131	13	,	,	PUNCT
ajlsi-2696	131	14	the	the	DET
ajlsi-2696	131	15	fda	fda	PROPN
ajlsi-2696	131	16	clinical	clinical	ADJ
ajlsi-2696	131	17	trials	trial	NOUN
ajlsi-2696	131	18	have	have	AUX
ajlsi-2696	131	19	yielded	yield	VERB
ajlsi-2696	131	20	strong	strong	ADJ
ajlsi-2696	131	21	evidence	evidence	NOUN
ajlsi-2696	131	22	for	for	ADP
ajlsi-2696	131	23	the	the	DET
ajlsi-2696	131	24	safety	safety	NOUN
ajlsi-2696	131	25	and	and	CCONJ
ajlsi-2696	131	26	effectiveness	effectiveness	NOUN
ajlsi-2696	131	27	of	of	ADP
ajlsi-2696	131	28	dupilumab	dupilumab	NOUN
ajlsi-2696	131	29	in	in	ADP
ajlsi-2696	131	30	treating	treat	VERB
ajlsi-2696	131	31	ailments	ailment	NOUN
ajlsi-2696	131	32	such	such	ADJ
ajlsi-2696	131	33	as	as	ADP
ajlsi-2696	131	34	atopic	atopic	NOUN
ajlsi-2696	131	35	dermatitis	dermatitis	NOUN
ajlsi-2696	131	36	.	.	PUNCT
ajlsi-2696	132	1	atopic	atopic	NOUN
ajlsi-2696	132	2	dermatitis	dermatitis	NOUN
ajlsi-2696	132	3	patients	patient	NOUN
ajlsi-2696	132	4	with	with	ADP
ajlsi-2696	132	5	moderate	moderate	ADJ
ajlsi-2696	132	6	-	-	PUNCT
ajlsi-2696	132	7	to	to	ADP
ajlsi-2696	132	8	-	-	PUNCT
ajlsi-2696	132	9	severe	severe	ADJ
ajlsi-2696	132	10	ad	ad	NOUN
ajlsi-2696	132	11	have	have	AUX
ajlsi-2696	132	12	shown	show	VERB
ajlsi-2696	132	13	notable	notable	ADJ
ajlsi-2696	132	14	improvements	improvement	NOUN
ajlsi-2696	132	15	in	in	ADP
ajlsi-2696	132	16	their	their	PRON
ajlsi-2696	132	17	quality	quality	NOUN
ajlsi-2696	132	18	of	of	ADP
ajlsi-2696	132	19	life	life	NOUN
ajlsi-2696	132	20	and	and	CCONJ
ajlsi-2696	132	21	a	a	DET
ajlsi-2696	132	22	reduction	reduction	NOUN
ajlsi-2696	132	23	in	in	ADP
ajlsi-2696	132	24	the	the	DET
ajlsi-2696	132	25	severity	severity	NOUN
ajlsi-2696	132	26	of	of	ADP
ajlsi-2696	132	27	their	their	PRON
ajlsi-2696	132	28	condition	condition	NOUN
ajlsi-2696	132	29	after	after	ADP
ajlsi-2696	132	30	using	use	VERB
ajlsi-2696	132	31	dupilumab	dupilumab	NOUN
ajlsi-2696	132	32	,	,	PUNCT
ajlsi-2696	132	33	an	an	DET
ajlsi-2696	132	34	interleukin-4	interleukin-4	NUM
ajlsi-2696	132	35	receptor	receptor	NOUN
ajlsi-2696	132	36	alpha	alpha	NOUN
ajlsi-2696	132	37	antagonist	antagonist	NOUN
ajlsi-2696	132	38	.	.	PUNCT
ajlsi-2696	133	1	dupilumab	dupilumab	NOUN
ajlsi-2696	133	2	is	be	AUX
ajlsi-2696	133	3	a	a	DET
ajlsi-2696	133	4	better	well	ADJ
ajlsi-2696	133	5	therapy	therapy	NOUN
ajlsi-2696	133	6	option	option	NOUN
ajlsi-2696	133	7	than	than	SCONJ
ajlsi-2696	133	8	tacrolimus	tacrolimus	NOUN
ajlsi-2696	133	9	for	for	ADP
ajlsi-2696	133	10	ad	ad	NOUN
ajlsi-2696	133	11	patients	patient	NOUN
ajlsi-2696	133	12	due	due	ADP
ajlsi-2696	133	13	to	to	ADP
ajlsi-2696	133	14	its	its	PRON
ajlsi-2696	133	15	great	great	ADJ
ajlsi-2696	133	16	efficacy	efficacy	NOUN
ajlsi-2696	133	17	in	in	ADP
ajlsi-2696	133	18	reducing	reduce	VERB
ajlsi-2696	133	19	symptoms	symptom	NOUN
ajlsi-2696	133	20	and	and	CCONJ
ajlsi-2696	133	21	enhancing	enhance	VERB
ajlsi-2696	133	22	quality	quality	NOUN
ajlsi-2696	133	23	of	of	ADP
ajlsi-2696	133	24	life	life	NOUN
ajlsi-2696	133	25	,	,	PUNCT
ajlsi-2696	133	26	as	as	SCONJ
ajlsi-2696	133	27	demonstrated	demonstrate	VERB
ajlsi-2696	133	28	by	by	ADP
ajlsi-2696	133	29	clinical	clinical	ADJ
ajlsi-2696	133	30	trials	trial	NOUN
ajlsi-2696	133	31	.	.	PUNCT
ajlsi-2696	134	1	dupilumab	dupilumab	NOUN
ajlsi-2696	134	2	is	be	AUX
ajlsi-2696	134	3	a	a	DET
ajlsi-2696	134	4	better	well	ADJ
ajlsi-2696	134	5	therapy	therapy	NOUN
ajlsi-2696	134	6	choice	choice	NOUN
ajlsi-2696	134	7	than	than	ADP
ajlsi-2696	134	8	tacrolimus	tacrolimus	NOUN
ajlsi-2696	134	9	because	because	SCONJ
ajlsi-2696	134	10	of	of	ADP
ajlsi-2696	134	11	its	its	PRON
ajlsi-2696	134	12	focused	focused	ADJ
ajlsi-2696	134	13	mechanism	mechanism	NOUN
ajlsi-2696	134	14	of	of	ADP
ajlsi-2696	134	15	action	action	NOUN
ajlsi-2696	134	16	and	and	CCONJ
ajlsi-2696	134	17	excellent	excellent	ADJ
ajlsi-2696	134	18	safety	safety	NOUN
ajlsi-2696	134	19	profile	profile	NOUN
ajlsi-2696	134	20	(	(	PUNCT
ajlsi-2696	134	21	fda	fda	PROPN
ajlsi-2696	134	22	,	,	PUNCT
ajlsi-2696	134	23	2019	2019	NUM
ajlsi-2696	134	24	)	)	PUNCT
ajlsi-2696	134	25	.	.	PUNCT
ajlsi-2696	135	1	summary	summary	NOUN
ajlsi-2696	135	2	of	of	ADP
ajlsi-2696	135	3	fda	fda	PROPN
ajlsi-2696	135	4	-	-	PUNCT
ajlsi-2696	135	5	approved	approve	VERB
ajlsi-2696	135	6	clinical	clinical	ADJ
ajlsi-2696	135	7	studies	study	NOUN
ajlsi-2696	135	8	according	accord	VERB
ajlsi-2696	135	9	to	to	ADP
ajlsi-2696	135	10	fda	fda	PROPN
ajlsi-2696	135	11	clinical	clinical	ADJ
ajlsi-2696	135	12	trials	trial	NOUN
ajlsi-2696	135	13	,	,	PUNCT
ajlsi-2696	135	14	dupilumab	dupilumab	NOUN
ajlsi-2696	135	15	has	have	AUX
ajlsi-2696	135	16	proven	prove	VERB
ajlsi-2696	135	17	to	to	PART
ajlsi-2696	135	18	be	be	AUX
ajlsi-2696	135	19	a	a	DET
ajlsi-2696	135	20	highly	highly	ADV
ajlsi-2696	135	21	effective	effective	ADJ
ajlsi-2696	135	22	and	and	CCONJ
ajlsi-2696	135	23	safe	safe	ADJ
ajlsi-2696	135	24	treatment	treatment	NOUN
ajlsi-2696	135	25	for	for	ADP
ajlsi-2696	135	26	moderateto	moderateto	NOUN
ajlsi-2696	135	27	-	-	PUNCT
ajlsi-2696	135	28	severe	severe	ADJ
ajlsi-2696	135	29	atopic	atopic	NOUN
ajlsi-2696	135	30	dermatitis	dermatitis	NOUN
ajlsi-2696	135	31	in	in	ADP
ajlsi-2696	135	32	children	child	NOUN
ajlsi-2696	135	33	.	.	PUNCT
ajlsi-2696	136	1	in	in	ADP
ajlsi-2696	136	2	children	child	NOUN
ajlsi-2696	136	3	with	with	ADP
ajlsi-2696	136	4	atopic	atopic	NOUN
ajlsi-2696	136	5	dermatitis	dermatitis	NOUN
ajlsi-2696	136	6	,	,	PUNCT
ajlsi-2696	136	7	aged	aged	ADJ
ajlsi-2696	136	8	“	"	PUNCT
ajlsi-2696	136	9	6	6	NUM
ajlsi-2696	136	10	to	to	PART
ajlsi-2696	136	11	11	11	NUM
ajlsi-2696	136	12	years	year	NOUN
ajlsi-2696	136	13	”	"	PUNCT
ajlsi-2696	136	14	,	,	PUNCT
ajlsi-2696	136	15	who	who	PRON
ajlsi-2696	136	16	are	be	AUX
ajlsi-2696	136	17	not	not	PART
ajlsi-2696	136	18	sufficiently	sufficiently	ADV
ajlsi-2696	136	19	managed	manage	VERB
ajlsi-2696	136	20	by	by	ADP
ajlsi-2696	136	21	traditional	traditional	ADJ
ajlsi-2696	136	22	therapy	therapy	NOUN
ajlsi-2696	136	23	such	such	ADJ
ajlsi-2696	136	24	as	as	ADP
ajlsi-2696	136	25	topical	topical	ADJ
ajlsi-2696	136	26	corticosteroids	corticosteroid	NOUN
ajlsi-2696	136	27	and	and	CCONJ
ajlsi-2696	136	28	emollients	emollient	NOUN
ajlsi-2696	136	29	,	,	PUNCT
ajlsi-2696	136	30	these	these	DET
ajlsi-2696	136	31	trials	trial	NOUN
ajlsi-2696	136	32	have	have	AUX
ajlsi-2696	136	33	assessed	assess	VERB
ajlsi-2696	136	34	the	the	DET
ajlsi-2696	136	35	real	real	ADJ
ajlsi-2696	136	36	-	-	PUNCT
ajlsi-2696	136	37	world	world	NOUN
ajlsi-2696	136	38	effectiveness	effectiveness	NOUN
ajlsi-2696	136	39	of	of	ADP
ajlsi-2696	136	40	dupilumab	dupilumab	NOUN
ajlsi-2696	136	41	.	.	PUNCT
ajlsi-2696	137	1	research	research	NOUN
ajlsi-2696	137	2	has	have	AUX
ajlsi-2696	137	3	indicated	indicate	VERB
ajlsi-2696	137	4	that	that	SCONJ
ajlsi-2696	137	5	dupilumab	dupilumab	NOUN
ajlsi-2696	137	6	significantly	significantly	ADV
ajlsi-2696	137	7	improves	improve	VERB
ajlsi-2696	137	8	overall	overall	ADJ
ajlsi-2696	137	9	quality	quality	NOUN
ajlsi-2696	137	10	of	of	ADP
ajlsi-2696	137	11	life	life	NOUN
ajlsi-2696	137	12	,	,	PUNCT
ajlsi-2696	137	13	pruritus	pruritus	PROPN
ajlsi-2696	137	14	,	,	PUNCT
ajlsi-2696	137	15	sleep	sleep	VERB
ajlsi-2696	137	16	quality	quality	NOUN
ajlsi-2696	137	17	,	,	PUNCT
ajlsi-2696	137	18	and	and	CCONJ
ajlsi-2696	137	19	disease	disease	NOUN
ajlsi-2696	137	20	severity	severity	NOUN
ajlsi-2696	137	21	in	in	ADP
ajlsi-2696	137	22	young	young	ADJ
ajlsi-2696	137	23	ad	ad	NOUN
ajlsi-2696	137	24	patients	patient	NOUN
ajlsi-2696	137	25	.	.	PUNCT
ajlsi-2696	138	1	more	more	ADV
ajlsi-2696	138	2	specifically	specifically	ADV
ajlsi-2696	138	3	,	,	PUNCT
ajlsi-2696	138	4	at	at	ADP
ajlsi-2696	138	5	week	week	NOUN
ajlsi-2696	138	6	sixteen	sixteen	NUM
ajlsi-2696	138	7	of	of	ADP
ajlsi-2696	138	8	treatment	treatment	NOUN
ajlsi-2696	138	9	,	,	PUNCT
ajlsi-2696	138	10	a	a	DET
ajlsi-2696	138	11	large	large	ADJ
ajlsi-2696	138	12	percentage	percentage	NOUN
ajlsi-2696	138	13	of	of	ADP
ajlsi-2696	138	14	patients	patient	NOUN
ajlsi-2696	138	15	showed	show	VERB
ajlsi-2696	138	16	statistically	statistically	ADV
ajlsi-2696	138	17	significant	significant	ADJ
ajlsi-2696	138	18	improvements	improvement	NOUN
ajlsi-2696	138	19	in	in	ADP
ajlsi-2696	138	20	the	the	DET
ajlsi-2696	138	21	“	"	PUNCT
ajlsi-2696	138	22	children	child	NOUN
ajlsi-2696	138	23	’s	’s	PART
ajlsi-2696	138	24	dermatology	dermatology	NOUN
ajlsi-2696	138	25	life	life	NOUN
ajlsi-2696	138	26	quality	quality	NOUN
ajlsi-2696	138	27	index	index	NOUN
ajlsi-2696	138	28	(	(	PUNCT
ajlsi-2696	138	29	c	c	NOUN
ajlsi-2696	138	30	-	-	PUNCT
ajlsi-2696	138	31	dlqi	dlqi	VERB
ajlsi-2696	138	32	)	)	PUNCT
ajlsi-2696	138	33	,	,	PUNCT
ajlsi-2696	138	34	sleep	sleep	VERB
ajlsi-2696	138	35	nrs	nrs	PROPN
ajlsi-2696	138	36	(	(	PUNCT
ajlsi-2696	138	37	s	s	NOUN
ajlsi-2696	138	38	-	-	PUNCT
ajlsi-2696	138	39	nrs	nrs	NOUN
ajlsi-2696	138	40	)	)	PUNCT
ajlsi-2696	138	41	,	,	PUNCT
ajlsi-2696	138	42	pruritus	pruritus	PROPN
ajlsi-2696	138	43	numerical	numerical	ADJ
ajlsi-2696	138	44	rating	rating	NOUN
ajlsi-2696	138	45	scale	scale	NOUN
ajlsi-2696	138	46	(	(	PUNCT
ajlsi-2696	138	47	p	p	NOUN
ajlsi-2696	138	48	-	-	PUNCT
ajlsi-2696	138	49	nrs	nrs	NOUN
ajlsi-2696	138	50	)	)	PUNCT
ajlsi-2696	138	51	,	,	PUNCT
ajlsi-2696	138	52	and	and	CCONJ
ajlsi-2696	138	53	eczema	eczema	PROPN
ajlsi-2696	138	54	area	area	NOUN
ajlsi-2696	138	55	severity	severity	PROPN
ajlsi-2696	138	56	index	index	NOUN
ajlsi-2696	138	57	(	(	PUNCT
ajlsi-2696	138	58	easi	easi	NOUN
ajlsi-2696	138	59	)	)	PUNCT
ajlsi-2696	138	60	scores	score	NOUN
ajlsi-2696	138	61	”	"	PUNCT
ajlsi-2696	138	62	.	.	PUNCT
ajlsi-2696	139	1	based	base	VERB
ajlsi-2696	139	2	on	on	ADP
ajlsi-2696	139	3	these	these	DET
ajlsi-2696	139	4	results	result	NOUN
ajlsi-2696	139	5	,	,	PUNCT
ajlsi-2696	139	6	young	young	ADJ
ajlsi-2696	139	7	patients	patient	NOUN
ajlsi-2696	139	8	with	with	ADP
ajlsi-2696	139	9	moderate	moderate	ADJ
ajlsi-2696	139	10	-	-	PUNCT
ajlsi-2696	139	11	to	to	ADP
ajlsi-2696	139	12	-	-	PUNCT
ajlsi-2696	139	13	severe	severe	ADJ
ajlsi-2696	139	14	atopic	atopic	NOUN
ajlsi-2696	139	15	dermatitis	dermatitis	NOUN
ajlsi-2696	139	16	can	can	AUX
ajlsi-2696	139	17	benefit	benefit	VERB
ajlsi-2696	139	18	from	from	ADP
ajlsi-2696	139	19	using	use	VERB
ajlsi-2696	139	20	dupilumab	dupilumab	NOUN
ajlsi-2696	139	21	as	as	ADP
ajlsi-2696	139	22	a	a	DET
ajlsi-2696	139	23	treatment	treatment	NOUN
ajlsi-2696	139	24	option	option	NOUN
ajlsi-2696	139	25	.	.	PUNCT
ajlsi-2696	140	1	it	it	PRON
ajlsi-2696	140	2	is	be	AUX
ajlsi-2696	140	3	a	a	DET
ajlsi-2696	140	4	viable	viable	ADJ
ajlsi-2696	140	5	therapeutic	therapeutic	ADJ
ajlsi-2696	140	6	alternative	alternative	NOUN
ajlsi-2696	140	7	beyond	beyond	ADP
ajlsi-2696	140	8	topical	topical	ADJ
ajlsi-2696	140	9	medications	medication	NOUN
ajlsi-2696	140	10	(	(	PUNCT
ajlsi-2696	140	11	fda	fda	PROPN
ajlsi-2696	140	12	,	,	PUNCT
ajlsi-2696	140	13	2019	2019	NUM
ajlsi-2696	140	14	;	;	PUNCT
ajlsi-2696	140	15	kamphuis	kamphuis	PROPN
ajlsi-2696	140	16	et	et	PROPN
ajlsi-2696	140	17	al	al	PROPN
ajlsi-2696	140	18	.	.	PROPN
ajlsi-2696	140	19	,	,	PUNCT
ajlsi-2696	140	20	2022	2022	NUM
ajlsi-2696	140	21	;	;	PUNCT
ajlsi-2696	140	22	napolitano	napolitano	PROPN
ajlsi-2696	140	23	et	et	PROPN
ajlsi-2696	140	24	al	al	PROPN
ajlsi-2696	140	25	.	.	PROPN
ajlsi-2696	140	26	,	,	PUNCT
ajlsi-2696	140	27	2022	2022	NUM
ajlsi-2696	140	28	)	)	PUNCT
ajlsi-2696	140	29	.	.	PUNCT
ajlsi-2696	141	1	discussion	discussion	NOUN
ajlsi-2696	141	2	eczema	eczema	NOUN
ajlsi-2696	141	3	,	,	PUNCT
ajlsi-2696	141	4	or	or	CCONJ
ajlsi-2696	141	5	atopic	atopic	NOUN
ajlsi-2696	141	6	dermatitis	dermatitis	NOUN
ajlsi-2696	141	7	,	,	PUNCT
ajlsi-2696	141	8	is	be	AUX
ajlsi-2696	141	9	a	a	DET
ajlsi-2696	141	10	chronic	chronic	NOUN
ajlsi-2696	141	11	,	,	PUNCT
ajlsi-2696	141	12	noncommunicable	noncommunicable	ADJ
ajlsi-2696	141	13	,	,	PUNCT
ajlsi-2696	141	14	inflammatory	inflammatory	ADJ
ajlsi-2696	141	15	skin	skin	NOUN
ajlsi-2696	141	16	ailment	ailment	NOUN
ajlsi-2696	141	17	mainly	mainly	ADV
ajlsi-2696	141	18	affecting	affect	VERB
ajlsi-2696	141	19	children	child	NOUN
ajlsi-2696	141	20	.	.	PUNCT
ajlsi-2696	142	1	it	it	PRON
ajlsi-2696	142	2	ranks	rank	VERB
ajlsi-2696	142	3	first	first	ADV
ajlsi-2696	142	4	among	among	ADP
ajlsi-2696	142	5	skin	skin	NOUN
ajlsi-2696	142	6	conditions	condition	NOUN
ajlsi-2696	142	7	and	and	CCONJ
ajlsi-2696	142	8	fifteenth	fifteenth	NOUN
ajlsi-2696	142	9	among	among	ADP
ajlsi-2696	142	10	non	non	ADJ
ajlsi-2696	142	11	-	-	ADJ
ajlsi-2696	142	12	fatal	fatal	ADJ
ajlsi-2696	142	13	diseases	disease	NOUN
ajlsi-2696	142	14	,	,	PUNCT
ajlsi-2696	142	15	and	and	CCONJ
ajlsi-2696	142	16	it	it	PRON
ajlsi-2696	142	17	can	can	AUX
ajlsi-2696	142	18	cause	cause	VERB
ajlsi-2696	142	19	mental	mental	ADJ
ajlsi-2696	142	20	health	health	NOUN
ajlsi-2696	142	21	problems	problem	NOUN
ajlsi-2696	142	22	.	.	PUNCT
ajlsi-2696	143	1	biological	biological	ADJ
ajlsi-2696	143	2	therapies	therapy	NOUN
ajlsi-2696	143	3	like	like	ADP
ajlsi-2696	143	4	dupilumab	dupilumab	NOUN
ajlsi-2696	143	5	,	,	PUNCT
ajlsi-2696	143	6	omalizumab	omalizumab	NOUN
ajlsi-2696	143	7	,	,	PUNCT
ajlsi-2696	143	8	and	and	CCONJ
ajlsi-2696	143	9	ustekinumab	ustekinumab	NOUN
ajlsi-2696	143	10	target	target	NOUN
ajlsi-2696	143	11	immune	immune	ADJ
ajlsi-2696	143	12	response	response	NOUN
ajlsi-2696	143	13	and	and	CCONJ
ajlsi-2696	143	14	inflammatory	inflammatory	ADJ
ajlsi-2696	143	15	processes	process	NOUN
ajlsi-2696	143	16	in	in	ADP
ajlsi-2696	143	17	atopic	atopic	NOUN
ajlsi-2696	143	18	dermatitis	dermatitis	NOUN
ajlsi-2696	143	19	,	,	PUNCT
ajlsi-2696	143	20	improving	improve	VERB
ajlsi-2696	143	21	symptoms	symptom	NOUN
ajlsi-2696	143	22	,	,	PUNCT
ajlsi-2696	143	23	quality	quality	NOUN
ajlsi-2696	143	24	of	of	ADP
ajlsi-2696	143	25	life	life	NOUN
ajlsi-2696	143	26	,	,	PUNCT
ajlsi-2696	143	27	and	and	CCONJ
ajlsi-2696	143	28	disease	disease	NOUN
ajlsi-2696	143	29	control	control	NOUN
ajlsi-2696	143	30	.	.	PUNCT
ajlsi-2696	144	1	in	in	ADP
ajlsi-2696	144	2	contrast	contrast	NOUN
ajlsi-2696	144	3	,	,	PUNCT
ajlsi-2696	144	4	nonbiological	nonbiological	ADJ
ajlsi-2696	144	5	systemic	systemic	ADJ
ajlsi-2696	144	6	therapy	therapy	NOUN
ajlsi-2696	144	7	for	for	ADP
ajlsi-2696	144	8	atopic	atopic	NOUN
ajlsi-2696	144	9	dermatitis	dermatitis	NOUN
ajlsi-2696	144	10	may	may	AUX
ajlsi-2696	144	11	not	not	PART
ajlsi-2696	144	12	be	be	AUX
ajlsi-2696	144	13	as	as	ADV
ajlsi-2696	144	14	effective	effective	ADJ
ajlsi-2696	144	15	in	in	ADP
ajlsi-2696	144	16	controlling	control	VERB
ajlsi-2696	144	17	symptoms	symptom	NOUN
ajlsi-2696	144	18	and	and	CCONJ
ajlsi-2696	144	19	preventing	prevent	VERB
ajlsi-2696	144	20	exacerbations	exacerbation	NOUN
ajlsi-2696	144	21	as	as	ADP
ajlsi-2696	144	22	biological	biological	ADJ
ajlsi-2696	144	23	treatments	treatment	NOUN
ajlsi-2696	144	24	.	.	PUNCT
ajlsi-2696	145	1	early	early	ADJ
ajlsi-2696	145	2	exposure	exposure	NOUN
ajlsi-2696	145	3	to	to	ADP
ajlsi-2696	145	4	antibiotics	antibiotic	NOUN
ajlsi-2696	145	5	can	can	AUX
ajlsi-2696	145	6	raise	raise	VERB
ajlsi-2696	145	7	a	a	DET
ajlsi-2696	145	8	child	child	NOUN
ajlsi-2696	145	9	’s	’s	PART
ajlsi-2696	145	10	vulnerability	vulnerability	NOUN
ajlsi-2696	145	11	to	to	ADP
ajlsi-2696	145	12	infections	infection	NOUN
ajlsi-2696	145	13	and	and	CCONJ
ajlsi-2696	145	14	resistance	resistance	NOUN
ajlsi-2696	145	15	rates	rate	NOUN
ajlsi-2696	145	16	,	,	PUNCT
ajlsi-2696	145	17	which	which	PRON
ajlsi-2696	145	18	can	can	AUX
ajlsi-2696	145	19	result	result	VERB
ajlsi-2696	145	20	in	in	ADP
ajlsi-2696	145	21	life	life	NOUN
ajlsi-2696	145	22	-	-	PUNCT
ajlsi-2696	145	23	threatening	threaten	VERB
ajlsi-2696	145	24	illnesses	illness	NOUN
ajlsi-2696	145	25	.	.	PUNCT
ajlsi-2696	146	1	the	the	DET
ajlsi-2696	146	2	severity	severity	NOUN
ajlsi-2696	146	3	of	of	ADP
ajlsi-2696	146	4	the	the	DET
ajlsi-2696	146	5	condition	condition	NOUN
ajlsi-2696	146	6	determines	determine	VERB
ajlsi-2696	146	7	how	how	SCONJ
ajlsi-2696	146	8	well	well	ADV
ajlsi-2696	146	9	biological	biological	ADJ
ajlsi-2696	146	10	therapy	therapy	NOUN
ajlsi-2696	146	11	and	and	CCONJ
ajlsi-2696	146	12	antibiotics	antibiotic	NOUN
ajlsi-2696	146	13	work	work	VERB
ajlsi-2696	146	14	for	for	ADP
ajlsi-2696	146	15	pediatric	pediatric	ADJ
ajlsi-2696	146	16	atopic	atopic	NOUN
ajlsi-2696	146	17	dermatitis	dermatitis	NOUN
ajlsi-2696	146	18	.	.	PUNCT
ajlsi-2696	147	1	dupilumab	dupilumab	NOUN
ajlsi-2696	147	2	and	and	CCONJ
ajlsi-2696	147	3	other	other	ADJ
ajlsi-2696	147	4	biological	biological	ADJ
ajlsi-2696	147	5	agents	agent	NOUN
ajlsi-2696	147	6	are	be	AUX
ajlsi-2696	147	7	suggested	suggest	VERB
ajlsi-2696	147	8	for	for	ADP
ajlsi-2696	147	9	children	child	NOUN
ajlsi-2696	147	10	with	with	ADP
ajlsi-2696	147	11	mild	mild	ADJ
ajlsi-2696	147	12	eczema	eczema	NOUN
ajlsi-2696	147	13	infections	infection	NOUN
ajlsi-2696	147	14	.	.	PUNCT
ajlsi-2696	148	1	topical	topical	ADJ
ajlsi-2696	148	2	corticosteroids	corticosteroid	NOUN
ajlsi-2696	148	3	can	can	AUX
ajlsi-2696	148	4	be	be	AUX
ajlsi-2696	148	5	used	use	VERB
ajlsi-2696	148	6	alone	alone	ADJ
ajlsi-2696	148	7	or	or	CCONJ
ajlsi-2696	148	8	with	with	ADP
ajlsi-2696	148	9	dupilumab	dupilumab	NOUN
ajlsi-2696	148	10	,	,	PUNCT
ajlsi-2696	148	11	a	a	DET
ajlsi-2696	148	12	medication	medication	NOUN
ajlsi-2696	148	13	used	use	VERB
ajlsi-2696	148	14	to	to	PART
ajlsi-2696	148	15	treat	treat	VERB
ajlsi-2696	148	16	atopic	atopic	NOUN
ajlsi-2696	148	17	dermatitis	dermatitis	NOUN
ajlsi-2696	148	18	.	.	PUNCT
ajlsi-2696	149	1	clinical	clinical	ADJ
ajlsi-2696	149	2	investigations	investigation	NOUN
ajlsi-2696	149	3	demonstrate	demonstrate	VERB
ajlsi-2696	149	4	that	that	SCONJ
ajlsi-2696	149	5	augmenting	augment	VERB
ajlsi-2696	149	6	corticosteroids	corticosteroid	NOUN
ajlsi-2696	149	7	with	with	ADP
ajlsi-2696	149	8	dupilumab	dupilumab	NOUN
ajlsi-2696	149	9	greatly	greatly	ADV
ajlsi-2696	149	10	improves	improve	VERB
ajlsi-2696	149	11	patients	patient	NOUN
ajlsi-2696	149	12	’	'	PUNCT
ajlsi-2696	149	13	symptoms	symptom	NOUN
ajlsi-2696	149	14	and	and	CCONJ
ajlsi-2696	149	15	quality	quality	NOUN
ajlsi-2696	149	16	of	of	ADP
ajlsi-2696	149	17	life	life	NOUN
ajlsi-2696	149	18	.	.	PUNCT
ajlsi-2696	150	1	according	accord	VERB
ajlsi-2696	150	2	to	to	ADP
ajlsi-2696	150	3	studies	study	NOUN
ajlsi-2696	150	4	,	,	PUNCT
ajlsi-2696	150	5	dupilumab	dupilumab	NOUN
ajlsi-2696	150	6	is	be	AUX
ajlsi-2696	150	7	a	a	DET
ajlsi-2696	150	8	better	well	ADJ
ajlsi-2696	150	9	treatment	treatment	NOUN
ajlsi-2696	150	10	option	option	NOUN
ajlsi-2696	150	11	for	for	ADP
ajlsi-2696	150	12	atopic	atopic	NOUN
ajlsi-2696	150	13	dermatitis	dermatitis	NOUN
ajlsi-2696	150	14	than	than	ADP
ajlsi-2696	150	15	a	a	DET
ajlsi-2696	150	16	placebo	placebo	NOUN
ajlsi-2696	150	17	,	,	PUNCT
ajlsi-2696	150	18	especially	especially	ADV
ajlsi-2696	150	19	when	when	SCONJ
ajlsi-2696	150	20	used	use	VERB
ajlsi-2696	150	21	with	with	ADP
ajlsi-2696	150	22	topical	topical	ADJ
ajlsi-2696	150	23	corticosteroids	corticosteroid	NOUN
ajlsi-2696	150	24	.	.	PUNCT
ajlsi-2696	151	1	according	accord	VERB
ajlsi-2696	151	2	to	to	ADP
ajlsi-2696	151	3	fda	fda	PROPN
ajlsi-2696	151	4	guidelines	guideline	NOUN
ajlsi-2696	151	5	,	,	PUNCT
ajlsi-2696	151	6	biological	biological	ADJ
ajlsi-2696	151	7	agents	agent	NOUN
ajlsi-2696	151	8	are	be	AUX
ajlsi-2696	151	9	preferred	prefer	VERB
ajlsi-2696	151	10	in	in	ADP
ajlsi-2696	151	11	paediatrics	paediatric	NOUN
ajlsi-2696	151	12	over	over	ADP
ajlsi-2696	151	13	immunosuppressant	immunosuppressant	NOUN
ajlsi-2696	151	14	including	include	VERB
ajlsi-2696	151	15	cyclosporine	cyclosporine	NOUN
ajlsi-2696	151	16	,	,	PUNCT
ajlsi-2696	151	17	mycophenolate	mycophenolate	PROPN
ajlsi-2696	151	18	,	,	PUNCT
ajlsi-2696	151	19	azathioprine	azathioprine	NOUN
ajlsi-2696	151	20	and	and	CCONJ
ajlsi-2696	151	21	antimetabolite	antimetabolite	NOUN
ajlsi-2696	151	22	methotrexate	methotrexate	NOUN
ajlsi-2696	151	23	because	because	SCONJ
ajlsi-2696	151	24	of	of	ADP
ajlsi-2696	151	25	their	their	PRON
ajlsi-2696	151	26	effectiveness	effectiveness	NOUN
ajlsi-2696	151	27	in	in	ADP
ajlsi-2696	151	28	enhancing	enhance	VERB
ajlsi-2696	151	29	immune	immune	ADJ
ajlsi-2696	151	30	results	result	NOUN
ajlsi-2696	151	31	rather	rather	ADV
ajlsi-2696	151	32	than	than	ADP
ajlsi-2696	151	33	inhibiting	inhibit	VERB
ajlsi-2696	151	34	the	the	DET
ajlsi-2696	151	35	body	body	NOUN
ajlsi-2696	151	36	’s	’s	PART
ajlsi-2696	151	37	immune	immune	ADJ
ajlsi-2696	151	38	system	system	NOUN
ajlsi-2696	151	39	.	.	PUNCT
ajlsi-2696	152	1	it	it	PRON
ajlsi-2696	152	2	was	be	AUX
ajlsi-2696	152	3	evident	evident	ADJ
ajlsi-2696	152	4	from	from	ADP
ajlsi-2696	152	5	fda	fda	PROPN
ajlsi-2696	152	6	clinical	clinical	ADJ
ajlsi-2696	152	7	trials	trial	NOUN
ajlsi-2696	152	8	that	that	PRON
ajlsi-2696	152	9	dupilumab	dupilumab	NOUN
ajlsi-2696	152	10	is	be	AUX
ajlsi-2696	152	11	a	a	DET
ajlsi-2696	152	12	safe	safe	ADJ
ajlsi-2696	152	13	and	and	CCONJ
ajlsi-2696	152	14	effective	effective	ADJ
ajlsi-2696	152	15	treatment	treatment	NOUN
ajlsi-2696	152	16	for	for	ADP
ajlsi-2696	152	17	children	child	NOUN
ajlsi-2696	152	18	with	with	ADP
ajlsi-2696	152	19	moderateto	moderateto	NOUN
ajlsi-2696	152	20	-	-	PUNCT
ajlsi-2696	152	21	severe	severe	ADJ
ajlsi-2696	152	22	atopic	atopic	NOUN
ajlsi-2696	152	23	dermatitis	dermatitis	NOUN
ajlsi-2696	152	24	,	,	PUNCT
ajlsi-2696	152	25	ages	age	NOUN
ajlsi-2696	152	26	6	6	NUM
ajlsi-2696	152	27	to	to	PART
ajlsi-2696	152	28	11	11	NUM
ajlsi-2696	152	29	.	.	PUNCT
ajlsi-2696	153	1	studies	study	NOUN
ajlsi-2696	153	2	reveal	reveal	VERB
ajlsi-2696	153	3	that	that	SCONJ
ajlsi-2696	153	4	in	in	ADP
ajlsi-2696	153	5	young	young	ADJ
ajlsi-2696	153	6	ad	ad	NOUN
ajlsi-2696	153	7	patients	patient	NOUN
ajlsi-2696	153	8	,	,	PUNCT
ajlsi-2696	153	9	it	it	PRON
ajlsi-2696	153	10	considerably	considerably	ADV
ajlsi-2696	153	11	reduces	reduce	VERB
ajlsi-2696	153	12	the	the	DET
ajlsi-2696	153	13	severity	severity	NOUN
ajlsi-2696	153	14	of	of	ADP
ajlsi-2696	153	15	the	the	DET
ajlsi-2696	153	16	disease	disease	NOUN
ajlsi-2696	153	17	,	,	PUNCT
ajlsi-2696	153	18	pruritus	pruritus	NOUN
ajlsi-2696	153	19	,	,	PUNCT
ajlsi-2696	153	20	and	and	CCONJ
ajlsi-2696	153	21	general	general	ADJ
ajlsi-2696	153	22	quality	quality	NOUN
ajlsi-2696	153	23	of	of	ADP
ajlsi-2696	153	24	life	life	NOUN
ajlsi-2696	153	25	.	.	PUNCT
ajlsi-2696	154	1	in	in	ADP
ajlsi-2696	154	2	addition	addition	NOUN
ajlsi-2696	154	3	to	to	ADP
ajlsi-2696	154	4	conventional	conventional	ADJ
ajlsi-2696	154	5	topical	topical	ADJ
ajlsi-2696	154	6	drugs	drug	NOUN
ajlsi-2696	154	7	,	,	PUNCT
ajlsi-2696	154	8	this	this	DET
ajlsi-2696	154	9	treatment	treatment	NOUN
ajlsi-2696	154	10	provides	provide	VERB
ajlsi-2696	154	11	a	a	DET
ajlsi-2696	154	12	good	good	ADJ
ajlsi-2696	154	13	therapeutic	therapeutic	ADJ
ajlsi-2696	154	14	alternative	alternative	NOUN
ajlsi-2696	154	15	.	.	PUNCT
ajlsi-2696	155	1	challenges	challenge	NOUN
ajlsi-2696	155	2	and	and	CCONJ
ajlsi-2696	155	3	considerations	consideration	NOUN
ajlsi-2696	155	4	cost	cost	NOUN
ajlsi-2696	155	5	-	-	PUNCT
ajlsi-2696	155	6	effectiveness	effectiveness	NOUN
ajlsi-2696	155	7	of	of	ADP
ajlsi-2696	155	8	dupilumab	dupilumab	NOUN
ajlsi-2696	155	9	in	in	ADP
ajlsi-2696	155	10	comparison	comparison	NOUN
ajlsi-2696	155	11	with	with	ADP
ajlsi-2696	155	12	non	non	ADJ
ajlsi-2696	155	13	-	-	ADJ
ajlsi-2696	155	14	biological	biological	ADJ
ajlsi-2696	155	15	treatments	treatment	NOUN
ajlsi-2696	155	16	the	the	DET
ajlsi-2696	155	17	analysis	analysis	NOUN
ajlsi-2696	155	18	revealed	reveal	VERB
ajlsi-2696	155	19	that	that	SCONJ
ajlsi-2696	155	20	although	although	SCONJ
ajlsi-2696	155	21	the	the	DET
ajlsi-2696	155	22	costs	cost	NOUN
ajlsi-2696	155	23	of	of	ADP
ajlsi-2696	155	24	dupilumab	dupilumab	NOUN
ajlsi-2696	155	25	may	may	AUX
ajlsi-2696	155	26	be	be	AUX
ajlsi-2696	155	27	higher	high	ADJ
ajlsi-2696	155	28	than	than	ADP
ajlsi-2696	155	29	those	those	PRON
ajlsi-2696	155	30	of	of	ADP
ajlsi-2696	155	31	non	non	ADJ
ajlsi-2696	155	32	-	-	ADJ
ajlsi-2696	155	33	biological	biological	ADJ
ajlsi-2696	155	34	treatments	treatment	NOUN
ajlsi-2696	155	35	like	like	ADP
ajlsi-2696	155	36	topical	topical	ADJ
ajlsi-2696	155	37	medicines	medicine	NOUN
ajlsi-2696	155	38	,	,	PUNCT
ajlsi-2696	155	39	it	it	PRON
ajlsi-2696	155	40	is	be	AUX
ajlsi-2696	155	41	related	relate	VERB
ajlsi-2696	155	42	to	to	ADP
ajlsi-2696	155	43	more	more	ADJ
ajlsi-2696	155	44	“	"	PUNCT
ajlsi-2696	155	45	quality	quality	NOUN
ajlsi-2696	155	46	-	-	PUNCT
ajlsi-2696	155	47	adjusted	adjust	VERB
ajlsi-2696	155	48	life	life	NOUN
ajlsi-2696	155	49	years	year	NOUN
ajlsi-2696	155	50	(	(	PUNCT
ajlsi-2696	155	51	qalys	qalys	NOUN
ajlsi-2696	155	52	)	)	PUNCT
ajlsi-2696	155	53	”	"	PUNCT
ajlsi-2696	155	54	and	and	CCONJ
ajlsi-2696	155	55	good	good	ADJ
ajlsi-2696	155	56	cost	cost	NOUN
ajlsi-2696	155	57	-	-	PUNCT
ajlsi-2696	155	58	effectiveness	effectiveness	NOUN
ajlsi-2696	155	59	ratios	ratio	NOUN
ajlsi-2696	155	60	.	.	PUNCT
ajlsi-2696	156	1	it	it	PRON
ajlsi-2696	156	2	suggests	suggest	VERB
ajlsi-2696	156	3	that	that	SCONJ
ajlsi-2696	156	4	compared	compare	VERB
ajlsi-2696	156	5	to	to	ADP
ajlsi-2696	156	6	more	more	ADJ
ajlsi-2696	156	7	affordable	affordable	ADJ
ajlsi-2696	156	8	standard	standard	ADJ
ajlsi-2696	156	9	treatments	treatment	NOUN
ajlsi-2696	156	10	like	like	ADP
ajlsi-2696	156	11	moisturizers	moisturizer	NOUN
ajlsi-2696	156	12	and	and	CCONJ
ajlsi-2696	156	13	emollients	emollient	NOUN
ajlsi-2696	156	14	,	,	PUNCT
ajlsi-2696	156	15	dupilumab	dupilumab	NOUN
ajlsi-2696	156	16	adds	add	VERB
ajlsi-2696	156	17	value	value	NOUN
ajlsi-2696	156	18	by	by	ADP
ajlsi-2696	156	19	significantly	significantly	ADV
ajlsi-2696	156	20	increasing	increase	VERB
ajlsi-2696	156	21	health	health	NOUN
ajlsi-2696	156	22	outcomes	outcome	NOUN
ajlsi-2696	156	23	.	.	PUNCT
ajlsi-2696	157	1	according	accord	VERB
ajlsi-2696	157	2	to	to	ADP
ajlsi-2696	157	3	the	the	DET
ajlsi-2696	157	4	research	research	NOUN
ajlsi-2696	157	5	,	,	PUNCT
ajlsi-2696	157	6	dupilumab	dupilumab	NOUN
ajlsi-2696	157	7	presents	present	VERB
ajlsi-2696	157	8	a	a	DET
ajlsi-2696	157	9	novel	novel	NOUN
ajlsi-2696	157	10	and	and	CCONJ
ajlsi-2696	157	11	efficacious	efficacious	ADJ
ajlsi-2696	157	12	therapeutic	therapeutic	ADJ
ajlsi-2696	157	13	option	option	NOUN
ajlsi-2696	157	14	for	for	ADP
ajlsi-2696	157	15	patients	patient	NOUN
ajlsi-2696	157	16	with	with	ADP
ajlsi-2696	157	17	moderate	moderate	ADJ
ajlsi-2696	157	18	-	-	PUNCT
ajlsi-2696	157	19	to	to	ADP
ajlsi-2696	157	20	-	-	PUNCT
ajlsi-2696	157	21	severe	severe	ADJ
ajlsi-2696	157	22	atopic	atopic	NOUN
ajlsi-2696	157	23	dermatitis	dermatitis	NOUN
ajlsi-2696	157	24	,	,	PUNCT
ajlsi-2696	157	25	particularly	particularly	ADV
ajlsi-2696	157	26	when	when	SCONJ
ajlsi-2696	157	27	the	the	DET
ajlsi-2696	157	28	effectiveness	effectiveness	NOUN
ajlsi-2696	157	29	of	of	ADP
ajlsi-2696	157	30	conventional	conventional	ADJ
ajlsi-2696	157	31	treatments	treatment	NOUN
ajlsi-2696	157	32	is	be	AUX
ajlsi-2696	157	33	compromised	compromise	VERB
ajlsi-2696	157	34	.	.	PUNCT
ajlsi-2696	158	1	the	the	DET
ajlsi-2696	158	2	severity	severity	NOUN
ajlsi-2696	158	3	of	of	ADP
ajlsi-2696	158	4	the	the	DET
ajlsi-2696	158	5	ailment	ailment	NOUN
ajlsi-2696	158	6	affects	affect	VERB
ajlsi-2696	158	7	how	how	SCONJ
ajlsi-2696	158	8	pa	pa	PROPN
ajlsi-2696	158	9	ge	ge	PROPN
ajlsi-2696	158	10	66	66	NUM
ajlsi-2696	158	11	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	158	12	am	am	NOUN
ajlsi-2696	158	13	.	.	PUNCT
ajlsi-2696	159	1	j.	j.	PROPN
ajlsi-2696	159	2	life	life	PROPN
ajlsi-2696	159	3	sci	sci	PROPN
ajlsi-2696	159	4	.	.	PUNCT
ajlsi-2696	159	5	innov	innov	PROPN
ajlsi-2696	159	6	.	.	PUNCT
ajlsi-2696	160	1	3(1	3(1	NUM
ajlsi-2696	160	2	)	)	PUNCT
ajlsi-2696	160	3	61	61	NUM
ajlsi-2696	160	4	-	-	SYM
ajlsi-2696	160	5	68	68	NUM
ajlsi-2696	160	6	,	,	PUNCT
ajlsi-2696	160	7	2024	2024	NUM
ajlsi-2696	160	8	cost	cost	NOUN
ajlsi-2696	160	9	-	-	PUNCT
ajlsi-2696	160	10	effective	effective	ADJ
ajlsi-2696	160	11	dupilumab	dupilumab	NOUN
ajlsi-2696	160	12	is	be	AUX
ajlsi-2696	160	13	compared	compare	VERB
ajlsi-2696	160	14	to	to	ADP
ajlsi-2696	160	15	non	non	ADJ
ajlsi-2696	160	16	-	-	ADJ
ajlsi-2696	160	17	biological	biological	ADJ
ajlsi-2696	160	18	treatments	treatment	NOUN
ajlsi-2696	160	19	;	;	PUNCT
ajlsi-2696	160	20	more	more	ADV
ajlsi-2696	160	21	severe	severe	ADJ
ajlsi-2696	160	22	patients	patient	NOUN
ajlsi-2696	160	23	are	be	AUX
ajlsi-2696	160	24	likely	likely	ADJ
ajlsi-2696	160	25	to	to	PART
ajlsi-2696	160	26	benefit	benefit	VERB
ajlsi-2696	160	27	more	more	ADV
ajlsi-2696	160	28	from	from	ADP
ajlsi-2696	160	29	dupilumab	dupilumab	NOUN
ajlsi-2696	160	30	in	in	ADP
ajlsi-2696	160	31	terms	term	NOUN
ajlsi-2696	160	32	of	of	ADP
ajlsi-2696	160	33	better	well	ADJ
ajlsi-2696	160	34	health	health	NOUN
ajlsi-2696	160	35	and	and	CCONJ
ajlsi-2696	160	36	quality	quality	NOUN
ajlsi-2696	160	37	of	of	ADP
ajlsi-2696	160	38	life	life	NOUN
ajlsi-2696	160	39	(	(	PUNCT
ajlsi-2696	160	40	anderson	anderson	PROPN
ajlsi-2696	160	41	iii	iii	PROPN
ajlsi-2696	160	42	&	&	CCONJ
ajlsi-2696	160	43	szefler	szefler	PROPN
ajlsi-2696	160	44	,	,	PUNCT
ajlsi-2696	160	45	2019	2019	NUM
ajlsi-2696	160	46	;	;	PUNCT
ajlsi-2696	161	1	sonya	sonya	PROPN
ajlsi-2696	161	2	kahn	kahn	PROPN
ajlsi-2696	161	3	et	et	PROPN
ajlsi-2696	161	4	al	al	PROPN
ajlsi-2696	161	5	.	.	PROPN
ajlsi-2696	161	6	,	,	PUNCT
ajlsi-2696	161	7	2018	2018	NUM
ajlsi-2696	161	8	)	)	PUNCT
ajlsi-2696	161	9	.	.	PUNCT
ajlsi-2696	162	1	adherence	adherence	NOUN
ajlsi-2696	162	2	to	to	ADP
ajlsi-2696	162	3	treatment	treatment	NOUN
ajlsi-2696	162	4	regimens	regimen	NOUN
ajlsi-2696	162	5	in	in	ADP
ajlsi-2696	162	6	pediatric	pediatric	ADJ
ajlsi-2696	162	7	patients	patient	NOUN
ajlsi-2696	162	8	in	in	ADP
ajlsi-2696	162	9	comparison	comparison	NOUN
ajlsi-2696	162	10	to	to	ADP
ajlsi-2696	162	11	non	non	ADJ
ajlsi-2696	162	12	-	-	ADJ
ajlsi-2696	162	13	biological	biological	ADJ
ajlsi-2696	162	14	therapy	therapy	NOUN
ajlsi-2696	162	15	,	,	PUNCT
ajlsi-2696	162	16	pediatric	pediatric	ADJ
ajlsi-2696	162	17	children	child	NOUN
ajlsi-2696	162	18	with	with	ADP
ajlsi-2696	162	19	atopic	atopic	NOUN
ajlsi-2696	162	20	dermatitis	dermatitis	NOUN
ajlsi-2696	162	21	seem	seem	VERB
ajlsi-2696	162	22	to	to	PART
ajlsi-2696	162	23	adhere	adhere	VERB
ajlsi-2696	162	24	better	well	ADJ
ajlsi-2696	162	25	to	to	PART
ajlsi-2696	162	26	dupilumab	dupilumab	VERB
ajlsi-2696	162	27	treatment	treatment	NOUN
ajlsi-2696	162	28	regimens	regimen	NOUN
ajlsi-2696	162	29	.	.	PUNCT
ajlsi-2696	163	1	research	research	NOUN
ajlsi-2696	163	2	has	have	AUX
ajlsi-2696	163	3	indicated	indicate	VERB
ajlsi-2696	163	4	that	that	SCONJ
ajlsi-2696	163	5	children	child	NOUN
ajlsi-2696	163	6	with	with	ADP
ajlsi-2696	163	7	moderate	moderate	ADJ
ajlsi-2696	163	8	-	-	PUNCT
ajlsi-2696	163	9	to	to	ADP
ajlsi-2696	163	10	-	-	PUNCT
ajlsi-2696	163	11	severe	severe	ADJ
ajlsi-2696	163	12	atopic	atopic	NOUN
ajlsi-2696	163	13	dermatitis	dermatitis	NOUN
ajlsi-2696	163	14	can	can	AUX
ajlsi-2696	163	15	experience	experience	VERB
ajlsi-2696	163	16	improvements	improvement	NOUN
ajlsi-2696	163	17	in	in	ADP
ajlsi-2696	163	18	disease	disease	NOUN
ajlsi-2696	163	19	severity	severity	NOUN
ajlsi-2696	163	20	,	,	PUNCT
ajlsi-2696	163	21	pruritus	pruritus	PROPN
ajlsi-2696	163	22	,	,	PUNCT
ajlsi-2696	163	23	sleep	sleep	VERB
ajlsi-2696	163	24	quality	quality	NOUN
ajlsi-2696	163	25	,	,	PUNCT
ajlsi-2696	163	26	and	and	CCONJ
ajlsi-2696	163	27	overall	overall	ADJ
ajlsi-2696	163	28	quality	quality	NOUN
ajlsi-2696	163	29	of	of	ADP
ajlsi-2696	163	30	life	life	NOUN
ajlsi-2696	163	31	while	while	SCONJ
ajlsi-2696	163	32	using	use	VERB
ajlsi-2696	163	33	the	the	DET
ajlsi-2696	163	34	completely	completely	ADV
ajlsi-2696	163	35	human	human	ADJ
ajlsi-2696	163	36	monoclonal	monoclonal	NOUN
ajlsi-2696	163	37	antibody	antibody	NOUN
ajlsi-2696	163	38	dupilumab	dupilumab	NOUN
ajlsi-2696	163	39	.	.	PUNCT
ajlsi-2696	164	1	based	base	VERB
ajlsi-2696	164	2	on	on	ADP
ajlsi-2696	164	3	actual	actual	ADJ
ajlsi-2696	164	4	data	datum	NOUN
ajlsi-2696	164	5	from	from	ADP
ajlsi-2696	164	6	clinical	clinical	ADJ
ajlsi-2696	164	7	trials	trial	NOUN
ajlsi-2696	164	8	,	,	PUNCT
ajlsi-2696	164	9	dupilumab	dupilumab	NOUN
ajlsi-2696	164	10	significantly	significantly	ADV
ajlsi-2696	164	11	improves	improve	VERB
ajlsi-2696	164	12	pediatric	pediatric	ADJ
ajlsi-2696	164	13	patients	patient	NOUN
ajlsi-2696	164	14	’	'	PUNCT
ajlsi-2696	164	15	scores	score	NOUN
ajlsi-2696	164	16	on	on	ADP
ajlsi-2696	164	17	the	the	DET
ajlsi-2696	164	18	“	"	PUNCT
ajlsi-2696	164	19	eczema	eczema	NOUN
ajlsi-2696	164	20	area	area	NOUN
ajlsi-2696	164	21	severity	severity	PROPN
ajlsi-2696	164	22	index	index	NOUN
ajlsi-2696	164	23	(	(	PUNCT
ajlsi-2696	164	24	easi	easi	NOUN
ajlsi-2696	164	25	)	)	PUNCT
ajlsi-2696	164	26	,	,	PUNCT
ajlsi-2696	164	27	pruritus	pruritus	PROPN
ajlsi-2696	164	28	numerical	numerical	ADJ
ajlsi-2696	164	29	rating	rating	NOUN
ajlsi-2696	164	30	scale	scale	NOUN
ajlsi-2696	164	31	(	(	PUNCT
ajlsi-2696	164	32	p	p	NOUN
ajlsi-2696	164	33	-	-	PUNCT
ajlsi-2696	164	34	nrs	nrs	NOUN
ajlsi-2696	164	35	)	)	PUNCT
ajlsi-2696	164	36	,	,	PUNCT
ajlsi-2696	164	37	sleep	sleep	VERB
ajlsi-2696	164	38	nrs	nrs	PROPN
ajlsi-2696	164	39	(	(	PUNCT
ajlsi-2696	164	40	s	s	NOUN
ajlsi-2696	164	41	-	-	NOUN
ajlsi-2696	164	42	nrs	nrs	NOUN
ajlsi-2696	164	43	)	)	PUNCT
ajlsi-2696	164	44	,	,	PUNCT
ajlsi-2696	164	45	and	and	CCONJ
ajlsi-2696	164	46	children	child	NOUN
ajlsi-2696	164	47	’s	’s	PART
ajlsi-2696	164	48	dermatology	dermatology	NOUN
ajlsi-2696	164	49	life	life	NOUN
ajlsi-2696	164	50	quality	quality	NOUN
ajlsi-2696	164	51	index	index	NOUN
ajlsi-2696	164	52	(	(	PUNCT
ajlsi-2696	164	53	c	c	NOUN
ajlsi-2696	164	54	-	-	PUNCT
ajlsi-2696	164	55	dlqi	dlqi	VERB
ajlsi-2696	164	56	)	)	PUNCT
ajlsi-2696	164	57	”	"	PUNCT
ajlsi-2696	164	58	.	.	PUNCT
ajlsi-2696	165	1	dupilumab	dupilumab	NOUN
ajlsi-2696	165	2	is	be	AUX
ajlsi-2696	165	3	well	well	ADV
ajlsi-2696	165	4	-	-	PUNCT
ajlsi-2696	165	5	tolerated	tolerate	VERB
ajlsi-2696	165	6	and	and	CCONJ
ajlsi-2696	165	7	efficacious	efficacious	ADJ
ajlsi-2696	165	8	in	in	ADP
ajlsi-2696	165	9	juvenile	juvenile	ADJ
ajlsi-2696	165	10	populations	population	NOUN
ajlsi-2696	165	11	,	,	PUNCT
ajlsi-2696	165	12	as	as	SCONJ
ajlsi-2696	165	13	evidenced	evidence	VERB
ajlsi-2696	165	14	by	by	ADP
ajlsi-2696	165	15	the	the	DET
ajlsi-2696	165	16	high	high	ADJ
ajlsi-2696	165	17	percentage	percentage	NOUN
ajlsi-2696	165	18	of	of	ADP
ajlsi-2696	165	19	patients	patient	NOUN
ajlsi-2696	165	20	achieving	achieve	VERB
ajlsi-2696	165	21	“	"	PUNCT
ajlsi-2696	165	22	easi75	easi75	NOUN
ajlsi-2696	165	23	”	"	PUNCT
ajlsi-2696	165	24	and	and	CCONJ
ajlsi-2696	165	25	the	the	DET
ajlsi-2696	165	26	significant	significant	ADJ
ajlsi-2696	165	27	mean	mean	ADJ
ajlsi-2696	165	28	percentage	percentage	NOUN
ajlsi-2696	165	29	reduction	reduction	NOUN
ajlsi-2696	165	30	in	in	ADP
ajlsi-2696	165	31	p	p	NOUN
ajlsi-2696	165	32	-	-	PUNCT
ajlsi-2696	165	33	nrs	nrs	NOUN
ajlsi-2696	165	34	,	,	PUNCT
ajlsi-2696	165	35	s	s	NOUN
ajlsi-2696	165	36	-	-	PUNCT
ajlsi-2696	165	37	nrs	nrs	NOUN
ajlsi-2696	165	38	,	,	PUNCT
ajlsi-2696	165	39	and	and	CCONJ
ajlsi-2696	165	40	c	c	X
ajlsi-2696	165	41	-	-	PUNCT
ajlsi-2696	165	42	dlqi	dlqi	VERB
ajlsi-2696	165	43	scores	score	NOUN
ajlsi-2696	165	44	(	(	PUNCT
ajlsi-2696	165	45	napolitano	napolitano	PROPN
ajlsi-2696	165	46	et	et	PROPN
ajlsi-2696	165	47	al	al	PROPN
ajlsi-2696	165	48	.	.	PROPN
ajlsi-2696	165	49	,	,	PUNCT
ajlsi-2696	165	50	2022	2022	NUM
ajlsi-2696	165	51	;	;	PUNCT
ajlsi-2696	165	52	papp	papp	PROPN
ajlsi-2696	165	53	et	et	PROPN
ajlsi-2696	165	54	al	al	PROPN
ajlsi-2696	165	55	.	.	PROPN
ajlsi-2696	165	56	,	,	PUNCT
ajlsi-2696	165	57	2021	2021	NUM
ajlsi-2696	165	58	)	)	PUNCT
ajlsi-2696	165	59	.	.	PUNCT
ajlsi-2696	166	1	conclusion	conclusion	NOUN
ajlsi-2696	166	2	potential	potential	ADJ
ajlsi-2696	166	3	advancements	advancement	NOUN
ajlsi-2696	166	4	in	in	ADP
ajlsi-2696	166	5	biological	biological	ADJ
ajlsi-2696	166	6	therapies	therapy	NOUN
ajlsi-2696	166	7	for	for	ADP
ajlsi-2696	166	8	atopic	atopic	NOUN
ajlsi-2696	166	9	dermatitis	dermatitis	NOUN
ajlsi-2696	166	10	targeted	target	VERB
ajlsi-2696	166	11	biological	biological	ADJ
ajlsi-2696	166	12	therapy	therapy	NOUN
ajlsi-2696	166	13	dupilumab	dupilumab	NOUN
ajlsi-2696	166	14	addresses	address	NOUN
ajlsi-2696	166	15	treatment	treatment	NOUN
ajlsi-2696	166	16	resistance	resistance	NOUN
ajlsi-2696	166	17	and	and	CCONJ
ajlsi-2696	166	18	lowers	lower	VERB
ajlsi-2696	166	19	the	the	DET
ajlsi-2696	166	20	likelihood	likelihood	NOUN
ajlsi-2696	166	21	of	of	ADP
ajlsi-2696	166	22	relapse	relapse	NOUN
ajlsi-2696	166	23	in	in	ADP
ajlsi-2696	166	24	patients	patient	NOUN
ajlsi-2696	166	25	with	with	ADP
ajlsi-2696	166	26	atopic	atopic	NOUN
ajlsi-2696	166	27	dermatitis	dermatitis	NOUN
ajlsi-2696	166	28	,	,	PUNCT
ajlsi-2696	166	29	improving	improve	VERB
ajlsi-2696	166	30	treatment	treatment	NOUN
ajlsi-2696	166	31	results	result	NOUN
ajlsi-2696	166	32	and	and	CCONJ
ajlsi-2696	166	33	quality	quality	NOUN
ajlsi-2696	166	34	of	of	ADP
ajlsi-2696	166	35	life	life	NOUN
ajlsi-2696	166	36	.	.	PUNCT
ajlsi-2696	167	1	this	this	DET
ajlsi-2696	167	2	development	development	NOUN
ajlsi-2696	167	3	in	in	ADP
ajlsi-2696	167	4	biological	biological	ADJ
ajlsi-2696	167	5	treatments	treatment	NOUN
ajlsi-2696	167	6	is	be	AUX
ajlsi-2696	167	7	immensely	immensely	ADV
ajlsi-2696	167	8	beneficial	beneficial	ADJ
ajlsi-2696	167	9	in	in	ADP
ajlsi-2696	167	10	treating	treat	VERB
ajlsi-2696	167	11	chronic	chronic	ADJ
ajlsi-2696	167	12	inflammatory	inflammatory	ADJ
ajlsi-2696	167	13	diseases	disease	NOUN
ajlsi-2696	167	14	like	like	ADP
ajlsi-2696	167	15	atopic	atopic	NOUN
ajlsi-2696	167	16	dermatitis	dermatitis	NOUN
ajlsi-2696	167	17	.	.	PUNCT
ajlsi-2696	168	1	importance	importance	NOUN
ajlsi-2696	168	2	of	of	ADP
ajlsi-2696	168	3	personalized	personalized	ADJ
ajlsi-2696	168	4	treatment	treatment	NOUN
ajlsi-2696	168	5	approaches	approach	NOUN
ajlsi-2696	168	6	optimizing	optimize	VERB
ajlsi-2696	168	7	results	result	NOUN
ajlsi-2696	168	8	for	for	ADP
ajlsi-2696	168	9	children	child	NOUN
ajlsi-2696	168	10	with	with	ADP
ajlsi-2696	168	11	disorders	disorder	NOUN
ajlsi-2696	168	12	such	such	ADJ
ajlsi-2696	168	13	as	as	ADP
ajlsi-2696	168	14	atopic	atopic	NOUN
ajlsi-2696	168	15	dermatitis	dermatitis	NOUN
ajlsi-2696	168	16	requires	require	VERB
ajlsi-2696	168	17	the	the	DET
ajlsi-2696	168	18	use	use	NOUN
ajlsi-2696	168	19	of	of	ADP
ajlsi-2696	168	20	personalized	personalized	ADJ
ajlsi-2696	168	21	therapy	therapy	NOUN
ajlsi-2696	168	22	techniques	technique	NOUN
ajlsi-2696	168	23	utilizing	utilize	VERB
ajlsi-2696	168	24	monoclonal	monoclonal	NOUN
ajlsi-2696	168	25	antibodies	antibody	NOUN
ajlsi-2696	168	26	,	,	PUNCT
ajlsi-2696	168	27	such	such	ADJ
ajlsi-2696	168	28	as	as	ADP
ajlsi-2696	168	29	dupilumab	dupilumab	NOUN
ajlsi-2696	168	30	.	.	PUNCT
ajlsi-2696	169	1	personalized	personalized	ADJ
ajlsi-2696	169	2	treatment	treatment	NOUN
ajlsi-2696	169	3	is	be	AUX
ajlsi-2696	169	4	a	a	DET
ajlsi-2696	169	5	helpful	helpful	ADJ
ajlsi-2696	169	6	therapeutic	therapeutic	ADJ
ajlsi-2696	169	7	option	option	NOUN
ajlsi-2696	169	8	for	for	ADP
ajlsi-2696	169	9	inadequately	inadequately	ADV
ajlsi-2696	169	10	controlled	control	VERB
ajlsi-2696	169	11	atopic	atopic	NOUN
ajlsi-2696	169	12	dermatitis	dermatitis	NOUN
ajlsi-2696	169	13	,	,	PUNCT
ajlsi-2696	169	14	as	as	SCONJ
ajlsi-2696	169	15	studies	study	NOUN
ajlsi-2696	169	16	in	in	ADP
ajlsi-2696	169	17	children	child	NOUN
ajlsi-2696	169	18	aged	age	VERB
ajlsi-2696	169	19	6	6	NUM
ajlsi-2696	169	20	-	-	SYM
ajlsi-2696	169	21	11	11	NUM
ajlsi-2696	169	22	reveal	reveal	VERB
ajlsi-2696	169	23	significant	significant	ADJ
ajlsi-2696	169	24	improvements	improvement	NOUN
ajlsi-2696	169	25	in	in	ADP
ajlsi-2696	169	26	disease	disease	NOUN
ajlsi-2696	169	27	severity	severity	NOUN
ajlsi-2696	169	28	,	,	PUNCT
ajlsi-2696	169	29	pruritus	pruritus	PROPN
ajlsi-2696	169	30	,	,	PUNCT
ajlsi-2696	169	31	sleep	sleep	VERB
ajlsi-2696	169	32	quality	quality	NOUN
ajlsi-2696	169	33	,	,	PUNCT
ajlsi-2696	169	34	and	and	CCONJ
ajlsi-2696	169	35	quality	quality	NOUN
ajlsi-2696	169	36	of	of	ADP
ajlsi-2696	169	37	life	life	NOUN
ajlsi-2696	169	38	.	.	PUNCT
ajlsi-2696	170	1	recommendations	recommendation	NOUN
ajlsi-2696	170	2	➢	➢	VERB
ajlsi-2696	170	3	real	real	ADJ
ajlsi-2696	170	4	-	-	PUNCT
ajlsi-2696	170	5	world	world	NOUN
ajlsi-2696	170	6	data	datum	NOUN
ajlsi-2696	170	7	on	on	ADP
ajlsi-2696	170	8	dupilumab	dupilumab	NOUN
ajlsi-2696	170	9	’s	’s	PART
ajlsi-2696	170	10	effectiveness	effectiveness	NOUN
ajlsi-2696	170	11	in	in	ADP
ajlsi-2696	170	12	diverse	diverse	ADJ
ajlsi-2696	170	13	pediatric	pediatric	ADJ
ajlsi-2696	170	14	populations	population	NOUN
ajlsi-2696	170	15	is	be	AUX
ajlsi-2696	170	16	needed	need	VERB
ajlsi-2696	170	17	to	to	PART
ajlsi-2696	170	18	validate	validate	VERB
ajlsi-2696	170	19	clinical	clinical	ADJ
ajlsi-2696	170	20	trials	trial	NOUN
ajlsi-2696	170	21	and	and	CCONJ
ajlsi-2696	170	22	provide	provide	VERB
ajlsi-2696	170	23	insights	insight	NOUN
ajlsi-2696	170	24	into	into	ADP
ajlsi-2696	170	25	its	its	PRON
ajlsi-2696	170	26	wider	wide	ADJ
ajlsi-2696	170	27	patient	patient	ADJ
ajlsi-2696	170	28	cohorts	cohort	NOUN
ajlsi-2696	170	29	.	.	PUNCT
ajlsi-2696	171	1	➢	➢	PROPN
ajlsi-2696	171	2	examine	examine	VERB
ajlsi-2696	171	3	the	the	DET
ajlsi-2696	171	4	long	long	ADJ
ajlsi-2696	171	5	-	-	PUNCT
ajlsi-2696	171	6	term	term	NOUN
ajlsi-2696	171	7	safety	safety	NOUN
ajlsi-2696	171	8	and	and	CCONJ
ajlsi-2696	171	9	efficacy	efficacy	NOUN
ajlsi-2696	171	10	of	of	ADP
ajlsi-2696	171	11	dupilumab	dupilumab	NOUN
ajlsi-2696	171	12	in	in	ADP
ajlsi-2696	171	13	treating	treat	VERB
ajlsi-2696	171	14	pediatric	pediatric	ADJ
ajlsi-2696	171	15	patients	patient	NOUN
ajlsi-2696	171	16	with	with	ADP
ajlsi-2696	171	17	atopic	atopic	NOUN
ajlsi-2696	171	18	dermatitis	dermatitis	NOUN
ajlsi-2696	171	19	,	,	PUNCT
ajlsi-2696	171	20	as	as	ADV
ajlsi-2696	171	21	well	well	ADV
ajlsi-2696	171	22	as	as	ADP
ajlsi-2696	171	23	any	any	DET
ajlsi-2696	171	24	possible	possible	ADJ
ajlsi-2696	171	25	negative	negative	ADJ
ajlsi-2696	171	26	effects	effect	NOUN
ajlsi-2696	171	27	and	and	CCONJ
ajlsi-2696	171	28	overall	overall	ADJ
ajlsi-2696	171	29	disease	disease	NOUN
ajlsi-2696	171	30	control	control	NOUN
ajlsi-2696	171	31	.	.	PUNCT
ajlsi-2696	172	1	➢	➢	PROPN
ajlsi-2696	172	2	evaluate	evaluate	VERB
ajlsi-2696	172	3	the	the	DET
ajlsi-2696	172	4	effectiveness	effectiveness	NOUN
ajlsi-2696	172	5	,	,	PUNCT
ajlsi-2696	172	6	safety	safety	NOUN
ajlsi-2696	172	7	,	,	PUNCT
ajlsi-2696	172	8	and	and	CCONJ
ajlsi-2696	172	9	tolerability	tolerability	NOUN
ajlsi-2696	172	10	of	of	ADP
ajlsi-2696	172	11	dupilumab	dupilumab	NOUN
ajlsi-2696	172	12	compared	compare	VERB
ajlsi-2696	172	13	to	to	ADP
ajlsi-2696	172	14	other	other	ADJ
ajlsi-2696	172	15	biologic	biologic	NOUN
ajlsi-2696	172	16	drugs	drug	NOUN
ajlsi-2696	172	17	in	in	ADP
ajlsi-2696	172	18	pediatric	pediatric	ADJ
ajlsi-2696	172	19	atopic	atopic	NOUN
ajlsi-2696	172	20	dermatitis	dermatitis	NOUN
ajlsi-2696	172	21	therapy	therapy	NOUN
ajlsi-2696	172	22	,	,	PUNCT
ajlsi-2696	172	23	such	such	ADJ
ajlsi-2696	172	24	as	as	ADP
ajlsi-2696	172	25	tralokinumab	tralokinumab	NOUN
ajlsi-2696	172	26	or	or	CCONJ
ajlsi-2696	172	27	omalizumab	omalizumab	NOUN
ajlsi-2696	172	28	.	.	PUNCT
ajlsi-2696	173	1	limitations	limitation	NOUN
ajlsi-2696	173	2	➢	➢	VERB
ajlsi-2696	173	3	the	the	DET
ajlsi-2696	173	4	severity	severity	NOUN
ajlsi-2696	173	5	of	of	ADP
ajlsi-2696	173	6	atopic	atopic	NOUN
ajlsi-2696	173	7	dermatitis	dermatitis	NOUN
ajlsi-2696	173	8	in	in	ADP
ajlsi-2696	173	9	children	child	NOUN
ajlsi-2696	173	10	significantly	significantly	ADV
ajlsi-2696	173	11	influenced	influence	VERB
ajlsi-2696	173	12	the	the	DET
ajlsi-2696	173	13	response	response	NOUN
ajlsi-2696	173	14	to	to	ADP
ajlsi-2696	173	15	dupilumab	dupilumab	NOUN
ajlsi-2696	173	16	treatment	treatment	NOUN
ajlsi-2696	173	17	,	,	PUNCT
ajlsi-2696	173	18	making	make	VERB
ajlsi-2696	173	19	it	it	PRON
ajlsi-2696	173	20	challenging	challenging	ADJ
ajlsi-2696	173	21	to	to	PART
ajlsi-2696	173	22	draw	draw	VERB
ajlsi-2696	173	23	definitive	definitive	ADJ
ajlsi-2696	173	24	conclusions	conclusion	NOUN
ajlsi-2696	173	25	.	.	PUNCT
ajlsi-2696	174	1	➢	➢	NOUN
ajlsi-2696	174	2	dupilumab	dupilumab	NOUN
ajlsi-2696	174	3	treatment	treatment	PROPN
ajlsi-2696	174	4	’s	’s	PART
ajlsi-2696	174	5	high	high	ADJ
ajlsi-2696	174	6	cost	cost	NOUN
ajlsi-2696	174	7	and	and	CCONJ
ajlsi-2696	174	8	accessibility	accessibility	NOUN
ajlsi-2696	174	9	issues	issue	NOUN
ajlsi-2696	174	10	in	in	ADP
ajlsi-2696	174	11	certain	certain	ADJ
ajlsi-2696	174	12	healthcare	healthcare	NOUN
ajlsi-2696	174	13	settings	setting	NOUN
ajlsi-2696	174	14	caused	cause	VERB
ajlsi-2696	174	15	hindrances	hindrance	NOUN
ajlsi-2696	174	16	in	in	ADP
ajlsi-2696	174	17	its	its	PRON
ajlsi-2696	174	18	widespread	widespread	ADJ
ajlsi-2696	174	19	adoption	adoption	NOUN
ajlsi-2696	174	20	and	and	CCONJ
ajlsi-2696	174	21	data	datum	NOUN
ajlsi-2696	174	22	availability	availability	NOUN
ajlsi-2696	174	23	in	in	ADP
ajlsi-2696	174	24	research	research	NOUN
ajlsi-2696	174	25	studies	study	NOUN
ajlsi-2696	174	26	.	.	PUNCT
ajlsi-2696	175	1	references	reference	NOUN
ajlsi-2696	175	2	albrecht	albrecht	PROPN
ajlsi-2696	175	3	,	,	PUNCT
ajlsi-2696	175	4	m.	m.	NOUN
ajlsi-2696	175	5	,	,	PUNCT
ajlsi-2696	175	6	&	&	CCONJ
ajlsi-2696	175	7	dittrich	dittrich	NOUN
ajlsi-2696	175	8	,	,	PUNCT
ajlsi-2696	175	9	a.	a.	NOUN
ajlsi-2696	175	10	(	(	PUNCT
ajlsi-2696	175	11	2015	2015	NUM
ajlsi-2696	175	12	)	)	PUNCT
ajlsi-2696	175	13	.	.	PUNCT
ajlsi-2696	176	1	expression	expression	NOUN
ajlsi-2696	176	2	and	and	CCONJ
ajlsi-2696	176	3	function	function	NOUN
ajlsi-2696	176	4	of	of	ADP
ajlsi-2696	176	5	histamine	histamine	NOUN
ajlsi-2696	176	6	and	and	CCONJ
ajlsi-2696	176	7	its	its	PRON
ajlsi-2696	176	8	receptors	receptor	NOUN
ajlsi-2696	176	9	in	in	ADP
ajlsi-2696	176	10	atopic	atopic	NOUN
ajlsi-2696	176	11	dermatitis	dermatitis	NOUN
ajlsi-2696	176	12	.	.	PUNCT
ajlsi-2696	177	1	molecular	molecular	ADJ
ajlsi-2696	177	2	and	and	CCONJ
ajlsi-2696	177	3	cellular	cellular	ADJ
ajlsi-2696	177	4	pediatrics	pediatric	NOUN
ajlsi-2696	177	5	,	,	PUNCT
ajlsi-2696	177	6	2	2	NUM
ajlsi-2696	177	7	,	,	PUNCT
ajlsi-2696	177	8	1	1	NUM
ajlsi-2696	177	9	-	-	SYM
ajlsi-2696	177	10	8	8	NUM
ajlsi-2696	177	11	.	.	PUNCT
ajlsi-2696	178	1	amber	amber	PROPN
ajlsi-2696	178	2	,	,	PUNCT
ajlsi-2696	178	3	t.	t.	PROPN
ajlsi-2696	178	4	,	,	PUNCT
ajlsi-2696	178	5	&	&	CCONJ
ajlsi-2696	178	6	tabassum	tabassum	PROPN
ajlsi-2696	178	7	,	,	PUNCT
ajlsi-2696	178	8	s.	s.	PROPN
ajlsi-2696	178	9	(	(	PUNCT
ajlsi-2696	178	10	2020	2020	NUM
ajlsi-2696	178	11	)	)	PUNCT
ajlsi-2696	178	12	.	.	PUNCT
ajlsi-2696	179	1	cyclosporin	cyclosporin	NOUN
ajlsi-2696	179	2	in	in	ADP
ajlsi-2696	179	3	dermatology	dermatology	NOUN
ajlsi-2696	179	4	:	:	PUNCT
ajlsi-2696	179	5	a	a	DET
ajlsi-2696	179	6	practical	practical	ADJ
ajlsi-2696	179	7	compendium	compendium	NOUN
ajlsi-2696	179	8	.	.	PUNCT
ajlsi-2696	180	1	dermatologic	dermatologic	ADJ
ajlsi-2696	180	2	therapy	therapy	NOUN
ajlsi-2696	180	3	,	,	PUNCT
ajlsi-2696	180	4	33(6	33(6	PROPN
ajlsi-2696	180	5	)	)	PUNCT
ajlsi-2696	180	6	,	,	PUNCT
ajlsi-2696	180	7	e13934	e13934	PROPN
ajlsi-2696	180	8	.	.	PUNCT
ajlsi-2696	181	1	anderson	anderson	PROPN
ajlsi-2696	181	2	iii	iii	PROPN
ajlsi-2696	181	3	,	,	PUNCT
ajlsi-2696	181	4	w.	w.	PROPN
ajlsi-2696	181	5	c.	c.	PROPN
ajlsi-2696	181	6	,	,	PUNCT
ajlsi-2696	181	7	&	&	CCONJ
ajlsi-2696	181	8	szefler	szefler	PROPN
ajlsi-2696	181	9	,	,	PUNCT
ajlsi-2696	181	10	s.	s.	PROPN
ajlsi-2696	181	11	j.	j.	PROPN
ajlsi-2696	181	12	(	(	PUNCT
ajlsi-2696	181	13	2019	2019	NUM
ajlsi-2696	181	14	)	)	PUNCT
ajlsi-2696	181	15	.	.	PUNCT
ajlsi-2696	182	1	costeffectiveness	costeffectiveness	NOUN
ajlsi-2696	182	2	and	and	CCONJ
ajlsi-2696	182	3	comparative	comparative	ADJ
ajlsi-2696	182	4	effectiveness	effectiveness	NOUN
ajlsi-2696	182	5	of	of	ADP
ajlsi-2696	182	6	biologic	biologic	NOUN
ajlsi-2696	182	7	therapy	therapy	NOUN
ajlsi-2696	182	8	for	for	ADP
ajlsi-2696	182	9	asthma	asthma	NOUN
ajlsi-2696	182	10	:	:	PUNCT
ajlsi-2696	182	11	to	to	PART
ajlsi-2696	182	12	biologic	biologic	VERB
ajlsi-2696	182	13	or	or	CCONJ
ajlsi-2696	182	14	not	not	PART
ajlsi-2696	182	15	to	to	PART
ajlsi-2696	182	16	biologic	biologic	VERB
ajlsi-2696	182	17	?	?	PUNCT
ajlsi-2696	183	1	annals	annal	NOUN
ajlsi-2696	183	2	of	of	ADP
ajlsi-2696	183	3	allergy	allergy	NOUN
ajlsi-2696	183	4	,	,	PUNCT
ajlsi-2696	183	5	asthma	asthma	PROPN
ajlsi-2696	183	6	&	&	CCONJ
ajlsi-2696	183	7	immunology	immunology	NOUN
ajlsi-2696	183	8	,	,	PUNCT
ajlsi-2696	183	9	122(4	122(4	NUM
ajlsi-2696	183	10	)	)	PUNCT
ajlsi-2696	183	11	,	,	PUNCT
ajlsi-2696	183	12	367	367	NUM
ajlsi-2696	183	13	-	-	SYM
ajlsi-2696	183	14	372	372	NUM
ajlsi-2696	183	15	.	.	PUNCT
ajlsi-2696	184	1	antti	antti	PROPN
ajlsi-2696	184	2	,	,	PUNCT
ajlsi-2696	184	3	a.	a.	NOUN
ajlsi-2696	184	4	,	,	PUNCT
ajlsi-2696	184	5	salava	salava	NOUN
ajlsi-2696	184	6	,	,	PUNCT
ajlsi-2696	184	7	a.	a.	NOUN
ajlsi-2696	184	8	,	,	PUNCT
ajlsi-2696	184	9	perälä	perälä	ADJ
ajlsi-2696	184	10	,	,	PUNCT
ajlsi-2696	184	11	m.	m.	NOUN
ajlsi-2696	184	12	,	,	PUNCT
ajlsi-2696	184	13	pelkonen	pelkonen	NOUN
ajlsi-2696	184	14	,	,	PUNCT
ajlsi-2696	184	15	a.	a.	PROPN
ajlsi-2696	184	16	s.	s.	PROPN
ajlsi-2696	184	17	,	,	PUNCT
ajlsi-2696	184	18	mäkelä	mäkelä	PROPN
ajlsi-2696	184	19	,	,	PUNCT
ajlsi-2696	184	20	m.	m.	NOUN
ajlsi-2696	184	21	j.	j.	PROPN
ajlsi-2696	184	22	,	,	PUNCT
ajlsi-2696	184	23	&	&	CCONJ
ajlsi-2696	184	24	remitz	remitz	PROPN
ajlsi-2696	184	25	,	,	PUNCT
ajlsi-2696	184	26	a.	a.	NOUN
ajlsi-2696	184	27	(	(	PUNCT
ajlsi-2696	184	28	2021	2021	NUM
ajlsi-2696	184	29	)	)	PUNCT
ajlsi-2696	184	30	.	.	PUNCT
ajlsi-2696	185	1	are	be	AUX
ajlsi-2696	185	2	infants	infant	NOUN
ajlsi-2696	185	3	and	and	CCONJ
ajlsi-2696	185	4	toddlers	toddler	NOUN
ajlsi-2696	185	5	with	with	ADP
ajlsi-2696	185	6	moderate	moderate	ADJ
ajlsi-2696	185	7	-	-	PUNCT
ajlsi-2696	185	8	to	to	ADP
ajlsi-2696	185	9	-	-	PUNCT
ajlsi-2696	185	10	severe	severe	ADJ
ajlsi-2696	185	11	atopic	atopic	NOUN
ajlsi-2696	185	12	dermatitis	dermatitis	NOUN
ajlsi-2696	185	13	undertreated	undertreate	VERB
ajlsi-2696	185	14	?	?	PUNCT
ajlsi-2696	186	1	experiences	experience	NOUN
ajlsi-2696	186	2	of	of	ADP
ajlsi-2696	186	3	a	a	DET
ajlsi-2696	186	4	finnish	finnish	ADJ
ajlsi-2696	186	5	tertiary	tertiary	ADJ
ajlsi-2696	186	6	care	care	NOUN
ajlsi-2696	186	7	hospital	hospital	NOUN
ajlsi-2696	186	8	.	.	PUNCT
ajlsi-2696	187	1	acta	acta	PROPN
ajlsi-2696	187	2	dermato	dermato	PROPN
ajlsi-2696	187	3	-	-	PUNCT
ajlsi-2696	187	4	venereologica	venereologica	PROPN
ajlsi-2696	187	5	,	,	PUNCT
ajlsi-2696	187	6	101(1	101(1	NUM
ajlsi-2696	187	7	)	)	PUNCT
ajlsi-2696	187	8	.	.	PUNCT
ajlsi-2696	188	1	axon	axon	PROPN
ajlsi-2696	188	2	,	,	PUNCT
ajlsi-2696	188	3	e.	e.	PROPN
ajlsi-2696	188	4	,	,	PUNCT
ajlsi-2696	188	5	chalmers	chalmers	PROPN
ajlsi-2696	188	6	,	,	PUNCT
ajlsi-2696	188	7	j.	j.	PROPN
ajlsi-2696	188	8	r.	r.	PROPN
ajlsi-2696	188	9	,	,	PUNCT
ajlsi-2696	188	10	santer	santer	PROPN
ajlsi-2696	188	11	,	,	PUNCT
ajlsi-2696	188	12	m.	m.	NOUN
ajlsi-2696	188	13	,	,	PUNCT
ajlsi-2696	188	14	ridd	ridd	PROPN
ajlsi-2696	188	15	,	,	PUNCT
ajlsi-2696	188	16	m.	m.	NOUN
ajlsi-2696	188	17	j.	j.	PROPN
ajlsi-2696	188	18	,	,	PUNCT
ajlsi-2696	188	19	lawton	lawton	PROPN
ajlsi-2696	188	20	,	,	PUNCT
ajlsi-2696	188	21	s.	s.	PROPN
ajlsi-2696	188	22	,	,	PUNCT
ajlsi-2696	188	23	langan	langan	PROPN
ajlsi-2696	188	24	,	,	PUNCT
ajlsi-2696	188	25	s.	s.	PROPN
ajlsi-2696	188	26	m.	m.	PROPN
ajlsi-2696	188	27	,	,	PUNCT
ajlsi-2696	188	28	grindlay	grindlay	PROPN
ajlsi-2696	188	29	,	,	PUNCT
ajlsi-2696	188	30	d.	d.	PROPN
ajlsi-2696	188	31	j.	j.	PROPN
ajlsi-2696	188	32	,	,	PUNCT
ajlsi-2696	188	33	muller	muller	PROPN
ajlsi-2696	188	34	,	,	PUNCT
ajlsi-2696	188	35	i.	i.	PROPN
ajlsi-2696	188	36	,	,	PUNCT
ajlsi-2696	188	37	roberts	roberts	PROPN
ajlsi-2696	188	38	,	,	PUNCT
ajlsi-2696	188	39	a.	a.	PROPN
ajlsi-2696	188	40	,	,	PUNCT
ajlsi-2696	188	41	&	&	CCONJ
ajlsi-2696	188	42	ahmed	ahmed	PROPN
ajlsi-2696	188	43	,	,	PUNCT
ajlsi-2696	188	44	a.	a.	NOUN
ajlsi-2696	188	45	(	(	PUNCT
ajlsi-2696	188	46	2021	2021	NUM
ajlsi-2696	188	47	)	)	PUNCT
ajlsi-2696	188	48	.	.	PUNCT
ajlsi-2696	189	1	safety	safety	NOUN
ajlsi-2696	189	2	of	of	ADP
ajlsi-2696	189	3	topical	topical	ADJ
ajlsi-2696	189	4	corticosteroids	corticosteroid	NOUN
ajlsi-2696	189	5	in	in	ADP
ajlsi-2696	189	6	atopic	atopic	ADJ
ajlsi-2696	189	7	eczema	eczema	NOUN
ajlsi-2696	189	8	:	:	PUNCT
ajlsi-2696	189	9	an	an	DET
ajlsi-2696	189	10	umbrella	umbrella	NOUN
ajlsi-2696	189	11	review	review	NOUN
ajlsi-2696	189	12	.	.	PUNCT
ajlsi-2696	190	1	bmj	bmj	PROPN
ajlsi-2696	190	2	open	open	ADJ
ajlsi-2696	190	3	,	,	PUNCT
ajlsi-2696	190	4	11(7	11(7	NUM
ajlsi-2696	190	5	)	)	PUNCT
ajlsi-2696	190	6	,	,	PUNCT
ajlsi-2696	190	7	e046476	e046476	PROPN
ajlsi-2696	190	8	.	.	PROPN
ajlsi-2696	190	9	berna	berna	PROPN
ajlsi-2696	190	10	-	-	PUNCT
ajlsi-2696	190	11	rico	rico	PROPN
ajlsi-2696	190	12	,	,	PUNCT
ajlsi-2696	190	13	e.	e.	PROPN
ajlsi-2696	190	14	,	,	PUNCT
ajlsi-2696	190	15	fiz	fiz	PROPN
ajlsi-2696	190	16	-	-	PUNCT
ajlsi-2696	190	17	benito	benito	PROPN
ajlsi-2696	190	18	,	,	PUNCT
ajlsi-2696	190	19	e.	e.	PROPN
ajlsi-2696	190	20	,	,	PUNCT
ajlsi-2696	190	21	busto	busto	NOUN
ajlsi-2696	190	22	-	-	PUNCT
ajlsi-2696	190	23	leis	leis	NOUN
ajlsi-2696	190	24	,	,	PUNCT
ajlsi-2696	190	25	j.	j.	PROPN
ajlsi-2696	190	26	m.	m.	PROPN
ajlsi-2696	190	27	,	,	PUNCT
ajlsi-2696	190	28	serveranegre	serveranegre	PROPN
ajlsi-2696	190	29	,	,	PUNCT
ajlsi-2696	190	30	g.	g.	PROPN
ajlsi-2696	190	31	,	,	PUNCT
ajlsi-2696	190	32	de	de	PROPN
ajlsi-2696	190	33	lucas	lucas	PROPN
ajlsi-2696	190	34	-	-	PUNCT
ajlsi-2696	190	35	laguna	laguna	PROPN
ajlsi-2696	190	36	,	,	PUNCT
ajlsi-2696	190	37	r.	r.	PROPN
ajlsi-2696	190	38	,	,	PUNCT
ajlsi-2696	190	39	&	&	CCONJ
ajlsi-2696	190	40	feito	feito	PROPN
ajlsi-2696	190	41	-	-	PROPN
ajlsi-2696	190	42	rodriguez	rodriguez	NOUN
ajlsi-2696	190	43	,	,	PUNCT
ajlsi-2696	190	44	m.	m.	NOUN
ajlsi-2696	190	45	(	(	PUNCT
ajlsi-2696	190	46	2023	2023	NUM
ajlsi-2696	190	47	)	)	PUNCT
ajlsi-2696	190	48	.	.	PUNCT
ajlsi-2696	191	1	effectiveness	effectiveness	NOUN
ajlsi-2696	191	2	and	and	CCONJ
ajlsi-2696	191	3	safety	safety	NOUN
ajlsi-2696	191	4	of	of	ADP
ajlsi-2696	191	5	dupilumab	dupilumab	NOUN
ajlsi-2696	191	6	in	in	ADP
ajlsi-2696	191	7	children	child	NOUN
ajlsi-2696	191	8	under	under	ADP
ajlsi-2696	191	9	6	6	NUM
ajlsi-2696	191	10	years	year	NOUN
ajlsi-2696	191	11	of	of	ADP
ajlsi-2696	191	12	age	age	NOUN
ajlsi-2696	191	13	with	with	ADP
ajlsi-2696	191	14	moderate	moderate	ADJ
ajlsi-2696	191	15	-	-	PUNCT
ajlsi-2696	191	16	tosevere	tosevere	NOUN
ajlsi-2696	191	17	atopic	atopic	NOUN
ajlsi-2696	191	18	dermatitis	dermatitis	NOUN
ajlsi-2696	191	19	:	:	PUNCT
ajlsi-2696	191	20	a	a	DET
ajlsi-2696	191	21	retrospective	retrospective	ADJ
ajlsi-2696	191	22	real	real	ADJ
ajlsi-2696	191	23	-	-	PUNCT
ajlsi-2696	191	24	world	world	NOUN
ajlsi-2696	191	25	study	study	NOUN
ajlsi-2696	191	26	.	.	PUNCT
ajlsi-2696	192	1	dermatology	dermatology	NOUN
ajlsi-2696	192	2	,	,	PUNCT
ajlsi-2696	192	3	1	1	NUM
ajlsi-2696	192	4	-	-	SYM
ajlsi-2696	192	5	1	1	NUM
ajlsi-2696	192	6	.	.	PUNCT
ajlsi-2696	192	7	berth	berth	NOUN
ajlsi-2696	192	8	-	-	PUNCT
ajlsi-2696	192	9	jones	jones	PROPN
ajlsi-2696	192	10	,	,	PUNCT
ajlsi-2696	192	11	j.	j.	PROPN
ajlsi-2696	192	12	,	,	PUNCT
ajlsi-2696	192	13	damstra	damstra	PROPN
ajlsi-2696	192	14	,	,	PUNCT
ajlsi-2696	192	15	r.	r.	PROPN
ajlsi-2696	192	16	j.	j.	PROPN
ajlsi-2696	192	17	,	,	PUNCT
ajlsi-2696	192	18	golsch	golsch	PROPN
ajlsi-2696	192	19	,	,	PUNCT
ajlsi-2696	192	20	s.	s.	PROPN
ajlsi-2696	192	21	,	,	PUNCT
ajlsi-2696	192	22	livden	livden	PROPN
ajlsi-2696	192	23	,	,	PUNCT
ajlsi-2696	192	24	j.	j.	PROPN
ajlsi-2696	192	25	k.	k.	PROPN
ajlsi-2696	192	26	,	,	PUNCT
ajlsi-2696	192	27	van	van	PROPN
ajlsi-2696	192	28	hooteghem	hooteghem	PROPN
ajlsi-2696	192	29	,	,	PUNCT
ajlsi-2696	192	30	o.	o.	PROPN
ajlsi-2696	192	31	,	,	PUNCT
ajlsi-2696	192	32	allegra	allegra	PROPN
ajlsi-2696	192	33	,	,	PUNCT
ajlsi-2696	192	34	f.	f.	PROPN
ajlsi-2696	192	35	,	,	PUNCT
ajlsi-2696	192	36	&	&	CCONJ
ajlsi-2696	192	37	parker	parker	PROPN
ajlsi-2696	192	38	,	,	PUNCT
ajlsi-2696	192	39	c.	c.	PROPN
ajlsi-2696	192	40	a.	a.	PROPN
ajlsi-2696	192	41	(	(	PUNCT
ajlsi-2696	192	42	2003	2003	NUM
ajlsi-2696	192	43	)	)	PUNCT
ajlsi-2696	192	44	.	.	PUNCT
ajlsi-2696	193	1	twice	twice	ADV
ajlsi-2696	193	2	weekly	weekly	ADJ
ajlsi-2696	193	3	fluticasone	fluticasone	NOUN
ajlsi-2696	193	4	propionate	propionate	NOUN
ajlsi-2696	193	5	added	add	VERB
ajlsi-2696	193	6	to	to	ADP
ajlsi-2696	193	7	emollient	emollient	NOUN
ajlsi-2696	193	8	maintenance	maintenance	NOUN
ajlsi-2696	193	9	treatment	treatment	NOUN
ajlsi-2696	193	10	to	to	PART
ajlsi-2696	193	11	reduce	reduce	VERB
ajlsi-2696	193	12	risk	risk	NOUN
ajlsi-2696	193	13	of	of	ADP
ajlsi-2696	193	14	relapse	relapse	NOUN
ajlsi-2696	193	15	in	in	ADP
ajlsi-2696	193	16	atopic	atopic	NOUN
ajlsi-2696	193	17	dermatitis	dermatitis	NOUN
ajlsi-2696	193	18	:	:	PUNCT
ajlsi-2696	193	19	randomised	randomise	VERB
ajlsi-2696	193	20	,	,	PUNCT
ajlsi-2696	193	21	double	double	ADV
ajlsi-2696	193	22	blind	blind	ADJ
ajlsi-2696	193	23	,	,	PUNCT
ajlsi-2696	193	24	parallel	parallel	ADJ
ajlsi-2696	193	25	group	group	NOUN
ajlsi-2696	193	26	study	study	NOUN
ajlsi-2696	193	27	.	.	PUNCT
ajlsi-2696	194	1	bmj	bmj	PROPN
ajlsi-2696	194	2	,	,	PUNCT
ajlsi-2696	194	3	326(7403	326(7403	NUM
ajlsi-2696	194	4	)	)	PUNCT
ajlsi-2696	194	5	,	,	PUNCT
ajlsi-2696	194	6	1367	1367	NUM
ajlsi-2696	194	7	.	.	PUNCT
ajlsi-2696	195	1	bohannon	bohannon	PROPN
ajlsi-2696	195	2	,	,	PUNCT
ajlsi-2696	195	3	m.	m.	NOUN
ajlsi-2696	195	4	,	,	PUNCT
ajlsi-2696	195	5	liu	liu	PROPN
ajlsi-2696	195	6	,	,	PUNCT
ajlsi-2696	195	7	m.	m.	NOUN
ajlsi-2696	195	8	,	,	PUNCT
ajlsi-2696	195	9	nadeau	nadeau	PROPN
ajlsi-2696	195	10	,	,	PUNCT
ajlsi-2696	195	11	p.	p.	PROPN
ajlsi-2696	195	12	,	,	PUNCT
ajlsi-2696	195	13	talton	talton	PROPN
ajlsi-2696	195	14	,	,	PUNCT
ajlsi-2696	195	15	j.	j.	PROPN
ajlsi-2696	195	16	,	,	PUNCT
ajlsi-2696	195	17	gibson	gibson	PROPN
ajlsi-2696	195	18	,	,	PUNCT
ajlsi-2696	195	19	d.	d.	PROPN
ajlsi-2696	195	20	,	,	PUNCT
ajlsi-2696	195	21	datta	datta	PROPN
ajlsi-2696	195	22	,	,	PUNCT
ajlsi-2696	195	23	s.	s.	PROPN
ajlsi-2696	195	24	,	,	PUNCT
ajlsi-2696	195	25	schultz	schultz	PROPN
ajlsi-2696	195	26	,	,	PUNCT
ajlsi-2696	195	27	g.	g.	PROPN
ajlsi-2696	195	28	,	,	PUNCT
ajlsi-2696	195	29	talton	talton	PROPN
ajlsi-2696	195	30	,	,	PUNCT
ajlsi-2696	195	31	j.	j.	PROPN
ajlsi-2696	195	32	,	,	PUNCT
ajlsi-2696	195	33	&	&	CCONJ
ajlsi-2696	195	34	de	de	X
ajlsi-2696	195	35	benedetto	benedetto	PROPN
ajlsi-2696	195	36	,	,	PUNCT
ajlsi-2696	195	37	a.	a.	NOUN
ajlsi-2696	195	38	(	(	PUNCT
ajlsi-2696	195	39	2020	2020	NUM
ajlsi-2696	195	40	)	)	PUNCT
ajlsi-2696	195	41	.	.	PUNCT
ajlsi-2696	196	1	topical	topical	ADJ
ajlsi-2696	196	2	doxycycline	doxycycline	NOUN
ajlsi-2696	196	3	monohydrate	monohydrate	PROPN
ajlsi-2696	196	4	hydrogel	hydrogel	NOUN
ajlsi-2696	196	5	1	1	NUM
ajlsi-2696	196	6	%	%	NOUN
ajlsi-2696	196	7	targeting	target	VERB
ajlsi-2696	196	8	proteases	protease	NOUN
ajlsi-2696	196	9	/	/	SYM
ajlsi-2696	196	10	par2	par2	PROPN
ajlsi-2696	196	11	pathway	pathway	NOUN
ajlsi-2696	196	12	is	be	AUX
ajlsi-2696	196	13	a	a	DET
ajlsi-2696	196	14	novel	novel	NOUN
ajlsi-2696	196	15	therapeutic	therapeutic	ADJ
ajlsi-2696	196	16	for	for	ADP
ajlsi-2696	196	17	atopic	atopic	NOUN
ajlsi-2696	196	18	dermatitis	dermatitis	NOUN
ajlsi-2696	196	19	.	.	PUNCT
ajlsi-2696	197	1	experimental	experimental	ADJ
ajlsi-2696	197	2	dermatology	dermatology	NOUN
ajlsi-2696	197	3	,	,	PUNCT
ajlsi-2696	197	4	29(12	29(12	NUM
ajlsi-2696	197	5	)	)	PUNCT
ajlsi-2696	197	6	,	,	PUNCT
ajlsi-2696	197	7	1171	1171	NUM
ajlsi-2696	197	8	-	-	SYM
ajlsi-2696	197	9	1175	1175	NUM
ajlsi-2696	197	10	.	.	PUNCT
ajlsi-2696	198	1	caffarelli	caffarelli	PROPN
ajlsi-2696	198	2	,	,	PUNCT
ajlsi-2696	198	3	c.	c.	PROPN
ajlsi-2696	198	4	,	,	PUNCT
ajlsi-2696	198	5	giannetti	giannetti	NOUN
ajlsi-2696	198	6	,	,	PUNCT
ajlsi-2696	198	7	a.	a.	NOUN
ajlsi-2696	198	8	,	,	PUNCT
ajlsi-2696	198	9	giannì	giannì	PROPN
ajlsi-2696	198	10	,	,	PUNCT
ajlsi-2696	198	11	g.	g.	PROPN
ajlsi-2696	198	12	,	,	PUNCT
ajlsi-2696	198	13	&	&	CCONJ
ajlsi-2696	198	14	ricci	ricci	PROPN
ajlsi-2696	198	15	,	,	PUNCT
ajlsi-2696	198	16	g.	g.	PROPN
ajlsi-2696	198	17	(	(	PUNCT
ajlsi-2696	198	18	2023	2023	NUM
ajlsi-2696	198	19	)	)	PUNCT
ajlsi-2696	198	20	.	.	PUNCT
ajlsi-2696	199	1	anti	anti	ADJ
ajlsi-2696	199	2	-	-	ADJ
ajlsi-2696	199	3	inflammatory	inflammatory	ADJ
ajlsi-2696	199	4	and	and	CCONJ
ajlsi-2696	199	5	biologic	biologic	ADJ
ajlsi-2696	199	6	drugs	drug	NOUN
ajlsi-2696	199	7	for	for	ADP
ajlsi-2696	199	8	atopic	atopic	NOUN
ajlsi-2696	199	9	dermatitis	dermatitis	NOUN
ajlsi-2696	199	10	:	:	PUNCT
ajlsi-2696	199	11	a	a	DET
ajlsi-2696	199	12	therapeutic	therapeutic	ADJ
ajlsi-2696	199	13	approach	approach	NOUN
ajlsi-2696	199	14	in	in	ADP
ajlsi-2696	199	15	children	child	NOUN
ajlsi-2696	199	16	and	and	CCONJ
ajlsi-2696	199	17	adolescents	adolescent	NOUN
ajlsi-2696	199	18	.	.	PUNCT
ajlsi-2696	200	1	frontiers	frontier	NOUN
ajlsi-2696	200	2	in	in	ADP
ajlsi-2696	200	3	medicine	medicine	NOUN
ajlsi-2696	200	4	,	,	PUNCT
ajlsi-2696	200	5	10	10	NUM
ajlsi-2696	200	6	.	.	PUNCT
ajlsi-2696	201	1	choi	choi	NOUN
ajlsi-2696	201	2	,	,	PUNCT
ajlsi-2696	201	3	c.	c.	PROPN
ajlsi-2696	201	4	w.	w.	PROPN
ajlsi-2696	201	5	,	,	PUNCT
ajlsi-2696	201	6	yang	yang	PROPN
ajlsi-2696	201	7	,	,	PUNCT
ajlsi-2696	201	8	b.	b.	PROPN
ajlsi-2696	201	9	r.	r.	PROPN
ajlsi-2696	201	10	,	,	PUNCT
ajlsi-2696	201	11	suh	suh	PROPN
ajlsi-2696	201	12	,	,	PUNCT
ajlsi-2696	201	13	d.	d.	PROPN
ajlsi-2696	201	14	i.	i.	PROPN
ajlsi-2696	201	15	,	,	PUNCT
ajlsi-2696	201	16	kim	kim	PROPN
ajlsi-2696	201	17	,	,	PUNCT
ajlsi-2696	201	18	m.	m.	PROPN
ajlsi-2696	201	19	s.	s.	PROPN
ajlsi-2696	201	20	,	,	PUNCT
ajlsi-2696	201	21	ohn	ohn	PROPN
ajlsi-2696	201	22	,	,	PUNCT
ajlsi-2696	201	23	j.	j.	PROPN
ajlsi-2696	201	24	,	,	PUNCT
ajlsi-2696	201	25	hong	hong	PROPN
ajlsi-2696	201	26	,	,	PUNCT
ajlsi-2696	201	27	j.	j.	PROPN
ajlsi-2696	201	28	s.	s.	PROPN
ajlsi-2696	201	29	,	,	PUNCT
ajlsi-2696	201	30	lee	lee	PROPN
ajlsi-2696	201	31	,	,	PUNCT
ajlsi-2696	201	32	j.	j.	PROPN
ajlsi-2696	201	33	,	,	PUNCT
ajlsi-2696	201	34	&	&	CCONJ
ajlsi-2696	201	35	kim	kim	PROPN
ajlsi-2696	201	36	,	,	PUNCT
ajlsi-2696	201	37	k.	k.	PROPN
ajlsi-2696	201	38	h.	h.	PROPN
ajlsi-2696	201	39	(	(	PUNCT
ajlsi-2696	201	40	2020	2020	NUM
ajlsi-2696	201	41	)	)	PUNCT
ajlsi-2696	201	42	.	.	PUNCT
ajlsi-2696	202	1	infection	infection	NOUN
ajlsi-2696	202	2	,	,	PUNCT
ajlsi-2696	202	3	antibiotic	antibiotic	ADJ
ajlsi-2696	202	4	exposure	exposure	NOUN
ajlsi-2696	202	5	and	and	CCONJ
ajlsi-2696	202	6	development	development	NOUN
ajlsi-2696	202	7	of	of	ADP
ajlsi-2696	202	8	atopic	atopic	NOUN
ajlsi-2696	202	9	dermatitis	dermatitis	NOUN
ajlsi-2696	202	10	:	:	PUNCT
ajlsi-2696	202	11	a	a	DET
ajlsi-2696	202	12	nationwide	nationwide	ADJ
ajlsi-2696	202	13	case	case	NOUN
ajlsi-2696	202	14	–	–	PUNCT
ajlsi-2696	202	15	control	control	NOUN
ajlsi-2696	202	16	study	study	NOUN
ajlsi-2696	202	17	.	.	PUNCT
ajlsi-2696	203	1	the	the	DET
ajlsi-2696	203	2	pa	pa	PROPN
ajlsi-2696	203	3	ge	ge	PROPN
ajlsi-2696	203	4	67	67	NUM
ajlsi-2696	203	5	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	203	6	am	am	NOUN
ajlsi-2696	203	7	.	.	PUNCT
ajlsi-2696	204	1	j.	j.	PROPN
ajlsi-2696	204	2	life	life	PROPN
ajlsi-2696	204	3	sci	sci	PROPN
ajlsi-2696	204	4	.	.	PUNCT
ajlsi-2696	204	5	innov	innov	PROPN
ajlsi-2696	204	6	.	.	PUNCT
ajlsi-2696	205	1	3(1	3(1	NUM
ajlsi-2696	205	2	)	)	PUNCT
ajlsi-2696	206	1	61	61	NUM
ajlsi-2696	206	2	-	-	SYM
ajlsi-2696	206	3	68	68	NUM
ajlsi-2696	206	4	,	,	PUNCT
ajlsi-2696	206	5	2024	2024	NUM
ajlsi-2696	206	6	journal	journal	NOUN
ajlsi-2696	206	7	of	of	ADP
ajlsi-2696	206	8	dermatology	dermatology	NOUN
ajlsi-2696	206	9	,	,	PUNCT
ajlsi-2696	206	10	47(7	47(7	NOUN
ajlsi-2696	206	11	)	)	PUNCT
ajlsi-2696	206	12	,	,	PUNCT
ajlsi-2696	206	13	707	707	NUM
ajlsi-2696	206	14	-	-	SYM
ajlsi-2696	206	15	713	713	NUM
ajlsi-2696	206	16	.	.	PUNCT
ajlsi-2696	207	1	chovatiya	chovatiya	PROPN
ajlsi-2696	207	2	,	,	PUNCT
ajlsi-2696	207	3	r.	r.	PROPN
ajlsi-2696	207	4	,	,	PUNCT
ajlsi-2696	207	5	&	&	CCONJ
ajlsi-2696	207	6	silverberg	silverberg	PROPN
ajlsi-2696	207	7	,	,	PUNCT
ajlsi-2696	207	8	j.	j.	PROPN
ajlsi-2696	207	9	i.	i.	PROPN
ajlsi-2696	207	10	(	(	PUNCT
ajlsi-2696	207	11	2019	2019	NUM
ajlsi-2696	207	12	)	)	PUNCT
ajlsi-2696	207	13	.	.	PUNCT
ajlsi-2696	208	1	pathophysiology	pathophysiology	NOUN
ajlsi-2696	208	2	of	of	ADP
ajlsi-2696	208	3	atopic	atopic	NOUN
ajlsi-2696	208	4	dermatitis	dermatitis	NOUN
ajlsi-2696	208	5	and	and	CCONJ
ajlsi-2696	208	6	psoriasis	psoriasis	NOUN
ajlsi-2696	208	7	:	:	PUNCT
ajlsi-2696	208	8	implications	implication	NOUN
ajlsi-2696	208	9	for	for	ADP
ajlsi-2696	208	10	management	management	NOUN
ajlsi-2696	208	11	in	in	ADP
ajlsi-2696	208	12	children	child	NOUN
ajlsi-2696	208	13	.	.	PUNCT
ajlsi-2696	209	1	children	child	NOUN
ajlsi-2696	209	2	,	,	PUNCT
ajlsi-2696	209	3	6(10	6(10	NUM
ajlsi-2696	209	4	)	)	PUNCT
ajlsi-2696	209	5	,	,	PUNCT
ajlsi-2696	209	6	108	108	NUM
ajlsi-2696	209	7	.	.	PUNCT
ajlsi-2696	210	1	chu	chu	PROPN
ajlsi-2696	210	2	,	,	PUNCT
ajlsi-2696	210	3	a.	a.	PROPN
ajlsi-2696	210	4	w.	w.	PROPN
ajlsi-2696	210	5	,	,	PUNCT
ajlsi-2696	210	6	wong	wong	PROPN
ajlsi-2696	210	7	,	,	PUNCT
ajlsi-2696	210	8	m.	m.	NOUN
ajlsi-2696	210	9	m.	m.	PROPN
ajlsi-2696	210	10	,	,	PUNCT
ajlsi-2696	210	11	rayner	rayner	PROPN
ajlsi-2696	210	12	,	,	PUNCT
ajlsi-2696	210	13	d.	d.	PROPN
ajlsi-2696	210	14	g.	g.	PROPN
ajlsi-2696	210	15	,	,	PUNCT
ajlsi-2696	210	16	guyatt	guyatt	PROPN
ajlsi-2696	210	17	,	,	PUNCT
ajlsi-2696	210	18	g.	g.	PROPN
ajlsi-2696	210	19	h.	h.	PROPN
ajlsi-2696	210	20	,	,	PUNCT
ajlsi-2696	210	21	martinez	martinez	PROPN
ajlsi-2696	210	22	,	,	PUNCT
ajlsi-2696	210	23	j.	j.	PROPN
ajlsi-2696	210	24	p.	p.	PROPN
ajlsi-2696	210	25	d.	d.	PROPN
ajlsi-2696	210	26	,	,	PUNCT
ajlsi-2696	210	27	ceccacci	ceccacci	PROPN
ajlsi-2696	210	28	,	,	PUNCT
ajlsi-2696	210	29	r.	r.	PROPN
ajlsi-2696	210	30	,	,	PUNCT
ajlsi-2696	210	31	zhao	zhao	PROPN
ajlsi-2696	210	32	,	,	PUNCT
ajlsi-2696	210	33	i.	i.	PROPN
ajlsi-2696	210	34	x.	x.	PROPN
ajlsi-2696	210	35	,	,	PUNCT
ajlsi-2696	210	36	mcmullen	mcmullen	PROPN
ajlsi-2696	210	37	,	,	PUNCT
ajlsi-2696	210	38	e.	e.	PROPN
ajlsi-2696	210	39	,	,	PUNCT
ajlsi-2696	210	40	srivastava	srivastava	PROPN
ajlsi-2696	210	41	,	,	PUNCT
ajlsi-2696	210	42	a.	a.	PROPN
ajlsi-2696	210	43	,	,	PUNCT
ajlsi-2696	210	44	&	&	CCONJ
ajlsi-2696	210	45	wang	wang	PROPN
ajlsi-2696	210	46	,	,	PUNCT
ajlsi-2696	210	47	j.	j.	PROPN
ajlsi-2696	210	48	(	(	PUNCT
ajlsi-2696	210	49	2023	2023	NUM
ajlsi-2696	210	50	)	)	PUNCT
ajlsi-2696	210	51	.	.	PUNCT
ajlsi-2696	211	1	systemic	systemic	ADJ
ajlsi-2696	211	2	treatments	treatment	NOUN
ajlsi-2696	211	3	for	for	ADP
ajlsi-2696	211	4	atopic	atopic	NOUN
ajlsi-2696	211	5	dermatitis	dermatitis	NOUN
ajlsi-2696	211	6	(	(	PUNCT
ajlsi-2696	211	7	eczema	eczema	NOUN
ajlsi-2696	211	8	):	):	PUNCT
ajlsi-2696	211	9	systematic	systematic	ADJ
ajlsi-2696	211	10	review	review	NOUN
ajlsi-2696	211	11	and	and	CCONJ
ajlsi-2696	211	12	network	network	NOUN
ajlsi-2696	211	13	meta	meta	ADJ
ajlsi-2696	211	14	-	-	PUNCT
ajlsi-2696	211	15	analysis	analysis	NOUN
ajlsi-2696	211	16	of	of	ADP
ajlsi-2696	211	17	randomized	randomized	ADJ
ajlsi-2696	211	18	trials	trial	NOUN
ajlsi-2696	211	19	.	.	PUNCT
ajlsi-2696	212	1	journal	journal	PROPN
ajlsi-2696	212	2	of	of	ADP
ajlsi-2696	212	3	allergy	allergy	PROPN
ajlsi-2696	212	4	and	and	CCONJ
ajlsi-2696	212	5	clinical	clinical	ADJ
ajlsi-2696	212	6	immunology	immunology	NOUN
ajlsi-2696	212	7	,	,	PUNCT
ajlsi-2696	212	8	152(6	152(6	NUM
ajlsi-2696	212	9	)	)	PUNCT
ajlsi-2696	212	10	,	,	PUNCT
ajlsi-2696	212	11	1470	1470	NUM
ajlsi-2696	212	12	-	-	SYM
ajlsi-2696	212	13	1492	1492	NUM
ajlsi-2696	212	14	.	.	PUNCT
ajlsi-2696	213	1	class	class	NOUN
ajlsi-2696	213	2	,	,	PUNCT
ajlsi-2696	213	3	i.	i.	NOUN
ajlsi-2696	213	4	,	,	PUNCT
ajlsi-2696	213	5	class	class	NOUN
ajlsi-2696	213	6	,	,	PUNCT
ajlsi-2696	213	7	i.	i.	NOUN
ajlsi-2696	213	8	,	,	PUNCT
ajlsi-2696	213	9	&	&	CCONJ
ajlsi-2696	213	10	class	class	PROPN
ajlsi-2696	213	11	,	,	PUNCT
ajlsi-2696	213	12	i.	i.	NOUN
ajlsi-2696	213	13	(	(	PUNCT
ajlsi-2696	213	14	2022	2022	NUM
ajlsi-2696	213	15	)	)	PUNCT
ajlsi-2696	213	16	.	.	PUNCT
ajlsi-2696	214	1	systemic	systemic	ADJ
ajlsi-2696	214	2	antibiotic	antibiotic	ADJ
ajlsi-2696	214	3	prophylaxis	prophylaxis	NOUN
ajlsi-2696	214	4	for	for	ADP
ajlsi-2696	214	5	recurrent	recurrent	ADJ
ajlsi-2696	214	6	infective	infective	ADJ
ajlsi-2696	214	7	flares	flare	NOUN
ajlsi-2696	214	8	in	in	ADP
ajlsi-2696	214	9	children	child	NOUN
ajlsi-2696	214	10	and	and	CCONJ
ajlsi-2696	214	11	adolescents	adolescent	NOUN
ajlsi-2696	214	12	with	with	ADP
ajlsi-2696	214	13	atopic	atopic	NOUN
ajlsi-2696	214	14	dermatitis	dermatitis	NOUN
ajlsi-2696	214	15	.	.	PUNCT
ajlsi-2696	215	1	ann	ann	PROPN
ajlsi-2696	215	2	acad	acad	PROPN
ajlsi-2696	215	3	med	med	PROPN
ajlsi-2696	215	4	singap	singap	PROPN
ajlsi-2696	215	5	,	,	PUNCT
ajlsi-2696	215	6	51(2	51(2	NUM
ajlsi-2696	215	7	)	)	PUNCT
ajlsi-2696	215	8	,	,	PUNCT
ajlsi-2696	215	9	113	113	NUM
ajlsi-2696	215	10	-	-	SYM
ajlsi-2696	215	11	114	114	NUM
ajlsi-2696	215	12	.	.	PUNCT
ajlsi-2696	216	1	cork	cork	NOUN
ajlsi-2696	216	2	,	,	PUNCT
ajlsi-2696	216	3	m.	m.	NOUN
ajlsi-2696	216	4	j.	j.	PROPN
ajlsi-2696	216	5	,	,	PUNCT
ajlsi-2696	216	6	danby	danby	PROPN
ajlsi-2696	216	7	,	,	PUNCT
ajlsi-2696	216	8	s.	s.	PROPN
ajlsi-2696	216	9	g.	g.	PROPN
ajlsi-2696	216	10	,	,	PUNCT
ajlsi-2696	216	11	rossi	rossi	PROPN
ajlsi-2696	216	12	,	,	PUNCT
ajlsi-2696	216	13	a.	a.	PROPN
ajlsi-2696	216	14	b.	b.	PROPN
ajlsi-2696	216	15	,	,	PUNCT
ajlsi-2696	216	16	&	&	CCONJ
ajlsi-2696	216	17	bansal	bansal	NOUN
ajlsi-2696	216	18	,	,	PUNCT
ajlsi-2696	216	19	a.	a.	NOUN
ajlsi-2696	216	20	(	(	PUNCT
ajlsi-2696	216	21	2024	2024	NUM
ajlsi-2696	216	22	)	)	PUNCT
ajlsi-2696	216	23	.	.	PUNCT
ajlsi-2696	217	1	dupilumab	dupilumab	NOUN
ajlsi-2696	217	2	treatment	treatment	NOUN
ajlsi-2696	217	3	in	in	ADP
ajlsi-2696	217	4	pediatric	pediatric	ADJ
ajlsi-2696	217	5	patients	patient	NOUN
ajlsi-2696	217	6	aged	age	VERB
ajlsi-2696	217	7	6–11	6–11	NOUN
ajlsi-2696	217	8	years	year	NOUN
ajlsi-2696	217	9	with	with	ADP
ajlsi-2696	217	10	severe	severe	ADJ
ajlsi-2696	217	11	atopic	atopic	NOUN
ajlsi-2696	217	12	dermatitis	dermatitis	NOUN
ajlsi-2696	217	13	whose	whose	DET
ajlsi-2696	217	14	disease	disease	NOUN
ajlsi-2696	217	15	is	be	AUX
ajlsi-2696	217	16	not	not	PART
ajlsi-2696	217	17	adequately	adequately	ADV
ajlsi-2696	217	18	controlled	control	VERB
ajlsi-2696	217	19	:	:	PUNCT
ajlsi-2696	217	20	a	a	DET
ajlsi-2696	217	21	review	review	NOUN
ajlsi-2696	217	22	.	.	PUNCT
ajlsi-2696	218	1	drug	drug	NOUN
ajlsi-2696	218	2	design	design	NOUN
ajlsi-2696	218	3	,	,	PUNCT
ajlsi-2696	218	4	development	development	NOUN
ajlsi-2696	218	5	and	and	CCONJ
ajlsi-2696	218	6	therapy	therapy	NOUN
ajlsi-2696	218	7	,	,	PUNCT
ajlsi-2696	218	8	277	277	NUM
ajlsi-2696	218	9	-	-	SYM
ajlsi-2696	218	10	289	289	NUM
ajlsi-2696	218	11	.	.	PUNCT
ajlsi-2696	219	1	coskey	coskey	PROPN
ajlsi-2696	219	2	,	,	PUNCT
ajlsi-2696	219	3	r.	r.	PROPN
ajlsi-2696	219	4	j.	j.	PROPN
ajlsi-2696	219	5	(	(	PUNCT
ajlsi-2696	219	6	1978	1978	NUM
ajlsi-2696	219	7	)	)	PUNCT
ajlsi-2696	219	8	.	.	PUNCT
ajlsi-2696	220	1	contact	contact	PROPN
ajlsi-2696	220	2	dermatitis	dermatitis	PROPN
ajlsi-2696	220	3	due	due	ADP
ajlsi-2696	220	4	to	to	ADP
ajlsi-2696	220	5	clindamycin	clindamycin	NOUN
ajlsi-2696	220	6	.	.	PUNCT
ajlsi-2696	221	1	archives	archive	NOUN
ajlsi-2696	221	2	of	of	ADP
ajlsi-2696	221	3	dermatology	dermatology	NOUN
ajlsi-2696	221	4	,	,	PUNCT
ajlsi-2696	221	5	114(3	114(3	NUM
ajlsi-2696	221	6	)	)	PUNCT
ajlsi-2696	221	7	,	,	PUNCT
ajlsi-2696	221	8	446	446	NUM
ajlsi-2696	221	9	-	-	SYM
ajlsi-2696	221	10	446	446	NUM
ajlsi-2696	221	11	.	.	PUNCT
ajlsi-2696	222	1	deleanu	deleanu	PROPN
ajlsi-2696	222	2	,	,	PUNCT
ajlsi-2696	222	3	d.	d.	PROPN
ajlsi-2696	222	4	,	,	PUNCT
ajlsi-2696	222	5	&	&	CCONJ
ajlsi-2696	222	6	nedelea	nedelea	PROPN
ajlsi-2696	222	7	,	,	PUNCT
ajlsi-2696	222	8	i.	i.	NOUN
ajlsi-2696	222	9	(	(	PUNCT
ajlsi-2696	222	10	2019	2019	NUM
ajlsi-2696	222	11	)	)	PUNCT
ajlsi-2696	222	12	.	.	PUNCT
ajlsi-2696	223	1	biological	biological	ADJ
ajlsi-2696	223	2	therapies	therapy	NOUN
ajlsi-2696	223	3	for	for	ADP
ajlsi-2696	223	4	atopic	atopic	NOUN
ajlsi-2696	223	5	dermatitis	dermatitis	NOUN
ajlsi-2696	223	6	:	:	PUNCT
ajlsi-2696	223	7	an	an	DET
ajlsi-2696	223	8	update	update	NOUN
ajlsi-2696	223	9	.	.	PUNCT
ajlsi-2696	224	1	experimental	experimental	ADJ
ajlsi-2696	224	2	and	and	CCONJ
ajlsi-2696	224	3	therapeutic	therapeutic	ADJ
ajlsi-2696	224	4	medicine	medicine	NOUN
ajlsi-2696	224	5	,	,	PUNCT
ajlsi-2696	224	6	17(2	17(2	NUM
ajlsi-2696	224	7	)	)	PUNCT
ajlsi-2696	224	8	,	,	PUNCT
ajlsi-2696	224	9	1061	1061	NUM
ajlsi-2696	224	10	-	-	SYM
ajlsi-2696	224	11	1067	1067	NUM
ajlsi-2696	224	12	.	.	PUNCT
ajlsi-2696	225	1	dhamija	dhamija	PROPN
ajlsi-2696	225	2	,	,	PUNCT
ajlsi-2696	225	3	s.	s.	PROPN
ajlsi-2696	225	4	,	,	PUNCT
ajlsi-2696	225	5	patel	patel	PROPN
ajlsi-2696	225	6	,	,	PUNCT
ajlsi-2696	225	7	r.	r.	PROPN
ajlsi-2696	225	8	,	,	PUNCT
ajlsi-2696	225	9	pol	pol	PROPN
ajlsi-2696	225	10	,	,	PUNCT
ajlsi-2696	225	11	s.	s.	PROPN
ajlsi-2696	225	12	a.	a.	PROPN
ajlsi-2696	225	13	,	,	PUNCT
ajlsi-2696	225	14	kulkarni	kulkarni	PROPN
ajlsi-2696	225	15	,	,	PUNCT
ajlsi-2696	225	16	s.	s.	PROPN
ajlsi-2696	225	17	,	,	PUNCT
ajlsi-2696	225	18	&	&	CCONJ
ajlsi-2696	225	19	yamagar	yamagar	PROPN
ajlsi-2696	225	20	,	,	PUNCT
ajlsi-2696	225	21	n.	n.	PROPN
ajlsi-2696	225	22	(	(	PUNCT
ajlsi-2696	225	23	2024	2024	NUM
ajlsi-2696	225	24	)	)	PUNCT
ajlsi-2696	225	25	.	.	PUNCT
ajlsi-2696	226	1	comparing	compare	VERB
ajlsi-2696	226	2	treatment	treatment	NOUN
ajlsi-2696	226	3	outcome	outcome	NOUN
ajlsi-2696	226	4	of	of	ADP
ajlsi-2696	226	5	allergic	allergic	ADJ
ajlsi-2696	226	6	rhinitis	rhinitis	NOUN
ajlsi-2696	226	7	patients	patient	NOUN
ajlsi-2696	226	8	after	after	ADP
ajlsi-2696	226	9	using	use	VERB
ajlsi-2696	226	10	fluticasone	fluticasone	PROPN
ajlsi-2696	226	11	nasal	nasal	PROPN
ajlsi-2696	226	12	spray	spray	NOUN
ajlsi-2696	226	13	and	and	CCONJ
ajlsi-2696	226	14	nasal	nasal	PROPN
ajlsi-2696	226	15	douching	douching	PROPN
ajlsi-2696	226	16	.	.	PUNCT
ajlsi-2696	227	1	journal	journal	PROPN
ajlsi-2696	227	2	of	of	ADP
ajlsi-2696	227	3	clinical	clinical	ADJ
ajlsi-2696	227	4	otorhinolaryngology	otorhinolaryngology	NOUN
ajlsi-2696	227	5	,	,	PUNCT
ajlsi-2696	227	6	6(1	6(1	NUM
ajlsi-2696	227	7	)	)	PUNCT
ajlsi-2696	227	8	.	.	PUNCT
ajlsi-2696	228	1	drucker	drucker	PROPN
ajlsi-2696	228	2	,	,	PUNCT
ajlsi-2696	228	3	a.	a.	NOUN
ajlsi-2696	228	4	,	,	PUNCT
ajlsi-2696	228	5	eyerich	eyerich	PROPN
ajlsi-2696	228	6	,	,	PUNCT
ajlsi-2696	228	7	k.	k.	PROPN
ajlsi-2696	228	8	,	,	PUNCT
ajlsi-2696	228	9	de	de	X
ajlsi-2696	228	10	bruin‐weller	bruin‐weller	NOUN
ajlsi-2696	228	11	,	,	PUNCT
ajlsi-2696	228	12	m.	m.	NOUN
ajlsi-2696	228	13	,	,	PUNCT
ajlsi-2696	228	14	thyssen	thyssen	PROPN
ajlsi-2696	228	15	,	,	PUNCT
ajlsi-2696	228	16	j.	j.	PROPN
ajlsi-2696	228	17	p.	p.	PROPN
ajlsi-2696	228	18	,	,	PUNCT
ajlsi-2696	228	19	spuls	spuls	ADJ
ajlsi-2696	228	20	,	,	PUNCT
ajlsi-2696	228	21	p.	p.	PROPN
ajlsi-2696	228	22	,	,	PUNCT
ajlsi-2696	228	23	irvine	irvine	PROPN
ajlsi-2696	228	24	,	,	PUNCT
ajlsi-2696	228	25	a.	a.	PROPN
ajlsi-2696	228	26	,	,	PUNCT
ajlsi-2696	228	27	girolomoni	girolomoni	NOUN
ajlsi-2696	228	28	,	,	PUNCT
ajlsi-2696	228	29	g.	g.	PROPN
ajlsi-2696	228	30	,	,	PUNCT
ajlsi-2696	228	31	dhar	dhar	PROPN
ajlsi-2696	228	32	,	,	PUNCT
ajlsi-2696	228	33	s.	s.	PROPN
ajlsi-2696	228	34	,	,	PUNCT
ajlsi-2696	228	35	flohr	flohr	PROPN
ajlsi-2696	228	36	,	,	PUNCT
ajlsi-2696	228	37	c.	c.	NOUN
ajlsi-2696	228	38	,	,	PUNCT
ajlsi-2696	228	39	&	&	CCONJ
ajlsi-2696	228	40	murrell	murrell	PROPN
ajlsi-2696	228	41	,	,	PUNCT
ajlsi-2696	228	42	d.	d.	PROPN
ajlsi-2696	228	43	(	(	PUNCT
ajlsi-2696	228	44	2018	2018	NUM
ajlsi-2696	228	45	)	)	PUNCT
ajlsi-2696	228	46	.	.	PUNCT
ajlsi-2696	229	1	use	use	NOUN
ajlsi-2696	229	2	of	of	ADP
ajlsi-2696	229	3	systemic	systemic	ADJ
ajlsi-2696	229	4	corticosteroids	corticosteroid	NOUN
ajlsi-2696	229	5	for	for	ADP
ajlsi-2696	229	6	atopic	atopic	NOUN
ajlsi-2696	229	7	dermatitis	dermatitis	NOUN
ajlsi-2696	229	8	:	:	PUNCT
ajlsi-2696	229	9	international	international	PROPN
ajlsi-2696	229	10	eczema	eczema	PROPN
ajlsi-2696	229	11	council	council	PROPN
ajlsi-2696	229	12	consensus	consensus	NOUN
ajlsi-2696	229	13	statement	statement	NOUN
ajlsi-2696	229	14	.	.	PUNCT
ajlsi-2696	230	1	british	british	ADJ
ajlsi-2696	230	2	journal	journal	PROPN
ajlsi-2696	230	3	of	of	ADP
ajlsi-2696	230	4	dermatology	dermatology	NOUN
ajlsi-2696	230	5	,	,	PUNCT
ajlsi-2696	230	6	178(3	178(3	NUM
ajlsi-2696	230	7	)	)	PUNCT
ajlsi-2696	230	8	,	,	PUNCT
ajlsi-2696	230	9	768	768	NUM
ajlsi-2696	230	10	-	-	SYM
ajlsi-2696	230	11	775	775	NUM
ajlsi-2696	230	12	.	.	PUNCT
ajlsi-2696	231	1	drug	drug	NOUN
ajlsi-2696	231	2	trials	trial	NOUN
ajlsi-2696	231	3	snapshots	snapshot	NOUN
ajlsi-2696	231	4	:	:	PUNCT
ajlsi-2696	231	5	dupixent	dupixent	NOUN
ajlsi-2696	231	6	(	(	PUNCT
ajlsi-2696	231	7	2017	2017	NUM
ajlsi-2696	231	8	)	)	PUNCT
ajlsi-2696	231	9	.	.	PUNCT
ajlsi-2696	232	1	food	food	NOUN
ajlsi-2696	232	2	and	and	CCONJ
ajlsi-2696	232	3	drug	drug	PROPN
ajlsi-2696	232	4	administration	administration	NOUN
ajlsi-2696	232	5	.	.	PUNCT
ajlsi-2696	233	1	fda	fda	PROPN
ajlsi-2696	233	2	.	.	PUNCT
ajlsi-2696	234	1	(	(	PUNCT
ajlsi-2696	234	2	2019	2019	NUM
ajlsi-2696	234	3	)	)	PUNCT
ajlsi-2696	234	4	.	.	PUNCT
ajlsi-2696	235	1	bla	bla	PROPN
ajlsi-2696	236	1	multi	multi	ADJ
ajlsi-2696	236	2	-	-	ADJ
ajlsi-2696	236	3	disciplinary	disciplinary	ADJ
ajlsi-2696	236	4	review	review	NOUN
ajlsi-2696	236	5	and	and	CCONJ
ajlsi-2696	236	6	evaluation	evaluation	NOUN
ajlsi-2696	236	7	.	.	PUNCT
ajlsi-2696	237	1	food	food	NOUN
ajlsi-2696	237	2	and	and	CCONJ
ajlsi-2696	237	3	drug	drug	PROPN
ajlsi-2696	237	4	administration	administration	NOUN
ajlsi-2696	237	5	.	.	PUNCT
ajlsi-2696	238	1	ferrucci	ferrucci	PROPN
ajlsi-2696	238	2	,	,	PUNCT
ajlsi-2696	238	3	s.	s.	PROPN
ajlsi-2696	238	4	m.	m.	PROPN
ajlsi-2696	238	5	,	,	PUNCT
ajlsi-2696	238	6	tavecchio	tavecchio	PROPN
ajlsi-2696	238	7	,	,	PUNCT
ajlsi-2696	238	8	s.	s.	PROPN
ajlsi-2696	238	9	,	,	PUNCT
ajlsi-2696	238	10	marzano	marzano	PROPN
ajlsi-2696	238	11	,	,	PUNCT
ajlsi-2696	238	12	a.	a.	NOUN
ajlsi-2696	238	13	v.	v.	PROPN
ajlsi-2696	238	14	,	,	PUNCT
ajlsi-2696	238	15	&	&	CCONJ
ajlsi-2696	238	16	buffon	buffon	PROPN
ajlsi-2696	238	17	,	,	PUNCT
ajlsi-2696	238	18	s.	s.	PROPN
ajlsi-2696	238	19	(	(	PUNCT
ajlsi-2696	238	20	2023	2023	NUM
ajlsi-2696	238	21	)	)	PUNCT
ajlsi-2696	238	22	.	.	PUNCT
ajlsi-2696	239	1	emerging	emerge	VERB
ajlsi-2696	239	2	systemic	systemic	ADJ
ajlsi-2696	239	3	treatments	treatment	NOUN
ajlsi-2696	239	4	for	for	ADP
ajlsi-2696	239	5	atopic	atopic	NOUN
ajlsi-2696	239	6	dermatitis	dermatitis	NOUN
ajlsi-2696	239	7	.	.	PUNCT
ajlsi-2696	240	1	dermatology	dermatology	NOUN
ajlsi-2696	240	2	and	and	CCONJ
ajlsi-2696	240	3	therapy	therapy	NOUN
ajlsi-2696	240	4	,	,	PUNCT
ajlsi-2696	240	5	13(5	13(5	NUM
ajlsi-2696	240	6	)	)	PUNCT
ajlsi-2696	240	7	,	,	PUNCT
ajlsi-2696	240	8	1071	1071	NUM
ajlsi-2696	240	9	-	-	SYM
ajlsi-2696	240	10	1081	1081	NUM
ajlsi-2696	240	11	.	.	PUNCT
ajlsi-2696	241	1	frazier	frazier	PROPN
ajlsi-2696	241	2	,	,	PUNCT
ajlsi-2696	241	3	w.	w.	PROPN
ajlsi-2696	241	4	,	,	PUNCT
ajlsi-2696	241	5	&	&	CCONJ
ajlsi-2696	241	6	bhardwaj	bhardwaj	PROPN
ajlsi-2696	241	7	,	,	PUNCT
ajlsi-2696	241	8	n.	n.	PROPN
ajlsi-2696	241	9	(	(	PUNCT
ajlsi-2696	241	10	2020	2020	NUM
ajlsi-2696	241	11	)	)	PUNCT
ajlsi-2696	241	12	.	.	PUNCT
ajlsi-2696	242	1	atopic	atopic	PROPN
ajlsi-2696	242	2	dermatitis	dermatitis	NOUN
ajlsi-2696	242	3	:	:	PUNCT
ajlsi-2696	242	4	diagnosis	diagnosis	NOUN
ajlsi-2696	242	5	and	and	CCONJ
ajlsi-2696	242	6	treatment	treatment	NOUN
ajlsi-2696	242	7	.	.	PUNCT
ajlsi-2696	243	1	american	american	ADJ
ajlsi-2696	243	2	family	family	PROPN
ajlsi-2696	243	3	physician	physician	NOUN
ajlsi-2696	243	4	,	,	PUNCT
ajlsi-2696	243	5	101(10	101(10	NUM
ajlsi-2696	243	6	)	)	PUNCT
ajlsi-2696	243	7	,	,	PUNCT
ajlsi-2696	243	8	590	590	NUM
ajlsi-2696	243	9	-	-	SYM
ajlsi-2696	243	10	598	598	NUM
ajlsi-2696	243	11	.	.	PUNCT
ajlsi-2696	244	1	grobe	grobe	PROPN
ajlsi-2696	244	2	,	,	PUNCT
ajlsi-2696	244	3	w.	w.	PROPN
ajlsi-2696	244	4	,	,	PUNCT
ajlsi-2696	244	5	bieber	bieber	PROPN
ajlsi-2696	244	6	,	,	PUNCT
ajlsi-2696	244	7	t.	t.	PROPN
ajlsi-2696	244	8	,	,	PUNCT
ajlsi-2696	244	9	&	&	CCONJ
ajlsi-2696	244	10	novak	novak	PROPN
ajlsi-2696	244	11	,	,	PUNCT
ajlsi-2696	244	12	n.	n.	PROPN
ajlsi-2696	244	13	(	(	PUNCT
ajlsi-2696	244	14	2019	2019	NUM
ajlsi-2696	244	15	)	)	PUNCT
ajlsi-2696	244	16	.	.	PUNCT
ajlsi-2696	245	1	pathophysiology	pathophysiology	NOUN
ajlsi-2696	245	2	of	of	ADP
ajlsi-2696	245	3	atopic	atopic	NOUN
ajlsi-2696	245	4	dermatitis	dermatitis	NOUN
ajlsi-2696	245	5	.	.	PUNCT
ajlsi-2696	246	1	jddg	jddg	PROPN
ajlsi-2696	246	2	:	:	PUNCT
ajlsi-2696	247	1	journal	journal	PROPN
ajlsi-2696	247	2	der	der	PROPN
ajlsi-2696	247	3	deutschen	deutschen	PROPN
ajlsi-2696	247	4	dermatologischen	dermatologischen	PROPN
ajlsi-2696	247	5	gesellschaft	gesellschaft	PROPN
ajlsi-2696	247	6	,	,	PUNCT
ajlsi-2696	247	7	17(4	17(4	NUM
ajlsi-2696	247	8	)	)	PUNCT
ajlsi-2696	247	9	,	,	PUNCT
ajlsi-2696	247	10	433	433	NUM
ajlsi-2696	247	11	-	-	SYM
ajlsi-2696	247	12	440	440	NUM
ajlsi-2696	247	13	.	.	PUNCT
ajlsi-2696	248	1	haeck	haeck	PROPN
ajlsi-2696	248	2	,	,	PUNCT
ajlsi-2696	248	3	i.	i.	NOUN
ajlsi-2696	248	4	m.	m.	PROPN
ajlsi-2696	248	5	,	,	PUNCT
ajlsi-2696	248	6	rouwen	rouwen	NOUN
ajlsi-2696	248	7	,	,	PUNCT
ajlsi-2696	248	8	t.	t.	PROPN
ajlsi-2696	248	9	j.	j.	PROPN
ajlsi-2696	248	10	,	,	PUNCT
ajlsi-2696	248	11	timmer	timmer	PROPN
ajlsi-2696	248	12	-	-	PROPN
ajlsi-2696	248	13	de	de	X
ajlsi-2696	248	14	mik	mik	PROPN
ajlsi-2696	248	15	,	,	PUNCT
ajlsi-2696	248	16	l.	l.	PROPN
ajlsi-2696	248	17	,	,	PUNCT
ajlsi-2696	248	18	de	de	X
ajlsi-2696	248	19	bruinweller	bruinweller	NOUN
ajlsi-2696	248	20	,	,	PUNCT
ajlsi-2696	248	21	m.	m.	NOUN
ajlsi-2696	248	22	s.	s.	PROPN
ajlsi-2696	248	23	,	,	PUNCT
ajlsi-2696	248	24	&	&	CCONJ
ajlsi-2696	248	25	bruijnzeel	bruijnzeel	NOUN
ajlsi-2696	248	26	-	-	PUNCT
ajlsi-2696	248	27	koomen	koomen	PROPN
ajlsi-2696	248	28	,	,	PUNCT
ajlsi-2696	248	29	c.	c.	PROPN
ajlsi-2696	248	30	a.	a.	PROPN
ajlsi-2696	248	31	(	(	PUNCT
ajlsi-2696	248	32	2011	2011	NUM
ajlsi-2696	248	33	)	)	PUNCT
ajlsi-2696	248	34	.	.	PUNCT
ajlsi-2696	249	1	topical	topical	ADJ
ajlsi-2696	249	2	corticosteroids	corticosteroid	NOUN
ajlsi-2696	249	3	in	in	ADP
ajlsi-2696	249	4	atopic	atopic	NOUN
ajlsi-2696	249	5	dermatitis	dermatitis	NOUN
ajlsi-2696	249	6	and	and	CCONJ
ajlsi-2696	249	7	the	the	DET
ajlsi-2696	249	8	risk	risk	NOUN
ajlsi-2696	249	9	of	of	ADP
ajlsi-2696	249	10	glaucoma	glaucoma	NOUN
ajlsi-2696	249	11	and	and	CCONJ
ajlsi-2696	249	12	cataracts	cataract	NOUN
ajlsi-2696	249	13	.	.	PUNCT
ajlsi-2696	250	1	journal	journal	NOUN
ajlsi-2696	250	2	of	of	ADP
ajlsi-2696	250	3	the	the	DET
ajlsi-2696	250	4	american	american	PROPN
ajlsi-2696	250	5	academy	academy	PROPN
ajlsi-2696	250	6	of	of	ADP
ajlsi-2696	250	7	dermatology	dermatology	NOUN
ajlsi-2696	250	8	,	,	PUNCT
ajlsi-2696	250	9	64(2	64(2	NUM
ajlsi-2696	250	10	)	)	PUNCT
ajlsi-2696	250	11	,	,	PUNCT
ajlsi-2696	250	12	275	275	NUM
ajlsi-2696	250	13	-	-	SYM
ajlsi-2696	250	14	281	281	NUM
ajlsi-2696	250	15	.	.	PUNCT
ajlsi-2696	251	1	harvey	harvey	PROPN
ajlsi-2696	251	2	,	,	PUNCT
ajlsi-2696	251	3	j.	j.	PROPN
ajlsi-2696	251	4	,	,	PUNCT
ajlsi-2696	251	5	lax	lax	PROPN
ajlsi-2696	251	6	,	,	PUNCT
ajlsi-2696	251	7	s.	s.	PROPN
ajlsi-2696	251	8	j.	j.	PROPN
ajlsi-2696	251	9	,	,	PUNCT
ajlsi-2696	251	10	lowe	lowe	PROPN
ajlsi-2696	251	11	,	,	PUNCT
ajlsi-2696	251	12	a.	a.	PROPN
ajlsi-2696	251	13	,	,	PUNCT
ajlsi-2696	251	14	santer	santer	NOUN
ajlsi-2696	251	15	,	,	PUNCT
ajlsi-2696	251	16	m.	m.	NOUN
ajlsi-2696	251	17	,	,	PUNCT
ajlsi-2696	251	18	lawton	lawton	PROPN
ajlsi-2696	251	19	,	,	PUNCT
ajlsi-2696	251	20	s.	s.	PROPN
ajlsi-2696	251	21	,	,	PUNCT
ajlsi-2696	251	22	langan	langan	PROPN
ajlsi-2696	251	23	,	,	PUNCT
ajlsi-2696	251	24	s.	s.	PROPN
ajlsi-2696	251	25	m.	m.	PROPN
ajlsi-2696	251	26	,	,	PUNCT
ajlsi-2696	251	27	roberts	roberts	PROPN
ajlsi-2696	251	28	,	,	PUNCT
ajlsi-2696	251	29	a.	a.	PROPN
ajlsi-2696	251	30	,	,	PUNCT
ajlsi-2696	251	31	stuart	stuart	PROPN
ajlsi-2696	251	32	,	,	PUNCT
ajlsi-2696	251	33	b.	b.	PROPN
ajlsi-2696	251	34	,	,	PUNCT
ajlsi-2696	251	35	williams	williams	PROPN
ajlsi-2696	251	36	,	,	PUNCT
ajlsi-2696	251	37	h.	h.	PROPN
ajlsi-2696	251	38	c.	c.	PROPN
ajlsi-2696	251	39	,	,	PUNCT
ajlsi-2696	251	40	&	&	CCONJ
ajlsi-2696	251	41	thomas	thomas	PROPN
ajlsi-2696	251	42	,	,	PUNCT
ajlsi-2696	251	43	k.	k.	PROPN
ajlsi-2696	251	44	s.	s.	PROPN
ajlsi-2696	251	45	(	(	PUNCT
ajlsi-2696	251	46	2023	2023	NUM
ajlsi-2696	251	47	)	)	PUNCT
ajlsi-2696	251	48	.	.	PUNCT
ajlsi-2696	252	1	the	the	DET
ajlsi-2696	252	2	long‐term	long‐term	NOUN
ajlsi-2696	252	3	safety	safety	NOUN
ajlsi-2696	252	4	of	of	ADP
ajlsi-2696	252	5	topical	topical	ADJ
ajlsi-2696	252	6	corticosteroids	corticosteroid	NOUN
ajlsi-2696	252	7	in	in	ADP
ajlsi-2696	252	8	atopic	atopic	NOUN
ajlsi-2696	252	9	dermatitis	dermatitis	NOUN
ajlsi-2696	252	10	:	:	PUNCT
ajlsi-2696	252	11	a	a	DET
ajlsi-2696	252	12	systematic	systematic	ADJ
ajlsi-2696	252	13	review	review	NOUN
ajlsi-2696	252	14	.	.	PUNCT
ajlsi-2696	253	1	skin	skin	NOUN
ajlsi-2696	253	2	health	health	NOUN
ajlsi-2696	253	3	and	and	CCONJ
ajlsi-2696	253	4	disease	disease	NOUN
ajlsi-2696	253	5	,	,	PUNCT
ajlsi-2696	253	6	3(5	3(5	NUM
ajlsi-2696	253	7	)	)	PUNCT
ajlsi-2696	253	8	,	,	PUNCT
ajlsi-2696	253	9	e268	e268	PROPN
ajlsi-2696	253	10	.	.	PUNCT
ajlsi-2696	253	11	hon	hon	PROPN
ajlsi-2696	253	12	,	,	PUNCT
ajlsi-2696	253	13	k.	k.	PROPN
ajlsi-2696	253	14	l.	l.	PROPN
ajlsi-2696	253	15	e.	e.	PROPN
ajlsi-2696	253	16	,	,	PUNCT
ajlsi-2696	253	17	chan	chan	PROPN
ajlsi-2696	253	18	,	,	PUNCT
ajlsi-2696	253	19	v.	v.	PROPN
ajlsi-2696	253	20	p.	p.	PROPN
ajlsi-2696	253	21	,	,	PUNCT
ajlsi-2696	253	22	&	&	CCONJ
ajlsi-2696	253	23	leung	leung	PROPN
ajlsi-2696	253	24	,	,	PUNCT
ajlsi-2696	253	25	a.	a.	PROPN
ajlsi-2696	253	26	k.	k.	PROPN
ajlsi-2696	253	27	(	(	PUNCT
ajlsi-2696	253	28	2021	2021	NUM
ajlsi-2696	253	29	)	)	PUNCT
ajlsi-2696	253	30	.	.	PUNCT
ajlsi-2696	254	1	experimental	experimental	ADJ
ajlsi-2696	254	2	drugs	drug	NOUN
ajlsi-2696	254	3	with	with	ADP
ajlsi-2696	254	4	the	the	DET
ajlsi-2696	254	5	potential	potential	NOUN
ajlsi-2696	254	6	to	to	PART
ajlsi-2696	254	7	treat	treat	VERB
ajlsi-2696	254	8	atopic	atopic	NOUN
ajlsi-2696	254	9	eczema	eczema	NOUN
ajlsi-2696	254	10	.	.	PUNCT
ajlsi-2696	255	1	journal	journal	NOUN
ajlsi-2696	255	2	of	of	ADP
ajlsi-2696	255	3	experimental	experimental	ADJ
ajlsi-2696	255	4	pharmacology	pharmacology	NOUN
ajlsi-2696	255	5	,	,	PUNCT
ajlsi-2696	255	6	487	487	NUM
ajlsi-2696	255	7	-	-	SYM
ajlsi-2696	255	8	498	498	NUM
ajlsi-2696	255	9	.	.	PUNCT
ajlsi-2696	256	1	hulme	hulme	PROPN
ajlsi-2696	256	2	,	,	PUNCT
ajlsi-2696	256	3	j.	j.	PROPN
ajlsi-2696	256	4	(	(	PUNCT
ajlsi-2696	256	5	2023	2023	NUM
ajlsi-2696	256	6	)	)	PUNCT
ajlsi-2696	256	7	.	.	PUNCT
ajlsi-2696	257	1	staphylococcus	staphylococcus	NOUN
ajlsi-2696	257	2	infection	infection	NOUN
ajlsi-2696	257	3	:	:	PUNCT
ajlsi-2696	257	4	relapsing	relapse	VERB
ajlsi-2696	257	5	atopic	atopic	NOUN
ajlsi-2696	257	6	dermatitis	dermatitis	NOUN
ajlsi-2696	257	7	and	and	CCONJ
ajlsi-2696	257	8	microbial	microbial	ADJ
ajlsi-2696	257	9	restoration	restoration	NOUN
ajlsi-2696	257	10	.	.	PUNCT
ajlsi-2696	258	1	antibiotics	antibiotic	NOUN
ajlsi-2696	258	2	,	,	PUNCT
ajlsi-2696	258	3	12(2	12(2	NUM
ajlsi-2696	258	4	)	)	PUNCT
ajlsi-2696	258	5	,	,	PUNCT
ajlsi-2696	258	6	222	222	NUM
ajlsi-2696	258	7	.	.	PUNCT
ajlsi-2696	259	1	kamal	kamal	PROPN
ajlsi-2696	259	2	,	,	PUNCT
ajlsi-2696	259	3	m.	m.	NOUN
ajlsi-2696	259	4	a.	a.	PROPN
ajlsi-2696	259	5	,	,	PUNCT
ajlsi-2696	259	6	kovalenko	kovalenko	PROPN
ajlsi-2696	259	7	,	,	PUNCT
ajlsi-2696	259	8	p.	p.	NOUN
ajlsi-2696	259	9	,	,	PUNCT
ajlsi-2696	259	10	kosloski	kosloski	PROPN
ajlsi-2696	259	11	,	,	PUNCT
ajlsi-2696	259	12	m.	m.	NOUN
ajlsi-2696	259	13	p.	p.	PROPN
ajlsi-2696	259	14	,	,	PUNCT
ajlsi-2696	259	15	srinivasan	srinivasan	NOUN
ajlsi-2696	259	16	,	,	PUNCT
ajlsi-2696	259	17	k.	k.	PROPN
ajlsi-2696	259	18	,	,	PUNCT
ajlsi-2696	259	19	zhang	zhang	PROPN
ajlsi-2696	259	20	,	,	PUNCT
ajlsi-2696	259	21	y.	y.	PROPN
ajlsi-2696	259	22	,	,	PUNCT
ajlsi-2696	259	23	rajadhyaksha	rajadhyaksha	PROPN
ajlsi-2696	259	24	,	,	PUNCT
ajlsi-2696	259	25	m.	m.	NOUN
ajlsi-2696	259	26	,	,	PUNCT
ajlsi-2696	259	27	lai	lai	PROPN
ajlsi-2696	259	28	,	,	PUNCT
ajlsi-2696	259	29	c.	c.	PROPN
ajlsi-2696	259	30	h.	h.	PROPN
ajlsi-2696	259	31	,	,	PUNCT
ajlsi-2696	259	32	kanamaluru	kanamaluru	PROPN
ajlsi-2696	259	33	,	,	PUNCT
ajlsi-2696	259	34	v.	v.	PROPN
ajlsi-2696	259	35	,	,	PUNCT
ajlsi-2696	259	36	xu	xu	PROPN
ajlsi-2696	259	37	,	,	PUNCT
ajlsi-2696	259	38	c.	c.	PROPN
ajlsi-2696	259	39	,	,	PUNCT
ajlsi-2696	259	40	&	&	CCONJ
ajlsi-2696	259	41	sun	sun	PROPN
ajlsi-2696	259	42	,	,	PUNCT
ajlsi-2696	259	43	x.	x.	NOUN
ajlsi-2696	259	44	(	(	PUNCT
ajlsi-2696	259	45	2021	2021	NUM
ajlsi-2696	259	46	)	)	PUNCT
ajlsi-2696	259	47	.	.	PUNCT
ajlsi-2696	260	1	the	the	DET
ajlsi-2696	260	2	posology	posology	NOUN
ajlsi-2696	260	3	of	of	ADP
ajlsi-2696	260	4	dupilumab	dupilumab	NOUN
ajlsi-2696	260	5	in	in	ADP
ajlsi-2696	260	6	pediatric	pediatric	ADJ
ajlsi-2696	260	7	patients	patient	NOUN
ajlsi-2696	260	8	with	with	ADP
ajlsi-2696	260	9	atopic	atopic	NOUN
ajlsi-2696	260	10	dermatitis	dermatitis	NOUN
ajlsi-2696	260	11	.	.	PUNCT
ajlsi-2696	261	1	clinical	clinical	ADJ
ajlsi-2696	261	2	pharmacology	pharmacology	NOUN
ajlsi-2696	261	3	&	&	CCONJ
ajlsi-2696	261	4	therapeutics	therapeutic	NOUN
ajlsi-2696	261	5	,	,	PUNCT
ajlsi-2696	261	6	110(5	110(5	NUM
ajlsi-2696	261	7	)	)	PUNCT
ajlsi-2696	261	8	,	,	PUNCT
ajlsi-2696	261	9	1318	1318	NUM
ajlsi-2696	261	10	-	-	SYM
ajlsi-2696	261	11	1328	1328	NUM
ajlsi-2696	261	12	.	.	PUNCT
ajlsi-2696	262	1	kamphuis	kamphuis	PROPN
ajlsi-2696	262	2	,	,	PUNCT
ajlsi-2696	262	3	e.	e.	PROPN
ajlsi-2696	262	4	,	,	PUNCT
ajlsi-2696	262	5	boesjes	boesjes	PROPN
ajlsi-2696	262	6	,	,	PUNCT
ajlsi-2696	262	7	c.	c.	PROPN
ajlsi-2696	262	8	m.	m.	NOUN
ajlsi-2696	262	9	,	,	PUNCT
ajlsi-2696	262	10	loman	loman	PROPN
ajlsi-2696	262	11	,	,	PUNCT
ajlsi-2696	262	12	l.	l.	PROPN
ajlsi-2696	262	13	,	,	PUNCT
ajlsi-2696	262	14	bakker	bakker	PROPN
ajlsi-2696	262	15	,	,	PUNCT
ajlsi-2696	262	16	d.	d.	PROPN
ajlsi-2696	262	17	s.	s.	PROPN
ajlsi-2696	262	18	,	,	PUNCT
ajlsi-2696	262	19	poelhekken	poelhekken	VERB
ajlsi-2696	262	20	,	,	PUNCT
ajlsi-2696	262	21	m.	m.	NOUN
ajlsi-2696	262	22	,	,	PUNCT
ajlsi-2696	262	23	zuithoff	zuithoff	PROPN
ajlsi-2696	262	24	,	,	PUNCT
ajlsi-2696	262	25	n.	n.	PROPN
ajlsi-2696	262	26	p.	p.	PROPN
ajlsi-2696	262	27	,	,	PUNCT
ajlsi-2696	262	28	kamsteeg	kamsteeg	PROPN
ajlsi-2696	262	29	,	,	PUNCT
ajlsi-2696	262	30	m.	m.	NOUN
ajlsi-2696	262	31	,	,	PUNCT
ajlsi-2696	262	32	romeijn	romeijn	PROPN
ajlsi-2696	262	33	,	,	PUNCT
ajlsi-2696	262	34	g.	g.	PROPN
ajlsi-2696	262	35	l.	l.	PROPN
ajlsi-2696	262	36	,	,	PUNCT
ajlsi-2696	262	37	van	van	PROPN
ajlsi-2696	262	38	wijk	wijk	PROPN
ajlsi-2696	262	39	,	,	PUNCT
ajlsi-2696	262	40	f.	f.	PROPN
ajlsi-2696	262	41	,	,	PUNCT
ajlsi-2696	262	42	&	&	CCONJ
ajlsi-2696	262	43	de	de	X
ajlsi-2696	262	44	bruin‐weller	bruin‐weller	NOUN
ajlsi-2696	262	45	,	,	PUNCT
ajlsi-2696	262	46	m.	m.	NOUN
ajlsi-2696	262	47	s.	s.	PROPN
ajlsi-2696	262	48	(	(	PUNCT
ajlsi-2696	262	49	2022	2022	NUM
ajlsi-2696	262	50	)	)	PUNCT
ajlsi-2696	262	51	.	.	PUNCT
ajlsi-2696	263	1	dupilumab	dupilumab	NOUN
ajlsi-2696	263	2	in	in	ADP
ajlsi-2696	263	3	daily	daily	ADJ
ajlsi-2696	263	4	practice	practice	NOUN
ajlsi-2696	263	5	for	for	ADP
ajlsi-2696	263	6	the	the	DET
ajlsi-2696	263	7	treatment	treatment	NOUN
ajlsi-2696	263	8	of	of	ADP
ajlsi-2696	263	9	pediatric	pediatric	ADJ
ajlsi-2696	263	10	atopic	atopic	NOUN
ajlsi-2696	263	11	dermatitis	dermatitis	NOUN
ajlsi-2696	263	12	:	:	PUNCT
ajlsi-2696	263	13	28‐week	28‐week	NUM
ajlsi-2696	263	14	clinical	clinical	ADJ
ajlsi-2696	263	15	and	and	CCONJ
ajlsi-2696	263	16	biomarker	biomarker	NOUN
ajlsi-2696	263	17	results	result	NOUN
ajlsi-2696	263	18	from	from	ADP
ajlsi-2696	263	19	the	the	DET
ajlsi-2696	263	20	bioday	bioday	ADJ
ajlsi-2696	263	21	registry	registry	NOUN
ajlsi-2696	263	22	.	.	PUNCT
ajlsi-2696	264	1	pediatric	pediatric	ADJ
ajlsi-2696	264	2	allergy	allergy	NOUN
ajlsi-2696	264	3	and	and	CCONJ
ajlsi-2696	264	4	immunology	immunology	NOUN
ajlsi-2696	264	5	,	,	PUNCT
ajlsi-2696	264	6	33(12	33(12	NUM
ajlsi-2696	264	7	)	)	PUNCT
ajlsi-2696	264	8	,	,	PUNCT
ajlsi-2696	264	9	e13887	e13887	PROPN
ajlsi-2696	264	10	.	.	PUNCT
ajlsi-2696	265	1	kim	kim	PROPN
ajlsi-2696	265	2	,	,	PUNCT
ajlsi-2696	265	3	j.	j.	PROPN
ajlsi-2696	265	4	,	,	PUNCT
ajlsi-2696	265	5	kim	kim	PROPN
ajlsi-2696	265	6	,	,	PUNCT
ajlsi-2696	265	7	b.	b.	PROPN
ajlsi-2696	265	8	e.	e.	PROPN
ajlsi-2696	265	9	,	,	PUNCT
ajlsi-2696	265	10	&	&	CCONJ
ajlsi-2696	265	11	leung	leung	PROPN
ajlsi-2696	265	12	,	,	PUNCT
ajlsi-2696	265	13	d.	d.	PROPN
ajlsi-2696	265	14	y.	y.	PROPN
ajlsi-2696	265	15	(	(	PUNCT
ajlsi-2696	265	16	2019	2019	NUM
ajlsi-2696	265	17	)	)	PUNCT
ajlsi-2696	265	18	.	.	PUNCT
ajlsi-2696	266	1	pathophysiology	pathophysiology	NOUN
ajlsi-2696	266	2	of	of	ADP
ajlsi-2696	266	3	atopic	atopic	NOUN
ajlsi-2696	266	4	dermatitis	dermatitis	NOUN
ajlsi-2696	266	5	:	:	PUNCT
ajlsi-2696	266	6	clinical	clinical	ADJ
ajlsi-2696	266	7	implications	implication	NOUN
ajlsi-2696	266	8	.	.	PUNCT
ajlsi-2696	267	1	allergy	allergy	NOUN
ajlsi-2696	267	2	and	and	CCONJ
ajlsi-2696	267	3	asthma	asthma	PROPN
ajlsi-2696	267	4	proceedings	proceeding	NOUN
ajlsi-2696	267	5	,	,	PUNCT
ajlsi-2696	267	6	kraft	kraft	NOUN
ajlsi-2696	267	7	,	,	PUNCT
ajlsi-2696	267	8	m.	m.	NOUN
ajlsi-2696	267	9	,	,	PUNCT
ajlsi-2696	267	10	&	&	CCONJ
ajlsi-2696	267	11	worm	worm	NOUN
ajlsi-2696	267	12	,	,	PUNCT
ajlsi-2696	267	13	m.	m.	NOUN
ajlsi-2696	267	14	(	(	PUNCT
ajlsi-2696	267	15	2017	2017	NUM
ajlsi-2696	267	16	)	)	PUNCT
ajlsi-2696	267	17	.	.	PUNCT
ajlsi-2696	268	1	dupilumab	dupilumab	NOUN
ajlsi-2696	268	2	in	in	ADP
ajlsi-2696	268	3	the	the	DET
ajlsi-2696	268	4	treatment	treatment	NOUN
ajlsi-2696	268	5	of	of	ADP
ajlsi-2696	268	6	moderate	moderate	ADJ
ajlsi-2696	268	7	-	-	PUNCT
ajlsi-2696	268	8	to	to	ADP
ajlsi-2696	268	9	-	-	PUNCT
ajlsi-2696	268	10	severe	severe	ADJ
ajlsi-2696	268	11	atopic	atopic	NOUN
ajlsi-2696	268	12	dermatitis	dermatitis	NOUN
ajlsi-2696	268	13	.	.	PUNCT
ajlsi-2696	269	1	expert	expert	NOUN
ajlsi-2696	269	2	review	review	NOUN
ajlsi-2696	269	3	of	of	ADP
ajlsi-2696	269	4	clinical	clinical	ADJ
ajlsi-2696	269	5	immunology	immunology	NOUN
ajlsi-2696	269	6	,	,	PUNCT
ajlsi-2696	269	7	13(4	13(4	NUM
ajlsi-2696	269	8	)	)	PUNCT
ajlsi-2696	269	9	,	,	PUNCT
ajlsi-2696	269	10	301	301	NUM
ajlsi-2696	269	11	-	-	SYM
ajlsi-2696	269	12	310	310	NUM
ajlsi-2696	269	13	.	.	PUNCT
ajlsi-2696	270	1	lee	lee	PROPN
ajlsi-2696	270	2	,	,	PUNCT
ajlsi-2696	270	3	j.	j.	PROPN
ajlsi-2696	270	4	h.	h.	PROPN
ajlsi-2696	270	5	,	,	PUNCT
ajlsi-2696	270	6	yun	yun	PROPN
ajlsi-2696	270	7	,	,	PUNCT
ajlsi-2696	270	8	s.-j	s.-j	PROPN
ajlsi-2696	270	9	.	.	PROPN
ajlsi-2696	270	10	,	,	PUNCT
ajlsi-2696	270	11	lee	lee	PROPN
ajlsi-2696	270	12	,	,	PUNCT
ajlsi-2696	270	13	j.-b	j.-b	PROPN
ajlsi-2696	270	14	.	.	PROPN
ajlsi-2696	270	15	,	,	PUNCT
ajlsi-2696	270	16	&	&	CCONJ
ajlsi-2696	270	17	lee	lee	PROPN
ajlsi-2696	270	18	,	,	PUNCT
ajlsi-2696	270	19	s.-c	s.-c	PROPN
ajlsi-2696	270	20	.	.	PUNCT
ajlsi-2696	271	1	(	(	PUNCT
ajlsi-2696	271	2	2020	2020	NUM
ajlsi-2696	271	3	)	)	PUNCT
ajlsi-2696	271	4	.	.	PUNCT
ajlsi-2696	272	1	therapeutic	therapeutic	ADJ
ajlsi-2696	272	2	efficacy	efficacy	NOUN
ajlsi-2696	272	3	and	and	CCONJ
ajlsi-2696	272	4	safety	safety	NOUN
ajlsi-2696	272	5	of	of	ADP
ajlsi-2696	272	6	methotrexate	methotrexate	NOUN
ajlsi-2696	272	7	in	in	ADP
ajlsi-2696	272	8	moderate	moderate	ADJ
ajlsi-2696	272	9	-	-	PUNCT
ajlsi-2696	272	10	to	to	ADP
ajlsi-2696	272	11	-	-	PUNCT
ajlsi-2696	272	12	severe	severe	ADJ
ajlsi-2696	272	13	atopic	atopic	NOUN
ajlsi-2696	272	14	dermatitis	dermatitis	NOUN
ajlsi-2696	272	15	:	:	PUNCT
ajlsi-2696	272	16	a	a	DET
ajlsi-2696	272	17	retrospective	retrospective	ADJ
ajlsi-2696	272	18	study	study	NOUN
ajlsi-2696	272	19	of	of	ADP
ajlsi-2696	272	20	korean	korean	ADJ
ajlsi-2696	272	21	patients	patient	NOUN
ajlsi-2696	272	22	at	at	ADP
ajlsi-2696	272	23	tertiary	tertiary	ADJ
ajlsi-2696	272	24	referral	referral	ADJ
ajlsi-2696	272	25	hospital	hospital	NOUN
ajlsi-2696	272	26	.	.	PUNCT
ajlsi-2696	273	1	annals	annal	NOUN
ajlsi-2696	273	2	of	of	ADP
ajlsi-2696	273	3	dermatology	dermatology	NOUN
ajlsi-2696	273	4	,	,	PUNCT
ajlsi-2696	273	5	32(5	32(5	NUM
ajlsi-2696	273	6	)	)	PUNCT
ajlsi-2696	273	7	,	,	PUNCT
ajlsi-2696	273	8	402	402	NUM
ajlsi-2696	273	9	.	.	PUNCT
ajlsi-2696	274	1	li	li	PROPN
ajlsi-2696	274	2	,	,	PUNCT
ajlsi-2696	274	3	y.	y.	PROPN
ajlsi-2696	274	4	,	,	PUNCT
ajlsi-2696	274	5	jing	jing	PROPN
ajlsi-2696	274	6	,	,	PUNCT
ajlsi-2696	274	7	d.	d.	PROPN
ajlsi-2696	274	8	,	,	PUNCT
ajlsi-2696	274	9	huang	huang	PROPN
ajlsi-2696	274	10	,	,	PUNCT
ajlsi-2696	274	11	y.	y.	PROPN
ajlsi-2696	274	12	,	,	PUNCT
ajlsi-2696	274	13	su	su	PROPN
ajlsi-2696	274	14	,	,	PUNCT
ajlsi-2696	274	15	j.	j.	PROPN
ajlsi-2696	274	16	,	,	PUNCT
ajlsi-2696	274	17	li	li	PROPN
ajlsi-2696	274	18	,	,	PUNCT
ajlsi-2696	274	19	j.	j.	PROPN
ajlsi-2696	274	20	,	,	PUNCT
ajlsi-2696	274	21	li	li	PROPN
ajlsi-2696	274	22	,	,	PUNCT
ajlsi-2696	274	23	j.	j.	PROPN
ajlsi-2696	274	24	,	,	PUNCT
ajlsi-2696	274	25	tao	tao	PROPN
ajlsi-2696	274	26	,	,	PUNCT
ajlsi-2696	274	27	j.	j.	PROPN
ajlsi-2696	274	28	,	,	PUNCT
ajlsi-2696	274	29	shan	shan	PROPN
ajlsi-2696	274	30	,	,	PUNCT
ajlsi-2696	274	31	s.	s.	PROPN
ajlsi-2696	274	32	,	,	PUNCT
ajlsi-2696	274	33	wang	wang	PROPN
ajlsi-2696	274	34	,	,	PUNCT
ajlsi-2696	274	35	x.	x.	PROPN
ajlsi-2696	274	36	,	,	PUNCT
ajlsi-2696	274	37	&	&	CCONJ
ajlsi-2696	274	38	kang	kang	PROPN
ajlsi-2696	274	39	,	,	PUNCT
ajlsi-2696	274	40	x.	x.	NOUN
ajlsi-2696	274	41	(	(	PUNCT
ajlsi-2696	274	42	2021	2021	NUM
ajlsi-2696	274	43	)	)	PUNCT
ajlsi-2696	274	44	.	.	PUNCT
ajlsi-2696	275	1	association	association	NOUN
ajlsi-2696	275	2	of	of	ADP
ajlsi-2696	275	3	antibiotics	antibiotic	NOUN
ajlsi-2696	275	4	use	use	VERB
ajlsi-2696	275	5	in	in	ADP
ajlsi-2696	275	6	preschool	preschool	ADJ
ajlsi-2696	275	7	age	age	NOUN
ajlsi-2696	275	8	with	with	ADP
ajlsi-2696	275	9	atopic	atopic	NOUN
ajlsi-2696	275	10	and	and	CCONJ
ajlsi-2696	275	11	allergic	allergic	ADJ
ajlsi-2696	275	12	skin	skin	NOUN
ajlsi-2696	275	13	diseases	disease	NOUN
ajlsi-2696	275	14	in	in	ADP
ajlsi-2696	275	15	young	young	ADJ
ajlsi-2696	275	16	adulthood	adulthood	NOUN
ajlsi-2696	275	17	:	:	PUNCT
ajlsi-2696	275	18	a	a	DET
ajlsi-2696	275	19	population	population	NOUN
ajlsi-2696	275	20	-	-	PUNCT
ajlsi-2696	275	21	based	base	VERB
ajlsi-2696	275	22	retrospective	retrospective	ADJ
ajlsi-2696	275	23	cohort	cohort	NOUN
ajlsi-2696	275	24	study	study	NOUN
ajlsi-2696	275	25	.	.	PUNCT
ajlsi-2696	276	1	bmj	bmj	PROPN
ajlsi-2696	276	2	open	open	ADJ
ajlsi-2696	276	3	,	,	PUNCT
ajlsi-2696	276	4	11(9	11(9	PROPN
ajlsi-2696	276	5	)	)	PUNCT
ajlsi-2696	276	6	,	,	PUNCT
ajlsi-2696	277	1	e047768	e047768	PROPN
ajlsi-2696	277	2	.	.	PUNCT
ajlsi-2696	277	3	mandlik	mandlik	PROPN
ajlsi-2696	277	4	,	,	PUNCT
ajlsi-2696	277	5	d.	d.	PROPN
ajlsi-2696	277	6	s.	s.	PROPN
ajlsi-2696	277	7	,	,	PUNCT
ajlsi-2696	277	8	&	&	CCONJ
ajlsi-2696	277	9	mandlik	mandlik	PROPN
ajlsi-2696	277	10	,	,	PUNCT
ajlsi-2696	277	11	s.	s.	PROPN
ajlsi-2696	277	12	k.	k.	PROPN
ajlsi-2696	277	13	(	(	PUNCT
ajlsi-2696	277	14	2021	2021	NUM
ajlsi-2696	277	15	)	)	PUNCT
ajlsi-2696	277	16	.	.	PUNCT
ajlsi-2696	278	1	atopic	atopic	PROPN
ajlsi-2696	278	2	dermatitis	dermatitis	PROPN
ajlsi-2696	278	3	:	:	PUNCT
ajlsi-2696	278	4	new	new	ADJ
ajlsi-2696	278	5	insight	insight	NOUN
ajlsi-2696	278	6	into	into	ADP
ajlsi-2696	278	7	the	the	DET
ajlsi-2696	278	8	etiology	etiology	NOUN
ajlsi-2696	278	9	,	,	PUNCT
ajlsi-2696	278	10	pathogenesis	pathogenesis	NOUN
ajlsi-2696	278	11	,	,	PUNCT
ajlsi-2696	278	12	diagnosis	diagnosis	NOUN
ajlsi-2696	278	13	and	and	CCONJ
ajlsi-2696	278	14	novel	novel	ADJ
ajlsi-2696	278	15	treatment	treatment	NOUN
ajlsi-2696	278	16	strategies	strategy	NOUN
ajlsi-2696	278	17	.	.	PUNCT
ajlsi-2696	279	1	immunopharmacology	immunopharmacology	NOUN
ajlsi-2696	279	2	and	and	CCONJ
ajlsi-2696	279	3	immunotoxicology	immunotoxicology	NOUN
ajlsi-2696	279	4	,	,	PUNCT
ajlsi-2696	279	5	43(2	43(2	PROPN
ajlsi-2696	279	6	)	)	PUNCT
ajlsi-2696	279	7	,	,	PUNCT
ajlsi-2696	279	8	105	105	NUM
ajlsi-2696	279	9	-	-	SYM
ajlsi-2696	279	10	125	125	NUM
ajlsi-2696	279	11	.	.	PUNCT
ajlsi-2696	280	1	martins	martin	NOUN
ajlsi-2696	280	2	,	,	PUNCT
ajlsi-2696	280	3	j.	j.	PROPN
ajlsi-2696	280	4	c.	c.	PROPN
ajlsi-2696	280	5	,	,	PUNCT
ajlsi-2696	280	6	martins	martins	PROPN
ajlsi-2696	280	7	,	,	PUNCT
ajlsi-2696	280	8	c.	c.	PROPN
ajlsi-2696	280	9	,	,	PUNCT
ajlsi-2696	280	10	aoki	aoki	PROPN
ajlsi-2696	280	11	,	,	PUNCT
ajlsi-2696	280	12	v.	v.	PROPN
ajlsi-2696	280	13	,	,	PUNCT
ajlsi-2696	280	14	gois	gois	NOUN
ajlsi-2696	280	15	,	,	PUNCT
ajlsi-2696	280	16	a.	a.	PROPN
ajlsi-2696	280	17	f.	f.	PROPN
ajlsi-2696	280	18	,	,	PUNCT
ajlsi-2696	280	19	ishii	ishii	PROPN
ajlsi-2696	280	20	,	,	PUNCT
ajlsi-2696	280	21	h.	h.	PROPN
ajlsi-2696	280	22	a.	a.	PROPN
ajlsi-2696	280	23	,	,	PUNCT
ajlsi-2696	280	24	&	&	CCONJ
ajlsi-2696	280	25	da	da	PROPN
ajlsi-2696	280	26	silva	silva	PROPN
ajlsi-2696	280	27	,	,	PUNCT
ajlsi-2696	280	28	e.	e.	PROPN
ajlsi-2696	280	29	m.	m.	PROPN
ajlsi-2696	280	30	(	(	PUNCT
ajlsi-2696	280	31	2015	2015	NUM
ajlsi-2696	280	32	)	)	PUNCT
ajlsi-2696	280	33	.	.	PUNCT
ajlsi-2696	281	1	topical	topical	ADJ
ajlsi-2696	281	2	tacrolimus	tacrolimus	NOUN
ajlsi-2696	281	3	for	for	ADP
ajlsi-2696	281	4	atopic	atopic	NOUN
ajlsi-2696	281	5	dermatitis	dermatitis	NOUN
ajlsi-2696	281	6	.	.	PUNCT
ajlsi-2696	282	1	cochrane	cochrane	NOUN
ajlsi-2696	282	2	database	database	NOUN
ajlsi-2696	282	3	of	of	ADP
ajlsi-2696	282	4	systematic	systematic	ADJ
ajlsi-2696	282	5	reviews(7	reviews(7	PROPN
ajlsi-2696	282	6	)	)	PUNCT
ajlsi-2696	282	7	.	.	PUNCT
ajlsi-2696	283	1	megna	megna	PROPN
ajlsi-2696	283	2	,	,	PUNCT
ajlsi-2696	283	3	m.	m.	NOUN
ajlsi-2696	283	4	,	,	PUNCT
ajlsi-2696	283	5	napolitano	napolitano	PROPN
ajlsi-2696	283	6	,	,	PUNCT
ajlsi-2696	283	7	m.	m.	NOUN
ajlsi-2696	283	8	,	,	PUNCT
ajlsi-2696	283	9	patruno	patruno	ADJ
ajlsi-2696	283	10	,	,	PUNCT
ajlsi-2696	283	11	c.	c.	PROPN
ajlsi-2696	283	12	,	,	PUNCT
ajlsi-2696	283	13	villani	villani	PROPN
ajlsi-2696	283	14	,	,	PUNCT
ajlsi-2696	283	15	a.	a.	PROPN
ajlsi-2696	283	16	,	,	PUNCT
ajlsi-2696	283	17	balato	balato	NOUN
ajlsi-2696	283	18	,	,	PUNCT
ajlsi-2696	283	19	a.	a.	NOUN
ajlsi-2696	283	20	,	,	PUNCT
ajlsi-2696	283	21	monfrecola	monfrecola	PROPN
ajlsi-2696	283	22	,	,	PUNCT
ajlsi-2696	283	23	g.	g.	PROPN
ajlsi-2696	283	24	,	,	PUNCT
ajlsi-2696	283	25	ayala	ayala	PROPN
ajlsi-2696	283	26	,	,	PUNCT
ajlsi-2696	283	27	f.	f.	PROPN
ajlsi-2696	283	28	,	,	PUNCT
ajlsi-2696	283	29	&	&	CCONJ
ajlsi-2696	283	30	balato	balato	PROPN
ajlsi-2696	283	31	,	,	PUNCT
ajlsi-2696	283	32	n.	n.	NOUN
ajlsi-2696	283	33	(	(	PUNCT
ajlsi-2696	283	34	2017	2017	NUM
ajlsi-2696	283	35	)	)	PUNCT
ajlsi-2696	283	36	.	.	PUNCT
ajlsi-2696	284	1	systemic	systemic	ADJ
ajlsi-2696	284	2	treatment	treatment	NOUN
ajlsi-2696	284	3	of	of	ADP
ajlsi-2696	284	4	adult	adult	NOUN
ajlsi-2696	284	5	atopic	atopic	NOUN
ajlsi-2696	284	6	dermatitis	dermatitis	NOUN
ajlsi-2696	284	7	:	:	PUNCT
ajlsi-2696	284	8	a	a	DET
ajlsi-2696	284	9	review	review	NOUN
ajlsi-2696	284	10	.	.	PUNCT
ajlsi-2696	285	1	dermatology	dermatology	NOUN
ajlsi-2696	285	2	and	and	CCONJ
ajlsi-2696	285	3	therapy	therapy	NOUN
ajlsi-2696	285	4	,	,	PUNCT
ajlsi-2696	285	5	7	7	NUM
ajlsi-2696	285	6	,	,	PUNCT
ajlsi-2696	285	7	1	1	NUM
ajlsi-2696	285	8	-	-	SYM
ajlsi-2696	285	9	23	23	NUM
ajlsi-2696	285	10	.	.	PUNCT
ajlsi-2696	286	1	mehta	mehta	PROPN
ajlsi-2696	286	2	,	,	PUNCT
ajlsi-2696	286	3	y.	y.	PROPN
ajlsi-2696	286	4	,	,	PUNCT
ajlsi-2696	286	5	&	&	CCONJ
ajlsi-2696	286	6	fulmali	fulmali	PROPN
ajlsi-2696	286	7	,	,	PUNCT
ajlsi-2696	286	8	d.	d.	PROPN
ajlsi-2696	286	9	g.	g.	PROPN
ajlsi-2696	286	10	(	(	PUNCT
ajlsi-2696	286	11	2022	2022	NUM
ajlsi-2696	286	12	)	)	PUNCT
ajlsi-2696	286	13	.	.	PUNCT
ajlsi-2696	287	1	relationship	relationship	NOUN
ajlsi-2696	287	2	between	between	ADP
ajlsi-2696	287	3	atopic	atopic	NOUN
ajlsi-2696	287	4	dermatitis	dermatitis	NOUN
ajlsi-2696	287	5	and	and	CCONJ
ajlsi-2696	287	6	food	food	NOUN
ajlsi-2696	287	7	allergy	allergy	NOUN
ajlsi-2696	287	8	in	in	ADP
ajlsi-2696	287	9	children	child	NOUN
ajlsi-2696	287	10	.	.	PUNCT
ajlsi-2696	288	1	cureus	cureus	NOUN
ajlsi-2696	288	2	,	,	PUNCT
ajlsi-2696	288	3	14(12	14(12	NUM
ajlsi-2696	288	4	)	)	PUNCT
ajlsi-2696	288	5	.	.	PUNCT
ajlsi-2696	289	1	montes	monte	NOUN
ajlsi-2696	289	2	-	-	PUNCT
ajlsi-2696	289	3	torres	torre	NOUN
ajlsi-2696	289	4	,	,	PUNCT
ajlsi-2696	289	5	a.	a.	NOUN
ajlsi-2696	289	6	,	,	PUNCT
ajlsi-2696	289	7	llamas	llamas	PROPN
ajlsi-2696	289	8	-	-	PUNCT
ajlsi-2696	289	9	velasco	velasco	PROPN
ajlsi-2696	289	10	,	,	PUNCT
ajlsi-2696	289	11	m.	m.	NOUN
ajlsi-2696	289	12	,	,	PUNCT
ajlsi-2696	289	13	pérez	pérez	NOUN
ajlsi-2696	289	14	-	-	PUNCT
ajlsi-2696	289	15	plaza	plaza	NOUN
ajlsi-2696	289	16	,	,	PUNCT
ajlsi-2696	289	17	a.	a.	NOUN
ajlsi-2696	289	18	,	,	PUNCT
ajlsi-2696	289	19	solano	solano	PROPN
ajlsi-2696	289	20	-	-	PUNCT
ajlsi-2696	289	21	lópez	lópez	PROPN
ajlsi-2696	289	22	,	,	PUNCT
ajlsi-2696	289	23	g.	g.	PROPN
ajlsi-2696	289	24	,	,	PUNCT
ajlsi-2696	289	25	&	&	CCONJ
ajlsi-2696	289	26	sánchez	sánchez	PROPN
ajlsi-2696	289	27	-	-	PUNCT
ajlsi-2696	289	28	pérez	pérez	NOUN
ajlsi-2696	289	29	,	,	PUNCT
ajlsi-2696	289	30	j.	j.	PROPN
ajlsi-2696	289	31	(	(	PUNCT
ajlsi-2696	289	32	2015	2015	NUM
ajlsi-2696	289	33	)	)	PUNCT
ajlsi-2696	289	34	.	.	PUNCT
ajlsi-2696	290	1	biological	biological	ADJ
ajlsi-2696	290	2	treatments	treatment	NOUN
ajlsi-2696	290	3	in	in	ADP
ajlsi-2696	290	4	atopic	atopic	NOUN
ajlsi-2696	290	5	dermatitis	dermatitis	NOUN
ajlsi-2696	290	6	.	.	PUNCT
ajlsi-2696	291	1	journal	journal	PROPN
ajlsi-2696	291	2	of	of	ADP
ajlsi-2696	291	3	clinical	clinical	ADJ
ajlsi-2696	291	4	medicine	medicine	NOUN
ajlsi-2696	291	5	,	,	PUNCT
ajlsi-2696	291	6	4(4	4(4	NUM
ajlsi-2696	291	7	)	)	PUNCT
ajlsi-2696	291	8	,	,	PUNCT
ajlsi-2696	291	9	593	593	NUM
ajlsi-2696	291	10	-	-	SYM
ajlsi-2696	291	11	613	613	NUM
ajlsi-2696	291	12	.	.	PUNCT
ajlsi-2696	291	13	mose	mose	NOUN
ajlsi-2696	291	14	,	,	PUNCT
ajlsi-2696	291	15	a.	a.	NOUN
ajlsi-2696	291	16	p.	p.	PROPN
ajlsi-2696	291	17	,	,	PUNCT
ajlsi-2696	291	18	usamah	usamah	PROPN
ajlsi-2696	291	19	,	,	PUNCT
ajlsi-2696	291	20	a.	a.	NOUN
ajlsi-2696	291	21	,	,	PUNCT
ajlsi-2696	291	22	&	&	CCONJ
ajlsi-2696	291	23	svedman	svedman	PROPN
ajlsi-2696	291	24	,	,	PUNCT
ajlsi-2696	291	25	c.	c.	PROPN
ajlsi-2696	291	26	(	(	PUNCT
ajlsi-2696	291	27	2022	2022	NUM
ajlsi-2696	291	28	)	)	PUNCT
ajlsi-2696	291	29	.	.	PUNCT
ajlsi-2696	292	1	allergic	allergic	ADJ
ajlsi-2696	292	2	contact	contact	NOUN
ajlsi-2696	292	3	dermatitis	dermatitis	NOUN
ajlsi-2696	292	4	to	to	ADP
ajlsi-2696	292	5	topical	topical	ADJ
ajlsi-2696	292	6	clindamycin	clindamycin	NOUN
ajlsi-2696	292	7	in	in	ADP
ajlsi-2696	292	8	a	a	DET
ajlsi-2696	292	9	patient	patient	NOUN
ajlsi-2696	292	10	with	with	ADP
ajlsi-2696	292	11	hidradenitis	hidradenitis	PROPN
ajlsi-2696	292	12	suppurativa	suppurativa	PROPN
ajlsi-2696	292	13	.	.	PUNCT
ajlsi-2696	293	1	acta	acta	PROPN
ajlsi-2696	293	2	dermatopa	dermatopa	PROPN
ajlsi-2696	293	3	ge	ge	PROPN
ajlsi-2696	293	4	68	68	NUM
ajlsi-2696	293	5	https://journals.e-palli.com/home/index.php/ajlsi	https://journals.e-palli.com/home/index.php/ajlsi	PROPN
ajlsi-2696	293	6	am	am	NOUN
ajlsi-2696	293	7	.	.	PUNCT
ajlsi-2696	294	1	j.	j.	PROPN
ajlsi-2696	294	2	life	life	PROPN
ajlsi-2696	294	3	sci	sci	PROPN
ajlsi-2696	294	4	.	.	PUNCT
ajlsi-2696	294	5	innov	innov	PROPN
ajlsi-2696	294	6	.	.	PUNCT
ajlsi-2696	295	1	3(1	3(1	NUM
ajlsi-2696	295	2	)	)	PUNCT
ajlsi-2696	295	3	61	61	NUM
ajlsi-2696	295	4	-	-	SYM
ajlsi-2696	295	5	68	68	NUM
ajlsi-2696	295	6	,	,	PUNCT
ajlsi-2696	295	7	2024	2024	NUM
ajlsi-2696	295	8	venereologica	venereologica	NOUN
ajlsi-2696	295	9	,	,	PUNCT
ajlsi-2696	295	10	102	102	NUM
ajlsi-2696	295	11	.	.	PUNCT
ajlsi-2696	296	1	mubanga	mubanga	NOUN
ajlsi-2696	296	2	,	,	PUNCT
ajlsi-2696	296	3	m.	m.	NOUN
ajlsi-2696	296	4	,	,	PUNCT
ajlsi-2696	296	5	lundholm	lundholm	PROPN
ajlsi-2696	296	6	,	,	PUNCT
ajlsi-2696	296	7	c.	c.	NOUN
ajlsi-2696	296	8	,	,	PUNCT
ajlsi-2696	296	9	d’onofrio	d’onofrio	PROPN
ajlsi-2696	296	10	,	,	PUNCT
ajlsi-2696	296	11	b.	b.	PROPN
ajlsi-2696	296	12	m.	m.	PROPN
ajlsi-2696	296	13	,	,	PUNCT
ajlsi-2696	296	14	stratmann	stratmann	PROPN
ajlsi-2696	296	15	,	,	PUNCT
ajlsi-2696	296	16	m.	m.	NOUN
ajlsi-2696	296	17	,	,	PUNCT
ajlsi-2696	296	18	hedman	hedman	PROPN
ajlsi-2696	296	19	,	,	PUNCT
ajlsi-2696	296	20	a.	a.	PROPN
ajlsi-2696	296	21	,	,	PUNCT
ajlsi-2696	296	22	&	&	CCONJ
ajlsi-2696	296	23	almqvist	almqvist	PROPN
ajlsi-2696	296	24	,	,	PUNCT
ajlsi-2696	296	25	c.	c.	PROPN
ajlsi-2696	296	26	(	(	PUNCT
ajlsi-2696	296	27	2021	2021	NUM
ajlsi-2696	296	28	)	)	PUNCT
ajlsi-2696	296	29	.	.	PUNCT
ajlsi-2696	297	1	association	association	NOUN
ajlsi-2696	297	2	of	of	ADP
ajlsi-2696	297	3	early	early	ADJ
ajlsi-2696	297	4	life	life	NOUN
ajlsi-2696	297	5	exposure	exposure	NOUN
ajlsi-2696	297	6	to	to	ADP
ajlsi-2696	297	7	antibiotics	antibiotic	NOUN
ajlsi-2696	297	8	with	with	ADP
ajlsi-2696	297	9	risk	risk	NOUN
ajlsi-2696	297	10	of	of	ADP
ajlsi-2696	297	11	atopic	atopic	NOUN
ajlsi-2696	297	12	dermatitis	dermatitis	NOUN
ajlsi-2696	297	13	in	in	ADP
ajlsi-2696	297	14	sweden	sweden	PROPN
ajlsi-2696	297	15	.	.	PROPN
ajlsi-2696	298	1	jama	jama	PROPN
ajlsi-2696	298	2	network	network	PROPN
ajlsi-2696	298	3	open	open	VERB
ajlsi-2696	298	4	,	,	PUNCT
ajlsi-2696	298	5	4(4	4(4	NUM
ajlsi-2696	298	6	)	)	PUNCT
ajlsi-2696	298	7	,	,	PUNCT
ajlsi-2696	298	8	e215245	e215245	NOUN
ajlsi-2696	298	9	-	-	PUNCT
ajlsi-2696	298	10	e215245	e215245	NOUN
ajlsi-2696	298	11	.	.	PUNCT
ajlsi-2696	299	1	nakahara	nakahara	ADJ
ajlsi-2696	299	2	,	,	PUNCT
ajlsi-2696	299	3	t.	t.	PROPN
ajlsi-2696	299	4	,	,	PUNCT
ajlsi-2696	299	5	kido‐nakahara	kido‐nakahara	PROPN
ajlsi-2696	299	6	,	,	PUNCT
ajlsi-2696	299	7	m.	m.	NOUN
ajlsi-2696	299	8	,	,	PUNCT
ajlsi-2696	299	9	tsuji	tsuji	PROPN
ajlsi-2696	299	10	,	,	PUNCT
ajlsi-2696	299	11	g.	g.	PROPN
ajlsi-2696	299	12	,	,	PUNCT
ajlsi-2696	299	13	&	&	CCONJ
ajlsi-2696	299	14	furue	furue	NOUN
ajlsi-2696	299	15	,	,	PUNCT
ajlsi-2696	299	16	m.	m.	NOUN
ajlsi-2696	299	17	(	(	PUNCT
ajlsi-2696	299	18	2021	2021	NUM
ajlsi-2696	299	19	)	)	PUNCT
ajlsi-2696	299	20	.	.	PUNCT
ajlsi-2696	300	1	basics	basic	NOUN
ajlsi-2696	300	2	and	and	CCONJ
ajlsi-2696	300	3	recent	recent	ADJ
ajlsi-2696	300	4	advances	advance	NOUN
ajlsi-2696	300	5	in	in	ADP
ajlsi-2696	300	6	the	the	DET
ajlsi-2696	300	7	pathophysiology	pathophysiology	NOUN
ajlsi-2696	300	8	of	of	ADP
ajlsi-2696	300	9	atopic	atopic	NOUN
ajlsi-2696	300	10	dermatitis	dermatitis	NOUN
ajlsi-2696	300	11	.	.	PUNCT
ajlsi-2696	301	1	the	the	DET
ajlsi-2696	301	2	journal	journal	NOUN
ajlsi-2696	301	3	of	of	ADP
ajlsi-2696	301	4	dermatology	dermatology	NOUN
ajlsi-2696	301	5	,	,	PUNCT
ajlsi-2696	301	6	48(2	48(2	NUM
ajlsi-2696	301	7	)	)	PUNCT
ajlsi-2696	301	8	,	,	PUNCT
ajlsi-2696	301	9	130	130	NUM
ajlsi-2696	301	10	-	-	SYM
ajlsi-2696	301	11	139	139	NUM
ajlsi-2696	301	12	.	.	PUNCT
ajlsi-2696	302	1	napolitano	napolitano	PROPN
ajlsi-2696	302	2	,	,	PUNCT
ajlsi-2696	302	3	m.	m.	NOUN
ajlsi-2696	302	4	,	,	PUNCT
ajlsi-2696	302	5	fabbrocini	fabbrocini	NOUN
ajlsi-2696	302	6	,	,	PUNCT
ajlsi-2696	302	7	g.	g.	PROPN
ajlsi-2696	302	8	,	,	PUNCT
ajlsi-2696	302	9	neri	neri	PROPN
ajlsi-2696	302	10	,	,	PUNCT
ajlsi-2696	302	11	i.	i.	NOUN
ajlsi-2696	302	12	,	,	PUNCT
ajlsi-2696	302	13	stingeni	stingeni	NOUN
ajlsi-2696	302	14	,	,	PUNCT
ajlsi-2696	302	15	l.	l.	PROPN
ajlsi-2696	302	16	,	,	PUNCT
ajlsi-2696	302	17	boccaletti	boccaletti	PROPN
ajlsi-2696	302	18	,	,	PUNCT
ajlsi-2696	302	19	v.	v.	NOUN
ajlsi-2696	302	20	,	,	PUNCT
ajlsi-2696	302	21	piccolo	piccolo	NOUN
ajlsi-2696	302	22	,	,	PUNCT
ajlsi-2696	302	23	v.	v.	PROPN
ajlsi-2696	302	24	,	,	PUNCT
ajlsi-2696	302	25	amoruso	amoruso	PROPN
ajlsi-2696	302	26	,	,	PUNCT
ajlsi-2696	302	27	g.	g.	PROPN
ajlsi-2696	302	28	f.	f.	PROPN
ajlsi-2696	302	29	,	,	PUNCT
ajlsi-2696	302	30	malara	malara	PROPN
ajlsi-2696	302	31	,	,	PUNCT
ajlsi-2696	302	32	g.	g.	PROPN
ajlsi-2696	302	33	,	,	PUNCT
ajlsi-2696	302	34	de	de	X
ajlsi-2696	302	35	pasquale	pasquale	PROPN
ajlsi-2696	302	36	,	,	PUNCT
ajlsi-2696	302	37	r.	r.	PROPN
ajlsi-2696	302	38	,	,	PUNCT
ajlsi-2696	302	39	&	&	CCONJ
ajlsi-2696	302	40	di	di	PROPN
ajlsi-2696	302	41	brizzi	brizzi	PROPN
ajlsi-2696	302	42	,	,	PUNCT
ajlsi-2696	302	43	e.	e.	PROPN
ajlsi-2696	302	44	v.	v.	PROPN
ajlsi-2696	302	45	(	(	PUNCT
ajlsi-2696	302	46	2022	2022	NUM
ajlsi-2696	302	47	)	)	PUNCT
ajlsi-2696	302	48	.	.	PUNCT
ajlsi-2696	303	1	dupilumab	dupilumab	NOUN
ajlsi-2696	303	2	treatment	treatment	NOUN
ajlsi-2696	303	3	in	in	ADP
ajlsi-2696	303	4	children	child	NOUN
ajlsi-2696	303	5	aged	age	VERB
ajlsi-2696	303	6	6–11	6–11	NOUN
ajlsi-2696	303	7	years	year	NOUN
ajlsi-2696	303	8	with	with	ADP
ajlsi-2696	303	9	atopic	atopic	NOUN
ajlsi-2696	303	10	dermatitis	dermatitis	NOUN
ajlsi-2696	303	11	:	:	PUNCT
ajlsi-2696	303	12	a	a	DET
ajlsi-2696	303	13	multicentre	multicentre	NOUN
ajlsi-2696	303	14	,	,	PUNCT
ajlsi-2696	303	15	real	real	ADJ
ajlsi-2696	303	16	-	-	PUNCT
ajlsi-2696	303	17	life	life	NOUN
ajlsi-2696	303	18	study	study	NOUN
ajlsi-2696	303	19	.	.	PUNCT
ajlsi-2696	304	1	pediatric	pediatric	ADJ
ajlsi-2696	304	2	drugs	drug	NOUN
ajlsi-2696	304	3	,	,	PUNCT
ajlsi-2696	304	4	24(6	24(6	NUM
ajlsi-2696	304	5	)	)	PUNCT
ajlsi-2696	304	6	,	,	PUNCT
ajlsi-2696	304	7	671	671	NUM
ajlsi-2696	304	8	-	-	SYM
ajlsi-2696	304	9	678	678	NUM
ajlsi-2696	304	10	.	.	PUNCT
ajlsi-2696	304	11	neri	neri	PROPN
ajlsi-2696	304	12	,	,	PUNCT
ajlsi-2696	304	13	l.	l.	PROPN
ajlsi-2696	304	14	(	(	PUNCT
ajlsi-2696	304	15	2015	2015	NUM
ajlsi-2696	304	16	)	)	PUNCT
ajlsi-2696	304	17	.	.	PUNCT
ajlsi-2696	305	1	antibiotic	antibiotic	ADJ
ajlsi-2696	305	2	therapy	therapy	NOUN
ajlsi-2696	305	3	in	in	ADP
ajlsi-2696	305	4	the	the	DET
ajlsi-2696	305	5	management	management	NOUN
ajlsi-2696	305	6	of	of	ADP
ajlsi-2696	305	7	atopic	atopic	NOUN
ajlsi-2696	305	8	dermatitis	dermatitis	NOUN
ajlsi-2696	305	9	.	.	PUNCT
ajlsi-2696	306	1	giornale	giornale	PROPN
ajlsi-2696	306	2	italiano	italiano	PROPN
ajlsi-2696	306	3	di	di	PROPN
ajlsi-2696	306	4	dermatologia	dermatologia	PROPN
ajlsi-2696	306	5	e	e	PROPN
ajlsi-2696	306	6	venereologia	venereologia	PROPN
ajlsi-2696	306	7	:	:	PUNCT
ajlsi-2696	306	8	organo	organo	ADJ
ajlsi-2696	306	9	ufficiale	ufficiale	NOUN
ajlsi-2696	306	10	,	,	PUNCT
ajlsi-2696	306	11	societa	societa	PROPN
ajlsi-2696	306	12	italiana	italiana	PROPN
ajlsi-2696	306	13	di	di	PROPN
ajlsi-2696	306	14	dermatologia	dermatologia	PROPN
ajlsi-2696	306	15	e	e	PROPN
ajlsi-2696	306	16	sifilografia	sifilografia	NOUN
ajlsi-2696	306	17	,	,	PUNCT
ajlsi-2696	306	18	150(3	150(3	NUM
ajlsi-2696	306	19	)	)	PUNCT
ajlsi-2696	306	20	,	,	PUNCT
ajlsi-2696	306	21	321	321	NUM
ajlsi-2696	306	22	-	-	SYM
ajlsi-2696	306	23	325	325	NUM
ajlsi-2696	306	24	.	.	PUNCT
ajlsi-2696	307	1	nicholas	nicholas	PROPN
ajlsi-2696	307	2	,	,	PUNCT
ajlsi-2696	307	3	m.	m.	NOUN
ajlsi-2696	307	4	n.	n.	PROPN
ajlsi-2696	307	5	,	,	PUNCT
ajlsi-2696	307	6	keown	keown	PROPN
ajlsi-2696	307	7	-	-	PUNCT
ajlsi-2696	307	8	stoneman	stoneman	PROPN
ajlsi-2696	307	9	,	,	PUNCT
ajlsi-2696	307	10	c.	c.	PROPN
ajlsi-2696	307	11	d.	d.	PROPN
ajlsi-2696	307	12	,	,	PUNCT
ajlsi-2696	307	13	maguire	maguire	PROPN
ajlsi-2696	307	14	,	,	PUNCT
ajlsi-2696	307	15	j.	j.	PROPN
ajlsi-2696	307	16	l.	l.	PROPN
ajlsi-2696	307	17	,	,	PUNCT
ajlsi-2696	307	18	&	&	CCONJ
ajlsi-2696	307	19	drucker	drucker	PROPN
ajlsi-2696	307	20	,	,	PUNCT
ajlsi-2696	307	21	a.	a.	NOUN
ajlsi-2696	307	22	m.	m.	NOUN
ajlsi-2696	307	23	(	(	PUNCT
ajlsi-2696	307	24	2022	2022	NUM
ajlsi-2696	307	25	)	)	PUNCT
ajlsi-2696	307	26	.	.	PUNCT
ajlsi-2696	308	1	association	association	NOUN
ajlsi-2696	308	2	between	between	ADP
ajlsi-2696	308	3	atopic	atopic	NOUN
ajlsi-2696	308	4	dermatitis	dermatitis	NOUN
ajlsi-2696	308	5	and	and	CCONJ
ajlsi-2696	308	6	height	height	NOUN
ajlsi-2696	308	7	,	,	PUNCT
ajlsi-2696	308	8	body	body	NOUN
ajlsi-2696	308	9	mass	mass	PROPN
ajlsi-2696	308	10	index	index	NOUN
ajlsi-2696	308	11	,	,	PUNCT
ajlsi-2696	308	12	and	and	CCONJ
ajlsi-2696	308	13	weight	weight	NOUN
ajlsi-2696	308	14	in	in	ADP
ajlsi-2696	308	15	children	child	NOUN
ajlsi-2696	308	16	.	.	PUNCT
ajlsi-2696	309	1	jama	jama	PROPN
ajlsi-2696	309	2	dermatology	dermatology	PROPN
ajlsi-2696	309	3	,	,	PUNCT
ajlsi-2696	309	4	158(1	158(1	NUM
ajlsi-2696	309	5	)	)	PUNCT
ajlsi-2696	309	6	,	,	PUNCT
ajlsi-2696	309	7	26	26	NUM
ajlsi-2696	309	8	-	-	SYM
ajlsi-2696	309	9	32	32	NUM
ajlsi-2696	309	10	.	.	PUNCT
ajlsi-2696	310	1	ohsawa	ohsawa	PROPN
ajlsi-2696	310	2	,	,	PUNCT
ajlsi-2696	310	3	y.	y.	PROPN
ajlsi-2696	310	4	,	,	PUNCT
ajlsi-2696	310	5	&	&	CCONJ
ajlsi-2696	310	6	hirasawa	hirasawa	PROPN
ajlsi-2696	310	7	,	,	PUNCT
ajlsi-2696	310	8	n.	n.	NOUN
ajlsi-2696	310	9	(	(	PUNCT
ajlsi-2696	310	10	2014	2014	NUM
ajlsi-2696	310	11	)	)	PUNCT
ajlsi-2696	310	12	.	.	PUNCT
ajlsi-2696	311	1	the	the	DET
ajlsi-2696	311	2	role	role	NOUN
ajlsi-2696	311	3	of	of	ADP
ajlsi-2696	311	4	histamine	histamine	NOUN
ajlsi-2696	311	5	h1	h1	NOUN
ajlsi-2696	311	6	and	and	CCONJ
ajlsi-2696	311	7	h4	h4	NOUN
ajlsi-2696	311	8	receptors	receptor	NOUN
ajlsi-2696	311	9	in	in	ADP
ajlsi-2696	311	10	atopic	atopic	NOUN
ajlsi-2696	311	11	dermatitis	dermatitis	NOUN
ajlsi-2696	311	12	:	:	PUNCT
ajlsi-2696	311	13	from	from	ADP
ajlsi-2696	311	14	basic	basic	ADJ
ajlsi-2696	311	15	research	research	NOUN
ajlsi-2696	311	16	to	to	ADP
ajlsi-2696	311	17	clinical	clinical	ADJ
ajlsi-2696	311	18	study	study	NOUN
ajlsi-2696	311	19	.	.	PUNCT
ajlsi-2696	312	1	allergology	allergology	NOUN
ajlsi-2696	312	2	international	international	PROPN
ajlsi-2696	312	3	,	,	PUNCT
ajlsi-2696	312	4	63(4	63(4	NOUN
ajlsi-2696	312	5	)	)	PUNCT
ajlsi-2696	312	6	,	,	PUNCT
ajlsi-2696	312	7	533	533	NUM
ajlsi-2696	312	8	-	-	SYM
ajlsi-2696	312	9	542	542	NUM
ajlsi-2696	312	10	.	.	PUNCT
ajlsi-2696	313	1	paolino	paolino	ADJ
ajlsi-2696	313	2	,	,	PUNCT
ajlsi-2696	313	3	a.	a.	NOUN
ajlsi-2696	313	4	,	,	PUNCT
ajlsi-2696	313	5	alexander	alexander	PROPN
ajlsi-2696	313	6	,	,	PUNCT
ajlsi-2696	313	7	h.	h.	PROPN
ajlsi-2696	313	8	,	,	PUNCT
ajlsi-2696	313	9	broderick	broderick	PROPN
ajlsi-2696	313	10	,	,	PUNCT
ajlsi-2696	313	11	c.	c.	PROPN
ajlsi-2696	313	12	,	,	PUNCT
ajlsi-2696	313	13	&	&	CCONJ
ajlsi-2696	313	14	flohr	flohr	PROPN
ajlsi-2696	313	15	,	,	PUNCT
ajlsi-2696	313	16	c.	c.	NOUN
ajlsi-2696	313	17	(	(	PUNCT
ajlsi-2696	313	18	2023	2023	NUM
ajlsi-2696	313	19	)	)	PUNCT
ajlsi-2696	313	20	.	.	PUNCT
ajlsi-2696	314	1	non‐biologic	non‐biologic	ADJ
ajlsi-2696	314	2	systemic	systemic	ADJ
ajlsi-2696	314	3	treatments	treatment	NOUN
ajlsi-2696	314	4	for	for	ADP
ajlsi-2696	314	5	atopic	atopic	NOUN
ajlsi-2696	314	6	dermatitis	dermatitis	NOUN
ajlsi-2696	314	7	:	:	PUNCT
ajlsi-2696	314	8	current	current	ADJ
ajlsi-2696	314	9	state	state	NOUN
ajlsi-2696	314	10	of	of	ADP
ajlsi-2696	314	11	the	the	DET
ajlsi-2696	314	12	art	art	NOUN
ajlsi-2696	314	13	and	and	CCONJ
ajlsi-2696	314	14	future	future	ADJ
ajlsi-2696	314	15	directions	direction	NOUN
ajlsi-2696	314	16	.	.	PUNCT
ajlsi-2696	315	1	clinical	clinical	ADJ
ajlsi-2696	315	2	&	&	CCONJ
ajlsi-2696	315	3	experimental	experimental	ADJ
ajlsi-2696	315	4	allergy	allergy	PROPN
ajlsi-2696	315	5	,	,	PUNCT
ajlsi-2696	315	6	53(5	53(5	NUM
ajlsi-2696	315	7	)	)	PUNCT
ajlsi-2696	315	8	,	,	PUNCT
ajlsi-2696	315	9	495510	495510	NUM
ajlsi-2696	315	10	.	.	PUNCT
ajlsi-2696	316	1	papp	papp	PROPN
ajlsi-2696	316	2	,	,	PUNCT
ajlsi-2696	316	3	k.	k.	PROPN
ajlsi-2696	316	4	a.	a.	PROPN
ajlsi-2696	316	5	,	,	PUNCT
ajlsi-2696	316	6	hong	hong	PROPN
ajlsi-2696	316	7	,	,	PUNCT
ajlsi-2696	316	8	c.-h	c.-h	PROPN
ajlsi-2696	316	9	.	.	PROPN
ajlsi-2696	316	10	,	,	PUNCT
ajlsi-2696	316	11	lansang	lansang	PROPN
ajlsi-2696	316	12	,	,	PUNCT
ajlsi-2696	316	13	m.	m.	NOUN
ajlsi-2696	316	14	p.	p.	PROPN
ajlsi-2696	316	15	,	,	PUNCT
ajlsi-2696	316	16	turchin	turchin	PROPN
ajlsi-2696	316	17	,	,	PUNCT
ajlsi-2696	316	18	i.	i.	PROPN
ajlsi-2696	316	19	,	,	PUNCT
ajlsi-2696	316	20	adam	adam	PROPN
ajlsi-2696	316	21	,	,	PUNCT
ajlsi-2696	316	22	d.	d.	PROPN
ajlsi-2696	316	23	n.	n.	PROPN
ajlsi-2696	316	24	,	,	PUNCT
ajlsi-2696	316	25	beecker	beecker	PROPN
ajlsi-2696	316	26	,	,	PUNCT
ajlsi-2696	316	27	j.	j.	PROPN
ajlsi-2696	316	28	r.	r.	PROPN
ajlsi-2696	316	29	,	,	PUNCT
ajlsi-2696	316	30	bissonnette	bissonnette	PROPN
ajlsi-2696	316	31	,	,	PUNCT
ajlsi-2696	316	32	r.	r.	PROPN
ajlsi-2696	316	33	,	,	PUNCT
ajlsi-2696	316	34	gooderham	gooderham	PROPN
ajlsi-2696	316	35	,	,	PUNCT
ajlsi-2696	316	36	m.	m.	NOUN
ajlsi-2696	316	37	j.	j.	PROPN
ajlsi-2696	316	38	,	,	PUNCT
ajlsi-2696	316	39	jack	jack	PROPN
ajlsi-2696	316	40	,	,	PUNCT
ajlsi-2696	316	41	c.	c.	PROPN
ajlsi-2696	316	42	,	,	PUNCT
ajlsi-2696	316	43	&	&	CCONJ
ajlsi-2696	316	44	joseph	joseph	PROPN
ajlsi-2696	316	45	,	,	PUNCT
ajlsi-2696	316	46	m.	m.	NOUN
ajlsi-2696	316	47	(	(	PUNCT
ajlsi-2696	316	48	2021	2021	NUM
ajlsi-2696	316	49	)	)	PUNCT
ajlsi-2696	316	50	.	.	PUNCT
ajlsi-2696	317	1	practical	practical	ADJ
ajlsi-2696	317	2	management	management	NOUN
ajlsi-2696	317	3	of	of	ADP
ajlsi-2696	317	4	patients	patient	NOUN
ajlsi-2696	317	5	with	with	ADP
ajlsi-2696	317	6	atopic	atopic	NOUN
ajlsi-2696	317	7	dermatitis	dermatitis	NOUN
ajlsi-2696	317	8	on	on	ADP
ajlsi-2696	317	9	dupilumab	dupilumab	NOUN
ajlsi-2696	317	10	.	.	PUNCT
ajlsi-2696	318	1	dermatology	dermatology	NOUN
ajlsi-2696	318	2	and	and	CCONJ
ajlsi-2696	318	3	therapy	therapy	NOUN
ajlsi-2696	318	4	,	,	PUNCT
ajlsi-2696	318	5	11	11	NUM
ajlsi-2696	318	6	,	,	PUNCT
ajlsi-2696	318	7	1805	1805	NUM
ajlsi-2696	318	8	-	-	SYM
ajlsi-2696	318	9	1828	1828	NUM
ajlsi-2696	318	10	.	.	PUNCT
ajlsi-2696	319	1	phan	phan	PROPN
ajlsi-2696	319	2	,	,	PUNCT
ajlsi-2696	319	3	k.	k.	PROPN
ajlsi-2696	319	4	,	,	PUNCT
ajlsi-2696	319	5	&	&	CCONJ
ajlsi-2696	319	6	smith	smith	PROPN
ajlsi-2696	319	7	,	,	PUNCT
ajlsi-2696	319	8	s.	s.	PROPN
ajlsi-2696	319	9	d.	d.	PROPN
ajlsi-2696	319	10	(	(	PUNCT
ajlsi-2696	319	11	2020	2020	NUM
ajlsi-2696	319	12	)	)	PUNCT
ajlsi-2696	319	13	.	.	PUNCT
ajlsi-2696	320	1	mycophenolate	mycophenolate	PROPN
ajlsi-2696	320	2	mofetil	mofetil	PROPN
ajlsi-2696	320	3	and	and	CCONJ
ajlsi-2696	320	4	atopic	atopic	NOUN
ajlsi-2696	320	5	dermatitis	dermatitis	NOUN
ajlsi-2696	320	6	:	:	PUNCT
ajlsi-2696	320	7	systematic	systematic	ADJ
ajlsi-2696	320	8	review	review	NOUN
ajlsi-2696	320	9	and	and	CCONJ
ajlsi-2696	320	10	metaanalysis	metaanalysis	NOUN
ajlsi-2696	320	11	.	.	PUNCT
ajlsi-2696	321	1	journal	journal	NOUN
ajlsi-2696	321	2	of	of	ADP
ajlsi-2696	321	3	dermatological	dermatological	ADJ
ajlsi-2696	321	4	treatment	treatment	NOUN
ajlsi-2696	321	5	,	,	PUNCT
ajlsi-2696	321	6	31(8	31(8	NUM
ajlsi-2696	321	7	)	)	PUNCT
ajlsi-2696	321	8	,	,	PUNCT
ajlsi-2696	321	9	810814	810814	NUM
ajlsi-2696	321	10	.	.	PUNCT
ajlsi-2696	322	1	rajagopalan	rajagopalan	NOUN
ajlsi-2696	322	2	,	,	PUNCT
ajlsi-2696	322	3	m.	m.	NOUN
ajlsi-2696	322	4	,	,	PUNCT
ajlsi-2696	322	5	saraswat	saraswat	NOUN
ajlsi-2696	322	6	,	,	PUNCT
ajlsi-2696	322	7	a.	a.	NOUN
ajlsi-2696	322	8	,	,	PUNCT
ajlsi-2696	322	9	chandrashekar	chandrashekar	PROPN
ajlsi-2696	322	10	,	,	PUNCT
ajlsi-2696	322	11	b.	b.	PROPN
ajlsi-2696	322	12	s.	s.	PROPN
ajlsi-2696	322	13	,	,	PUNCT
ajlsi-2696	322	14	dhar	dhar	PROPN
ajlsi-2696	322	15	,	,	PUNCT
ajlsi-2696	322	16	s.	s.	PROPN
ajlsi-2696	322	17	,	,	PUNCT
ajlsi-2696	322	18	dogra	dogra	PROPN
ajlsi-2696	322	19	,	,	PUNCT
ajlsi-2696	322	20	s.	s.	PROPN
ajlsi-2696	322	21	,	,	PUNCT
ajlsi-2696	322	22	tahiliani	tahiliani	PROPN
ajlsi-2696	322	23	,	,	PUNCT
ajlsi-2696	322	24	s.	s.	PROPN
ajlsi-2696	322	25	,	,	PUNCT
ajlsi-2696	322	26	&	&	CCONJ
ajlsi-2696	322	27	raj	raj	PROPN
ajlsi-2696	322	28	,	,	PUNCT
ajlsi-2696	322	29	p.	p.	NOUN
ajlsi-2696	322	30	(	(	PUNCT
ajlsi-2696	322	31	2022	2022	NUM
ajlsi-2696	322	32	)	)	PUNCT
ajlsi-2696	322	33	.	.	PUNCT
ajlsi-2696	323	1	role	role	NOUN
ajlsi-2696	323	2	of	of	ADP
ajlsi-2696	323	3	cyclosporine	cyclosporine	PROPN
ajlsi-2696	323	4	(	(	PUNCT
ajlsi-2696	323	5	csa	csa	PROPN
ajlsi-2696	323	6	)	)	PUNCT
ajlsi-2696	323	7	in	in	ADP
ajlsi-2696	323	8	immuno	immuno	ADJ
ajlsi-2696	323	9	-	-	ADJ
ajlsi-2696	323	10	dermatological	dermatological	ADJ
ajlsi-2696	323	11	conditions	condition	NOUN
ajlsi-2696	323	12	.	.	PUNCT
ajlsi-2696	324	1	indian	indian	ADJ
ajlsi-2696	324	2	dermatology	dermatology	PROPN
ajlsi-2696	324	3	online	online	PROPN
ajlsi-2696	324	4	journal	journal	PROPN
ajlsi-2696	324	5	,	,	PUNCT
ajlsi-2696	324	6	13(5	13(5	NUM
ajlsi-2696	324	7	)	)	PUNCT
ajlsi-2696	324	8	,	,	PUNCT
ajlsi-2696	324	9	585	585	NUM
ajlsi-2696	324	10	-	-	SYM
ajlsi-2696	324	11	599	599	NUM
ajlsi-2696	324	12	.	.	PUNCT
ajlsi-2696	325	1	rist	rist	NOUN
ajlsi-2696	325	2	,	,	PUNCT
ajlsi-2696	325	3	t.	t.	PROPN
ajlsi-2696	325	4	,	,	PUNCT
ajlsi-2696	325	5	parish	parish	PROPN
ajlsi-2696	325	6	,	,	PUNCT
ajlsi-2696	325	7	l.	l.	PROPN
ajlsi-2696	325	8	,	,	PUNCT
ajlsi-2696	325	9	capin	capin	PROPN
ajlsi-2696	325	10	,	,	PUNCT
ajlsi-2696	325	11	l.	l.	PROPN
ajlsi-2696	325	12	,	,	PUNCT
ajlsi-2696	325	13	sulica	sulica	PROPN
ajlsi-2696	325	14	,	,	PUNCT
ajlsi-2696	325	15	v.	v.	PROPN
ajlsi-2696	325	16	,	,	PUNCT
ajlsi-2696	325	17	bushnell	bushnell	PROPN
ajlsi-2696	325	18	,	,	PUNCT
ajlsi-2696	325	19	w.	w.	PROPN
ajlsi-2696	325	20	,	,	PUNCT
ajlsi-2696	325	21	&	&	CCONJ
ajlsi-2696	325	22	cupo	cupo	PROPN
ajlsi-2696	325	23	,	,	PUNCT
ajlsi-2696	325	24	m.	m.	NOUN
ajlsi-2696	325	25	(	(	PUNCT
ajlsi-2696	325	26	2002	2002	NUM
ajlsi-2696	325	27	)	)	PUNCT
ajlsi-2696	325	28	.	.	PUNCT
ajlsi-2696	326	1	a	a	DET
ajlsi-2696	326	2	comparison	comparison	NOUN
ajlsi-2696	326	3	of	of	ADP
ajlsi-2696	326	4	the	the	DET
ajlsi-2696	326	5	efficacy	efficacy	NOUN
ajlsi-2696	326	6	and	and	CCONJ
ajlsi-2696	326	7	safety	safety	NOUN
ajlsi-2696	326	8	of	of	ADP
ajlsi-2696	326	9	mupirocin	mupirocin	NOUN
ajlsi-2696	326	10	cream	cream	NOUN
ajlsi-2696	326	11	and	and	CCONJ
ajlsi-2696	326	12	cephalexin	cephalexin	NOUN
ajlsi-2696	326	13	in	in	ADP
ajlsi-2696	326	14	the	the	DET
ajlsi-2696	326	15	treatment	treatment	NOUN
ajlsi-2696	326	16	of	of	ADP
ajlsi-2696	326	17	secondarily	secondarily	ADV
ajlsi-2696	326	18	infected	infect	VERB
ajlsi-2696	326	19	eczema	eczema	NOUN
ajlsi-2696	326	20	.	.	PUNCT
ajlsi-2696	327	1	clinical	clinical	ADJ
ajlsi-2696	327	2	and	and	CCONJ
ajlsi-2696	327	3	experimental	experimental	ADJ
ajlsi-2696	327	4	dermatology	dermatology	NOUN
ajlsi-2696	327	5	,	,	PUNCT
ajlsi-2696	327	6	27(1	27(1	NUM
ajlsi-2696	327	7	)	)	PUNCT
ajlsi-2696	327	8	,	,	PUNCT
ajlsi-2696	327	9	14	14	NUM
ajlsi-2696	327	10	-	-	SYM
ajlsi-2696	327	11	20	20	NUM
ajlsi-2696	327	12	.	.	PUNCT
ajlsi-2696	328	1	rusiñol	rusiñol	PROPN
ajlsi-2696	328	2	,	,	PUNCT
ajlsi-2696	328	3	l.	l.	PROPN
ajlsi-2696	328	4	,	,	PUNCT
ajlsi-2696	328	5	&	&	CCONJ
ajlsi-2696	328	6	puig	puig	PROPN
ajlsi-2696	328	7	,	,	PUNCT
ajlsi-2696	328	8	l.	l.	PROPN
ajlsi-2696	328	9	(	(	PUNCT
ajlsi-2696	328	10	2024	2024	NUM
ajlsi-2696	328	11	)	)	PUNCT
ajlsi-2696	328	12	.	.	PUNCT
ajlsi-2696	329	1	multi	multi	ADJ
ajlsi-2696	329	2	-	-	ADJ
ajlsi-2696	329	3	omics	omics	ADJ
ajlsi-2696	329	4	approach	approach	NOUN
ajlsi-2696	329	5	to	to	ADP
ajlsi-2696	329	6	improved	improved	ADJ
ajlsi-2696	329	7	diagnosis	diagnosis	NOUN
ajlsi-2696	329	8	and	and	CCONJ
ajlsi-2696	329	9	treatment	treatment	NOUN
ajlsi-2696	329	10	of	of	ADP
ajlsi-2696	329	11	atopic	atopic	NOUN
ajlsi-2696	329	12	dermatitis	dermatitis	NOUN
ajlsi-2696	329	13	and	and	CCONJ
ajlsi-2696	329	14	psoriasis	psoriasis	NOUN
ajlsi-2696	329	15	.	.	PUNCT
ajlsi-2696	330	1	international	international	ADJ
ajlsi-2696	330	2	journal	journal	NOUN
ajlsi-2696	330	3	of	of	ADP
ajlsi-2696	330	4	molecular	molecular	ADJ
ajlsi-2696	330	5	sciences	science	NOUN
ajlsi-2696	330	6	,	,	PUNCT
ajlsi-2696	330	7	25(2	25(2	NUM
ajlsi-2696	330	8	)	)	PUNCT
ajlsi-2696	330	9	,	,	PUNCT
ajlsi-2696	330	10	1042	1042	NUM
ajlsi-2696	330	11	.	.	PUNCT
ajlsi-2696	331	1	schaper‐gerhardt	schaper‐gerhardt	PROPN
ajlsi-2696	331	2	,	,	PUNCT
ajlsi-2696	331	3	k.	k.	PROPN
ajlsi-2696	331	4	,	,	PUNCT
ajlsi-2696	331	5	rossbach	rossbach	PROPN
ajlsi-2696	331	6	,	,	PUNCT
ajlsi-2696	331	7	k.	k.	PROPN
ajlsi-2696	331	8	,	,	PUNCT
ajlsi-2696	331	9	nikolouli	nikolouli	PROPN
ajlsi-2696	331	10	,	,	PUNCT
ajlsi-2696	331	11	e.	e.	PROPN
ajlsi-2696	331	12	,	,	PUNCT
ajlsi-2696	331	13	werfel	werfel	NOUN
ajlsi-2696	331	14	,	,	PUNCT
ajlsi-2696	331	15	t.	t.	PROPN
ajlsi-2696	331	16	,	,	PUNCT
ajlsi-2696	331	17	gutzmer	gutzmer	NOUN
ajlsi-2696	331	18	,	,	PUNCT
ajlsi-2696	331	19	r.	r.	PROPN
ajlsi-2696	331	20	,	,	PUNCT
ajlsi-2696	331	21	&	&	CCONJ
ajlsi-2696	331	22	mommert	mommert	PROPN
ajlsi-2696	331	23	,	,	PUNCT
ajlsi-2696	331	24	s.	s.	PROPN
ajlsi-2696	331	25	(	(	PUNCT
ajlsi-2696	331	26	2020	2020	NUM
ajlsi-2696	331	27	)	)	PUNCT
ajlsi-2696	331	28	.	.	PUNCT
ajlsi-2696	332	1	the	the	DET
ajlsi-2696	332	2	role	role	NOUN
ajlsi-2696	332	3	of	of	ADP
ajlsi-2696	332	4	the	the	DET
ajlsi-2696	332	5	histamine	histamine	NOUN
ajlsi-2696	332	6	h4	h4	NOUN
ajlsi-2696	332	7	receptor	receptor	NOUN
ajlsi-2696	332	8	in	in	ADP
ajlsi-2696	332	9	atopic	atopic	NOUN
ajlsi-2696	332	10	dermatitis	dermatitis	NOUN
ajlsi-2696	332	11	and	and	CCONJ
ajlsi-2696	332	12	psoriasis	psoriasis	NOUN
ajlsi-2696	332	13	.	.	PUNCT
ajlsi-2696	333	1	british	british	ADJ
ajlsi-2696	333	2	journal	journal	PROPN
ajlsi-2696	333	3	of	of	ADP
ajlsi-2696	333	4	pharmacology	pharmacology	NOUN
ajlsi-2696	333	5	,	,	PUNCT
ajlsi-2696	333	6	177(3	177(3	NUM
ajlsi-2696	333	7	)	)	PUNCT
ajlsi-2696	333	8	,	,	PUNCT
ajlsi-2696	333	9	490	490	NUM
ajlsi-2696	333	10	-	-	SYM
ajlsi-2696	333	11	502	502	NUM
ajlsi-2696	333	12	.	.	PUNCT
ajlsi-2696	334	1	shah	shah	NOUN
ajlsi-2696	334	2	,	,	PUNCT
ajlsi-2696	334	3	n.	n.	NOUN
ajlsi-2696	334	4	,	,	PUNCT
ajlsi-2696	334	5	alhusayen	alhusayen	NOUN
ajlsi-2696	334	6	,	,	PUNCT
ajlsi-2696	334	7	r.	r.	PROPN
ajlsi-2696	334	8	,	,	PUNCT
ajlsi-2696	334	9	walsh	walsh	PROPN
ajlsi-2696	334	10	,	,	PUNCT
ajlsi-2696	334	11	s.	s.	PROPN
ajlsi-2696	334	12	,	,	PUNCT
ajlsi-2696	334	13	&	&	CCONJ
ajlsi-2696	334	14	shear	shear	PROPN
ajlsi-2696	334	15	,	,	PUNCT
ajlsi-2696	334	16	n.	n.	PROPN
ajlsi-2696	334	17	h.	h.	PROPN
ajlsi-2696	334	18	(	(	PUNCT
ajlsi-2696	334	19	2018	2018	NUM
ajlsi-2696	334	20	)	)	PUNCT
ajlsi-2696	334	21	.	.	PUNCT
ajlsi-2696	335	1	methotrexate	methotrexate	VERB
ajlsi-2696	335	2	in	in	ADP
ajlsi-2696	335	3	the	the	DET
ajlsi-2696	335	4	treatment	treatment	NOUN
ajlsi-2696	335	5	of	of	ADP
ajlsi-2696	335	6	moderate	moderate	ADJ
ajlsi-2696	335	7	to	to	ADP
ajlsi-2696	335	8	severe	severe	ADJ
ajlsi-2696	335	9	atopic	atopic	NOUN
ajlsi-2696	335	10	dermatitis	dermatitis	NOUN
ajlsi-2696	335	11	:	:	PUNCT
ajlsi-2696	335	12	a	a	DET
ajlsi-2696	335	13	retrospective	retrospective	ADJ
ajlsi-2696	335	14	study	study	NOUN
ajlsi-2696	335	15	.	.	PUNCT
ajlsi-2696	336	1	journal	journal	NOUN
ajlsi-2696	336	2	of	of	ADP
ajlsi-2696	336	3	cutaneous	cutaneous	ADJ
ajlsi-2696	336	4	medicine	medicine	NOUN
ajlsi-2696	336	5	and	and	CCONJ
ajlsi-2696	336	6	surgery	surgery	NOUN
ajlsi-2696	336	7	,	,	PUNCT
ajlsi-2696	336	8	22(5	22(5	NOUN
ajlsi-2696	336	9	)	)	PUNCT
ajlsi-2696	336	10	,	,	PUNCT
ajlsi-2696	336	11	484	484	NUM
ajlsi-2696	336	12	-	-	SYM
ajlsi-2696	336	13	487	487	NUM
ajlsi-2696	336	14	.	.	PUNCT
ajlsi-2696	337	1	soares	soares	PROPN
ajlsi-2696	337	2	,	,	PUNCT
ajlsi-2696	337	3	g.	g.	PROPN
ajlsi-2696	337	4	b.	b.	PROPN
ajlsi-2696	337	5	,	,	PUNCT
ajlsi-2696	337	6	hashimoto	hashimoto	NOUN
ajlsi-2696	337	7	,	,	PUNCT
ajlsi-2696	337	8	t.	t.	PROPN
ajlsi-2696	337	9	,	,	PUNCT
ajlsi-2696	337	10	&	&	CCONJ
ajlsi-2696	337	11	yosipovitch	yosipovitch	PROPN
ajlsi-2696	337	12	,	,	PUNCT
ajlsi-2696	337	13	g.	g.	PROPN
ajlsi-2696	337	14	(	(	PUNCT
ajlsi-2696	337	15	2024	2024	NUM
ajlsi-2696	337	16	)	)	PUNCT
ajlsi-2696	337	17	.	.	PUNCT
ajlsi-2696	338	1	atopic	atopic	NOUN
ajlsi-2696	338	2	dermatitis	dermatitis	NOUN
ajlsi-2696	338	3	itch	itch	NOUN
ajlsi-2696	338	4	:	:	PUNCT
ajlsi-2696	338	5	scratching	scratch	VERB
ajlsi-2696	338	6	for	for	ADP
ajlsi-2696	338	7	an	an	DET
ajlsi-2696	338	8	explanation	explanation	NOUN
ajlsi-2696	338	9	.	.	PUNCT
ajlsi-2696	339	1	journal	journal	PROPN
ajlsi-2696	339	2	of	of	ADP
ajlsi-2696	339	3	investigative	investigative	ADJ
ajlsi-2696	339	4	dermatology	dermatology	NOUN
ajlsi-2696	339	5	.	.	PUNCT
ajlsi-2696	340	1	sonya	sonya	PROPN
ajlsi-2696	340	2	kahn	kahn	PROPN
ajlsi-2696	340	3	,	,	PUNCT
ajlsi-2696	340	4	m.	m.	NOUN
ajlsi-2696	340	5	,	,	PUNCT
ajlsi-2696	340	6	rind	rind	NOUN
ajlsi-2696	340	7	,	,	PUNCT
ajlsi-2696	340	8	d.	d.	PROPN
ajlsi-2696	340	9	,	,	PUNCT
ajlsi-2696	340	10	chapman	chapman	PROPN
ajlsi-2696	340	11	,	,	PUNCT
ajlsi-2696	340	12	r.	r.	PROPN
ajlsi-2696	340	13	,	,	PUNCT
ajlsi-2696	340	14	kumar	kumar	PROPN
ajlsi-2696	340	15	,	,	PUNCT
ajlsi-2696	340	16	v.	v.	PROPN
ajlsi-2696	340	17	,	,	PUNCT
ajlsi-2696	340	18	kahn	kahn	PROPN
ajlsi-2696	340	19	,	,	PUNCT
ajlsi-2696	340	20	s.	s.	PROPN
ajlsi-2696	340	21	,	,	PUNCT
ajlsi-2696	340	22	&	&	CCONJ
ajlsi-2696	340	23	carlson	carlson	PROPN
ajlsi-2696	340	24	,	,	PUNCT
ajlsi-2696	340	25	j.	j.	PROPN
ajlsi-2696	340	26	(	(	PUNCT
ajlsi-2696	340	27	2018	2018	NUM
ajlsi-2696	340	28	)	)	PUNCT
ajlsi-2696	340	29	.	.	PUNCT
ajlsi-2696	341	1	economic	economic	ADJ
ajlsi-2696	341	2	evaluation	evaluation	NOUN
ajlsi-2696	341	3	of	of	ADP
ajlsi-2696	341	4	dupilumab	dupilumab	NOUN
ajlsi-2696	341	5	for	for	ADP
ajlsi-2696	341	6	moderate	moderate	ADJ
ajlsi-2696	341	7	-	-	PUNCT
ajlsi-2696	341	8	to	to	ADP
ajlsi-2696	341	9	-	-	PUNCT
ajlsi-2696	341	10	severe	severe	ADJ
ajlsi-2696	341	11	atopic	atopic	NOUN
ajlsi-2696	341	12	dermatitis	dermatitis	NOUN
ajlsi-2696	341	13	:	:	PUNCT
ajlsi-2696	341	14	a	a	DET
ajlsi-2696	341	15	cost	cost	NOUN
ajlsi-2696	341	16	-	-	PUNCT
ajlsi-2696	341	17	utility	utility	NOUN
ajlsi-2696	341	18	analysis	analysis	NOUN
ajlsi-2696	341	19	.	.	PUNCT
ajlsi-2696	342	1	j	j	PROPN
ajlsi-2696	342	2	drugs	drug	NOUN
ajlsi-2696	342	3	dermatol	dermatol	NOUN
ajlsi-2696	342	4	,	,	PUNCT
ajlsi-2696	342	5	17(7	17(7	NUM
ajlsi-2696	342	6	)	)	PUNCT
ajlsi-2696	342	7	,	,	PUNCT
ajlsi-2696	342	8	750	750	NUM
ajlsi-2696	342	9	-	-	SYM
ajlsi-2696	342	10	756	756	NUM
ajlsi-2696	342	11	.	.	PUNCT
ajlsi-2696	343	1	stacey	stacey	PROPN
ajlsi-2696	343	2	,	,	PUNCT
ajlsi-2696	343	3	s.	s.	PROPN
ajlsi-2696	343	4	k.	k.	PROPN
ajlsi-2696	343	5	,	,	PUNCT
ajlsi-2696	343	6	&	&	CCONJ
ajlsi-2696	343	7	mceleney	mceleney	NOUN
ajlsi-2696	343	8	,	,	PUNCT
ajlsi-2696	343	9	m.	m.	NOUN
ajlsi-2696	343	10	(	(	PUNCT
ajlsi-2696	343	11	2021	2021	NUM
ajlsi-2696	343	12	)	)	PUNCT
ajlsi-2696	343	13	.	.	PUNCT
ajlsi-2696	344	1	topical	topical	ADJ
ajlsi-2696	344	2	corticosteroids	corticosteroid	NOUN
ajlsi-2696	344	3	:	:	PUNCT
ajlsi-2696	344	4	choice	choice	NOUN
ajlsi-2696	344	5	and	and	CCONJ
ajlsi-2696	344	6	application	application	NOUN
ajlsi-2696	344	7	.	.	PUNCT
ajlsi-2696	345	1	american	american	ADJ
ajlsi-2696	345	2	family	family	PROPN
ajlsi-2696	345	3	physician	physician	NOUN
ajlsi-2696	345	4	,	,	PUNCT
ajlsi-2696	345	5	103(6	103(6	NUM
ajlsi-2696	345	6	)	)	PUNCT
ajlsi-2696	345	7	,	,	PUNCT
ajlsi-2696	345	8	337	337	NUM
ajlsi-2696	345	9	-	-	SYM
ajlsi-2696	345	10	343	343	NUM
ajlsi-2696	345	11	.	.	PUNCT
ajlsi-2696	346	1	study	study	NOUN
ajlsi-2696	346	2	of	of	ADP
ajlsi-2696	346	3	dupilumab	dupilumab	NOUN
ajlsi-2696	346	4	.	.	PUNCT
ajlsi-2696	347	1	(	(	PUNCT
ajlsi-2696	347	2	2017	2017	NUM
ajlsi-2696	347	3	)	)	PUNCT
ajlsi-2696	347	4	.	.	PUNCT
ajlsi-2696	348	1	clinical	clinical	ADJ
ajlsi-2696	348	2	trials	trial	NOUN
ajlsi-2696	348	3	.	.	PUNCT
ajlsi-2696	349	1	gov	gov	PROPN
ajlsi-2696	349	2	.	.	PROPN
ajlsi-2696	349	3	subramanian	subramanian	PROPN
ajlsi-2696	349	4	,	,	PUNCT
ajlsi-2696	349	5	i.	i.	PROPN
ajlsi-2696	349	6	,	,	PUNCT
ajlsi-2696	349	7	singh	singh	PROPN
ajlsi-2696	349	8	,	,	PUNCT
ajlsi-2696	349	9	v.	v.	PROPN
ajlsi-2696	349	10	k.	k.	PROPN
ajlsi-2696	349	11	,	,	PUNCT
ajlsi-2696	349	12	&	&	CCONJ
ajlsi-2696	349	13	jere	jere	PROPN
ajlsi-2696	349	14	,	,	PUNCT
ajlsi-2696	349	15	a.	a.	NOUN
ajlsi-2696	349	16	(	(	PUNCT
ajlsi-2696	349	17	2018	2018	NUM
ajlsi-2696	349	18	)	)	PUNCT
ajlsi-2696	349	19	.	.	PUNCT
ajlsi-2696	350	1	elucidating	elucidate	VERB
ajlsi-2696	350	2	mechanistic	mechanistic	ADJ
ajlsi-2696	350	3	insights	insight	NOUN
ajlsi-2696	350	4	into	into	ADP
ajlsi-2696	350	5	drug	drug	NOUN
ajlsi-2696	350	6	action	action	NOUN
ajlsi-2696	350	7	for	for	ADP
ajlsi-2696	350	8	atopic	atopic	NOUN
ajlsi-2696	350	9	dermatitis	dermatitis	NOUN
ajlsi-2696	350	10	:	:	PUNCT
ajlsi-2696	350	11	a	a	DET
ajlsi-2696	350	12	systems	system	NOUN
ajlsi-2696	350	13	biology	biology	NOUN
ajlsi-2696	350	14	approach	approach	NOUN
ajlsi-2696	350	15	.	.	PUNCT
ajlsi-2696	351	1	bmc	bmc	ADJ
ajlsi-2696	351	2	dermatology	dermatology	NOUN
ajlsi-2696	351	3	,	,	PUNCT
ajlsi-2696	351	4	18	18	NUM
ajlsi-2696	351	5	,	,	PUNCT
ajlsi-2696	351	6	1	1	NUM
ajlsi-2696	351	7	-	-	SYM
ajlsi-2696	351	8	12	12	NUM
ajlsi-2696	351	9	.	.	PUNCT
ajlsi-2696	352	1	umar	umar	PROPN
ajlsi-2696	352	2	,	,	PUNCT
ajlsi-2696	352	3	b.	b.	PROPN
ajlsi-2696	352	4	u.	u.	PROPN
ajlsi-2696	352	5	,	,	PUNCT
ajlsi-2696	352	6	rahman	rahman	PROPN
ajlsi-2696	352	7	,	,	PUNCT
ajlsi-2696	352	8	s.	s.	PROPN
ajlsi-2696	352	9	,	,	PUNCT
ajlsi-2696	352	10	dutta	dutta	PROPN
ajlsi-2696	352	11	,	,	PUNCT
ajlsi-2696	352	12	s.	s.	PROPN
ajlsi-2696	352	13	,	,	PUNCT
ajlsi-2696	352	14	islam	islam	PROPN
ajlsi-2696	352	15	,	,	PUNCT
ajlsi-2696	352	16	t.	t.	PROPN
ajlsi-2696	352	17	,	,	PUNCT
ajlsi-2696	352	18	nusrat	nusrat	PROPN
ajlsi-2696	352	19	,	,	PUNCT
ajlsi-2696	352	20	n.	n.	PROPN
ajlsi-2696	352	21	,	,	PUNCT
ajlsi-2696	352	22	chowdhury	chowdhury	PROPN
ajlsi-2696	352	23	,	,	PUNCT
ajlsi-2696	352	24	k.	k.	PROPN
ajlsi-2696	352	25	,	,	PUNCT
ajlsi-2696	352	26	ahmad	ahmad	PROPN
ajlsi-2696	352	27	,	,	PUNCT
ajlsi-2696	352	28	w.	w.	PROPN
ajlsi-2696	352	29	f.	f.	PROPN
ajlsi-2696	352	30	s.	s.	PROPN
ajlsi-2696	352	31	b.	b.	PROPN
ajlsi-2696	352	32	w.	w.	PROPN
ajlsi-2696	352	33	,	,	PUNCT
ajlsi-2696	352	34	haque	haque	PROPN
ajlsi-2696	352	35	,	,	PUNCT
ajlsi-2696	352	36	m.	m.	NOUN
ajlsi-2696	352	37	,	,	PUNCT
ajlsi-2696	352	38	umar	umar	PROPN
ajlsi-2696	352	39	,	,	PUNCT
ajlsi-2696	352	40	b.	b.	PROPN
ajlsi-2696	352	41	u.	u.	PROPN
ajlsi-2696	352	42	u.	u.	PROPN
ajlsi-2696	352	43	,	,	PUNCT
ajlsi-2696	352	44	&	&	CCONJ
ajlsi-2696	352	45	fakuradzi	fakuradzi	PROPN
ajlsi-2696	352	46	,	,	PUNCT
ajlsi-2696	352	47	w.	w.	PROPN
ajlsi-2696	352	48	f.	f.	PROPN
ajlsi-2696	352	49	s.	s.	PROPN
ajlsi-2696	352	50	w.	w.	PROPN
ajlsi-2696	352	51	a.	a.	PROPN
ajlsi-2696	352	52	(	(	PUNCT
ajlsi-2696	352	53	2022	2022	NUM
ajlsi-2696	352	54	)	)	PUNCT
ajlsi-2696	352	55	.	.	PUNCT
ajlsi-2696	353	1	management	management	NOUN
ajlsi-2696	353	2	of	of	ADP
ajlsi-2696	353	3	atopic	atopic	NOUN
ajlsi-2696	353	4	dermatitis	dermatitis	NOUN
ajlsi-2696	353	5	:	:	PUNCT
ajlsi-2696	353	6	the	the	DET
ajlsi-2696	353	7	role	role	NOUN
ajlsi-2696	353	8	of	of	ADP
ajlsi-2696	353	9	tacrolimus	tacrolimus	NOUN
ajlsi-2696	353	10	.	.	PUNCT
ajlsi-2696	354	1	cureus	cureus	NOUN
ajlsi-2696	354	2	,	,	PUNCT
ajlsi-2696	354	3	14(8	14(8	NUM
ajlsi-2696	354	4	)	)	PUNCT
ajlsi-2696	354	5	.	.	PUNCT
ajlsi-2696	355	1	xu	xu	INTJ
ajlsi-2696	355	2	,	,	PUNCT
ajlsi-2696	355	3	x.	x.	PROPN
ajlsi-2696	355	4	,	,	PUNCT
ajlsi-2696	355	5	van	van	PROPN
ajlsi-2696	355	6	galen	galen	PROPN
ajlsi-2696	355	7	,	,	PUNCT
ajlsi-2696	355	8	l.	l.	PROPN
ajlsi-2696	355	9	s.	s.	PROPN
ajlsi-2696	355	10	,	,	PUNCT
ajlsi-2696	355	11	koh	koh	PROPN
ajlsi-2696	355	12	,	,	PUNCT
ajlsi-2696	355	13	m.	m.	PROPN
ajlsi-2696	355	14	j.	j.	PROPN
ajlsi-2696	355	15	a.	a.	PROPN
ajlsi-2696	355	16	,	,	PUNCT
ajlsi-2696	355	17	bajpai	bajpai	PROPN
ajlsi-2696	355	18	,	,	PUNCT
ajlsi-2696	355	19	r.	r.	PROPN
ajlsi-2696	355	20	,	,	PUNCT
ajlsi-2696	355	21	thng	thng	PROPN
ajlsi-2696	355	22	,	,	PUNCT
ajlsi-2696	355	23	s.	s.	PROPN
ajlsi-2696	355	24	,	,	PUNCT
ajlsi-2696	355	25	yew	yew	PROPN
ajlsi-2696	355	26	,	,	PUNCT
ajlsi-2696	355	27	y.	y.	PROPN
ajlsi-2696	355	28	w.	w.	PROPN
ajlsi-2696	355	29	,	,	PUNCT
ajlsi-2696	355	30	ho	ho	PROPN
ajlsi-2696	355	31	,	,	PUNCT
ajlsi-2696	355	32	v.	v.	PUNCT
ajlsi-2696	355	33	p.	p.	PROPN
ajlsi-2696	355	34	y.	y.	PROPN
ajlsi-2696	355	35	,	,	PUNCT
ajlsi-2696	355	36	alagappan	alagappan	PROPN
ajlsi-2696	355	37	,	,	PUNCT
ajlsi-2696	355	38	u.	u.	PROPN
ajlsi-2696	355	39	,	,	PUNCT
ajlsi-2696	355	40	järbrink	järbrink	PROPN
ajlsi-2696	355	41	,	,	PUNCT
ajlsi-2696	355	42	k.	k.	PROPN
ajlsi-2696	355	43	s.	s.	PROPN
ajlsi-2696	355	44	a.	a.	PROPN
ajlsi-2696	355	45	,	,	PUNCT
ajlsi-2696	355	46	&	&	CCONJ
ajlsi-2696	355	47	car	car	PROPN
ajlsi-2696	355	48	,	,	PUNCT
ajlsi-2696	355	49	j.	j.	PROPN
ajlsi-2696	355	50	(	(	PUNCT
ajlsi-2696	355	51	2019	2019	NUM
ajlsi-2696	355	52	)	)	PUNCT
ajlsi-2696	355	53	.	.	PUNCT
ajlsi-2696	356	1	factors	factor	NOUN
ajlsi-2696	356	2	influencing	influence	VERB
ajlsi-2696	356	3	quality	quality	NOUN
ajlsi-2696	356	4	of	of	ADP
ajlsi-2696	356	5	life	life	NOUN
ajlsi-2696	356	6	in	in	ADP
ajlsi-2696	356	7	children	child	NOUN
ajlsi-2696	356	8	with	with	ADP
ajlsi-2696	356	9	atopic	atopic	NOUN
ajlsi-2696	356	10	dermatitis	dermatitis	NOUN
ajlsi-2696	356	11	and	and	CCONJ
ajlsi-2696	356	12	their	their	PRON
ajlsi-2696	356	13	caregivers	caregiver	NOUN
ajlsi-2696	356	14	:	:	PUNCT
ajlsi-2696	356	15	a	a	DET
ajlsi-2696	356	16	cross	cross	ADJ
ajlsi-2696	356	17	-	-	ADJ
ajlsi-2696	356	18	sectional	sectional	ADJ
ajlsi-2696	356	19	study	study	NOUN
ajlsi-2696	356	20	.	.	PUNCT
ajlsi-2696	357	1	scientific	scientific	ADJ
ajlsi-2696	357	2	reports	report	NOUN
ajlsi-2696	357	3	,	,	PUNCT
ajlsi-2696	357	4	9(1	9(1	NUM
ajlsi-2696	357	5	)	)	PUNCT
ajlsi-2696	357	6	,	,	PUNCT
ajlsi-2696	357	7	15990	15990	NUM
ajlsi-2696	357	8	.	.	PUNCT
ajlsi-2696	358	1	zhou	zhou	PROPN
ajlsi-2696	358	2	,	,	PUNCT
ajlsi-2696	358	3	s.	s.	PROPN
ajlsi-2696	358	4	,	,	PUNCT
ajlsi-2696	358	5	qi	qi	PROPN
ajlsi-2696	358	6	,	,	PUNCT
ajlsi-2696	358	7	f.	f.	PROPN
ajlsi-2696	358	8	,	,	PUNCT
ajlsi-2696	358	9	gong	gong	PROPN
ajlsi-2696	358	10	,	,	PUNCT
ajlsi-2696	358	11	y.	y.	PROPN
ajlsi-2696	358	12	,	,	PUNCT
ajlsi-2696	358	13	zhang	zhang	PROPN
ajlsi-2696	358	14	,	,	PUNCT
ajlsi-2696	358	15	j.	j.	PROPN
ajlsi-2696	358	16	,	,	PUNCT
ajlsi-2696	358	17	&	&	CCONJ
ajlsi-2696	358	18	zhu	zhu	PROPN
ajlsi-2696	358	19	,	,	PUNCT
ajlsi-2696	358	20	b.	b.	PROPN
ajlsi-2696	358	21	(	(	PUNCT
ajlsi-2696	358	22	2021	2021	NUM
ajlsi-2696	358	23	)	)	PUNCT
ajlsi-2696	358	24	.	.	PUNCT
ajlsi-2696	359	1	biological	biological	ADJ
ajlsi-2696	359	2	therapies	therapy	NOUN
ajlsi-2696	359	3	for	for	ADP
ajlsi-2696	359	4	atopic	atopic	NOUN
ajlsi-2696	359	5	dermatitis	dermatitis	NOUN
ajlsi-2696	359	6	:	:	PUNCT
ajlsi-2696	359	7	a	a	DET
ajlsi-2696	359	8	systematic	systematic	ADJ
ajlsi-2696	359	9	review	review	NOUN
ajlsi-2696	359	10	.	.	PUNCT
ajlsi-2696	360	1	dermatology	dermatology	NOUN
ajlsi-2696	360	2	,	,	PUNCT
ajlsi-2696	360	3	237(4	237(4	NUM
ajlsi-2696	360	4	)	)	PUNCT
ajlsi-2696	360	5	,	,	PUNCT
ajlsi-2696	360	6	542	542	NUM
ajlsi-2696	360	7	-	-	SYM
ajlsi-2696	360	8	552	552	NUM
ajlsi-2696	360	9	.	.	PUNCT